## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **FORM 10-K**

(Muik One)	(N	1ark	One)
------------	----	------	------

X

#### ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE **SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 31, 2013

#### TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE **SECURITIES EXCHANGE ACT OF 1934**

For the transition period from Commission file number: 001-16751

## WELLPOINT, INC.

(Exact name of registrant as specified in its charter)

**INDIANA** 

35-2145715

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

120 MONUMENT CIRCLE INDIANAPOLIS, INDIANA (Address of principal executive offices)

46204

(Zip Code)

Registrant's telephone number, including area code: (317) 488-6000 Securities registered pursuant to Section 12(b) of the Act:

Title	of	each	class

Name of each exchange on which registered

Common Stock, Par Value \$0.01

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: NONE

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes 🖾 No 🗆 Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes 🗆 No 🗵 Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⊠ No □

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ⊠ No □

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ⊠

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Non-accelerated filer □ (Do not check if a smaller reporting company □ Smaller reporting company □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (assuming solely for the purposes of this calculation that all Directors and executive officers of the registrant are "affiliates") as of June 28, 2013 was approximately \$24,439,366,963.

As of February 7, 2014, 282,459,121 shares of the Registrant's Common Stock were outstanding.

#### DOCUMENTS INCORPORATED BY REFERENCE

Part III of this Annual Report on Form 10-K incorporates by reference information from the registrant's Definitive Proxy Statement for the Annual Meeting of Shareholders to be held May 14, 2014.

### WellPoint, Inc.

### Annual Report on Form 10-K For the Year Ended December 31, 2013

### **Table of Contents**

PART I		
ITEM 1.	BUSINESS	<u>3</u>
ITEM 1A.	RISK FACTORS	<u>23</u>
ITEM 1B.	UNRESOLVED SEC STAFF COMMENTS	<u>37</u>
ITEM 2.	<u>PROPERTIES</u>	<u>37</u>
ITEM 3.	LEGAL PROCEEDINGS	37 37
ITEM 4.	MINE SAFETY DISCLOSURES	<u>37</u>
PART II		
ITEM 5.	MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER	
	PURCHASES OF EQUITY SECURITIES	<u>38</u>
ITEM 6.	SELECTED FINANCIAL DATA	<u>41</u>
ITEM 7.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	<u>42</u>
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	<u>75</u>
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	<u>77</u>
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	<u>137</u>
ITEM 9A.	CONTROLS AND PROCEDURES	<u>137</u>
ITEM 9B.	OTHER INFORMATION	<u>140</u>
PART III		
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	<u>140</u>
ITEM 11.	EXECUTIVE COMPENSATION	<u>140</u>
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	<u>140</u>
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	140
ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	140
PART IV		
ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	<u>141</u>
SIGNATURES		<u>148</u>
INDEX TO EXH	IBITS .	<u>149</u>

This Annual Report on Form 10-K, including Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our views about future events and financial performance. When used in this report, the words "may," "will," "should," "anticipate," "estimate," "expect," "plan," "believe," "feel," "predict," "project," "potential," "intend" and similar expressions are intended to identify forward-looking statements, which are generally not historical in nature. Forward-looking statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various disclosures made by us, which attempt to advise interested parties of the factors that affect our business, including "Risk Factors" set forth in Part I, Item 1A hereof and our reports filed with the U.S. Securities and Exchange Commission, or SEC, from time to time. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

References in this Annual Report on Form 10-K to the terms "we," "our," "us," "WellPoint" or the "Company" refer to WellPoint, Inc., an Indiana corporation, and its direct and indirect subsidiaries, as the context requires.

#### PART I

#### ITEM 1. BUSINESS.

#### General

We are one of the largest health benefits companies in terms of medical membership in the United States, serving 35.7 million medical members through our affiliated health plans and more than 67.8 million individuals through all subsidiaries as of December 31, 2013. We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for: Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as BCBS in 10 New York city metropolitan and surrounding counties and as Blue Cross or BCBS in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), and Wisconsin. In a majority of these service areas we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Georgia, and Empire Blue Cross Blue Shield, or Empire Blue Cross (in our New York service areas). We also conduct business through our AMERIGROUP Corporation, or Amerigroup, subsidiary in Florida, Georgia, Kansas, Louisiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas and Washington. Amerigroup also provided services in the state of Ohio through June 30, 2013 and in the state of New Mexico through December 31, 2013. We also serve customers throughout the country as HealthLink, UniCare and in certain Arizona, California, Nevada, New York and Virginia markets through our CareMore Health Group, Inc., or CareMore, subsidiary. We are licensed to conduct insurance operations in all 50 states through our subsidiaries.

We have a vision of becoming America's valued health partner. Together we are transforming health care with trusted and caring solutions and as a result, we focus on delivering quality products and services that give members access to the care they need. With an unyielding commitment to meeting the needs of our diverse customers, we are guided by the following values:

- Accountable
- Caring
- Easy to do business with
- Innovative
- Trustworthy

We offer a broad spectrum of network-based managed care health benefit plans to the large and small employer, individual, Medicaid and Medicare markets. Our managed care plans include: preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; point-of-service plans, or POS plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance. We also provide services to the Federal Government in connection with the Federal Employee Program, or FEP, and various Medicare programs. Finally, prior to January 31, 2014, we sold contact lenses, eyeglasses and other ocular products through our 1-800 CONTACTS, Inc., or 1-800 CONTACTS, business. In preparation for the coming changes to the health care system and to focus on our core growth opportunities across our Commercial and Specialty Business and Government Business segments, we entered into a definitive agreement in December 2013 to sell our 1-800 CONTACTS subsidiary to the private equity firm Thomas H. Lee Partners, L.P. Concurrently, we entered into an asset purchase agreement with Luxottica Group to sell our glasses.com related assets. The divestitures were completed on January 31, 2014.

The increased focus on health care costs by employers, the government and consumers has continued to drive the growth of alternatives to traditional indemnity health insurance. HMO, PPO and hybrid plans, such as POS plans and CDHPs, are among the various forms of managed care products that have been developed. Through these types of products, insurers

attempt to contain the cost of health care by negotiating contracts with hospitals, physicians and other providers to deliver high quality health care to members at favorable rates. These products usually feature medical management and other quality and cost optimization measures such as pre-admission review and approval for certain non-emergency services, pre-authorization of outpatient surgical procedures, network credentialing to determine that network doctors and hospitals have the required certifications and expertise, and various levels of care management programs to help members better understand and navigate the health care system. In addition, providers may have incentives to achieve certain quality measures, may share medical cost risk or may have other incentives to deliver quality medical services in a cost-effective manner. Also, certain plans offer members incentives for healthy behaviors, such as smoking cessation and weight management. Members are charged periodic, prepaid premiums and generally pay co-payments, coinsurance and/or deductibles when they receive services. While the distinctions between the various types of plans have lessened over recent years, PPO, POS and CDHP products generally provide reduced benefits for out-of-network services, while traditional HMO products generally provide little to no reimbursement for non-emergency out-of-network utilization, but often offer more generous benefit coverage. An HMO plan may also require members to select one of the network primary care physicians to coordinate their care and approve any specialist or other services.

Economic factors and greater consumer awareness have resulted in the increasing popularity of products that offer larger, more extensive networks, more member choice related to coverage, physicians and hospitals, and a desire for greater flexibility for customers to assume larger deductibles and co-payments in return for lower premiums. CDHPs, which are relatively high deductible PPO products and are often paired with some type of member tax-advantaged health care expenditure account that can be used at the member's discretion to help fund member out-of-pocket costs, help to meet this demand. CDHPs also usually incorporate member education, wellness, and care management programs to help customers make better informed health care decisions. We believe we are well-positioned in each of our regions to respond to these market preferences.

For our fully-insured products, we charge a premium and assume all of the health care risk. Under self-funded and partially-insured products, we charge a fee for services, and the employer or plan sponsor reimburses us for all or most of the health care costs. In addition, we charge a premium to provide administrative services to large group employers that maintain self-funded health plans and we underwrite stop loss insurance for self-funded plans.

Our medical membership includes seven different customer types:

- Local Group
- Individual
- National Accounts
- BlueCard<sup>®</sup>
- Medicare
- Medicaid
- FEP

BCBS-branded business generally refers to members in our service areas licensed by the BCBSA. Non-BCBS-branded business refers to members in our non-BCBS-branded Amerigroup and CareMore plans, as well as HealthLink and UniCare members. In addition to the above medical membership, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health business.

Our products are generally developed and marketed with an emphasis on the differing needs of our customers. In particular, our product development and marketing efforts take into account the differing characteristics between the various customers served by us, as well as the unique needs of educational and public entities, labor groups, federal employee health and benefit programs, national employers and state-run programs servicing low-income, high-risk and under-served markets. Each business unit is responsible for product design, pricing, enrolling, underwriting and servicing customers in specific customer types. Overall, we seek to establish pricing and product designs to achieve an appropriate level of profitability for each of our customer categories balanced with the competitive objective to grow market share. We believe that one of the keys to our success has been our focus on these distinct customer types, which better enables us to develop benefit plans and services that meet our customers' unique needs.

We market our products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for Individual and Medicare customers, and for certain Local Group customers with a smaller employee base. Products for National Accounts and Local Group customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer and working with industry specialists from our in-house sales force. In the individual and small group markets we offer on-exchange products through state or federally facilitated marketplaces and off-exchange products. Federal premium subsidies are available only for certain on-exchange individual products.

Each of the BCBS member companies, of which there were 37 independent primary licensees as of December 31, 2013, works cooperatively in a number of ways that create significant market advantages, especially when competing for very large multi-state employer groups. As a result of this cooperation, each BCBS member company is able to take advantage of other BCBS licensees' substantial provider networks and discounts when any BCBS member works or travels outside of the state in which their policy is written. This program is referred to as BlueCard® and is a source of revenue when we provide member services in the states where we are the BCBS licensee to individuals who are customers of BCBS plans not affiliated with us. This program also provides a national provider network for our members when they travel to other states.

For additional information describing each of our customer types, detailed marketing efforts and changes in medical membership over the last three years, see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this Form 10-K.

Our results of operations depend in large part on accurately predicting health care costs and our ability to manage future health care costs through adequate product pricing, medical management, product design and negotiation of favorable provider contracts.

The aging of the population and other demographic characteristics and advances in medical technology continue to contribute to rising health care costs. Our managed care plans and products are designed to encourage providers and members to participate in quality, cost-effective health benefit programs by using the full range of our innovative medical management services, quality initiatives and financial incentives. Our leading market share and high business retention rates enable us to realize the long-term benefits of investing in preventive and early detection programs. Our ability to provide cost-effective health benefits products and services is enhanced through a disciplined approach to internal cost containment, prudent management of our risk exposure and successful integration of acquired businesses. In addition, our ability to manage selling, general and administrative costs continues to be a driver of our overall profitability.

Our future results of operations will also be impacted by certain external forces and resulting changes in our business model and strategy. In 2010, the U.S. Congress passed and the President signed into law the Patient Protection and Affordable Care Act, or ACA, as well as the Health Care and Education Reconciliation Act of 2010, or collectively, Health Care Reform, which represents significant changes to the U.S. health care system. The legislation is far-reaching and is intended to expand access to health insurance coverage over time by increasing the eligibility thresholds for state Medicaid programs and providing certain other individuals and small businesses with tax credits to subsidize a portion of the cost of health insurance coverage. As a result of the complexity of the law, its impact on health care in the United States and the continuing modification and interpretation of Health Care Reform's rules, we continue to analyze the impact and refine our estimates of the ultimate impact of Health Care Reform on our business, cash flows, financial condition and results of operations. A list of certain material changes resulting from Health Care Reform include:

- · Requirements to modify our products to cover essential health benefits and comply with other defined criteria;
- Requirement to cancel existing products and enroll new and renewing members in the new ACA-compliant products;
- · Introduction of exchanges, subsidies and mandates to require and allow previously uninsured customers to enter the market; and
- Significant new taxes and fees which will be paid by health insurers, and which may or may not be passed through to customers.

The above changes resulting from Health Care Reform will provide growth opportunities for health insurers, but also introduce new risks and uncertainties, and require changes in the way products are designed, underwritten, priced, distributed

and administered.

For additional discussion, see "Regulation," herein and Part I, Item 1A "Risk Factors" in this Form 10-K.

In addition to the external forces discussed in the preceding paragraph, our results of operations are impacted by levels and mix of membership. In recent years, we experienced significant membership declines due to unfavorable economic conditions driving increased unemployment. In addition, we believe the self-insured portion of our group membership base will continue to increase as a percentage of total group membership. These membership trends could have a material adverse effect on our future results of operations. See Part I, Item 1A "Risk Factors" and Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this Form 10-K.

We continue to believe health care is local and feel that we have the strong local presence required to understand and meet local customer needs. We believe we are well-positioned to deliver what customers want: innovative, choice-based and affordable products; distinctive service; simplified transactions; and better access to information for quality care. Our local presence, combined with our national expertise, has created opportunities for collaborative programs that reward physicians and hospitals for clinical quality and excellence. We feel that our commitment to health improvement and care management provides added value to customers and health care professionals. We believe that an essential ingredient for practical and sustainable improvements in health care is raising health care quality while managing costs for total cost affordability. We have identified initiatives that we believe will deliver better health care while reducing costs. These include driving innovation in paying and partnering with providers to compel improved cost, quality and health along with finding new, effective ways to manage risk and engage the member as a consumer. In addition, we seek to achieve efficiencies from our national scale while optimizing service performance for our customers. Finally, we seek to continue to rationalize our portfolio of businesses and products, and align our investments to capitalize on new opportunities to drive growth in both our existing and new markets in the future.

We continue to enhance interactions with customers, brokers, agents, employees and other stakeholders through web-enabled technology and improving internal operations. Our approach includes not only sales and distribution of health benefits products on the Internet, but also implementation of advanced capabilities that improve services benefiting customers, agents, brokers, and providers while optimizing administrative costs. These enhancements can also help improve the quality, coordination and safety of health care through increased communications between patients and their physicians.

We intend to continue pursuing our vision of becoming America's valued health partner by transforming health care with trusted and caring solutions and by delivering quality products and services that give members access to the care they need. At the same time, we will focus on earnings per share, or EPS, growth through organic membership gains, improvements in our operating cost structure, strategic acquisitions and the efficient use of capital.

#### **Significant Transactions**

The more significant transactions that have occurred over the last five years that have impacted or will impact our capital structure or that have or will influence how we conduct our business operations include:

- Use of Capital—Board of Directors declaration of dividends on common stock (2013, 2012 and 2011) and a 16.7% increase in the quarterly dividend to \$0.4375 per share (2014); authorization for repurchases of our common stock (2013 and prior); and debt repurchases and new debt issuance (2013 and prior);
- Acquisition of Amerigroup and the related debt issuance (2012);
- Acquisition of 1-800 CONTACTS (2012) and subsequent divestiture (2014);
- Acquisition of CareMore (2011);
- Sale of our pharmacy benefits management, or PBM, business to Express Scripts, Inc., or Express Scripts (2009); and
- Acquisition of DeCare Dental, LLC, or DeCare (2009).

For additional information regarding certain of these transactions, see Note 3, "Business Acquisitions and Divestitures," Note 13, "Debt," and Note 15, "Capital Stock," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

### Competition

The managed care industry is highly competitive, both nationally and in our regional markets. Competition continues to be intense due to aggressive marketing, business consolidations, a proliferation of new products, the impact of Health Care Reform, and increased quality awareness and price sensitivity among customers.

Health benefits industry participants compete for customers mainly on the following factors:

- quality of service;
- price;
- access to provider networks;
- access to care management and wellness programs, including health information;
- innovation, breadth and flexibility of products and benefits;
- reputation (including National Committee on Quality Assurance, or NCQA, accreditation status);
- · brand recognition; and
- · financial stability.

Over the last few years, a health plan's ability to interact with employers, members and other third parties (including health care professionals) via the Internet has become a more important competitive factor and we have made significant investments in technology to enhance our electronic interaction with providers, employers, members and third parties.

We believe our exclusive right to market products under the most recognized brand in the industry, BCBS, in our most significant markets provides us with an advantage over our competition. Our provider networks in our markets enable us to achieve efficiencies and distinctive service levels enabling us to offer a broad range of health benefits to our customers on a more cost-effective basis than many of our competitors. We strive to distinguish our products through provider access, service, care management, product value and brand recognition.

Pricing in our Commercial and Specialty Business segment (defined below), including our individual and small group lines of business, remains highly competitive and we strive to price our health care benefit products consistent with anticipated underlying medical trends. We believe our pricing strategy, based on predictive modeling, proprietary research and data-driven processes, as well as our overall investments for Health Care Reform, have positioned us to benefit from the potential growth opportunities available in fully-insured commercial products as a result of Health Care Reform. The ultimate level of exchange enrollment cannot be predicted and although it is not yet clear whether our products sold on the exchanges will be more or less profitable products, we believe that our pricing strategy, brand name and network quality will provide a strong foundation for commercial risk membership growth opportunities in the future.

To build our provider networks, we compete with other health benefits plans for the best contracts with hospitals, physicians and other providers. We believe that physicians and other providers primarily consider member volume, reimbursement rates, timeliness of reimbursement and administrative service capabilities along with the reduction of non-value added administrative tasks when deciding whether to contract with a health benefits plan.

At the sales and distribution level, we compete for qualified agents and brokers to recommend and distribute our products. Strong competition exists among insurance companies and health benefits plans for agents and brokers with demonstrated ability to secure new business and maintain existing accounts. We believe that the quality and price of our products, support services, reputation and prior relationships, along with a reasonable commission structure are the factors agents and brokers consider in choosing whether to market our products. We believe that we have good relationships with our agents and brokers, and that our products, support services and commission structure compare favorably to those of our competitors in all of our markets. Typically, we are the largest competitor in each of our Blue-branded markets and, thus, are a closely watched target by other insurance competitors.

#### Reportable Segments

On May 20, 2013, we announced certain organizational and executive leadership changes to align with how our new Chief Executive Officer is managing our operations. Beginning with the three months ended June 30, 2013, our organizational structure is comprised of three reportable segments: Commercial and Specialty Business; Government Business; and Other. Prior period segment information has been reclassified to conform to the new segment reporting structure.

Our Commercial and Specialty Business and Government Business segments both offer a diversified mix of managed care products, including PPOs, HMOs, traditional indemnity benefits and POS plans, as well as a variety of hybrid benefit plans including CDHPs, hospital only and limited benefit products.

Our Commercial and Specialty Business segment includes Local Group, National Accounts, Individual and Specialty businesses. Business units in the Commercial and Specialty Business segment offer fully-insured products; provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services; and provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance.

Our Government Business segment includes Medicare and Medicaid businesses, National Government Services, or NGS, and services provided to the Federal Government in connection with FEP. Medicare business includes services such as Medicare Advantage, Medicare Part D, and Medicare Supplement, while Medicaid business includes our managed care alternatives through publicly funded health care programs, including Medicaid, state Children's Health Insurance Programs, or CHIP, and Medicaid expansion programs. NGS acts as a Medicare contractor in several regions across the nation.

Our Other segment includes other businesses that do not meet the quantitative thresholds for an operating segment as defined by Financial Accounting Standards Board, or FASB, guidance, as well as corporate expenses not allocated to the other reportable segments.

Through our participation in various federal government programs, we generated approximately 20.3%, 23.7% and 23.5% of our total consolidated revenues from agencies of the U.S. government for the years ended December 31, 2013, 2012 and 2011, respectively. These revenues are contained in the Government Business segment. An immaterial amount of our total consolidated revenues are derived from activities outside of the U.S.

For additional information regarding the operating results of our segments, see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Note 20, "Segment Information," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### **Products and Services**

A general description of our products and services is provided below:

*Preferred Provider Organization:* PPO products offer the member an option to select any health care provider, with benefits reimbursed by us at a higher level when care is received from a participating network provider. Coverage is subject to co-payments or deductibles and coinsurance, with member cost sharing usually limited by out-of-pocket maximums.

Consumer-Driven Health Plans: CDHPs provide consumers with increased financial responsibility, choice and control regarding how their health care dollars are spent. Generally, CDHPs combine a high-deductible PPO plan with an employer-funded and/or employee-funded personal care account, which may result in tax benefits to the employee. Some or all of the dollars remaining in the personal care account at year-end can be rolled over to the next year for future health care needs.

*Traditional Indemnity:* Indemnity products offer the member an option to select any health care provider for covered services. Coverage is subject to deductibles and coinsurance, with member cost sharing usually limited by out-of-pocket maximums.

Health Maintenance Organization: HMO products include comprehensive managed care benefits, generally through a

participating network of physicians, hospitals and other providers. A member in one of our HMOs must typically select a primary care physician, or PCP, from our network. PCPs generally are family practitioners, internists or pediatricians who provide necessary preventive and primary medical care, and are generally responsible for coordinating other necessary health care services. We offer HMO plans with varying levels of co-payments, which result in different levels of premium rates.

*Point-of-Service:* POS products blend the characteristics of HMO, PPO and indemnity plans. Members can have comprehensive HMO-style benefits through participating network providers with minimum out-of-pocket expenses (co-payments) and also can go directly, without a referral, to any provider they choose, subject to, among other things, certain deductibles and coinsurance. Member cost sharing is limited by out-of-pocket maximums.

ACA On- and Off-Exchange Products: ACA requires the modification of existing products and development of new products to meet the requirements of the legislation. Individual and small group products must cover essential health benefits as defined in ACA along with many other requirements and cost sharing changes. Individual and small group products offered on and off the exchanges must meet the definition of the "metal" product requirements (bronze, silver, gold and platinum). Each metal product must satisfy a specific actuarial value. Health insurers participating on exchanges must offer at least one silver and one gold product.

In our individual markets we offer bronze, silver and gold products, both on and off the exchanges, in the states of California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia and Wisconsin. Additionally, we offer platinum products, both on and off the exchanges, in the states of California and New York.

In our small group markets, we offer bronze, silver and gold products, both on and off the exchanges, in the states of Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, Ohio and Virginia and we offer bronze, silver and gold products, off the exchanges, in the states of California, New York and Wisconsin. Additionally, we offer platinum products, off the exchanges, in the states of California, Connecticut, Georgia, Maine and Virginia.

Administrative Services: In addition to fully-insured products, we provide administrative services to large group employers that maintain self-funded health plans. These administrative services include underwriting, actuarial services, medical cost management, disease management, wellness programs, claims processing and other administrative services for self-funded employers. Self-funded health plans are also able to use our provider networks and to realize savings through our negotiated provider arrangements, while allowing employers the ability to design certain health benefit plans in accordance with their own requirements and objectives. We also underwrite stop loss insurance for self-funded plans.

BlueCard®: BlueCard® host members are generally members who reside in or travel to a state in which a WellPoint subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer sponsored health plan serviced by a non-WellPoint controlled BCBS licensee, who is the "home" plan. We perform certain administrative functions for BlueCard® host members, for which we receive administrative fees from the BlueCard® members' home plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan.

Medicare Plans: We offer a wide variety of senior plans, products and options such as Medicare supplement plans, Medicare Advantage (including private fee-for-service plans and special needs plans) and Medicare Part D Prescription Drug Plans, or Medicare Part D. Medicare supplement plans typically pay the difference between health care costs incurred by a beneficiary and amounts paid by Medicare. Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our Medicare Advantage special needs plans provide tailored benefits to Medicare beneficiaries who have chronic diseases and also cover certain dual eligible customers, who are low-income seniors and persons under age 65 with disabilities who are enrolled in both Medicare and Medicaid plans. Medicare Part D offers a prescription drug plan to Medicare and dual eligible (Medicare and Medicaid) beneficiaries. We offer these plans to customers through our health benefit subsidiaries throughout the country, including Amerigroup and CareMore.

Individual Plans: We offer a full range of health insurance plans with a variety of options and deductibles for individuals under age 65 who are not covered by employer-sponsored coverage. Some of our products target certain demographic populations such as uninsured younger individuals between the ages of 19 and 29, families, those transitioning between jobs or early retirees. Individual policies are generally sold through independent agents and brokers, retail

partnerships, our in-house sales force or via the Internet. Individual business is sold on a fully-insured basis. We offer on-exchange products through state or federally facilitated marketplaces and off-exchange products. Federal premium subsidies are available only for certain on-exchange products. Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network, and the efficiency of administration.

Medicaid Plans and Other State-Sponsored Programs: We have contracts to serve members enrolled in publicly funded health care programs, including Medicaid, CHIP, and Medicaid expansion programs. The Medicaid program makes federal matching funds available to all states for the delivery of health care benefits for low income and/or high medical risk individuals. These programs are managed by the individual states based on broad federal guidelines. CHIP is a state and federally funded program that provides health care coverage to children not otherwise covered by Medicaid or other insurance programs. Our Medicaid plans also cover certain dual eligible customers, as previously described above, who also receive Medicare benefits. We provide Medicaid and other State-Sponsored services in California, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland, Massachusetts, Nevada, New Jersey, New York, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia and Wisconsin and began providing Medicaid services in Kentucky on January 1, 2014. Amerigroup also provided services in the state of Ohio through June 30, 2013 and in the state of New Mexico through December 31, 2013.

Pharmacy Products: We market and sell an integrated prescription drug product to both fully-insured and self-funded customers through our health benefit subsidiaries throughout the country. This comprehensive product includes features such as drug formularies, a pharmacy network and maintenance of a prescription drug database and mail order capabilities. Since December 1, 2009, we have delegated certain functions and administrative services related to our integrated prescription drug products to Express Scripts under a ten year contract, excluding Amerigroup and certain self-insured members, which have exclusive agreements with different PBM service providers, provided however that Amerigroup will be transitioning to the Express Scripts agreement during 2014. Express Scripts manages the network of pharmacy providers, operates mail order pharmacies and processes prescription drug claims on our behalf, while we sell and support the product for clients, make formulary decisions and set drug benefit design strategy and provide front line member support.

*Life Insurance:* We offer an array of competitive individual and group life insurance benefit products to both large and small group customers in conjunction with our health plans. The life products include term life and accidental death and dismemberment.

Disability: We offer short-term and long-term disability products, usually in conjunction with our health plans.

Behavioral Health: We offer specialized behavioral health plans and benefit management. These plans cover mental health and substance abuse treatment services on both an inpatient and an outpatient basis. We have implemented employee assistance and behavioral managed care programs for a wide variety of businesses throughout the United States. These programs are offered through our subsidiaries.

Radiology Benefit Management: We offer outpatient diagnostic imaging management services to health plans. These services include utilization management for advanced diagnostic imaging procedures, network development and optimization, patient safety, claims adjudication and provider payment.

*Personal Health Care Guidance:* We offer leading evidence-based and analytics-driven personal health care guidance. These services help improve the quality, coordination and safety of health care, enhance communications between patients and their physicians, and reduce medical costs.

Dental: Our dental plans include networks in certain states in which we operate. Many of the dental benefits are provided to customers enrolled in our health plans and are offered on both a fully-insured and self-funded basis. Our members also have access to additional dental providers through our participation in the National Dental GRID, a national dental network developed by and for BCBS plans. The National Dental GRID includes dentists in all 50 states and provides multi-state customers with a national solution providing in-network discounts across the country. Additionally, we offer managed dental services to other health care plans to assist those plans in providing dental benefits to their customers.

Vision Services and Products: Our vision plans include networks within the states in which we operate. Many of the vision benefits are provided to customers enrolled in our health plans and are offered on both a fully-insured and self-funded

basis. In addition to vision plans, we sold contact lenses, eyeglasses and other ocular products through our 1-800 CONTACTS subsidiary which we divested on January 31, 2014.

Long-Term Care Insurance: We offer long-term care insurance products to our California members through a subsidiary. The long-term care products include tax-qualified and non-tax qualified versions of a skilled nursing home care plan and comprehensive policies covering skilled, intermediate and custodial long-term care and home health services.

Medicare Administrative Operations: Through our subsidiary, NGS, we serve as a fiscal intermediary, carrier and Medicare administrative contractor providing administrative services for the Medicare program, which generally provides coverage for persons who are 65 or older and for persons who are disabled or with end-stage renal disease. Part A of the Medicare program provides coverage for services provided by hospitals, skilled nursing facilities and other health care facilities. Part B of the Medicare program provides coverage for services provided by physicians, physical and occupational therapists and other professional providers, as well as certain durable medical equipment and medical supplies.

#### **Networks and Provider Relations**

Our relationships with physicians, hospitals and professionals that render health care services to our members are guided by local, regional and national standards for network development, reimbursement and contract methodologies. While following industry standards, we are simultaneously seeking to lead and transform our health care system from our current fragmented model premised on episodic intervention to one based on proactive, coordinated care built around the needs of the patient. A key element of this transformation involves a transition from traditional fee-for-service payment models to models where providers are paid based on the value, both in quality and affordability, of the care they deliver.

We establish "market-based" hospital reimbursement payments that we believe are fair, but aggressive, and among the most competitive in the market. We also seek to ensure that physicians in our network are paid in a timely manner at appropriate rates. In many instances, we deploy multi-year contracting strategies, including case or fixed rates, to limit our exposure to medical cost inflation and to increase cost predictability. We maintain both broad and narrow provider networks to ensure member choice, based on both price and access needs, while implementing programs designed to improve the quality of care received by our members. Increasingly, we are supplementing our broad based networks with smaller or more cost-effective networks that are designed to be attractive to a more price-sensitive customer segment, such as health care exchange customers.

Depending on the consolidation and integration of physician groups and hospitals, reimbursement strategies vary across markets. Fee-for-service is our predominant reimbursement methodology for physicians, but as noted above, and more fully described below, we are transitioning to a value-based payment program. More traditional physician fee schedules are developed at the state level based on an assessment of several factors and conditions, including the Centers for Medicare & Medicaid Services, or CMS, resource-based relative value system, or RBRVS, medical practice cost inflation and physician supply. We utilize CMS RBRVS fee schedules as a reference point for fee schedule development and analysis. The RBRVS structure was developed and is maintained by CMS, and is used by the Medicare program and other major payers. In addition, we have implemented and continue to expand physician incentive contracting, or "pay for performance", which ties physician payment levels to performance on clinical measures.

It is generally our philosophy not to delegate full financial responsibility to our physician providers in the form of capitation-based reimbursement. However, in certain markets we believe capitation can be a useful method to lower costs and reduce underwriting risk, and we therefore have some capitation contracts.

Our hospital contracts provide for a variety of reimbursement arrangements depending on local market dynamics and current hospital utilization efficiency. Most hospitals are reimbursed a fixed amount per day or reimbursed a per-case amount, per admission, for inpatient covered services. A small percentage of hospitals, primarily rural, sole community hospitals, are reimbursed on a discount from approved charge basis for covered services. Our "per-case" reimbursement methods utilize many of the same attributes contained in Medicare's Diagnosis Related Groups, or DRG, methodology. Hospital outpatient services are reimbursed by fixed case rates, fee schedules or percent of approved charges. Our hospital contracts recognize unique hospital attributes, such as academic medical centers or community hospitals, and the volume of care performed for our members. To improve predictability of expected cost, we frequently use a multi-year contracting approach and have been transitioning to case rate payment methodologies. Many of our hospital contracts include a "pay for performance" component where reimbursement levels are linked to improved clinical performance, patient safety and medical error reduction.

Fee-for-service currently remains our predominant reimbursement methodology for physicians, but as noted above, we are rapidly transitioning to value-based payment programs. Though fee-for-service or fee-for-service combined with pay for performance remains our predominant payment model today, our provider engagement and contracting strategies are moving away from "unit price" or volume-based payment models to payment models that align compensation with the value delivered as measured by health care, quality and cost. We launched the most significant of these efforts, our Enhanced Personal Health Care program, in the fourth quarter of 2012. This program augments traditional fee-for-service with a shared savings program that allows participating providers to share in any achieved savings, when actual health care costs are below projected costs, provided that they meet threshold performance on quality measures. The quality measures are based on nationally accepted, credible standards (e.g. NCQA, the American Diabetes Association and the American Academy of Pediatrics) and span preventive, acute and chronic care. We combine this payment model with a highly collaborative relationship approach under which we give participating providers the tools and information they need to proactively manage the health of their patient population, improve health outcomes and reduce the cost associated with preventable medical events. In some of these arrangements, participating physician practices receive a per-member, permonth clinical coordination fee to compensate them for important care management activities that occur outside of the patient visit, fostering a move away from episodic visit-based interventions to a proactive patient engagement and coordinated care model. Since the launch of Enhanced Personal Health Care, we now have arrangements with provider organizations covering nearly 25% of our primary care physicians and have rolled this program out in all 14 of our Commercial and Specialty Business markets. Thereafter, through 2015, we intend to continue to expand the breadth of our programs in each market by adding additional physicians until the majority of physicians participate in a value-based payment program.

#### **Medical Management Programs**

Our medical management programs include a broad array of activities that facilitate improvements in the quality of care provided to our members and promote cost-effective medical care. These medical management activities and programs are administered and directed by physicians and trained nurses. The goals of our medical management strategies are to ensure that the care delivered to our members is supported by appropriate medical and scientific evidence, is received on a timely basis and occurs in the most appropriate location.

Precertification: A traditional medical management program involves assessment of the appropriateness of certain hospitalizations and other medical services prior to the service being rendered. For example, precertification is used to determine whether a set of hospital and medical services is being appropriately applied to the member's clinical condition, in accordance with criteria for medical necessity as that term is defined in the member's benefits contract. All of our health plans have implemented precertification programs for common high-tech radiology studies, including cardiac diagnostic testing, addressing an area of historically significant cost trends. Through our American Imaging Management Specialty Health subsidiary we promote appropriate, safe and affordable member care in imaging as well as oncology, sleep management and specialty pharmacy benefits. These expanded specialty benefit management solutions leverage clinical expertise and technology to engage our provider communities and members in more effective and efficient use of outpatient services.

Care Coordination: Another traditional medical management strategy we use is care coordination, which is based on nationally recognized criteria developed by third-party medical specialists. With inpatient care coordination, the requirements and intensity of services during a patient's hospital stay are reviewed, at times by an onsite skilled nurse professional in collaboration with the hospital's medical and nursing staff, in order to coordinate care and determine the most effective transition of care from the hospital setting. In addition, guidance for many continued stay cases is reviewed with physician medical directors to ensure appropriate utilization of medical services. We also coordinate care for outpatient services to help ensure that patients with chronic conditions who receive care from multiple physicians are able to manage the exchange of information between physicians and coordinate office visits to their physicians.

Case Management: We have implemented a medical management strategy focused on identifying the small percentage of the membership that will require a high level of intervention to manage their health care needs. The registered nurses and medical directors focus on members likely to be readmitted to the hospital and help them coordinate their care through pharmacy compliance, post-hospital care, follow-up visits to see their physician and support in their home.

Formulary management: We have developed formularies, which are selections of drugs based on clinical quality and effectiveness. A pharmacy and therapeutics committee of physicians uses scientific and clinical evidence to ensure that our

members have access to the appropriate drug therapies.

*Medical policy:* A medical policy group comprised of physician leaders from various areas of the country, working in cooperation with academic medical centers, practicing community physicians and medical specialty organizations such as the American College of Radiology and national organizations such as the Centers for Disease Control and Prevention and the American Cancer Society, determines our national policy for the application of new medical technologies and treatments.

Quality programs: We are actively engaged with our hospital and physician networks to enable them to improve medical and surgical care and achieve better outcomes for our members. We endorse, encourage and incent hospitals and physicians to support national initiatives to improve the quality of clinical care and patient outcomes and to reduce medication errors and hospital infections. We have demonstrated our leadership in developing hospital quality programs.

*External review procedures:* We work with outside experts through a process of external review to provide our members scientifically and clinically, evidence-based medical care. When we receive member concerns, we have formal appeals procedures that ultimately allow coverage disputes related to medical necessity decisions under the benefits contract to be settled by independent expert physicians.

*Service management:* In HMO and POS networks, primary care physicians serve as the overall coordinators of members' health care needs by providing an array of preventive health services and overseeing referrals to specialists for appropriate medical care. In PPO networks, patients have access to network physicians without a primary care physician serving as the coordinator of care.

Estimate Your Cost & Anthem Care Comparison: These health care provider comparison tools disclose typical cost estimates and quality data for common services at contracted providers, with cost estimates accounting for facility, professional and ancillary services. The cost estimates bundle related services typically performed at the time of the procedure, not just for the procedure itself. Users can review cost data for over 350 procedures in 49 states. The Estimate Your Cost tool also includes member out-of-pocket cost estimates based on a member's own benefit coverage, deductible, and out of pocket maximum. We also offer information on overall facility ratings and patient experience using trusted third party data. We continue to work on enhancing and evolving our tools to assist members in making informed and value-based health care decisions. In addition, we collaborate with an external independent vendor to support employers wanting to purchase a transparency and consumer engagement web solution with certain additional functionality.

*Personal Health Care Guidance:* These services help improve the quality, coordination and safety of health care, enhance communications between patients and their physicians, and reduce medical costs. Examples of services include member and physician messaging, providing access to evidence-based medical guidelines, physician quality profiling, and other consulting services.

Anthem Health Guide: Anthem Health Guide integrates customer service with clinical and wellness coaching to provide easier navigation of health care services for our members. Members are supported by a team of nurses, coaches, educators, and social workers using voice, click-to-chat, secure email and mobile technology. Our Smart Engagement Platform supports this integrated team using our smart engagement triggers for speech recognition, preventative and clinical gaps in care and highlighting when we have members who are identified for health care support and we have been unable to reach them. This caring team of professionals also supports our members with our shared decision making support portfolio.

#### **Care Management Programs**

We continue to expand our 360° Health suite of integrated care management programs and tools. 360° Health offers the following programs, among others, that have been proven to increase quality and reduce medical costs for our members:

ConditionCare and FutureMoms are care management and maternity management programs that serve as adjuncts to physician care. Skilled nurse professionals with added support from our team of dietitians, social workers, pharmacists, health educators and other health professionals help participants understand their condition, their doctor's orders and how to become a better self-manager of their condition. We also offer members infertility consultation through our SpecialOffers@Anthem program, a comprehensive and integrated assembly of discounted health and wellness products and services from a variety of the nation's leading retailers.

24/7 NurseLine offers access to qualified, registered nurses anytime. This allows our members to make informed

decisions about the appropriate level of care and avoid unnecessary worry. This program also includes a referral process to the nearest urgent care facility, a robust audiotape library, accessible by phone, with more than 400 health and wellness topics, as well as on-line health education topics designed to educate members about symptoms and treatment of many common health concerns.

ComplexCare is an advanced care management program that reaches out to participants with multiple health care issues who are at risk for frequent and high levels of medical care in order to offer support and assistance in managing their health care needs. ComplexCare identifies candidates through claims analysis using predictive modeling techniques, the use of health risk assessment data, utilization management reports and referrals from a physician or one of our other programs, such as the 24/7 NurseLine.

MyHealth Advantage utilizes integrated information systems and sophisticated data analytics to help our members improve their compliance with evidence-based care guidelines, providing personal care notes that alert members to potential gaps in care, enable more prudent health care choices, and assist in the realization of member out-of-pocket cost savings. Key opportunities are also shared with physicians through Availity® at the time of membership eligibility verification. Availity® is an electronic data interchange system that allows for the exchange of health information among providers over a secure network.

MyHealth Coach provides our members with a professional guide who helps them navigate the health care system and make better decisions about their well-being. MyHealth Coach proactively reaches out to people who are at risk for serious health issues or have complex health care needs. Our health coaches help participants understand and manage chronic conditions, handle any health and wellness related services they need and make smart lifestyle choices.

*HealthyLifestyles* helps employees transform unhealthy habits into positive ones by focusing on behaviors that can have a positive effect on their health and their employer's financial well-being. *HealthyLifestyles* programs include smoking cessation, weight management, stress management, physical activity and diet and nutrition.

MyHealth@Anthem is our secure web-based solution, complementing other programs by reinforcing telephonic coaching and mail campaigns. The website engages participants in regularly assessing their health status, gives them feedback about their progress, and tracks important health measures such as blood pressure, weight and blood glucose levels.

Employee Assistance Programs provide many resources that allow members to balance work and personal life by providing quick and easy access to confidential resources to help meet the challenges of daily life. Examples of services available in person as well as via telephone or internet are counseling for child care, health and wellness, financial issues, legal issues, adoption and daily living.

#### **Health Care Quality Initiatives**

Increasingly, the health care industry is able to define quality health care based on preventive health measurements, outcomes of care and optimal care management for chronic disease. A key to our success has been our ability to work with our network physicians and hospitals to improve the quality and outcomes of the health care services provided to our members. Our ability to promote quality medical care has been recognized by the NCQA, the largest and most respected national accreditation program for managed care health plans.

Several quality health care measures, including the Healthcare Effectiveness Data and Information Set, or HEDIS®, have been incorporated into the NCQA's accreditation processes. HEDIS® measures range from preventive services, such as screening mammography and pediatric immunization, to elements of care, including decreasing the complications of diabetes and improving treatment for patients with heart disease. For health plans, NCQA's highest accreditation status of Excellent is granted only to those plans that demonstrate levels of service and clinical quality that meet or exceed NCQA's rigorous requirements for consumer protection and quality improvement. Plans earning this accreditation level must also achieve HEDIS® results that are in the highest range of national or regional performance. Details for each of our plans' accreditation levels can be found at www.ncqa.org.

We have committed to measuring our progress in improving the quality of care that our members and our communities receive through our proprietary Member Health Index, or MHI, and State Health Index, or SHI. The MHI is comprised of 23 clinically relevant measures for our health plan members and combines prevention, care management, clinical outcome and

patient safety metrics. The SHI measures the health of all the residents in our BCBSA licensed states, not just our members, using public data from the Centers for Disease Control and Prevention.

Our wholly-owned clinical research and health outcomes research subsidiary, HealthCore, has supported biopharmaceutical manufacturers, health professionals, and health plans by enabling more effective medical management and increased physician adherence to evidence-based care, and creating new knowledge on the value of clinical therapies, resulting in better care decisions. In addition, HealthCore works closely with government entities, including the Food and Drug Administration and the Centers for Disease Control and Prevention, on initiatives aimed at improving healthcare safety and enhancing national safety surveillance capabilities.

Our wholly-owned specialty benefit management subsidiary, AIM Specialty Health, or AIM, has supported quality by implementing clinical appropriateness and patient safety solutions for advanced imaging procedures, cardiology, sleep medicine, specialty pharmaceuticals and oncology, including drugs covered under medical benefit and radiation therapy. These programs, based on widely accepted clinical guidelines, promote the most appropriate use of diagnostic and therapeutic services to improve the quality of overall health care delivered to our members and members of other health plans that are covered under AIM's programs. To provide additional impact to its clinical appropriateness program, AIM has also implemented a provider assessment program, OptiNet®, which promotes more informed selection of diagnostic imaging and testing facilities by providing cost and facility information to physicians at the point that a procedure is ordered. We have also leveraged AIM's provider network assessment information to proactively engage and educate our members about imaging providers and sleep testing choices based on site capabilities and cost differences. This program is another example of how we facilitate improvements in the quality of care provided to our members and promote cost effective medical care. In addition, AIM radiology, cardiology, sleep medicine, radiation therapy, network assessment and member engagement solutions have been evaluated as quality improvement expenses under the National Association of Insurance Commissioners, or NAIC, medical loss ratio, or MLR, regulations. Fees for these programs can be included in calculations of a health plan's MLR.

Our wholly-owned analytics-driven personal health care guidance subsidiary, Resolution Health, Inc., has supported quality by helping our members take action to get healthy, stay healthy and better manage chronic illness. Our analysis of an individual member's health data identifies opportunities to improve health care quality and safety; we then send personalized messages to the member, their doctor and care manager to take action. For example, our drug safety messages inform a member's doctor, pharmacist or care manager of potentially dangerous drug-drug, drug-condition, drug-age, or drug-dose interactions identified in our Drug Safety Scan. This helps improve safety, drug effectiveness and medication adherence.

#### **Pricing and Underwriting of Our Products**

We price our products based on our assessment of current health care claim costs and emerging health care cost trends, combined with charges for administrative expenses, risk and profit, including charges for new ACA taxes and fees. We continually review our product designs and pricing guidelines on a national and regional basis so that our products remain competitive and consistent with our profitability goals and strategies.

In applying our pricing to each employer group and customer, we maintain consistent, competitive, disciplined underwriting standards. We employ our proprietary accumulated actuarial data in determining underwriting and pricing parameters. Where allowed by law and regulation, we underwrite large groups based on each group's aggregate claim experience. Also, we employ credit underwriting procedures with respect to our self-funded products.

In most circumstances, our pricing and underwriting decisions follow a prospective rating process in which a fixed premium is determined at the beginning of the contract period. For fully-insured business, any deviation, favorable or unfavorable, from the medical costs assumed in determining the premium is our responsibility. Some of our larger groups employ retrospective rating reviews, where positive experience is partially refunded to the group, and negative experience is charged against a rate stabilization fund established from the group's favorable experience, or charged against future favorable experience.

#### **BCBSA Licenses**

We are a party to license agreements with the BCBSA that entitle us to the exclusive, and in certain areas, non-exclusive use of the Blue Cross and Blue Shield names and marks in assigned geographic territories. BCBSA is a national trade

association of Blue Cross and Blue Shield licensees, the primary function of which is to promote and preserve the integrity of the BCBS names and marks, as well as provide certain coordination among the member companies. Each BCBSA licensee is an independent legal organization and is not responsible for obligations of other BCBSA member organizations. We have no right to market products and services using the BCBS names and marks outside of the states in which we are licensed to sell BCBS products. We are required to pay an annual license fee to the BCBSA based on enrollment and also to comply with various operational and financial standards set forth in the licenses.

We believe that we and our licensed affiliates are currently in compliance with these standards. The standards under the license agreements may be modified in certain instances by the BCBSA. See Part I, Item 1A "Risk Factors" in this Form 10-K for additional details of our licensing requirements and the impact if we were not to comply with these license agreements.

#### Regulation

#### General

Our operations are subject to comprehensive and detailed state, federal and international regulation throughout the jurisdictions in which we do business. As discussed below, the regulatory aspects of the U.S. health care system have been and will continue to be significantly affected by Health Care Reform. Supervisory agencies, including state health, insurance and corporation departments, have broad authority to:

- grant, suspend and revoke licenses to transact business;
- · regulate many aspects of our products and services;
- monitor our solvency and reserve adequacy;
- · scrutinize our investment activities on the basis of quality, diversification and other quantitative criteria; and
- impose monetary and criminal sanctions for non-compliance with regulatory requirements.

To carry out these tasks, these regulators periodically examine our operations and accounts.

Regulation of Insurance Company and HMO Business Activity

The governments of the states in which we conduct business, as well as the federal government, have adopted laws and regulations that govern our business activities in various ways. Further, Health Care Reform has resulted in increased federal regulation that is likely to have a significant impact on our business. These laws and regulations, which vary significantly from state to state and on the federal level, may restrict how we conduct our businesses and may result in additional burdens and costs to us. Areas of governmental regulation include but are not limited to:

- medical loss ratios;
- tax deductibility of certain compensation and Health Care Reform related fees;
- licensure;
- premium rates;
- · benefits;
- eligibility requirements;
- guaranteed availability and renewability;
- service areas;
- market conduct;
- sales and marketing activities, including use and compensation of brokers and other distribution channels;
- · quality assurance procedures;
- plan design and disclosures, including mandated benefits;
- underwriting, marketing, pricing and rating restrictions for insurance products;

- · utilization review activities;
- prompt payment of claims;
- · member rights and responsibilities;
- collection, access or use of protected health information;
- data reporting, including financial data and standards for electronic transactions;
- payment of dividends;
- provider rates of payment;
- surcharges on provider payments;
- provider contract forms;
- provider access standards;
- premium taxes, assessments for the uninsured and/or underinsured and insolvency guaranty payments;
- member and provider complaints and appeals;
- financial condition (including reserves and minimum capital or risk based capital requirements and investments);
- reimbursement or payment levels for government funded business; and
- corporate governance.

These state and federal laws and regulations are subject to amendments and changing interpretations in each jurisdiction.

States generally require health insurers and HMOs to obtain a certificate of authority prior to commencing operations. If we were to establish a health insurance company or an HMO in any jurisdiction where we do not presently operate, we generally would have to obtain such a certificate. The time necessary to obtain such a certificate varies from jurisdiction to jurisdiction. Each health insurer and HMO must file periodic financial and operating reports with the states in which it does business. In addition, health insurers and HMOs are subject to state examination and periodic license renewal. The health benefits business also may be adversely impacted by court and regulatory decisions that expand the interpretations of existing statutes and regulations. It is uncertain whether we can recoup, through higher premiums or other measures, the increased costs of mandated benefits or other increased costs caused by potential legislation, regulation or court rulings. See Part I, Item 1A "Risk Factors" in this Form 10-K.

#### Patient Protection and Affordable Care Act

The ACA, signed into law on March 23, 2010, has created significant changes and will continue to create significant changes for health insurance markets for the next several years. Specifically, many of the near-term changes were effective for certain groups and individuals on their first renewal on or after September 23, 2010, including a prohibition on lifetime limits, certain annual limits, member cost-sharing on specified preventive benefits, pre-existing condition exclusions for children, increased restrictions on rescinding coverage and extension of coverage of dependents to the age of 26. Certain requirements for insurers were also effective in 2011, including changes to Medicare Advantage payments and the minimum MLR provision that requires insurers to pay rebates to customers when insurers do not meet or exceed the specified MLR thresholds. Most of the provisions of ACA with more significant effects on the health insurance marketplace, both state and federal, went into effect on January 1, 2014, including a requirement that insurers guarantee the issuance of coverage to all individuals regardless of health status, strict rules on how health insurance is rated, the assessment of new taxes and fees (including annual fees on health insurance companies), the creation of new insurance exchanges for individuals and small groups, the availability of premium subsidies for certain individual products, and substantial expansions in eligibility for Medicaid.

Despite significant preparation for the advent of the new federal and state health insurance exchanges, there have been many technical difficulties in the implementation of the exchanges, which entail uncertainties associated with mix and volume of business. In November 2013, CMS notified the various state Insurance Commissioners that, under a transitional policy, health insurance coverage in the individual or small group market that is renewed for a policy year starting between

January 1, 2014 and October 1, 2014 that would otherwise have been deemed non-compliant with certain market reforms under Health Care Reform will nonetheless not be considered by CMS to be out of compliance with respect to such market reforms provided certain conditions are met. CMS further encouraged state agencies responsible for enforcing the specified market reforms to adopt the same transitional policy with respect to this coverage. Some states have adopted the transitional policy, some have not adopted it and yet others have not taken a position.

Due to the impact of the transitional policy, we may be adversely selected by individuals who will have a higher acuity level than the anticipated pool of participants in the exchange markets. In addition, the risk adjustment, reinsurance, and risk corridor premium stabilization programs of Health Care Reform, or Health Care Reform Premium Stabilization Programs, established to apportion risk amongst insurers, may not be effective in appropriately mitigating the financial risks related to our exchange products. These factors, along with the limited information about the individuals who have access to these newly established exchanges that was available when we established premiums, may have a material adverse effect on our results of operations if premiums are not adequate or do not appropriately reflect the acuity of these individuals. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions utilized in setting adequate premium rates could have a material adverse effect on our results of operations, financial position, and cash flows.

In addition, there have been other material changes and delays in the implementation of ACA that could have a material adverse effect on our results of operations, financial position, and cash flows. These include:

- Delay in the effective date of the employer mandate from 2014 to 2015;
- Extension of the 2013 open enrollment period to December 23, 2013 for a January 1, 2014 effective date;
- Delay of the commencement of the 2014 open enrollment period from October 15 to November 15 through January 15, 2015;
- Changes to the annual fees on health insurance companies;
- Deferral of the online Small Business Health Options Program (SHOP) enrollment capabilities; and
- Other yet to be announced changes and delays.

These delays and changes may have a material and significant impact on anticipated enrollment in on- and off-exchange products, thus affecting the risk pools and premium rates. The technical difficulties in implementing exchanges have impacted the sharing of enrollment information between the federal government and health insurers and will significantly delay payment and subsidies to insurers. Finally, implementation of ACA brings with it significant oversight responsibilities by health insurers that may result in increased governmental audits, increased assertions of False Claims Act violations, and an increased risk of other litigation.

ACA continues to require additional guidance and specificity to be provided by the Department of Health and Human Services, or HHS, the Department of Labor, CMS and the Department of the Treasury. These regulatory agencies continue to consider recommendations from external groups, such as the NAIC. Many provisions have final rules available for review while some proposed regulations have been released for comment or have yet to be released and others are in-process. Of particular note is the yet to be issued regulation pertaining to administrative simplification to create uniformity in implementing electronic standards. We continue to carefully evaluate each rule as it is issued; and, therefore, it continues to be too early to fully understand the impacts of the legislation on our overall business. Some of the more significant considerations of ACA are described below:

MLR regulations were issued by HHS in December 2011; however, significant changes could still occur to the MLR requirements through
additional regulatory guidance and/or modification of the regulation. The minimum MLR thresholds by line of business, as defined by
HHS, are as follows:

Line of Business	9/0
Large Group	85
Small Group	80
Individual	80

New York state regulations require us to meet a more restrictive MLR threshold of 82% for both Small Group and Individual lines of business. Certain other states have received approval from HHS to phase-in the MLR requirements in the Individual markets in those states and, as a result, are currently using lower thresholds for determination of potential rebates. The minimum MLR thresholds disclosed above are based on definitions of an MLR calculation provided by HHS, or specific states, as applicable, and differ from our calculation of "benefit expense ratio" based on premium revenue and benefit expense as reported in accordance with U.S. generally accepted accounting principles, or GAAP. Furthermore, the definitions of the lines of business differ under the various state and federal regulations and may not correspond to our lines of business. Definitions under the MLR regulation also impact insurers differently depending upon their organizational structure or tax status, which could result in a competitive advantage to some insurance providers that may not be available to us, resulting in an uneven playing field in the industry. Significant changes to the MLR requirements may occur through additional regulatory action by HHS.

Approximately 63.1% and 27.3% of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of and for the year ended December 31, 2013. Approximately 74.4% and 28.5% of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of and for the year ended December 31, 2012. Beginning with rebates paid in 2014 for the 2013 benefit year, MLR rebates will be based on a three year average. This calculation will determine an average MLR for each market segment within each state for the previous three calendar years. Additionally, insurers will be able to adjust experience to account for prior MLR rebates refunded to groups or individuals. Once the three year average MLR is calculated and compared to the minimum MLR threshold, the rebate percentage will be applied to current year premiums as defined by Health Care Reform. Beginning with MLR rebates paid in 2015 for the 2014 benefit year, insurers will adjust for the Health Care Reform Premium Stabilization Programs.

Health Care Reform also imposes a separate minimum MLR threshold of 85% for Medicare Advantage plans beginning in 2014. Medicare Advantage plans that do not meet this threshold will have to pay a minimum MLR rebate. If a plan's MLR is below 85% for three consecutive years beginning with 2014, enrollment will be restricted. A Medicare Advantage plan contract will be terminated if the plan's MLR is below 85% for five consecutive years.

- ACA required states to establish health insurance exchanges by January 1, 2014 through which qualified individuals and qualified small employers may access coverage. If a state failed to establish a health insurance exchange, the federal government established a health insurance exchange in that state. To date sixteen states plus the District of Columbia have elected to operate state-based exchanges. The remaining states have either a federal partnership exchange (seven states) or a federally operated exchange (twenty-seven states). In the states in which we offer products on exchanges, six states have passed legislation or executive orders establishing state-based health insurance exchanges (California, Colorado, Connecticut, Kentucky, Nevada and New York).
- ACA requires the modification of existing products and development of new products to meet the requirements of the legislation.
   Products must cover essential health benefits as defined in ACA along with many other requirements and cost sharing changes. Health insurers must offer individual and small group products that meet the definition of the "metal" requirements (bronze, silver, gold and platinum). Each metal product must satisfy a specific actuarial value. Health insurers participating in exchanges must offer at least one silver and one gold product. Additionally, effective January 1, 2014, health insurers were required to cancel or discontinue the sale of existing non-ACA-compliant individual and small group products, subject to the conditions of the November 2013 CMS transitional policy discussed above.
- Regulations became effective in September 2011 that require filings for premium rate increases for small group and individual products above specified thresholds, generally 10%, to be reviewed. The regulations provide for state insurance regulators to conduct the reviews, except for cases where a state does not have an "effective" rate review program, in which case HHS will conduct the reviews for any rate increase filed.
- The Health Care Reform Premium Stabilization Programs introduce new requirements to the MLR calculation, beginning with the 2014 benefit year for the individual and small group markets. The risk adjustment program is a permanent program that transfers dollars from insurers who enroll individuals with lower relative health risk to insurers who enroll individuals with higher relative health risk. Risk adjustment payments/receipts will be determined separately for each state and for individual and small group. The second premium stabilization program is the transitional reinsurance program, a temporary program that runs from 2014 through 2016. The transitional

reinsurance program is intended to help stabilize premiums by reimbursing issuers of ACA-compliant non-grandfathered individual market plans for eligible claims between a defined attachment point and ceiling, at a coinsurance rate defined by HHS. The program will be funded through assessments per covered enrollee upon the commercial health insurance market and sponsors of self-funded health benefit plans of approximately \$12.0 billion, \$8.0 billion and \$5.0 billion in 2014, 2015 and 2016, respectively. The final premium stabilization program is the temporary risk corridors program, also a three year program through 2016, that protects insurers from inaccurate pricing of individual and small group qualified health plans and substantially similar off-exchange products.

Beginning in 2014, MLR rebate calculations will be adjusted to reflect the Health Care Reform Premium Stabilization Programs. To determine an insurer's MLR, the numerator of the MLR will be reduced by receipts from the risk adjustment, reinsurance, and risk corridors programs, or increased by payments from the risk adjustment and risk corridors programs. The denominator of the MLR formula will be reduced by reinsurance contributions. This adjusted insurer-specific MLR will then be compared to the minimum MLR threshold for each line of business. The Health Care Reform Premium Stabilization Programs are not applicable to Large Group business.

- Through December 31, 2013 and depending on the laws in each state, health insurers were allowed to consider factors such as health status, gender and age in determining the appropriate premium for products in the individual and small group markets. Some states have adopted rules that limit the variation between the highest and lowest premium for the identical insurance policy. The differential in pricing is commonly referred to as "rating bands". The process of using these rating bands allows health insurers to appropriately price for products and to spread the risk more broadly across all policyholders. Except for policies issued under the CMS transitional policy, beginning in 2014, ACA precludes health insurers from using health status and gender in the determination of the appropriate insurance premium. In addition, rating bands for age cannot vary by more than 3 to 1 and the rating bands for tobacco use cannot vary by more than 1.5 to 1. This change will likely have a significant impact on the majority of individual and small group customers and could lead to adverse selection in the market.
- In 2014 significant new taxes and fees will be paid by health insurers, some of which may or may not be passed through to customers. The most significant of the taxes and fees is the annual fee on health insurance companies. For 2014, a total of \$8.0 billion will be collected from all health insurance companies to which the annual fee is assessed. The annual fee is \$11.3 billion for 2015 and 2016, \$13.9 billion for 2017 and \$14.3 billion for 2018. For 2019 and beyond, the annual fee will equal the amount for the preceding year increased by the rate of premium growth for the preceding year. The annual fee will be allocated to health insurers based on the ratio of the amount of an insurer's net premium revenues written during the preceding calendar year to the amount of health insurance for all U.S. health risk for those certain lines of business during the preceding calendar year.
- Medicare Advantage reimbursement rates will not increase as much as they would otherwise due to a new payment formula promulgated by ACA that is expected to significantly reduce reimbursements in the future. We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including the Medicare Advantage MLR, evolving methodology for ratings and quality bonus payments and potential action on an audit methodology to review data submitted under "risk adjuster" programs.

In June 2012, the U.S. Supreme Court issued a decision affirming that the majority of the provisions of the ACA were constitutional. However, the provision of the ACA related to the mandatory expansion of state Medicaid programs was declared unconstitutional. Several cases pertaining to the constitutionality of the contraceptive mandate are currently pending before the U.S. Supreme Court and will likely be heard and decided during the coming year. Other pending cases pertain to challenges to the premium tax subsidies and whether the subsidies are available for eligible residents in all states or only those residents in states which have established state-based exchanges. In January 2014, the D.C. District Court upheld the subsidies for both state-based and federal exchanges and an appeal is anticipated.

#### Dodd-Frank Wall Street Reform and Consumer Protection Act

During 2010, the U.S. Congress passed and the President signed into law the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act. The Dodd-Frank Act represents a far-reaching overhaul of the framework for the U.S. financial services industry. Even though we are primarily a health benefits company, our business has been impacted by the Dodd-Frank Act. Many of its provisions require the adoption of rules for implementation, including those that govern which non-bank financial companies may become subject to the oversight of the Federal Reserve. These non-bank financial companies are defined as those that could pose a threat to the economy's financial stability either due to the

potential of material financial distress at the company or due to the company's ongoing activities. While we are not currently considered a non-bank financial company for purposes of Federal Reserve oversight, future regulations or interpretations could change that result. Further, our investments in derivative instruments are subject to new rules regarding the reporting and clearing of transactions and new margin requirements.

In addition, the Dodd-Frank Act creates a Federal Insurance Office, with limited powers that include information-gathering and subpoena authority. Although the Federal Insurance Office does not have authority over health insurance, it may have authority over other parts of our business, such as life insurance.

#### HIPAA and Gramm-Leach-Bliley Act

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes obligations for issuers of health insurance coverage and health benefit plan sponsors. This law requires guaranteed renewability of health care coverage for most group health plans and certain individuals. Also, the law limits exclusions based on preexisting medical conditions.

The administrative simplification provisions of HIPAA imposed a number of requirements on covered entities (including insurers, HMOs, group health plans, providers and clearinghouses). These requirements include uniform standards of common electronic health care transactions; privacy and security regulations; and unique identifier rules for employers, health plans and providers. Additional federal privacy and security requirements, including breach notification, improved enforcement and additional limitations on use and disclosure of protected health information were passed through the Health Information Technology for Economic and Clinical Health, or HITECH, Act provisions of the American Recovery and Reinvestment Act of 2009 and corresponding implementing regulations. CMS posted the Interim Final Rule with Comment, or IFC, adopting operating rules for two electronic transactions: eligibility for a health plan and health care claims status. Based on the comments received on the IFC, CMS has decided not to change any of the policies established in the rule. Thus, the interim final rule became the final rule. The rule had a January 1, 2013 compliance date and we believe we have effectively complied with the requirements of the new rule.

In addition, there are proposed regulations on the HIPAA Privacy Accounting of Disclosures provisions and the HIPAA Security Rule that will greatly increase our administrative costs if they are enacted as proposed.

The federal Gramm-Leach-Bliley Act generally places restrictions on the disclosure of non-public information to non-affiliated third parties, and requires financial institutions, including insurers, to provide customers with notice regarding how their non-public personal information is used, including an opportunity to "opt out" of certain disclosures. State departments of insurance and certain federal agencies adopted implementing regulations as required by federal law. In addition, a number of states have adopted data security laws and/or regulations, regulating data security and/or requiring security breach notification, which may apply to us in certain circumstances.

#### Employee Retirement Income Security Act of 1974

The provision of services to certain employee welfare benefit plans is subject to the Employee Retirement Income Security Act of 1974, as amended, or ERISA, a complex set of laws and regulations subject to interpretation and enforcement by the Internal Revenue Service and the Department of Labor. ERISA regulates certain aspects of the relationships between us, the employers that maintain employee welfare benefit plans subject to ERISA and participants in such plans. Some of our administrative services and other activities may also be subject to regulation under ERISA. In addition, certain states require licensure or registration of companies providing third party claims administration services for benefit plans. We provide a variety of products and services to employee welfare benefit plans that are covered by ERISA. Plans subject to ERISA can also be subject to state laws and the question of whether and to what extent ERISA preempts a state law has been, and will continue to be, interpreted by many courts.

#### HMO and Insurance Holding Company Laws, including Risk-Based Capital Requirements

We are regulated as an insurance holding company and are subject to the insurance holding company acts of the states in which our insurance company and HMO subsidiaries are domiciled. These acts contain certain reporting requirements as well as restrictions on transactions between an insurer or HMO and its affiliates. These holding company laws and regulations generally require insurance companies and HMOs within an insurance holding company system to register with the insurance department of each state where they are domiciled and to file with those states' insurance departments certain reports

describing capital structure, ownership, financial condition, certain intercompany transactions and general business operations. In addition, various notice and reporting requirements generally apply to transactions between insurance companies and HMOs and their affiliates within an insurance holding company system, depending on the size and nature of the transactions. Some insurance holding company laws and regulations require prior regulatory approval or, in certain circumstances, prior notice of certain material intercompany transfers of assets as well as certain transactions between insurance companies, HMOs, their parent holding companies and affiliates. Among other provisions, state insurance and HMO laws may restrict the ability of our regulated subsidiaries to pay dividends.

Additionally, the holding company acts of the states in which our subsidiaries are domiciled restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Under those statutes, without such approval (or an exemption), no person may acquire any voting security of an insurance holding company, which controls an insurance company or HMO, or merge with such a holding company, if as a result of such transaction such person would "control" the insurance holding company. "Control" is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or controls 10% or more of the voting securities of another person.

The states of domicile of our regulated subsidiaries have statutory risk-based capital, or RBC, requirements for health and other insurance companies and HMOs based on the RBC Model Act. These RBC requirements are intended to assess the capital adequacy of life and health insurers and HMOs, taking into account the risk characteristics of a company's investments and products. In general, under these laws, an insurance company or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile for each calendar year. The law requires increasing degrees of regulatory oversight and intervention as a company's RBC declines. As of December 31, 2013, the RBC levels of our insurance and HMO subsidiaries exceeded all RBC thresholds.

#### Guaranty Fund Assessments

Under insolvency or guaranty association laws in most states, insurance companies can be assessed for amounts paid by guaranty funds for policyholder losses incurred when an insurance company becomes insolvent. Most state insolvency or guaranty association laws currently provide for assessments based upon the amount of premiums received on insurance underwritten within such state (with a minimum amount payable even if no premium is received). Under many of these guaranty association laws, assessments against insurance companies that issue policies of accident or sickness insurance are made retrospectively. Some states permit insurers to recover assessments paid through full or partial premium tax offsets or through future policyholder assessments.

States' adoption of the revised NAIC Model Guaranty Fund Act will tend to decrease our liability for insolvent insurers. The revised act reduces the premium base on which assessments are calculated, by omitting Medicare Parts C and D premium from the assessment base.

While the amount and timing of any future assessments cannot be predicted with certainty, we believe that future guaranty association assessments for insurer insolvencies will not have a material adverse effect on our liquidity and capital resources with the exception of potential exposure related to the Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company insolvency as discussed in Note 14, "Commitments and Contingencies", to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### **Employees**

At December 31, 2013, we had approximately 48,200 employees. Our employees are an important asset, and we seek to develop them to their full potential. We believe that our relationship with our employees is good.

#### **Available Information**

We are a large accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or Exchange Act) and are required, pursuant to Item 101 of Regulation S-K, to provide certain information regarding our website and the availability of certain documents filed with or furnished to the U.S. Securities and Exchange Commission, or SEC. Our Internet website is <a href="www.wellpoint.com">www.wellpoint.com</a>. We have included our Internet website address throughout this Annual Report on Form 10-K as textual reference only. The information contained on our Internet website is not incorporated into

this Annual Report on Form 10-K. We make available, free of charge, by mail or through our Internet website, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15 (d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or furnish it to the SEC. We also include on our Internet website our Corporate Governance Guidelines, our Standards of Ethical Business Conduct and the charter of each standing committee of our Board of Directors. In addition, we intend to disclose on our Internet website any amendments to, or waivers from, our Standards of Ethical Business Conduct that are required to be publicly disclosed pursuant to rules of the SEC and the New York Stock Exchange, or NYSE. WellPoint, Inc. is an Indiana corporation incorporated on July 17, 2001.

#### ITEM 1A. RISK FACTORS.

The following factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this Annual Report on Form 10-K and presented elsewhere by management from time to time. Such factors, among others, may have a material adverse effect on our business, financial condition, and results of operations and you should carefully consider them. It is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete statement of all our potential risks or uncertainties. Because of these and other factors, past performance should not be considered an indication of future performance.

Federal Health Care Reform legislation, together with the changes in federal and state regulations that have been enacted to implement Health Care Reform, could adversely affect our business, cash flows, financial condition and results of operations.

The passage of Health Care Reform during 2010 and subsequent regulations represent significant changes to the U.S. health care system. The legislation is far-reaching and is intended to expand access to health insurance coverage over time by increasing the eligibility thresholds for most state Medicaid programs and providing certain other individuals and small businesses with tax credits to subsidize a portion of the cost of health insurance coverage. The legislation includes a requirement that most individuals obtain health insurance coverage beginning in 2014. In addition, the new laws impose significant fees, assessments and taxes on us and other health insurers, health plans and other industry participants. Health Care Reform imposes an annual industry-wide \$8.0 billion health insurer fee beginning in 2014 and growing to \$14.3 billion by 2018 and increasing annually thereafter. This health insurance fee is not deductible for income tax purposes and will be allocated pro rata among us and other industry participants based on net premiums written. Health Care Reform also imposes industry-wide reinsurance assessments of \$12.0 billion, \$8.0 billion and \$5.0 billion in 2014, 2015 and 2016, respectively. Insurance companies will pay the fees based upon insured members whereas self-insured entities will pay them directly to HHS. As we are one of the nation's largest health benefits companies, we expect our share of the Health Care Reform fees, assessments and taxes to be significant. There is some uncertainty whether we will be able to include all or a portion of these fees, assessments and taxes in our premium rates.

Health Care Reform also imposes new regulations on the health insurance sector, including, but not limited to, guaranteed coverage and expanded benefit requirements, prohibitions on some annual and all lifetime limits on amounts paid on behalf of or to our members, increased restrictions on rescinding coverage, establishment of minimum MLR and customer rebate requirements, creation of a federal rate review process, a requirement to cover preventive services on a first dollar basis, the establishment of insurance exchanges and essential benefit packages and greater limitations on how we price certain of our products. The legislation also reduces the reimbursement levels for our health plans participating in the Medicare Advantage program over time. There are also limitations on the amount of compensation that is deductible for income tax purposes.

The legislation also contains risk adjustment provisions applicable to the individual and small group markets that take effect in 2014. These risk adjustment provisions will effectively transfer funds from health plans with relatively lower risk enrollees to plans with relatively higher risk enrollees to help protect against adverse selection. Effectively adapting to these risk adjustment provisions may require us to modify our operational and strategic initiatives to focus on and manage different populations of potential members than we have in the past. If we are not able to successfully design and implement operational and strategic initiatives to adapt to these changes in certain of our markets, our financial condition and results of operations may be adversely affected.

Some of the provisions of Health Care Reform became effective immediately upon enactment, while most of the other provisions became effective in January 2014, with the remaining provisions to be phased in over the next several years. These

changes could impact us through potential disruption to the employer-based market, potential cost shifting in the health care delivery system to insurance companies and limitations on the ability to increase premiums to meet costs. We have dedicated, and will continue to dedicate, material resources and incurred, and will continue to incur, material expenses to implement and comply with Health Care Reform at both the state and federal levels, including implementing and complying with future regulations that provide guidance on and clarification of significant portions of the legislation. The Health Care Reform law and regulations are likely to have significant effects on our future operations, which, in turn, could impact the value of our business model and results of operations, including potential impairments of our goodwill and other intangible assets. Difficulties and delays with regard to implementation of provisions of Health Care Reform at the end of 2013, including with regard to the functionality of the federal and state health insurance exchanges and the lack of full cooperation and coordination between federal and state authorities as to implementation of Health Care Reform, have increased uncertainties and made our planning relating to Health Care Reform more difficult and unpredictable, which increases the risk that we will experience unanticipated adverse consequences arising out of Heath Care Reform.

Finally, federal and state regulatory agencies may further restrict our ability to obtain new product approvals, implement changes in premium rates or impose additional restrictions, under new or existing laws that could adversely affect our business, cash flows, financial condition and results of operations.

## Changes in the regulation of our business by state and federal regulators may adversely affect our business, cash flows, financial condition and results of operations.

Our insurance, managed health care and HMO subsidiaries are subject to extensive regulation and supervision by the insurance, managed health care or HMO regulatory authorities of each state in which they are licensed or authorized to do business, as well as to regulation by federal and local agencies. We cannot assure that future regulatory action by state insurance or HMO authorities or federal regulatory authorities will not have a material adverse effect on the profitability or marketability of our health benefits or managed care products or on our business, financial condition and results of operations. In addition, because of our participation in government-sponsored programs such as Medicare and Medicaid, a number of our subsidiaries are also subject to regulation by CMS and state Medicaid agencies, and to changes in government regulations or policy with respect to, among other things, reimbursement levels, eligibility requirements and additional governmental participation which could also adversely affect our business, financial condition and results of operations. In addition, we cannot ensure that application of the federal and/or state tax regulatory regime that currently applies to us will not, or future tax regulation by either federal and/or state governmental authorities concerning us could not, have a material adverse effect on our business, operations or financial condition.

State legislatures will continue to focus on health care delivery and financing issues. Most states are very focused on how to manage and reduce their budgets and are exploring ways to mitigate costs. As such, some states have acted to reduce or limit increases to premium payments. Others have enacted, or are contemplating enacting, significant reform of their health insurance markets to include provisions affecting both public programs and privately-financed health insurance arrangements. We cannot assure you that, if enacted into law, these proposals would not have a negative impact on our business, operations or financial condition. In addition, California has enacted legislation to establish minimum benefit expense ratio thresholds and continues to consider legislative proposals to require prior regulatory approval of premium rate increases. California also has a November 2014 ballot initiative requiring prior regulatory approval of rate increases for the individual and small group products, which, if passed, could prevent us from securing necessary rate and benefit changes. If enacted, these state proposals could have a material adverse impact on our business, cash flows, financial condition or results of operations.

The U.S. Supreme Court has determined that significant portions of the ACA, including the provisions regarding health care exchanges, are constitutional. As a result, some states have developed their own exchanges, while other states are relying on HHS to operate the exchange in their states or are implementing partnership exchanges with the Federal government. These multiple exchange options have led to increased uncertainties and made our planning for these health insurance exchanges more difficult. The Supreme Court decision also permitted states to opt out of the elements of Health Care Reform that require expansion of Medicaid coverage in January 2014 without losing their current federal Medicaid funding. A number of states, including Florida, Georgia, Indiana, Maine, Tennessee, Texas, Virginia and Wisconsin, have indicated their current decision to opt out of Medicaid expansion, at least for the present time. If states allow certain programs to expire or choose to opt out of Medicaid expansion, we could experience reduced Medicaid enrollment and reduced growth opportunities.

Additionally, from time to time, Congress has considered, or may consider in the future, various forms of managed care reform legislation which, if adopted, could fundamentally alter the treatment of coverage decisions under ERISA. There have been legislative attempts to limit ERISA's preemptive effect on state laws and litigants' ability to seek damages beyond the benefits offered under their plans. If adopted, such limitations could increase our liability exposure, could permit greater state regulation of our operations, and could expand the scope of damages, including punitive damages, litigants could be awarded. While we cannot predict if any of these initiatives will ultimately become effective or, if enacted, what their terms will be, their enactment could increase our costs, expose us to expanded liability or require us to revise the ways in which we conduct business.

Our inability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain our current provider agreements may adversely affect our business and profitability.

Our profitability depends in large part on accurately predicting health care costs and on our ability to manage future health care costs through underwriting criteria, medical management, product design and negotiation of favorable provider contracts. Last minute changes in the implementation of Health Care Reform at the end of 2013, in particular those relating to difficulties with the functionality of federal and state health insurance exchanges, may increase the likelihood that our assumptions underlying the pricing and design of our exchange products prove to be inaccurate in a way that materially adversely affects the expected profitability of those products. Government-imposed limitations on Medicare and Medicaid reimbursement have also caused the private sector to bear a greater share of increasing health care costs. Changes in health care practices, demographic characteristics, inflation, new technologies, the cost of prescription drugs, clusters of high cost cases, changes in the regulatory environment and numerous other factors affecting the cost of health care may adversely affect our ability to predict and manage health care costs, as well as our business, financial condition and results of operations. Relatively small differences between predicted and actual health care costs as a percentage of premium revenues can result in significant changes in our results of operations, particularly with respect to our products sold through the federal and state health insurance exchanges, as neither we nor our competitors have any prior experience with pricing such products or the utilization rates for medical or other covered services by members who purchase our products through such exchanges. The exchanges may increase the risk that our products will be selected by individuals who have a higher risk profile or utilization rate than the pool of participants we anticipated when we established the pricing for these exchange products. Therefore, health care benefit costs in excess of our cost projections reflected in our exchange product pricing cannot be recovered in the current premium period through higher premiums; however, in certain circumstances, Federal risk adjustment mechanisms, including risk adjustment payments, risk corridors and reinsurance, could help offset health care benefit costs in excess of our projections. If it is determined that our assumptions regarding cost trends, utilization, enrollment, adverse selection, acuity and other assumptions utilized in setting our premium rates are significantly different than actual results, even with these risk adjustment mechanisms, our income statement and financial position could be adversely affected.

In addition to the challenge of managing health care costs, we face pressure to contain premium rates. Our customers may renegotiate their contracts to seek to contain their costs or may move to a competitor to obtain more favorable premiums. Further, federal and state regulatory agencies may restrict our ability to implement changes in premium rates. For example, ACA includes an annual rate review requirement to prohibit unreasonable rate increases, and beginning in 2014, our plans may be excluded from participating in the health insurance exchanges if they are deemed to have a history of "unreasonable" rate increases. Fiscal concerns regarding the continued viability of programs such as Medicare and Medicaid may cause decreasing reimbursement rates, delays in premium payments or a lack of sufficient increase in reimbursement rates for government-sponsored programs in which we participate. A limitation on our ability to increase or maintain our premium or reimbursement levels or a significant loss of membership resulting from our need to increase or maintain premium or reimbursement levels could adversely affect our business, cash flows, financial condition and results of operations.

The reserves that we establish for health insurance policy benefits and other contractual rights and benefits are based upon assumptions concerning a number of factors, including trends in health care costs, expenses, general economic conditions and other factors. To the extent the actual claims experience is less favorable than estimated based on our underlying assumptions, our incurred losses would increase and future earnings could be adversely affected.

Our profitability is dependent in part upon our ability to contract on favorable terms with hospitals, physicians and other

health care providers. The failure to maintain or to secure cost-effective health care provider contracts may result in a loss of membership or higher medical costs, which could adversely affect our business. In addition, accountable care organizations, or ACO, practice management companies, which aggregate physician practices for administrative efficiency and marketing leverage, and other organizational structures that physicians, hospitals and other care providers choose may change the way that these providers interact with us and may change the competitive landscape. Such organizations or groups of physicians may compete directly with us, which may impact our relationship with these providers or affect the way that we price our products and estimate our costs and may require us to incur costs to change our operations, and our results of operations, financial position and cash flow could be adversely affected. Further, our inability to contract with providers, or if providers attempt to use their market position to negotiate more favorable contracts or place us at a competitive disadvantage, or the inability of providers to provide adequate care, could adversely affect our business. In addition, we do not have contracts with all providers that render services to our members and, as a result, do not have a pre-established agreement about the amount of compensation those out-of-network providers will accept for the services they render, which can result in significant litigation or arbitration proceedings.

#### A significant reduction in the enrollment in our health benefits programs could have an adverse effect on our business and profitability.

A significant reduction in the number of enrollees in our health benefits programs could adversely affect our business, financial condition and results of operations. Factors that could contribute to a reduction in enrollment include: reductions in workforce by existing customers; general economic downturn that results in business failures; employers no longer offering certain health care coverage as an employee benefit or electing to offer this coverage on a voluntary, employee-funded basis; state and federal regulatory changes; failure to obtain new customers or retain existing customers; premium increases and benefit changes; our exit from a specific market; negative publicity and news coverage; implementation of federal and state exchanges and underwriting changes in 2014; and failure to attain or maintain nationally recognized accreditations.

There are various risks associated with participating in Medicaid and Medicare programs, including dependence upon government funding, compliance with government contracts and increased regulatory oversight.

We contract with various state and federal agencies, including CMS, to provide managed health care services, including Medicare Advantage plans, Medicare Supplement plans, Medicare approved prescription drug plans, Medicaid programs and CHIP. We also provide various administrative services for several other entities offering medical and/or prescription drug plans to their Medicare eligible members through our affiliated companies and we offer employer group waiver plans which provide medical and/or prescription drug coverage to retirees. We are also participating in Medicare and Medicaid dual eligible programs in several states. These programs in our Government Business segment have been the subject of recent regulatory reform initiatives, including Health Care Reform, which are still in the process of being implemented. It is difficult to predict the future impact of Health Care Reform on our Government Business segment due to Health Care Reform's complexity, gradual and delayed implementation, and possible amendment. Health Care Reform, other regulatory reform initiatives or additional changes in existing laws or regulations, or their interpretations, could have a material adverse effect on our business, financial condition and results of operations.

Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. The base premium rate paid by each state or federal agency differs depending upon a combination of various factors such as defined upper payment limits, a member's health status, age, gender, county or region, benefit mix, member eligibility category and risk scores. Future levels of Medicare and Medicaid rates may be affected by continued government efforts to contain costs and may be further affected by state and federal budgetary constraints. If the federal government or any state in which we operate were to decrease rates paid to us, or pay us less than the amount necessary to keep pace with our cost trends, it could have a material adverse effect on our business, financial condition and results of operations. Further, certain of our contracts with the states are subject to cancellation in the event of the unavailability of state funds. In addition, the various states' new Medicare and Medicaid dual eligible programs are still subject to uncertainty surrounding payment rates and other requirements, which could affect where we seek to participate in these new programs. An unexpected reduction, inadequate government funding or significantly delayed payments for these programs may adversely affect our revenues and financial results.

A portion of our premium revenue comes from CMS through our Medicare Advantage and Medicare Part D contracts. As a consequence, our Medicare Advantage and Medicare Part D plans are dependent on federal government funding levels. The

premium rates paid to Medicare plans are established based on benchmarks which are now tied to a percentage of Medicare fee for service, although the rates differ depending on a combination of factors, including upper payment limits established by CMS, a member's health profile and status, age, gender, county or region, benefit mix, member eligibility categories and risk scores. Beginning in 2014, Medicare Advantage and Medicare Part D plans will be subject to MLR rules. Continuing government efforts to contain health care related expenditures, including prescription drug cost, and other federal budgetary constraints that result in changes in the Medicare program, including changes with respect to funding, could lead to reductions in the amount of reimbursement, or other changes that could have a material adverse effect on our business, financial condition and results of operations.

Risks associated with the Medicare Advantage and Medicare Part D plans include potential uncollectability of receivables resulting from processing and/or verifying enrollment, inadequacy of underwriting assumptions, inability to receive and process correct information (including inability due to systems issues by the federal government, the applicable state government or us), uncollectability of premiums from members, increased medical or pharmaceutical costs, and the limited enrollment periods in this business. While we believe we have adequately reviewed our assumptions and estimates regarding these complex and wide-ranging programs under Medicare Parts C and D, including those related to collectability of receivables and establishment of liabilities, the actual results may be materially different than our assumptions and estimates and could have a material adverse effect on our business, financial condition and results of operations.

Our contracts with the various state governmental agencies and CMS contain certain provisions regarding data submission, provider network maintenance, quality measures, claims payment, continuity of care, call center performance and other requirements specific to state and federal program regulations. If we fail to comply with these requirements, we may be subject to fines, penalties, liquidated damages and retrospective adjustments in payments made to our health plans, that could impact our profitability. Additionally, we could be required to file a corrective plan of action with additional penalties for noncompliance, including a negative impact on future membership enrollment levels. Further, certain of our CMS and state Medicaid contracts are subject to a competitive procurement process, and if our existing contracts are not renewed or if we are not awarded new contracts as a result of this competitive procurement process, this could have a material adverse effect on our business, cash flows, financial condition and results of operations.

In addition to the contractual requirements affecting our participation in Medicaid and Medicare programs, we are also subject to various state and federal health care laws and regulations, including those directed at preventing fraud and abuse in government funded programs. Failure to comply with these laws and regulations could result in investigations or litigation, with the imposition of fines, restrictions or exclusions from program participation or the imposition of corporate integrity agreements or other agreements with a federal or state governmental agency that could adversely impact our business, cash flows, financial condition and results of operations.

Further, CMS has been conducting audits of our Medicare Advantage health plans to validate the diagnostic data and patient claims that are submitted to CMS. These audits may result in retrospective adjustments in payments made to our health plans. In addition, if we fail to report and correct errors discovered through our own auditing procedures or during a CMS audit or otherwise fail to comply with the applicable laws and regulations, we could be subject to fines, civil penalties or other sanctions which could have a material adverse effect on our ability to participate in these programs, and on our financial condition, cash flows and results of operations. The ACA also established recovery audit programs for Medicare Parts C and D. The Medicare Part D Recovery Audit Contractor, or RAC, has been auditing Medicare Part D claims and recouping overpayments since 2012, and CMS expects to award a Medicare Part C RAC contract in fiscal year 2014, which could increase the amount of audits and subsequent recoupments by the federal government.

#### Regional concentrations of our business may subject us to economic downturns in those regions.

Most of our revenues are generated in the states of California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Maryland, Missouri, Nevada, New Hampshire, New York, Ohio, Tennessee, Texas, Virginia and Wisconsin. Due to this concentration of business in these states, we are exposed to potential losses resulting from the risk of state specific or regional economic downturns impacting these states. If such negative economic conditions do not improve, we may experience a reduction in existing and new business, which could have a material adverse effect on our business, cash flows, financial condition and results of operations.

#### The health benefits industry is subject to negative publicity, which can adversely affect our business and profitability.

The health benefits industry is subject to negative publicity, which can arise from, among other things, the ongoing debate over Health Care Reform. Negative publicity may result in increased regulation and legislative review of industry practices, which may further increase our costs of doing business and adversely affect our profitability by: adversely affecting our ability to market our products and services; requiring us to change our products and services; or increasing the regulatory burdens under which we operate.

In addition, as long as we use the Blue Cross and Blue Shield names and marks in marketing our health benefits products and services, any negative publicity concerning the BCBSA or other BCBSA licensees may adversely affect us and the sale of our health benefits products and services. Any such negative publicity could adversely affect our business, cash flows, financial condition and results of operations.

#### We face competition in many of our markets and customers and brokers have flexibility in moving between competitors.

As a health benefits company, we operate in a highly competitive environment and in an industry that is currently subject to significant changes from legislative reform, business consolidations, new strategic alliances, aggressive marketing practices by other health benefits organizations and market pressures brought about by an informed and organized customer base, particularly among large employers. For example, beginning in 2014, we have started to compete for sales on insurance exchanges, which has required, and will continue to require, us to develop or acquire the tools (including social media tools) necessary to interact with the exchanges and with consumers using the exchanges, increase our focus on individual customers and improve our consumer-focused marketing, customer interfaces and product offerings. These factors have produced and will likely continue to produce significant pressures on the profitability of health benefits companies.

We are currently dependent on the non-exclusive services of independent agents and brokers in the marketing of our health care products, particularly with respect to individuals, seniors and small employer group customers. We face intense competition for the services and allegiance of these independent agents and brokers, who may also market the products of our competitors. Our relationship with our brokers and independent agents could be adversely impacted by changes in our business practices to address Health Care Reform legislation, including potential reductions in commissions and consulting fees paid to agents and brokers. We cannot ensure that we will be able to compete successfully against current and future competitors or that competitive pressures faced by us will not materially and adversely affect our business, cash flows, financial condition and results of operations.

## We face intense competition to attract and retain employees. Further, managing key executive succession and retention is critical to our success.

We are dependent on retaining existing employees, attracting additional qualified employees to meet current and future needs and achieving productivity gains from our investment in technology. We face intense competition for qualified employees, and there can be no assurance that we will be able to attract and retain such employees or that such competition among potential employers will not result in increasing salaries. An inability to retain existing employees or attract additional employees could have a material adverse effect on our business, cash flows, financial condition and results of operations.

We would be adversely affected if we fail to adequately plan for succession of our Chief Executive Officer and other senior management and retention of key executives. While we have succession plans in place for members of our senior management, and continue to review and update those plans, and we have employment arrangements with certain key executives, these plans and arrangements do not guarantee that the services of our senior executives will continue to be available to us or that we will be able to attract and retain suitable successors.

#### A change in our health care product mix may impact our profitability.

Our health care products that involve greater potential risk generally tend to be more profitable than administrative services products and those health care products where the employer groups assume the underwriting risks. Individuals and small employer groups are more likely to purchase our higher-risk health care products because such purchasers are generally unable or unwilling to bear greater liability for health care expenditures. Typically, government-sponsored programs also

involve our higher-risk health care products. It is not yet clear whether our products sold on the federal and state health insurance exchanges will be more or less profitable products. A shift of enrollees from more profitable products to less profitable products could have a material adverse effect on our financial condition and results of operations.

As a holding company, we are dependent on dividends from our subsidiaries. These dividends are necessary to pay our outstanding indebtedness. Our regulated subsidiaries are subject to state regulations, including restrictions on the payment of dividends, maintenance of minimum levels of capital and restrictions on investment portfolios.

We are a holding company whose assets include all of the outstanding shares of common stock (or other ownership interest) of our subsidiaries including our intermediate holding companies and regulated insurance and HMO subsidiaries. Our subsidiaries are separate legal entities. As a holding company, we depend on dividends from our subsidiaries. Furthermore, our subsidiaries are not obligated to make funds available to us, and creditors of our subsidiaries will have a superior claim to certain of our subsidiaries' assets. Among other restrictions, state insurance and HMO laws may restrict the ability of our regulated subsidiaries to pay dividends. In some states we have made special undertakings that may limit the ability of our regulated subsidiaries to pay dividends. In addition, our subsidiaries' ability to make any payments to us will also depend on their earnings, the terms of their indebtedness, business and tax considerations and other legal restrictions. Our ability to repurchase shares or pay dividends in the future to our shareholders and meet our obligations, including paying operating expenses and debt service on our outstanding and future indebtedness, will depend upon the receipt of dividends from our subsidiaries. An inability of our subsidiaries to pay dividends in the future in an amount sufficient for us to meet our financial obligations may materially adversely affect our business, cash flows, financial condition and results of operations.

Most of our regulated subsidiaries are subject to RBC standards, imposed by their states of domicile. These laws are based on the RBC Model Act adopted by the NAIC and require our regulated subsidiaries to report their results of risk-based capital calculations to the departments of insurance and the NAIC. Failure to maintain the minimum RBC standards could subject our regulated subsidiaries to corrective action, including state supervision or liquidation. Our regulated subsidiaries are currently in compliance with the risk-based capital or other similar requirements imposed by their respective states of domicile. As discussed in more detail below, we are a party to license agreements with the BCBSA which contain certain requirements and restrictions regarding our operations, including minimum capital and liquidity requirements, which could restrict the ability of our regulated subsidiaries to pay dividends.

Our regulated subsidiaries are subject to state laws and regulations that require diversification of our investment portfolios and limit the amount of investments in certain riskier investment categories, such as below-investment-grade fixed maturity securities, mortgage loans, real estate and equity investments, which could generate higher returns on our investments. Failure to comply with these laws and regulations might cause investments exceeding regulatory limitations to be treated as non-admitted assets for purposes of measuring statutory surplus and risk-based capital, and, in some instances, require the sale of those investments.

We have substantial indebtedness outstanding and may incur additional indebtedness in the future. Such indebtedness could also adversely affect our ability to pursue desirable business opportunities.

Our debt service obligations require us to use a portion of our cash flow to pay interest and principal on debt instead of for other corporate purposes, including funding future expansion. If our cash flow and capital resources are insufficient to service our debt obligations, we may be forced to seek extraordinary dividends from our subsidiaries, sell assets, seek additional equity or debt capital or restructure our debt. However, these measures might be unsuccessful or inadequate in permitting us to meet scheduled debt service obligations.

We may also incur future debt obligations that might subject us to restrictive covenants that could affect our financial and operational flexibility. Our breach or failure to comply with any of these covenants could result in a default under our credit agreement. If we default under our credit agreement, the lenders could cease to make further extensions of credit or cause all of our outstanding debt obligations under our credit agreement to become immediately due and payable, together with accrued and unpaid interest. If the indebtedness under our notes or our credit agreement is accelerated, we may be unable to repay or finance the amounts due. Indebtedness could also limit our ability to pursue desirable business opportunities, and may affect our ability to maintain an investment grade rating for our indebtedness.

#### A downgrade in our credit ratings could have an adverse effect on our business, financial condition and results of operations.

Claims-paying ability and financial strength ratings by nationally recognized statistical rating organizations are an important factor in establishing the competitive position of insurance companies and health benefits companies. Each of the credit rating agencies reviews its ratings periodically and there can be no assurance that our current credit ratings will be maintained in the future. We believe our strong credit ratings are an important factor in marketing our products to customers, since credit ratings information is broadly disseminated and generally used throughout the industry. If our credit ratings are downgraded or placed under review, with possible negative implications, such actions could adversely affect our business, financial condition and results of operations. These credit ratings reflect each credit rating agency's opinion of our financial strength, operating performance and ability to meet our obligations to policyholders and creditors, and are not evaluations directed toward the protection of investors in our common stock.

#### We face risks related to litigation.

We are, or may in the future, be a party to a variety of legal actions that affect any business, such as employment and employment discrimination-related suits and administrative charges before government agencies, employee benefit claims, breach of contract actions, tort claims and intellectual property-related litigation. In addition, because of the nature of our business, we are subject to a variety of legal actions relating to our business operations, including the design, management and offering of our products and services. These could include claims relating to the denial of health care benefits; the rescission of health insurance policies; development or application of medical policy; medical malpractice actions; product liability claims; allegations of anti-competitive and unfair business activities; provider disputes over compensation; provider tiering programs; termination of provider contracts; the recovery of overpayments from providers; self-funded business; disputes over co-payment calculations; reimbursement of out-of-network claims; the failure to disclose certain business or corporate governance practices; the failure to comply with various state or federal laws, including but not limited to, ERISA and the Mental Health Parity Act; and customer audits and contract performance, including government contracts. These actions or proceedings could have a material adverse effect on our business, cash flows, financial condition and results of operations.

In addition, we are also involved in, or may in the future be party to, pending or threatened litigation of the character incidental to the business transacted, arising out of our operations or our 2001 demutualization, including, but not limited to, breaches of security and violations of privacy requirements, shareholder actions, compliance with federal and state laws and regulations (including *qui tam* or "whistleblower" actions), or sales and acquisitions of businesses or assets, and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings, including challenges to the award of government contracts by disappointed bidders. These investigations, audits and reviews include routine and special investigations by various state insurance departments, state attorneys general and the U.S. Attorney General. Such investigations could result in the imposition of civil or criminal fines, penalties and other sanctions. Liabilities that may result from these actions could have a material adverse effect on our cash flows, results of operations or financial position.

Recent court decisions and legislative activity may increase our exposure for any of these types of claims. In some cases, substantial non-economic (including injunctive relief), treble or punitive damages may be sought. We currently have insurance coverage for some of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be enough to cover the damages awarded. In addition, certain types of damages, such as punitive damages, may not be covered by insurance, and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. Any adverse judgment against us resulting in such damage awards could have an adverse effect on our cash flows, results of operations and financial condition.

# Our future obligations for state guaranty association assessments could increase in the event that Health Care Reform and its implementation result in increased insolvencies of health plans.

Under insolvency or guaranty association laws in most states, insurance companies can be assessed for amounts paid by guaranty funds for policyholder losses incurred when an insurance company becomes insolvent. Most state insolvency or guaranty association laws provide for assessments based upon the amount of premiums received on insurance underwritten within such state. While in the past, health insurance company insolvencies have been infrequent, the changes to the U.S. health care system and markets and related uncertainties from implementation of Health Care Reform may result in increased

insolvencies of health insurance companies covered by these state insolvency or guaranty association laws. In that event, we may experience increased guaranty association assessments for health insurer insolvencies, the amount and timing of which cannot be predicted with certainty.

#### There are various risks associated with providing health care services.

The direct provision of health care services by our CareMore subsidiary involves risks of additional litigation arising from medical malpractice actions based on our treatment decisions or brought against us or our physician associates for alleged malpractice or professional liability claims arising out of the delivery of health care and related services. In addition, liability may arise from maintaining health care premises that serve the public. If we fail to maintain adequate insurance coverage for these liabilities, or if such insurance is not available, the resulting costs could adversely affect our cash flows, financial condition or results of operations.

Additionally, many states in which we operate our CareMore subsidiary limit the practice of medicine to licensed individuals or professional organizations comprised of licensed individuals. Business corporations generally may not exercise control over the medical decisions of physicians ("corporate practice of medicine") and we are not licensed to practice medicine. Rules and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources, and similar issues vary from state to state. Further, certain federal and state laws, including those covering our Medicare and Medicaid plans, prohibit the offer, payment, solicitation, or receipt of any form of remuneration to induce, or in return for, the referral of patient care opportunities, including, but not limited to, Medicare patients ("anti-kickback rules"), and also generally prohibit physicians from making referrals to any entity providing certain designated health services if the referring physician or related person has an ownership or financial interest in the entity ("self-referral rules").

We believe that our health care service operations comply with applicable rules and regulations regarding the corporate practice of medicine, fee-splitting, anti-kickback, self-referral and similar issues. However, any enforcement actions by governmental officials alleging non-compliance with these rules and regulations could adversely affect our business, cash flows, financial condition or results of operations.

We are a party to license agreements with the BCBSA that entitle us to the exclusive and in certain areas non-exclusive use of the Blue Cross and Blue Shield names and marks in our geographic territories. The termination of these license agreements or changes in the terms and conditions of these license agreements could adversely affect our business, financial condition and results of operations.

We use the Blue Cross and Blue Shield names and marks as identifiers for our products and services under licenses from the BCBSA. Our license agreements with the BCBSA contain certain requirements and restrictions regarding our operations and our use of the Blue Cross and Blue Shield names and marks, including: minimum capital and liquidity requirements imposed by the BCBSA; enrollment and customer service performance requirements; participation in programs that provide portability of membership between plans; disclosures to the BCBSA relating to enrollment and financial conditions; disclosures as to the structure of the Blue Cross and Blue Shield system in contracts with third parties and in public statements; plan governance requirements; a requirement that at least 80% (or, in the case of Blue Cross of California, substantially all) of a licensee's annual combined local net revenue, as defined by the BCBSA, attributable to health care plans and related services within its service areas must be sold, marketed, administered or underwritten under the Blue Cross and Blue Shield names and marks; a requirement that at least 66 2/3% of a licensee's annual combined national net revenue, as defined by the BCBSA, attributable to health care plans and related services must be sold, marketed, administered or underwritten under the Blue Cross and Blue Shield names and marks; a requirement that neither a plan nor any of its licensed affiliates may permit an entity other than a plan or a licensed affiliate to obtain control of the plan or the licensed affiliate or to acquire a substantial portion of its assets related to licensable services; a requirement that we divide our Board of Directors into three classes serving staggered three-year terms; a requirement that we guarantee certain contractual and financial obligations of our licensed affiliates; and a requirement that we indemnify the BCBSA against any claims asserted against it resulting from the contractual and financial obligations of any subsidiary that serves as a fiscal intermediary providing administrative services for Medicare Parts A and B. Failure to comply with the foregoing requirements could result in a termination of the license agreements.

The standards under the license agreements may be modified in certain instances by the BCBSA. For example, from time to time there have been proposals considered by the BCBSA to modify the terms of the license agreements to restrict various potential business activities of licensees. These proposals have included, among other things, a limitation on the ability of a

licensee to make its provider networks available to insurance carriers or other entities not holding a Blue Cross or Blue Shield license. To the extent that such amendments to the license agreements are adopted in the future, they could have a material adverse effect on our future expansion plans or results of operations. Further, BCBS licensees have certain requirements to perform administrative services for members of other BCBS licensees. If we or another BCBS licensee is not in compliance with all legal requirements or are unable to perform administrative services as required, this could have an adverse effect on our members and our ability to maintain our licenses, which could have a material adverse effect on our business, cash flows, financial condition and results of operations.

Upon the occurrence of an event causing termination of the license agreements, we would no longer have the right to use the Blue Cross and Blue Shield names and marks in one or more of our service areas. Furthermore, the BCBSA would be free to issue a license to use the Blue Cross and Blue Shield names and marks in these service areas to another entity. Events that could cause the termination of a license agreement with the BCBSA include failure to comply with minimum capital requirements imposed by the BCBSA, a change of control or violation of the BCBSA ownership limitations on our capital stock, impending financial insolvency and the appointment of a trustee or receiver or the commencement of any action against a licensee seeking its dissolution. We believe that the Blue Cross and Blue Shield names and marks are valuable identifiers of our products and services in the marketplace. Accordingly, termination of the license agreements could have a material adverse effect on our business, financial condition and results of operations.

Upon termination of a license agreement, the BCBSA would impose a "Re-establishment Fee" upon us, which would allow the BCBSA to "re-establish" a Blue Cross and/or Blue Shield license in the vacated service area. The fee is set at \$98.33 per licensed enrollee. As of December 31, 2013 we reported 26.6 million Blue Cross and/or Blue Shield enrollees. If the Re-establishment Fee was applied to our total Blue Cross and/or Blue Shield enrollees, we would be assessed approximately \$2.6 billion by the BCBSA.

## Large-scale medical emergencies may have a material adverse effect on our business, cash flows, financial condition and results of operations.

Large-scale medical emergencies can take many forms and can cause widespread illness and death. For example, federal and state law enforcement officials have issued warnings about potential terrorist activity involving biological and other weapons. In addition, natural disasters such as hurricanes and the potential for a wide-spread pandemic of influenza coupled with the lack of availability of appropriate preventative medicines can have a significant impact on the health of the population of wide-spread areas. If the United States were to experience widespread bioterrorism or other attacks, large-scale natural disasters in our concentrated coverage areas or a large-scale pandemic or epidemic, our covered medical expenses could rise and we could experience a material adverse effect on our business, cash flows, financial condition and results of operations or, in the event of extreme circumstances, our viability could be threatened.

## We have built a significant portion of our current business through mergers and acquisitions, joint ventures and strategic alliances and we expect to pursue such opportunities in the future.

The following are some of the risks associated with mergers and acquisitions, joint ventures and strategic alliances (collectively, "business combinations") that could have a material adverse effect on our business, financial condition and results of operations:

- some of the acquired businesses may not achieve anticipated revenues, earnings or cash flow, business opportunities, synergies, growth prospects and other anticipated benefits;
- the goodwill or other intangible assets established as a result of our business combinations may be incorrectly valued or become non-recoverable;
- · we may assume liabilities that were not disclosed to us or which were under-estimated;
- we may experience difficulties in integrating acquired businesses, be unable to integrate acquired businesses successfully or as quickly as expected, and be unable to realize anticipated economic, operational and other benefits in a timely manner, which could result in substantial costs and delays or other operational, technical or financial problems;
- business combinations could disrupt our ongoing business, distract management, result in the loss of key employees, divert resources, result in tax costs or inefficiencies and make it difficult to maintain our current business standards,

controls, information technology systems, policies and procedures;

- we may finance future business combinations by issuing common stock for some or all of the purchase price, which could dilute the ownership interests of our shareholders;
- we may also incur additional debt related to future business combinations; and
- we would be competing with other firms, some of which may have greater financial and other resources, to acquire attractive companies.

#### The value of our intangible assets may become impaired.

Due largely to our past mergers, acquisitions and divestitures, goodwill and other intangible assets represent a substantial portion of our assets. If we make additional acquisitions it is likely that we will record additional intangible assets on our consolidated balance sheets.

In accordance with applicable accounting standards, we periodically evaluate our goodwill and other intangible assets to determine whether all or a portion of their carrying values may no longer be recoverable, in which case a charge to income may be necessary. This impairment testing requires us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets (with indefinite lives). In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately. Estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used. If estimated fair values are less than the carrying values of goodwill and other intangible assets with indefinite lives in future impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

Any future evaluations requiring an impairment of our goodwill and other intangible assets could materially affect our results of operations and shareholders' equity in the period in which the impairment occurs. A material decrease in shareholders' equity could, in turn, negatively impact our debt ratings or potentially impact our compliance with existing debt covenants.

In addition, the estimated value of our reporting units may be impacted as a result of business decisions we make associated with the implementation of the various Health Care Reform regulations. Such decisions, which could unfavorably affect our ability to support the carrying value of certain goodwill and other intangible assets, could result in impairment charges in future periods.

#### Adverse securities and credit market conditions may significantly affect our ability to meet liquidity needs.

The securities and credit markets have in the past experienced higher than normal volatility, although current market conditions are more stable. In some cases, the markets have exerted downward pressure on availability of liquidity and credit capacity for certain issuers. We need liquidity to pay our operating expenses, make payments on our indebtedness and pay capital expenditures. The principal sources of our cash receipts are premiums, administrative fees, investment income, other revenue, proceeds from the sale or maturity of our investment securities, proceeds from borrowings and proceeds from the exercise of stock options.

Our access to additional financing will depend on a variety of factors such as market conditions, the general availability of credit, the volume of trading activities, the overall availability of credit to our industry, our credit ratings and credit capacity, as well as the possibility that customers or lenders could develop a negative perception of our long- or short-term financial prospects. Similarly, our access to funds may be impaired if regulatory authorities or rating agencies take negative actions against us. If one or a combination of these factors were to occur, our internal sources of liquidity may prove to be insufficient, and in such case, we may not be able to successfully obtain additional financing on favorable terms. One of our sources of liquidity is our \$2,500.0 million commercial paper program under which we had only \$379.2 outstanding at December 31, 2013. Should commercial paper issuance be unavailable, we intend to use a combination of cash on hand and/or our \$2,000.0 million senior revolving credit facility to redeem our commercial paper when it matures. We believe the lenders participating in our senior credit facility will be willing and able to provide financing in accordance with their legal obligations.

The value of our investments is influenced by varying economic and market conditions, and a decrease in value may result in a loss charged to income.

The market values of our investments vary from time to time depending on economic and market conditions. For various reasons, we may sell certain of our investments at prices that are less than the carrying value of the investments. In addition, in periods of declining interest rates, bond calls and mortgage loan prepayments generally increase, resulting in the reinvestment of these funds at the then lower market rates. In periods of rising interest rates, the market values of our fixed maturity securities will generally decrease, which could result in material unrealized or realized losses on investments in future periods. In addition, defaults by issuers, primarily from investments in corporate and municipal bonds, who fail to pay or perform their obligations, could reduce net investment income, which would adversely affect our profitability. We cannot assure you that our investment portfolios will produce positive returns in future periods.

In accordance with FASB guidance for debt and equity investments, we classify fixed maturity and equity securities in our investment portfolio as "available-for-sale" or "trading" and report those securities at fair value. Current and long-term available-for-sale investment securities represented a significant percentage of our total consolidated assets at December 31, 2013. Also, in accordance with applicable FASB accounting guidance, we review our investment securities to determine if declines in fair value below cost are other-than-temporary. This review is subjective and requires a high degree of judgment. We conduct this review on a quarterly basis analyzing both quantitative and qualitative factors. Such factors considered include the length of time and the extent to which market value has been less than cost, financial condition and near term prospects of the issuer, recommendations of investment advisors and forecasts of economic, market or industry trends.

Changes in the economic environment, including periods of increased volatility of the securities markets, can increase the difficulty of assessing investment impairment and the same influences tend to increase the risk of potential impairment of these assets. We believe we have adequately reviewed our investment securities for impairment and we believe that we have appropriately estimated the fair values of our investment securities. However, over time, the economic and market environment may provide additional insight, which could change our judgment regarding the fair value of certain securities and/or impairment. Given the sometimes rapidly changing market conditions and the significant judgments involved, there is continuing risk that further declines in fair value may occur and material other-than-temporary impairments may be charged to income in future periods, resulting in realized losses.

#### We may not be able to realize the value of our deferred tax assets.

In accordance with applicable accounting standards, we separately recognize deferred tax assets and deferred tax liabilities. Such deferred tax assets and deferred tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at tax rates enacted at the time the deferred tax asset or liability is recorded.

At each financial reporting date, we evaluate our deferred tax assets to determine the likely realization of the benefit of the temporary differences. Our evaluation includes a review of the types of temporary differences that created the deferred tax asset; the amount of taxes paid on both capital gains and ordinary income in prior periods and available for a carry-back claim; the forecasted future taxable income, and therefore, the likely future deduction of the deferred tax item; and any other significant issues that might impact the realization of the deferred tax asset. If it is "more likely than not" that all or a portion of the deferred tax asset may not be realized, we establish a valuation allowance. Significant judgment is required in determining an appropriate valuation allowance.

Any future increase in the valuation allowance would result in additional income tax expense and a decrease in shareholders' equity, which could materially affect our financial position and results of operations in the period in which the increase occurs. A material decrease in shareholders' equity could, in turn, negatively impact our debt ratings or potentially impact our compliance with existing debt covenants.

An unauthorized disclosure of sensitive or confidential member information could have an adverse effect on our business, reputation and profitability.

As part of our normal operations, we collect, process and retain sensitive and confidential member information. We are subject to various federal, state and international laws and rules regarding the use and disclosure of sensitive or confidential

member and provider information, including HIPAA, the HITECH Act, the Gramm-Leach-Bliley Act, and numerous state laws governing personal information. Despite the security measures we have in place to help ensure compliance with applicable laws and rules, our facilities and systems, and those of our third party service providers, are vulnerable to cyber-attacks, security breaches, acts of vandalism, computer viruses, misplaced or lost data, programming and/or human errors or other similar events. Noncompliance with any privacy or security laws and regulations, or any security breach, cyber-attack or cyber security breach, and any incident involving the misappropriation, loss or other unauthorized disclosure of, or access to, sensitive or confidential member information, whether by us or by one of our vendors, could require us to expend significant resources to remediate any damage, interrupt our operations and damage our reputation, and could also result in regulatory enforcement actions, material fines and penalties, litigation or other actions which could have a material adverse effect on our business, reputation and results of operations.

#### The failure to effectively maintain and upgrade our information systems could adversely affect our business.

Our business depends significantly on effective information systems, and we have many different information systems for our various businesses. As a result of our merger and acquisition activities, we have acquired additional systems. Our information systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in information processing technology, emerging cyber security risks and threats, evolving industry and regulatory standards including the minimum MLR rebates, exchanges and other aspects of Health Care Reform, compliance with legal requirements (such as a new set of standardized diagnostic codes, known as ICD-10), private insurance exchanges and changing customer preferences. In addition, we may from time to time obtain significant portions of our systems-related or other services or facilities from independent third parties, which may make our operations vulnerable to such third parties' failure to perform adequately.

Our failure to maintain effective and efficient information systems, or our failure to efficiently and effectively consolidate our information systems to eliminate redundant or obsolete applications, could have a material adverse effect on our business, financial condition and results of operations. If the information we rely upon to run our business were found to be inaccurate or unreliable or if we fail to maintain our information systems and data integrity effectively, we could have a decrease in membership, have problems in determining medical cost estimates and establishing appropriate pricing and reserves, have disputes with customers and providers, have regulatory problems, sanctions or penalties imposed, have increases in operating expenses or suffer other adverse consequences. In addition, federal regulations require that we begin using ICD-10 by October 2014, which will require significant information technology investment. If we fail to adequately implement ICD-10 or comply with the operating rules, we may incur losses with respect to the resources invested and have other material adverse effects on our business and results of operations. Also, as we convert or migrate members to our more efficient and effective systems, the risk of disruption in our customer service is increased during the migration or conversion process and such disruption could have a material adverse effect on our business, cash flow, financial condition and results of operations.

We continue to implement initiatives for more effective and efficient information technology systems by modernizing interactions with customers, brokers, agents, providers, employees and other stakeholders through web-enabling technology and redesigning internal operations. We cannot assure you that we will be able to fully implement all desired products or systems in a timely and effective manner. The failure to implement and maintain the most advanced technological capabilities could result in competitive and cost disadvantages to us as compared to our competitors.

We are dependent on the success of our relationship with a large vendor for a significant portion of our information system resources and certain other vendors for various other services.

We have an agreement with International Business Machines Corporation, or IBM, pursuant to which we outsourced a significant portion of our data center operations and certain core applications development. We are dependent upon IBM for these support functions. The IBM agreement includes service level agreements, or SLAs, related to issues such as performance and job disruption, with significant financial penalties if these SLAs are not met, as well as termination assistance provisions obligating IBM to provide services during periods following transitions or terminations. If our relationship with IBM is significantly disrupted for any reason, we may not be able to find an alternative partner in a timely manner or on acceptable financial terms. As a result, we may not be able to meet the demands of our customers and, in turn, our business, cash flows, financial condition and results of operations may be harmed. We may not be adequately indemnified

against all possible losses through the terms and conditions of the IBM agreement. In addition, some of our termination rights are contingent upon payment of a fee, which may be significant.

We are a party to an agreement with Express Scripts whereby Express Scripts is the exclusive provider of PBM services to certain of our members, excluding Amerigroup and certain self-insured members that have exclusive agreements with different PBM service providers, provided however that Amerigroup will be transitioning to the Express Scripts agreement during 2014. The Express Scripts PBM services include, but are not limited to, pharmacy network management, home delivery, pharmacy customer service, claims processing, rebate management, drug utilization and specialty pharmaceutical management services. Accordingly, the agreement contains certain financial and operational requirements obligating both Express Scripts and us. The failure of either party to meet the respective requirements could potentially serve as a basis for early termination of the contract. If this relationship was terminated for any reason, we may not be able to find alternative partners in a timely manner or on acceptable financial terms. As a result, we may not be able to meet the full demands of our customers, which could have a material adverse effect on our business, reputation and results of operations. In addition, our failure to meet certain minimum script volume requirements may result in financial penalties that could have a material adverse effect on our results of operations.

We have also entered into agreements with certain vendors pursuant to which we have outsourced certain back-office functions. If any of these vendor relationships were terminated for any reason, we may not be able to find an alternative partner in a timely manner or on acceptable financial terms. In addition, if for any reason there is a business continuity interruption resulting from loss of access to or availability of data, the physical location, technological resources and/or adequate human assets, we may not be able to meet the full demands of our customers and, in turn, our business, cash flow, financial conditions and results of operations may be unfavorably impacted.

Indiana law, and other applicable laws, and our articles of incorporation and bylaws, may prevent or discourage takeovers and business combinations that our shareholders might consider in their best interest.

Indiana law and our articles of incorporation and bylaws may delay, defer, prevent or render more difficult a takeover attempt that our shareholders might consider in their best interests. For instance, they may prevent our shareholders from receiving the benefit from any premium to the market price of our common stock offered by a bidder in a takeover context. Even in the absence of a takeover attempt, the existence of these provisions may adversely affect the prevailing market price of our common stock if they are viewed as discouraging takeover attempts in the future.

We are regulated as an insurance holding company and subject to the insurance holding company acts of the states in which our insurance company subsidiaries are domiciled, as well as similar provisions included in the health statutes and regulations of certain states where these subsidiaries are regulated as managed care companies or HMOs. The insurance holding company acts and regulations and these similar health provisions restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Under those statutes and regulations, without such approval (or an exemption), no person may acquire any voting security of a domestic insurance company or HMO, or an insurance holding company which controls an insurance company or HMO, or merge with such a holding company, if as a result of such transaction such person would "control" the insurance holding company, insurance company or HMO. "Control" is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or controls 10% or more of the voting securities of another person. Further, the Indiana business corporation law contains business combination provisions that, in general, prohibit for five years any business combination with a beneficial owner of 10% or more of our common stock unless the holder's acquisition of the stock was approved in advance by our Board of Directors.

Our articles of incorporation restrict the beneficial ownership of our capital stock in excess of specific ownership limits. The ownership limits restrict beneficial ownership of our voting capital stock to less than 10% for institutional investors and less than 5% for non-institutional investors, both as defined in our articles of incorporation. Additionally, no person may beneficially own shares of our common stock representing a 20% or more ownership interest in us. These restrictions are intended to ensure our compliance with the terms of our licenses with the BCBSA. Our articles of incorporation prohibit ownership of our capital stock beyond these ownership limits without prior approval of a majority of our continuing directors (as defined in our articles of incorporation). In addition, as discussed above in the risk factor describing our license

agreements with the BCBSA, such license agreements are subject to termination upon a change of control and re-establishment fees would be imposed upon termination of the license agreements.

Certain other provisions included in our articles of incorporation and bylaws may also have anti-takeover effects and may delay, defer or prevent a takeover attempt that our shareholders might consider in their best interests. In particular, our articles of incorporation and bylaws: divide our Board of Directors into three classes serving staggered three-year terms (which is required by our license agreement with the BCBSA); permit our Board of Directors to determine the terms of and issue one or more series of preferred stock without further action by shareholders; restrict the maximum number of directors; limit the ability of shareholders to remove directors; impose restrictions on shareholders' ability to fill vacancies on our Board of Directors; prohibit shareholders from calling special meetings of shareholders; impose advance notice requirements for shareholder proposals and nominations of directors to be considered at meetings of shareholders; and prohibit shareholders from amending our bylaws.

# We also face other risks that could adversely affect our business, financial condition or results of operations, which include:

- · any requirement to restate financial results in the event of inappropriate application of accounting principles;
- a significant failure of our internal control over financial reporting;
- our inability to convert to international financial reporting standards, if required;
- failure of our prevention and control systems related to employee compliance with internal policies, including data security;
- · provider fraud that is not prevented or detected and impacts our medical costs or those of self-insured customers;
- failure to protect our proprietary information; and
- failure of our corporate governance policies or procedures.

# ITEM 1B. UNRESOLVED SEC STAFF COMMENTS.

None.

#### ITEM 2. PROPERTIES.

Our principal executive offices are located at 120 Monument Circle, Indianapolis, Indiana. In addition to this location, we have other principal operating facilities located in each of the 14 states where we operate as licensees of the BCBSA, in each of the eight additional states where Amerigroup conducts business and in the additional state of Arizona where CareMore maintains a branch office. A majority of these locations are leased properties. Our facilities support our various business segments. We believe that our properties are adequate and suitable for our business as presently conducted as well as for the foreseeable future.

# ITEM 3. LEGAL PROCEEDINGS.

For information regarding our legal proceedings, see the "Litigation" and "Other Contingencies" sections of Note 14, "Commitments and Contingencies" to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

## ITEM 4. MINE SAFETY DISCLOSURES.

Not Applicable.

#### PART II

# ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

#### **Market Prices**

Our common stock, par value \$0.01 per share, is listed on the NYSE under the symbol "WLP." On February 7, 2014, the closing price on the NYSE was \$84.68. As of February 7, 2014, there were 78,847 shareholders of record of our common stock. The following table presents high and low sales prices for our common stock on the NYSE for the periods indicated.

	High	Low
2013		
First Quarter	\$ 66.62	\$ 58.75
Second Quarter	82.33	65.82
Third Quarter	90.00	80.75
Fourth Quarter	94.36	83.13
2012		
First Quarter	\$ 74.73	\$ 63.34
Second Quarter	73.80	63.22
Third Quarter	64.66	52.52
Fourth Quarter	63.63	53.69

#### **Dividends**

The quarterly cash dividend declared by our Board of Directors was \$0.3750, \$0.2875 and \$0.2500 per share in 2013, 2012 and 2011, respectively. On January 28, 2014, our Board of Directors declared a quarterly cash dividend to shareholders of \$0.4375 per share.

We regularly review the appropriate use of capital, including common stock repurchases, repurchases of debt and dividends to shareholders. The declaration and payment of any dividends or repurchases of common stock or debt securities is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. Further, our ability to pay dividends to our shareholders, if authorized by our Board of Directors, is significantly dependent upon the receipt of dividends from our subsidiaries, including Anthem Insurance Companies, Inc., Anthem Southeast, Inc., Anthem Holding Corp., WellPoint Holding Corp., WellPoint Acquisition, LLC, WellPoint Insurance Services, Inc., ATH Holding Company, LLC and SellCore, Inc. The payment of dividends by our insurance subsidiaries without prior approval of the insurance department of each subsidiary's domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective insurance departments.

# Securities Authorized for Issuance under Equity Compensation Plans

The information required by this Item concerning securities authorized for issuance under our equity compensation plans is set forth in or incorporated by reference into Part III, Item 12 "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in this Form 10-K.

# **Issuer Purchases of Equity Securities**

The following table presents information related to our repurchases of common stock for the periods indicated:

Period	Total Number Average of Shares Price Pai Purchased per Shar		ice Paid	Total Number of Shares Purchased as Part of Publicly Announced Programs <sup>2</sup>	0	Approximate Dollar Value f Shares that May Yet Be Purchased Under the Programs <sup>3</sup>
(In millions, except share and per share data)						
October 1, 2013 to October 31, 2013	2,121,081	\$	86.10	2,114,200	\$	3,965.9
November 1, 2013 to November 30, 2013	948,874		87.62	933,809		3,876.9
December 1, 2013 to December 31, 2013	2,118,533		90.01	2,066,685		3,691.0
	5,188,488			5,114,694		

Total number of shares purchased includes 73,794 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders' equity are shown net of these shares purchased.


<sup>2</sup> Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board evaluates periodically. During the year ended December 31, 2013, we repurchased 20,748,394 shares at a cost of \$1,645.9 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The Board's most recent authorized increase to the program was \$3,500.0 on September 25, 2013. Between January 1, 2014 and February 7, 2014, we repurchased 5.4 shares at a cost of \$457.6, bringing our current availability to \$2,633.4 at February 7, 2014 (see note 3 below for additional discussion of current availability). No duration has been placed on our common stock repurchase program and we reserve the right to discontinue the program at any time.

On February 4, 2014, we entered into an accelerated share repurchase, or ASR, program with a counterparty. The agreement provides for a repurchase of a number of shares, equal to \$600.0, as determined by the dollar volume weighted-average share price during a period up through at least March 14, 2014, but not to exceed March 31, 2014. At the end of the term of the ASR, the initial amount of shares will be adjusted up or down based on the dollar volume weighted-average price during the same period. On February 4, 2014, we repurchased 6.0 shares under this program. These ASR shares are not included in the shares repurchased subsequent to December 31, 2013, discussed in note 2 above, as the final shares to be repurchased will not be determined until the completion of the program in March 2014. However, the \$600.0 has been removed from the authorization remaining as of February 7, 2014 discussed in note 2 above.

## **Performance Graph**

The following Performance Graph and related information compares the cumulative total return to shareholders of our common stock for the period from December 31, 2008 through December 31, 2013, with the cumulative total return over such period of (i) the Standard & Poor's 500 Stock Index (the "S&P 500 Index") and (ii) the Standard & Poor's Managed Health Care Index (the "S&P Managed Health Care Index"). The graph assumes an investment of \$100 on December 31, 2008 in each of our common stock, the S&P 500 Index and the S&P Managed Health Care Index (and the reinvestment of all dividends).

The comparisons shown in the graph below are based on historical data and we caution that the stock price performance shown in the graph below is not indicative of, and is not intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from S&P Capital IQ, a source believed to be reliable, but we are not responsible for any errors or omissions in such information. The following graph and related information shall not be deemed "soliciting materials" or to be "filed" with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.



	December 31,											
	2008		2008 2009		2010		2011		2012			2013
WellPoint, Inc.	\$	100	\$	138	\$	135	\$	160	\$	149	\$	231
S&P 500 Index		100		126		146		149		172		228
S&P Managed Health Care Index		100		128		139		187		198		293

Based upon an initial investment of \$100 on December 31, 2008 with dividends reinvested.

#### ITEM 6. SELECTED FINANCIAL DATA.

The table below provides selected consolidated financial data of WellPoint. The information has been derived from our consolidated financial statements for each of the years in the five year period ended December 31, 2013. You should read this selected consolidated financial data in conjunction with the audited consolidated financial statements and notes as of and for the year ended December 31, 2013 included in Part II, Item 8 "Financial Statements and Supplementary Data", and Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this Form

10-K.

		As of and fo	r the	Years Ended	Dece	ember 31			
	2013 1	2012 1,2		2011 2	2010			2009 2	
(in millions, except where indicated and except per share data)									
Income Statement Data									
Total operating revenue <sup>3</sup>	\$ 70,191.4	\$ 60,514.0	\$	59,865.2	\$	57,740.5	\$	60,740.0	
Total revenues	71,023.5	61,497.2		60,710.7		58,698.5		64,939.5	
Income from continuing operations	2,634.3	2,651.0		2,646.7		2,887.1		4,745.9	
Net income	2,489.7	2,655.5		2,646.7		2,887.1		4,745.9	
Per Share Data									
Basic net income per share - continuing operations	\$ 8.83	\$ 8.25	\$	7.35	\$	7.03	\$	9.96	
Diluted net income per share - continuing operations	8.67	8.17		7.25		6.94		9.88	
Dividends per share	1.50	1.15		1.00		_		_	
Other Data (unaudited)									
Benefit expense ratio <sup>4</sup>	85.1%	85.3%		85.1%		83.2%		83.6%	
Selling, general and administrative expense ratio <sup>5</sup>	14.2%	14.3%		14.1%		15.1%		14.8%	
Income from continuing operations before income taxes as a percentage of total revenues	5.4%	6.3%		6.5%		7.4%		11.4%	
Net income as a percentage of total revenues	3.5%	4.3%		4.4%		4.9%		7.3%	
Medical membership (in thousands)	35,653	36,130		34,251		33,323		33,670	
Balance Sheet Data									
Cash and investments	\$ 22,395.9	\$ 22,464.6	\$	20,696.5	\$	20,311.8	\$	22,610.9	
Total assets	59,574.5	58,955.4		52,163.2		50,242.5		52,147.9	
Long-term debt, less current portion	13,573.6	14,170.8		8,465.7		8,147.8		8,338.3	
Total liabilities	34,809.3	35,152.7		28,875.0		26,429.9		27,284.6	
Total shareholders' equity	24,765.2	23,802.7		23,288.2		23,812.6		24,863.3	

The operating results of 1-800 CONTACTS, Inc. are reported as discontinued operations at December 31, 2013 as a result of the pending divestiture. Included in Net income for the year ended December 31, 2013 is a loss from discontinued operations, net of tax, of \$144.6. Included in Net income for the year ended December 31, 2012 is income from discontinued operations, net of tax, of \$4.5.

The net assets of and results of operations for AMERIGROUP Corporation are included from its acquisition date of December 24, 2012. The net assets of and results of operations for CareMore Health Group, Inc. are included from its acquisition date of August 22, 2011. The net assets of and results of operations for DeCare Dental, LLC are included from its acquisition date of April 9, 2009. The results of operations for our pharmacy benefits management, or PBM, business are included until its sale on December 1, 2009. The results of operations for the year ended December 31, 2009 includes pre-tax and after-tax gains related to the sale of our PBM business of \$3,792.3 and \$2,361.2, respectively.

<sup>3</sup> Operating revenue is obtained by adding premiums, administrative fees and other revenue.

<sup>4</sup> The benefit expense ratio represents benefit expenses as a percentage of premium revenue.

<sup>5</sup> The selling, general and administrative expense ratio represents selling, general and administrative expenses as a percentage of total operating revenue.

#### ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(In Millions, Except Per Share Data or As Otherwise Stated Herein)

References to the terms "we", "our" or "us" used throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, refer to WellPoint, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.

This MD&A should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### Overview

On May 20, 2013, we announced certain organizational and executive leadership changes to align with how our new Chief Executive Officer is managing our operations. Beginning with the three months ended June 30, 2013, our organizational structure is comprised of three reportable segments: Commercial and Specialty Business; Government Business; and Other. Prior period segment information has been reclassified to conform to the new segment reporting structure.

Our Commercial and Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the Commercial and Specialty Business segment offer fully-insured products; provide a broad array of managed care services to self-funded customers including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services; and provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance.

Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, or NGS, and services provided to the Federal Government in connection with the Federal Employee Program, or FEP. Our Medicare business includes services such as Medicare Advantage, Medicare Part D, and Medicare Supplement, while our Medicaid business includes our managed care alternatives through publicly funded health care programs, including Medicaid, state Children's Health Insurance Programs, or CHIP, and Medicaid expansion programs. NGS acts as a Medicare contractor in several regions across the nation.

Our Other segment includes other businesses that do not meet the quantitative thresholds for an operating segment as defined by Financial Accounting Standards Board, or FASB, guidance, as well as corporate expenses not allocated to the other reportable segments.

In preparation for the coming changes to the health care system and to focus on our core growth opportunities across our Commercial and Specialty Business and Government Business segments, we entered into a definitive agreement in December 2013 to sell our 1-800 CONTACTS, Inc., or 1-800 CONTACTS, business to the private equity firm Thomas H. Lee Partners, L.P. Concurrently, we entered into an asset purchase agreement with Luxottica Group to sell our glasses.com related assets. The divestitures were completed on January 31, 2014. The operating results for 1-800 CONTACTS are reported as discontinued operations as a result of the pending divestiture at December 31, 2013. These results were previously reported in the Commercial and Specialty Business segment. Additionally, the assets and liabilities of 1-800-CONTACTS are reported as held for sale in the consolidated balance sheets included in this Form 10-K. Unless otherwise specified, all financial information, other than cash flows, disclosed in this MD&A is from continuing operations. In accordance with FASB guidance, we have elected to not separately disclose net cash provided by or used in operating, investing, and financing activities and the net effect of those cash flows on cash and cash equivalents for discontinued operations during the periods presented. For additional information regarding these transactions, see Note 3, "Business Acquisitions and Divestitures," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

Our operating revenue consists of premiums, administrative fees and other revenue. Premium revenue comes from fully-insured contracts where we indemnify our policyholders against costs for covered health and life benefits. Administrative fees come from contracts where our customers are self-insured, or where the fee is based on either processing of transactions or a percent of network discount savings realized. Additionally, we earn administrative fee revenues from our Medicare

processing business and from other health-related businesses including disease management programs. Other revenue includes miscellaneous income other than premium revenue and administrative fees.

Our benefit expense primarily includes costs of care for health services consumed by our members, such as outpatient care, inpatient hospital care, professional services (primarily physician care) and pharmacy benefit costs. All four components are affected both by unit costs and utilization rates. Unit costs include the cost of outpatient medical procedures per visit, inpatient hospital care per admission, physician fees per office visit and prescription drug prices. Utilization rates represent the volume of consumption of health services and typically vary with the age and health status of our members and their social and lifestyle choices, along with clinical protocols and medical practice patterns in each of our markets. A portion of benefit expense recognized in each reporting period consists of actuarial estimates of claims incurred but not yet paid by us. Any changes in these estimates are recorded in the period the need for such an adjustment arises. While we offer a diversified mix of managed care products and services through our managed care plans, our aggregate cost of care can fluctuate based on a change in the overall mix of these products and services. Our managed care plans include: preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; point-of-service plans, or POS plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans, or CDHPs; and hospital only and limited benefit products.

We classify certain claims-related costs as benefit expense to reflect costs incurred for our members' traditional medical care, as well as those expenses which improve our members' health and medical outcomes. These claims-related costs may be comprised of expenses incurred for:
(i) medical management, including case and utilization management; (ii) health and wellness, including disease management services for such conditions as diabetes, high-risk pregnancies, congestive heart failure and asthma management and wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii) clinical health policy. These types of claims-related costs are designed to ultimately lower our members' cost of care.

Our selling expense consists of external broker commission expenses, and generally varies with premium or membership volume. Our general and administrative expense consists of fixed and variable costs. Examples of fixed costs are depreciation, amortization and certain facilities expenses. Other costs are variable or discretionary in nature. Certain variable costs, such as premium taxes, vary directly with premium volume. Other variable costs, such as salaries and benefits, do not vary directly with changes in premium, but are more aligned with changes in membership. The acquisition or loss of a significant block of business would likely impact staffing levels, and thus associated compensation expense. Examples of discretionary costs include professional and consulting expenses and advertising. Other factors can impact our administrative cost structure, including systems efficiencies, inflation and changes in productivity.

Our results of operations depend in large part on our ability to accurately predict and effectively manage health care costs through effective contracting with providers of care to our members and our medical management and health and wellness programs. Several economic factors related to health care costs, such as regulatory mandates of coverage as well as direct-to-consumer advertising by providers and pharmaceutical companies, have a direct impact on the volume of care consumed by our members. The potential effect of escalating health care costs, any changes in our ability to negotiate competitive rates with our providers and any regulatory or market driven restrictions on our ability to obtain adequate premium rates to offset overall inflation in health care costs, including increases in unit costs and utilization resulting from the aging of the population and other demographics, as well as advances in medical technology, may impose further risks to our ability to profitably underwrite our business, and may have a material impact on our results of operations.

Our future results of operations will also be impacted by certain external forces and resulting changes in our business model and strategy. In 2010, the U.S. Congress passed and the President signed into law the Patient Protection and Affordable Care Act, or ACA, as well as the Health Care and Education Reconciliation Act of 2010, or collectively, Health Care Reform, which represents significant changes to the U.S. health care system. The legislation is far-reaching and is intended to expand access to health insurance coverage over time by increasing the eligibility thresholds for state Medicaid programs and providing certain other individuals and small businesses with tax credits to subsidize a portion of the cost of health insurance coverage. As a result of the complexity of the law, its impacts on health care in the United States and the continuing modification and interpretation of Health Care Reform's rules, we continue to analyze the impact and refine our estimates of the ultimate impact of Health Care Reform on our business, cash flows, financial condition and results of operations. A list of certain material changes resulting from Health Care Reform include:

- Requirements to modify our products to cover essential health benefits and comply with other defined criteria;
- · Requirement to cancel existing products and enroll new and renewing members in the new ACA-compliant "metal"

products (bronze, silver, gold and platinum);

- · Introduction of exchanges, subsidies and mandates to require and allow previously uninsured customers to enter the market; and
- Significant new taxes and fees which will be paid by health insurers, and which may or may not be passed through to customers.

The above changes resulting from Health Care Reform will provide growth opportunities for health insurers, but also introduce new risks and uncertainties, and require changes in the way our products are designed, underwritten, priced, distributed and administered.

Pricing in our Commercial and Specialty Business segment, including our individual and small group lines of business, remains highly competitive and we strive to price our health care benefit products consistent with anticipated underlying medical trends. We believe our pricing strategy, based on predictive modeling, proprietary research and data-driven processes, as well as our overall investments for Health Care Reform, have positioned us to benefit from the potential growth opportunities available in fully-insured commercial products as a result of Health Care Reform. While the ultimate level of exchange enrollment cannot be predicted, we have experienced a greater number of policy applications for new members through the exchanges than expected, including geographical regions with lower price competition. The exchanges may increase the risk that our products will be selected by individuals who have a higher risk profile or utilization rate than the pool of participants we anticipated when we established the pricing for these exchange products. However, early indications of the risk characteristics of new applicants appear to be tracking closely to the risk levels utilized in the development of our pricing assumptions. Although it is not yet clear whether our products sold on the exchanges will be more or less profitable products, we believe that our pricing strategy, brand name and network quality will provide a strong foundation for commercial risk membership growth opportunities in the future.

In our individual markets we offer bronze, silver and gold products, both on and off the exchanges, in the states of California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia and Wisconsin. Additionally, we offer platinum products, both on and off the exchanges, in the states of California and New York.

In our small group markets, we offer bronze, silver and gold products, both on and off the exchanges, in the states of Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, Ohio and Virginia and we offer bronze, silver and gold products, off the exchanges, in the states of California, New York and Wisconsin. Additionally, we offer platinum products, off the exchanges, in the states of California, Connecticut, Georgia, Maine and Virginia.

The legislation also imposes new regulations on the health insurance sector, including, but not limited to, guaranteed coverage requirements; prohibitions on some annual and all lifetime limits on amounts paid on behalf of or to our members; increased restrictions on rescinding coverage; establishment of minimum medical loss ratio, or MLR, requirements; a requirement to cover preventive services on a first dollar basis; the establishment of state insurance exchanges and essential benefit packages; and greater limitations on how we price certain of our products. The legislation also reduces the reimbursement levels for health plans participating in the Medicare Advantage program over time.

As a result of Health Care Reform, the Department of Health and Human Services, or HHS, issued MLR regulations that require us to meet minimum MLR thresholds for large group, small group and individual lines of business. For purposes of determining MLR rebates, HHS has defined the types of costs that should be included in the MLR rebate calculation. However, certain components of the MLR calculation as defined by HHS cannot be classified consistently under U.S. generally accepted accounting principles, or GAAP. While considered benefit expense or a reduction of premium revenue by HHS, certain of these costs are classified as other types of expense, such as income tax expense or selling, general and administrative expense, in our GAAP basis financial statements. Accordingly, the benefit expense ratio determined using our consolidated GAAP operating results is not comparable to the MLR calculated under HHS regulations.

Beginning with rebates paid in 2014 for the 2013 benefit year, MLR rebates will be based on a three year average. This calculation will determine an average MLR for each market segment within each state for the previous three calendar years. Additionally, insurers will be able to adjust experience to account for prior MLR rebates refunded to groups or individuals. Once the three year average MLR is calculated and compared to the minimum MLR threshold, the rebate percentage will be applied to current year premiums as defined by Health Care Reform. Beginning with MLR rebates paid in 2015 for the 2014

benefit year, insurers will adjust for the risk adjustment, reinsurance, and risk corridor premium stabilization programs of Health Care Reform.

Health Care Reform also imposes a separate minimum MLR threshold of 85% for Medicare Advantage plans beginning in 2014. Medicare Advantage plans that do not meet this threshold will have to pay a minimum MLR rebate. If a plan's MLR is below 85% for three consecutive years beginning with 2014, enrollment will be restricted. A Medicare Advantage plan contract will be terminated if the plan's MLR is below 85% for five consecutive years.

These and other provisions of Health Care Reform are likely to have significant effects on our future operations, which, in turn, could impact the value of our business model and results of operations, including potential impairments of our goodwill and other intangible assets. We will continue to evaluate the impact of Health Care Reform as key aspects go into effect and additional guidance is made available. For additional discussion regarding Health Care Reform, see Part I, Item 1 "Business—Regulation" and Part I, Item 1A "Risk Factors" in this Form 10-K.

Finally, federal and state regulatory agencies may further restrict our ability to obtain new product approvals, implement changes in premium rates or impose additional restrictions, under new or existing laws that could adversely affect our business, cash flows, financial condition and results of operations.

We are also subject to regulations that may result in assessments under state insurance guarantee association laws. The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary organization consisting of the state life and health insurance guaranty associations located throughout the U.S. State life and health insurance guaranty associations, working together with NOLHGA, provide a safety net for their state's policyholders, ensuring that they continue to receive coverage even if their insurer is declared insolvent. We are aware that the Pennsylvania Insurance Commissioner, or Insurance Commissioner, has placed Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, or collectively Penn Treaty, in rehabilitation, an intermediate action before insolvency. The state court denied the Insurance Commissioner's petition for the liquidation of Penn Treaty and ordered the Insurance Commissioner to file an updated plan of rehabilitation, which proposed plan was filed on April 30, 2013. The state court has ordered a hearing on the proposed plan for which a date has not yet been set. The Insurance Commissioner has filed a Notice of Appeal asking the Pennsylvania Supreme Court to reverse the order denying the liquidation petition. The Supreme Court has probable jurisdiction over the appeal and issued a schedule for filing briefs. In the event rehabilitation of Penn Treaty is unsuccessful and Penn Treaty is declared insolvent and placed in liquidation, we and other insurers may be required to pay a portion of their policyholder claims through state guaranty association assessments in future periods. Given the uncertainty around whether Penn Treaty will ultimately be declared insolvent and, if so, the amount of the insolvency, the amount and timing of any associated future guaranty fund assessments and the availability and amount of any potential premium tax and other offsets, we currently cannot estimate our net exposure, if any, to this potential insolvency. We will continue to monitor the situation and may record a liability and expense in future reporting periods, which could be material to our cash flows and results of operations.

In addition to external forces discussed in the preceding paragraphs, our results of operations are impacted by levels and mix of membership. In recent years, we experienced membership declines due to unfavorable economic conditions driving increased unemployment. In addition, we believe the self-insured portion of our group membership base will continue to increase as a percentage of total group membership. Further, our mix of membership may include more individuals with a higher acuity level obtaining coverage through our products available on the exchanges, which may not be appropriately adjusted for in our premium rates. These membership trends could have a material adverse effect on our future results of operations. Also see Part I, Item 1A "Risk Factors" in this Form 10-K.

# **Executive Summary**

We are one of the largest health benefits companies in terms of medical membership in the United States, serving 35.7 medical members through our affiliated health plans and a total of 67.8 individuals through all subsidiaries as of December 31, 2013. We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for: Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as BCBS in 10 New York City metropolitan and surrounding counties, and as Blue Cross or BCBS in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), and Wisconsin. In a majority of these service areas we do

business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Georgia, and Empire Blue Cross Blue Shield, or Empire Blue Cross (in our New York service areas). We also conduct business through our AMERIGROUP Corporation, or Amerigroup, subsidiary in Florida, Georgia, Kansas, Louisiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas and Washington. Amerigroup also provided services in the state of Ohio through June 30, 2013 and in the state of New Mexico through December 31, 2013. We also serve customers throughout the country as HealthLink, UniCare and in certain Arizona, California, Nevada, New York and Virginia markets through our CareMore Health Group, Inc., or CareMore, subsidiary. We are licensed to conduct insurance operations in all 50 states through our subsidiaries. We also sold contact lenses, eyeglasses and other ocular products through our 1-800 CONTACTS business, which was divested on January 31, 2014.

Operating revenue for the year ended December 31, 2013 was \$70,191.4, an increase of \$9,677.4, or 16.0%, from the year ended December 31, 2012, primarily reflecting higher premium revenue in our Government Business segment, partially offset by lower premium revenue in our Commercial and Specialty Business segment. The higher premium revenue in our Government Business segment primarily resulted from the acquisition of Amerigroup in December 2012, growth in our FEP business resulting from both premium rate increases designed to cover overall cost trends and increases in membership as well as increased membership in our CareMore subsidiary. These increases were partially offset by lower revenues in our non-CareMore Medicare Advantage and Medicare Part D businesses primarily due to membership losses as a result of our product repositioning strategy toward HMO product offerings. The premium revenue decrease in our Commercial and Specialty Business segment was driven primarily by fully-insured membership declines in our Local Group business resulting from strategic product portfolio changes in certain states, competitive pressure in certain markets and, we believe, affordability challenges affecting healthcare consumers in general. This decrease was partially offset by premium rate increases in our Local Group, Individual and National Accounts businesses designed to cover overall cost trends as well as premium rate and membership increases in our Specialty businesses, primarily related to our dental and vision products, and increased administrative fees resulting from pricing increases for self-funded members in our Commercial businesses.

Net income for the year ended December 31, 2013 was \$2,489.7, a decrease of \$165.8, or 6.2%, from the year ended December 31, 2012. The decrease in net income was primarily driven by the loss on disposal of our 1-800 CONTACTS business, costs incurred in preparation for the implementation of Health Care Reform effective in 2014, realized losses on extinguishment of debt, an increase in interest expense resulting from higher outstanding debt balances associated with our acquisition of Amerigroup and lower operating results in our Commercial and Specialty Business segment. These decreases were partially offset by higher operating results in our Government Business segment, primarily from Amerigroup.

Our diluted earnings per share, or EPS, for the year ended December 31, 2013 was \$8.20, an increase of \$0.02, or 0.2%, from the year ended December 31, 2012. Our diluted EPS from continuing operations for the year ended December 31, 2013 was \$8.67, an increase of \$0.50, or 6.1%, from the year ended December 31, 2012. Our diluted shares for the year ended December 31, 2013 were 303.8 million, a decrease of 21.0 million, or 6.5%, compared to the year ended December 31, 2012. The increase in diluted EPS resulted primarily from the lower number of shares outstanding in 2013 due to share buyback activity under our share repurchase program partially offset by the decrease in net income.

Our results of operations discussed throughout this MD&A are determined in accordance with GAAP. We also calculate adjusted net income, adjusted EPS and operating gain, which are non-GAAP measures, to further aid investors in understanding and analyzing our core operating results and comparing them among periods. Adjusted net income and adjusted EPS exclude realized gains and losses on investments, other-than-temporary losses on investments recognized in income, impairment of other intangible assets and certain other items, if applicable, that we do not consider a part of our core operating results. Operating gain is calculated as total operating revenue less benefit expense, selling, general and administrative expense. We use these measures as a basis for evaluating segment performance, allocating resources, setting incentive compensation targets and forecasting future operating periods. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, net income or diluted EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For additional details on operating gain, see our "Reportable Segments Results of Operations" discussion included in this MD&A.

The table below reconciles net income and diluted EPS calculated in accordance with GAAP to adjusted net income and adjusted diluted EPS for the years ended December 31, 2013 and 2012.

Years Ended

2013		2012		Change	% Change
\$ 2,489.7	\$	2,655.5	\$	(165.8)	(6.2)%
176.7		217.7		(41.0)	
(64.3)		(24.6)		(39.7)	
(94.4)		_		(94.4)	
65.0		_		65.0	
(164.5)		_		(164.5)	
(16.3)		(68.4)		52.1	
_		(24.0)		24.0	
_		140.1		(140.1)	
_		(41.4)		41.4	
\$ 2,587.5	\$	2,456.1	\$	131.4	5.3 %
\$ 8.20	\$	8.18	\$	0.02	0.2 %
0.58		0.67		(0.09)	
(0.21)		(0.07)		(0.14)	
(0.31)		_		(0.31)	
0.21		_		0.21	
(0.54)		_		(0.54)	
(0.05)		(0.21)		0.16	
_		(0.07)		0.07	
_		0.43		(0.43)	
_		(0.13)		0.13	
\$ 8.52	\$	7.56	\$	0.96	12.7 %
\$	\$ 2,587.5  \$ 8.20  \$ 0.58 (0.21) (0.05) (0.05)	\$ 2,489.7 \$ 176.7 (64.3) (94.4) 65.0 (164.5) (16.3) — \$ 2,587.5 \$ \$ \$ 8.20 \$ \$ 0.58 (0.21) (0.31) 0.21 (0.54) (0.05) — — — —	\$ 2,489.7 \$ 2,655.5  176.7 217.7 (64.3) (24.6) (94.4) — 65.0 — (164.5) — (16.3) (68.4) ————————————————————————————————————	December 31           2013         2012           \$ 2,489.7         \$ 2,655.5           176.7         217.7           (64.3)         (24.6)           (94.4)         —           65.0         —           (164.5)         —           (16.3)         (68.4)           —         (24.0)           —         140.1           —         (41.4)           \$ 2,587.5         \$ 2,456.1           \$         8.20           \$ 8.18         \$           0.58         0.67           (0.21)         (0.07)           (0.31)         —           (0.54)         —           (0.05)         (0.21)           —         (0.07)           —         0.43           —         (0.13)	December 31   2013   2012   Change   \$ 2,489.7   \$ 2,655.5   \$ (165.8)   \$ (165.8)   \$ (165.8)   \$ (165.8)   \$ (165.8)   \$ (165.8)   \$ (165.8)   \$ (165.8)   \$ (164.3)   (24.6)   (39.7)   (94.4)   — (94.4)   — (94.4)   — (94.4)   — (55.0)   — (55.0)   — (164.5)   — (164.5)   — (164.5)   — (164.5)   — (164.5)   — (24.0)   24.0   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)   — (41.4)

Operating cash flow for the year ended December 31, 2013 was \$3,052.3, or 1.2 times net income. Operating cash flow for the year ended December 31, 2012 was \$2,744.6, or 1.0 times net income. The increase in operating cash flow from 2012 of \$307.7 was driven primarily by an increase in net income adjusted for non-cash items, primarily due to the loss on disposal of discontinued operations, changes in amortization expense and realized losses on extinguishment of debt. The increase was further attributable to lower payments for litigation related matters, incentive compensation and minimum MLR rebates; and a net increase in the collection of income tax refunds in 2013.

We intend to expand through a combination of organic growth, strategic acquisitions and efficient use of capital in both existing and new markets. Our growth strategy is designed to enable us to take advantage of additional economies of scale as well as providing us access to new and evolving technologies and products. In addition, we believe geographic and product diversity reduces our exposure to local or regional regulatory, economic and competitive pressures and provides us with increased opportunities for growth. While we have achieved strong growth as a result of strategic mergers and acquisitions, we have also achieved organic growth in our existing markets over time by providing excellent service, offering competitively priced products, access to high quality provider networks and effectively capitalizing on the brand strength of the Blue Cross and Blue Shield names and marks.

#### **Significant Transactions**

The more significant transactions that have occurred over the last three years that have impacted or will impact our capital structure or that have or will influence how we conduct our business operations include:

- Use of Capital—Board of Directors declaration of dividends on common stock (2013, 2012 and 2011) and a 16.7% increase in the quarterly dividend to \$0.4375 per share (2014); authorization for repurchases of our common stock (2013 and prior); and debt repurchases and new debt issuance (2013 and prior);
- Acquisition of Amerigroup and the related debt issuance (2012);
- Acquisition of 1-800 CONTACTS (2012) and subsequent divestiture (2014); and
- Acquisition of CareMore (2011).

For additional information regarding these transactions, see Note 3, "Business Acquisitions and Divestitures," Note 13, "Debt" and Note 15, "Capital Stock," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

# Membership

Our medical membership includes seven different customer types: Local Group, Individual, National Accounts, BlueCard®, Medicare, Medicaid and FEP. BCBS-branded business generally refers to members in our service areas licensed by the BCBSA. Non-BCBS-branded business refers to Amerigroup and CareMore members as well as Healthlink and UniCare members predominantly outside of our BCBSA service areas.

- Local Group consists of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees. In addition, Local Group includes UniCare local group members. These groups are generally sold through brokers or consultants working with industry specialists from our in-house sales force. Local Group insurance premiums may be based on claims incurred by the group or sold on a self-insured basis. The customer's buying decision is typically based upon the size and breadth of our networks, customer service, the quality of our medical management services, the administrative cost included in our quoted price, our financial stability, reputation and our ability to effectively service large complex accounts. Local Group accounted for 41.2%, 40.5% and 44.4% of our medical members at December 31, 2013, 2012 and 2011, respectively.
- Individual consists of individual customers under age 65 (including UniCare) and their covered dependents. Individual policies are generally sold through independent agents and brokers, retail partnerships, our in-house sales force or via the Internet. Individual business is sold on a fully-insured basis. We offer on-exchange products through state or federally facilitated marketplaces and offexchange products. Federal premium subsidies are available only for certain on-exchange individual products. Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network, and the efficiency of administration. Account turnover is generally higher with Individual as compared to Local Group. Individual business accounted for 4.9%, 5.1% and 5.4% of our medical members at December 31, 2013, 2012 and 2011, respectively.
- National Accounts generally consist of multi-state employer groups primarily headquartered in a WellPoint service area with at least 5% of the eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some exceptions are allowed based on broker relationships. Service area is defined as the geographic area in which we are licensed to sell BCBS products. National Accounts are generally sold through independent brokers or consultants retained by the customer working with our in-house sales force. We have an advantage when competing for very large National Accounts due to the size and breadth of our networks and our ability to access the national provider networks of BCBS companies at their competitive local market rates. National Accounts represented 19.0%, 19.4% and 21.6% of our medical members at December 31, 2013, 2012 and 2011, respectively.
- BlueCard® host customers represent enrollees of Blue Cross and/or Blue Shield plans not owned by WellPoint who receive health care services in our BCBSA licensed markets. BlueCard® membership consists of estimated host members using the national BlueCard® program. Host members are generally members who reside in or travel to a state in which a WellPoint subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer-sponsored health plan issued by a non-WellPoint controlled BCBSA licensee (i.e., the "home plan"). We perform certain administrative functions for BlueCard® members, for which we receive administrative fees from the BlueCard® members' home plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan. Host members are computed using, among other things, the

average number of BlueCard<sup>®</sup> claims received per month. BlueCard<sup>®</sup> host membership accounted for 14.2%, 13.9% and 14.4% of our medical members at December 31, 2013, 2012 and 2011, respectively.

- Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Advantage, a managed care alternative for the Medicare program, who have purchased Medicare Supplement benefit coverage, some disabled under 65, or all ages with End Stage Renal Disease. Medicare Supplement policies are sold to Medicare recipients as supplements to the benefits they receive from the Medicare program. Rates are filed with and in some cases approved by state insurance departments. Most of the premium for Medicare Advantage is paid directly by the Federal government on behalf of the participant who may also be charged a small premium. Medicare Supplement and Medicare Advantage products are marketed in the same manner, primarily through independent agents and brokers. Medicare business accounted for 4.1%, 4.4% and 4.3% of our medical members at December 31, 2013, 2012 and 2011, respectively.
- Medicaid membership represents eligible members who receive health care benefits through publicly funded health care programs, including Medicaid, CHIP and Medicaid expansion programs. Total Medicaid program business accounted for 12.3%, 12.5% and 5.5% of our medical members at December 31, 2013, 2012 and 2011, respectively.
- FEP members consist of United States government employees and their dependents within our geographic markets through our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management. FEP business accounted for 4.3%, 4.2% and 4.4% of our medical members at December 31, 2013, 2012 and 2011, respectively.

In addition to reporting our medical membership by customer type, we report by funding arrangement according to the level of risk that we assume in the product contract. Our two principal funding arrangement categories are fully-insured and self-funded. Fully-insured products are products in which we indemnify our policyholders against costs for health benefits. Self-funded products are offered to customers, generally larger employers, who elect to retain most or all of the financial risk associated with their employees' health care costs. Some self-funded customers choose to purchase stop-loss coverage to limit their retained risk.

The following table presents our medical membership by customer type, funding arrangement and reportable segment as of December 31, 2013, 2012 and 2011. Also included below is other membership by product. The medical membership and other membership presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period.

	1	December 31		2013	vs. 2012	2012	vs. 2011
(In thousands)	2013	2012	2011	Change	% Change	Change	% Change
Medical Membership							
Customer Type							
Local Group	14,690	14,634	15,212	56	0.4	(578)	(3.8)
Individual	1,755	1,855	1,846	(100)	(5.4)	9	0.5
National:							
National Accounts	6,775	6,999	7,401	(224)	(3.2)	(402)	(5.4)
BlueCard®	5,050	5,016	4,935	34	0.7	81	1.6
Total National	11,825	12,015	12,336	(190)	(1.6)	(321)	(2.6)
Medicare	1,478	1,586	1,471	(108)	(6.8)	115	7.8
Medicaid	4,378	4,520	1,867	(142)	(3.1)	2,653	142.1
FEP	1,527	1,520	1,519	7	0.5	1	0.1
Total Medical Membership by Customer Type	35,653	36,130	34,251	(477)	(1.3)	1,879	5.5
Funding Arrangement							
Self-Funded	20,294	20,176	20,506	118	0.6	(330)	(1.6)
Fully-Insured	15,359	15,954	13,745	(595)	(3.7)	2,209	16.1
Total Medical Membership by Funding							
Arrangement	35,653	36,130	34,251	(477)	(1.3)	1,879	5.5
Reportable Segment							
Commercial and Specialty Business	28,270	28,504	29,394	(234)	(0.8)	(890)	(3.0)
Government Business	7,383	7,626	4,857	(243)	(3.2)	2,769	57.0
Total Medical Membership by Reportable							
Segment	35,653	36,130	34,251	(477)	(1.3)	1,879	5.5
Other Membership & Customers							
Behavioral Health Members	24,372	24,156	25,135	216	0.9	(979)	(3.9)
Life and Disability Members	4,819	4,838	5,012	(19)	(0.4)	(174)	(3.5)
Dental Members	4,895	4,863	5,069	32	0.7	(206)	(4.1)
Dental Administration Members	4,886	4,103	4,162	783	19.1	(59)	(1.4)
Vision Members	4,743	4,519	3,783	224	5.0	736	19.5
Medicare Advantage Part D Members	628	734	635	(106)	(14.4)	99	15.6
Medicare Part D Standalone Members	474	574	667	(100)	(17.4)	(93)	(13.9)
Retail Vision Customers	3,114	3,130	_	(16)	(0.5)	3,130	_

# December 31, 2013 Compared to December 31, 2012

# Medical Membership (in thousands)

During the year ended December 31, 2013, total medical membership decreased 477, or 1.3%, primarily due to decreases in our National Accounts, Medicaid, Medicare and Individual membership.

Self-funded medical membership increased 118, or 0.6%, primarily due to increases in our Local Group self-funded accounts, partially offset by lapses in our National Accounts and BlueCard® business.

Fully-insured membership decreased 595, or 3.7%, primarily due to membership losses in certain Local Group and Individual markets, as well as membership losses in our Medicaid and Medicare business, described below.

Local Group membership increased 56, or 0.4%, primarily due to new sales in several markets, partially offset by insured membership losses from strategic product portfolio changes in certain states, competitive pressure in certain markets and, we believe, affordability challenges affecting healthcare consumers in general.

Individual membership decreased 100, or 5.4%, primarily due to a heightened competitive environment in certain markets.

National Accounts membership decreased 224, or 3.2%, primarily due to lapses in our self-funded business.

BlueCard® membership increased 34, or 0.7%, primarily due to favorable membership activity at other BCBSA plans whose members reside in or travel to our licensed areas.

Medicare membership decreased 108, or 6.8%, primarily due to our product repositioning strategy toward HMO product offerings.

Medicaid membership decreased 142, or 3.1%, primarily due to membership losses in our California and New York plans and termination of the Ohio contract on June 30, 2013, partially offset by an increase in membership in various other states.

FEP membership increased 7, or 0.5%, primarily due to favorable in-group change.

# Other Membership & Customers (in thousands)

Our Other products are often ancillary to our health business and can therefore be impacted by corresponding changes in our medical membership.

Behavioral health membership increased 216, or 0.9%, primarily due to increased penetration into the Commercial market.

Life and disability membership decreased 19, or 0.4%, primarily due to the overall declines in our Commercial and Specialty Business medical membership. Life and disability products are generally offered as part of Commercial and Specialty Business medical membership sales.

Dental membership increased 32, or 0.7%, primarily due to growth from the launch of new product offerings, partially offset by declines in our Commercial and Specialty Business membership.

Dental administration membership increased 783, or 19.1%, primarily due to the acquisition of a large managed dental contract pursuant to which we provide dental administrative services.

Vision membership increased 224, or 5.0%, primarily due to strong sales and in-group change in our Local Group business.

Medicare Advantage Part D membership decreased 106, or 14.4%, primarily due to our product repositioning strategy toward HMO product offerings.

Medicare Part D standalone membership decreased 100, or 17.4%, primarily due to competitive pressure in certain markets.

Retail vision customers decreased 16, or 0.5%, primarily due to a contract termination with a large independent retailer.

#### December 31, 2012 Compared to December 31, 2011

# Medical Membership (in thousands)

During the year ended December 31, 2012, total medical membership increased 1,879, or 5.5%, primarily due to Medicaid membership acquired with the acquisition of Amerigroup and growth in our Medicare membership, partially offset by decreases in our Local Group and National Accounts membership.

Self-funded medical membership decreased 330, or 1.6%, primarily due to pricing increases in our National Accounts business.

Fully-insured membership increased 2,209, or 16.1%, primarily due to Medicaid membership acquired with the acquisition of Amerigroup and growth in our Medicare membership, partially offset by membership losses in certain Local Group markets resulting primarily from strategic product portfolio changes and heightened competition.

Local Group membership decreased 578, or 3.8%, primarily due to increased competition, strategic product portfolio changes in the New York market and network rental markets and negative in-group change.

Individual membership increased 9, or 0.5%, primarily due to an overall improved competitive position in our California market.

National Accounts membership decreased 402, or 5.4%, primarily driven by pricing increases in our self-funded National Accounts business and negative in-group change.

BlueCard® membership increased 81, or 1.6%, primarily due to favorable net sales and in-group change at other BCBSA plans whose members reside in or travel to our licensed areas.

Medicare membership increased 115, or 7.8%, primarily due to strong sales during the open enrollment period resulting from our geographic expansion into several new counties and Medicare Advantage membership acquired with the acquisition of Amerigroup, partially offset by the withdrawal of the California Regional PPO Medicare Advantage product.

Medicaid membership increased 2,653, or 142.1%, primarily due to 2,621 members acquired with the acquisition of Amerigroup and growth in Wisconsin, California and Kansas, partially offset by exiting selected markets.

FEP membership increased 1, or 0.1%, primarily due to favorable in-group change.

#### Other Membership & Customers (in thousands)

Our Other products are often ancillary to our health business and can therefore be impacted by corresponding changes in our medical membership.

Behavioral health membership decreased 979, or 3.9%, primarily due to the overall declines in our fully-insured medical membership and negative in-group change.

Life and disability membership decreased 174, or 3.5%, primarily due to the overall declines in our commercial fully-insured medical membership and negative in-group change. Life and disability products are generally offered as part of commercial medical fully-insured membership sales.

Dental membership decreased 206, or 4.1%, primarily due to the lapse of a large dental contract, partially offset by the launch of new dental products in 2012.

Dental administration membership decreased 59, or 1.4%, primarily due to the lapse of a large contract pursuant to which we provided dental administrative services.

Vision membership increased 736, or 19.5%, primarily due to strong sales and positive in-group change in our National Accounts, Local Group and Medicare businesses.

Medicare Advantage Part D membership increased 99, or 15.6%, primarily due to strong sales during the open enrollment period resulting from our geographic expansion into several new counties and members acquired with the

acquisition of Amerigroup, partially offset by our withdrawal of the California Regional PPO Medicare Advantage product.

Medicare Part D standalone membership decreased 93, or 13.9%, primarily due to competitive pressure in certain markets.

Retail vision customers increased 3,130 due to our acquisition of 1-800 CONTACTS.

#### **Cost of Care**

The following discussion summarizes our aggregate underlying cost of care trends for the year ended December 31, 2013 for our Local Group fully-insured business only.

Our cost of care trends are calculated by comparing the year-over-year change in average per member per month claim costs, including member co-payments and deductibles. While our cost of care trend varies by geographic location, based on underlying medical cost trends, we estimate that our aggregate cost of care trend was approximately 6.0% for the full year of 2013. We anticipate that medical cost trends will increase by approximately 50 basis points in 2014.

Overall, our medical cost trend is driven by unit cost. Inpatient hospital trend is in the mid-to-high single digit range and is 80% cost driven and 20% utilization driven. While provider rate increases are a primary driver of unit cost trends, we continually negotiate with hospitals to manage these cost trends. We remain committed to optimizing our reimbursement rates and strategies to help address the cost pressures faced by employers and consumers. Inpatient admission counts per thousand members and inpatient day counts per thousand members are both slightly higher than the prior year. The average length of stay is slightly lower than the prior year. In addition to our re-contracting efforts, a number of clinical management initiatives are in place to help mitigate the inpatient trend. Focused review efforts continue in key areas, including targeting outlier facilities for length of stay and readmission, and spinal surgery cases, among others. Additionally, we continue to refine our programs related to readmission management, focused behavioral health readmission reduction and post-discharge follow-up care.

Outpatient trend is in the mid-single digit range and is 90% cost driven and 10% utilization driven. Outpatient costs are a collection of different types of expenses, such as outpatient facilities, labs, x-rays, emergency room, and occupational and physical therapy. Per visit costs are still the largest contributor to overall outpatient trend, influenced largely by price increases within certain provider contracts. Outpatient utilization (visits per thousand members) is slightly higher than the prior year. We continue to work with vendors and providers to help optimize site of service decisions, including key areas such as emergency room, lab, radiology, sleep studies, and surgery settings. As an example, we have launched a Sleep Management Program through our American Imaging Management subsidiary in west, central and north-east states. The program aligns the diagnosis and treatment of sleep apnea with clinical guidelines based on widely accepted medical literature, while at the same time enhancing member access to high value providers and ensuring treatment compliance for the continuing payment for equipment rental and ongoing supplies. Programs like this, along with continued expansion and optimization of our utilization management programs, are serving to moderate trend.

Physician services trend is in the mid-single digit range and is unit cost driven. Increases in the physician care category are partially driven by contracting changes. We continue to collaborate with physicians to improve quality of care through pay-for-performance programs and bundled payment initiatives. Additionally, we continue to enhance our ability to detect and deter fraud and abuse, reducing waste in the system.

Pharmacy trend is in the mid-single digit range and is 50% unit cost related and 50% utilization related. Continued inflation in the average wholesale price of drugs is applying upward pressure to the overall cost per prescription, as is the increasing cost of specialty drugs. The increase in cost per prescription measures continues to be mitigated by improvements in our generic usage rates and benefit plan design changes. We are continuously evaluating our drug formulary to ensure the most effective pharmaceutical therapies are available to our members.

In response to cost trends, we continue to pursue contracting and plan design changes, promote and implement performance-based contracts that reward clinical outcomes and quality, and expand our radiology management, disease management and advanced care management programs. We believe we are taking a leading role in the area of payment reform as evidenced by our Enhanced Personal Health Care program (previously the Patient Centered Primary Care program). By establishing the primary care doctor as central to the coordination of a patient's health care needs, the initiative

builds on the success of current patient-centered medical home programs in helping to improve patient care while lowering costs. We have instituted clinical liaisons working with participating provider offices sharing reports and cost of care data with providers as well as facilitating referrals to and from care management programs. Additionally, our value-based contracting initiative continues to underscore our commitment to partnering with providers to improve quality and lower cost.

# **Consolidated Results of Operations**

Our consolidated summarized results of operations for the years ended December 31, 2013, 2012 and 2011 are discussed in the following section.

Change

						Change					
	 Yea	rs E	nded Decemb	er 3	1		2013 vs	. 2012		. 2011	
	2013		2012		2011		\$	%		\$	%
Total operating revenue	\$ 70,191.4	\$	60,514.0	\$	59,865.2	\$	9,677.4	16.0	\$	648.8	1.1
Net investment income	659.1		686.1		703.7		(27.0)	(3.9)		(17.6)	(2.5)
Net realized gains on investments	271.9		334.9		235.1		(63.0)	(18.8)		99.8	42.5
Other-than-temporary impairment losses on investments	(98.9)		(37.8)		(93.3)		(61.1)	(161.6)		55.5	59.5
Total revenues	71,023.5		61,497.2		60,710.7		9,526.3	15.5		786.5	1.3
Benefit expense	56,237.1		48,213.6		47,647.5		8,023.5	16.6		566.1	1.2
Selling, general and administrative expense	9,952.9		8,680.5		8,435.6		1,272.4	14.7		244.9	2.9
Other expense <sup>1</sup>	993.3		744.8		669.7		248.5	33.4		75.1	11.2
Total expenses	67,183.3		57,638.9		56,752.8		9,544.4	16.6		886.1	1.6
Income from continuing operations before income tax expense	3,840.2		3,858.3		3,957.9		(18.1)	(0.5)		(99.6)	(2.5)
Income tax expense	1,205.9		1,207.3		1,311.2		(1.4)	(0.1)		(103.9)	(7.9)
Income from continuing operations	2,634.3		2,651.0		2,646.7		(16.7)	(0.6)		4.3	0.2
(Loss) income from discontinued operations, net of $\tan^2$	(144.6)		4.5		_		(149.1)	$NM^3$		4.5	_
Net income	\$ 2,489.7	\$	2,655.5	\$	2,646.7	\$	(165.8)	(6.2)	\$	8.8	0.3
				_							
Average diluted shares outstanding	303.8		324.8		365.1		(21.0)	(6.5)		(40.3)	(11.0)
Diluted net income (loss) per share:											
Diluted - continuing operations	\$ 8.67	\$	8.17	\$	7.25	\$	0.50	6.1	\$	0.92	12.7
Diluted - discontinued operations <sup>2</sup>	(0.47)		0.01		_		(0.48)	$NM^3$		0.01	_
Diluted net income per share	\$ 8.20	\$	8.18	\$	7.25	\$	0.02	0.2	\$	0.93	12.8
Benefit expense ratio <sup>4</sup>	85.1%		85.3%		85.1%			(20)bp <sup>5</sup>			20bp <sup>5</sup>
Selling, general and administrative expense ratio <sup>6</sup>	14.2%		14.3%		14.1%			(10)bp <sup>5</sup>			20bp <sup>5</sup>
Income from continuing operations before income taxes as a percentage of total revenue	5.4%		6.3%		6.5%			(90)bp <sup>5</sup>			(20)bp <sup>5</sup>
Net income as a percentage of total revenue	3.5%		4.3%		4.4%			(80)bp <sup>5</sup>			(10)bp <sup>5</sup>

Certain of the following definitions are also applicable to all other results of operations tables in this discussion:

<sup>1</sup> Includes interest expense, amortization of other intangible assets and loss on extinguishment of debt.

<sup>2</sup> The operating results of 1-800 CONTACTS are reported as discontinued operations at December 31, 2013 as a result of the pending divestiture.

<sup>3</sup> Calculation not meaningful.

<sup>4</sup> Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the years ended December 31, 2013, 2012 and 2011 were \$66,119.1, \$56,496.7 and \$55,969.6, respectively. Premiums are included in total operating revenue presented above.

<sup>5</sup> bp = basis point; one hundred basis points = 1%.

<sup>6</sup> Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.

#### Year Ended December 31, 2013 Compared to the Year Ended December 31, 2012

Total operating revenue increased \$9,677.4, or 16.0%, to \$70,191.4 in 2013, resulting primarily from higher premiums and, to a lesser extent, increased administrative fees. The higher premiums were mainly due to increases in our Medicaid business primarily as a result of our acquisition of Amerigroup in December 2012. Rate increases in our Local Group, FEP, Individual and National businesses designed to cover overall cost trends as well as premium rate and membership increases in our Specialty businesses and increased administrative fees resulting from pricing increases for self-funded members in our Commercial businesses also contributed to the increased operating revenue. These increases were partially offset by fully-insured membership declines in our Local Group business due to strategic portfolio changes in certain states, competitive pressure in certain markets and, we believe, affordability challenges affecting healthcare consumers in general. Additionally, lower revenues in our Medicare Advantage and Medicare Part D businesses primarily due to membership declines as a result of our product repositioning strategy toward HMO product offerings, partially offset the increased operating revenues.

Net investment income decreased \$27.0, or 3.9%, to \$659.1 in 2013, primarily due to lower investment yields.

Net realized gains on investments decreased \$63.0, or 18.8%, to \$271.9 in 2013, primarily due to lower net realized gains on sales of fixed maturity securities partially offset by an increase in net realized gains on sales of equity securities, a realized gain on the partial divestiture of an equity method investment and an increase in net realized gains on sales and settlements of derivative financial instruments.

Other-than-temporary impairment losses on investments increased \$61.1, or 161.6%, to \$98.9 in 2013, primarily due to the impairment of certain joint venture investments and fixed maturity securities.

Benefit expense increased \$8,023.5, or 16.6%, to \$56,237.1 in 2013, primarily from our acquisition of Amerigroup and increased benefit costs in our Local Group, Individual and FEP businesses. These increases were partially offset by the fully-insured membership declines in our Local Group and Medicare Advantage businesses as described above.

Our benefit expense ratio decreased 20.0 basis points to 85.1% in 2013, due, in part, to our product repositioning strategy in certain Medicare Advantage plans toward HMO product offerings with lower benefit costs. The decrease was further attributable to the favorable impact of declines in membership in our Local Group business in products with higher benefit costs and lower than expected medical cost trends. These improvements were partially offset by the acquisition of Amerigroup, which carries higher average benefit expense ratios than our consolidated average as well as higher than expected medical cost trends in our Individual business.

Selling, general and administrative expense increased \$1,272.4, or 14.7%, to \$9,952.9 in 2013, primarily due to the inclusion of selling, general and administrative expense related to our Amerigroup subsidiary in 2013. The increase was further attributable to costs incurred in preparation for the implementation of Health Care Reform effective in 2014 as well as increases in incentive compensation as a result of our operating performance.

Our selling, general and administrative expense ratio decreased 10.0 basis points to 14.2% in 2013, primarily due to the effect of the increase in operating revenue from Amerigroup partially offset by the increased selling general and administrative expense discussed in the preceding paragraph.

Other expenses increased \$248.5, or 33.4%, to \$993.3 in 2013, primarily due to losses on debt extinguishment of \$145.3 associated with our early redemption and repurchases of \$1,100.0 aggregate principal amount of outstanding notes. On July 30, 2013, we initiated a cash tender offer and consent solicitation to purchase certain of our outstanding 5.875% Notes due 2017, 7.000% Notes due 2019, 5.950% Notes due 2034, 5.850% Notes due 2036, 6.375% Notes due 2037 and 5.800% Notes due 2040 (collectively, the "Tendered Notes"). On August 13, 2013, we repurchased \$700.0 of the Tendered Notes for cash totaling \$837.7. Holders who tendered their notes prior to the early tender date received the principal amounts, applicable premium for early redemption and accrued and unpaid interest to the early tender offer settlement date. Additionally, on September 5, 2013, we redeemed the \$400.0 outstanding principal balance of our 6.000% senior unsecured notes due 2014, plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling \$411.0. The increase in other expense was further attributable to increased interest expense resulting from higher outstanding debt balances associated with our acquisition of Amerigroup and the issuance on July 30, 2013 of \$650.0 of 2.300% notes due 2018 and \$600.0 of 5.100% notes due 2044 to fund, in part, the early redemption and repurchases discussed above.

Income tax expense decreased \$1.4, or 0.1%, to \$1,205.9 in 2013. The effective tax rates in 2013 and 2012 were 31.4% and 31.3%, respectively. The effective tax rate in 2013 includes benefits resulting from a favorable tax election made subsequent to the Amerigroup acquisition and inclusion of Amerigroup in our state apportionment factors calculation, which produces a lower effective state tax rate. The effective tax rate in 2012 includes benefits resulting from settlement with the IRS of items related to not-for-profit conversions and corporate reorganizations prior to 2012, as well as issues related to certain of our acquired companies incurred prior to our acquisition of those companies. These favorable items in the 2012 effective tax rate were partially offset by increases due to the impact of non-tax deductible litigation settlement expenses and an increase in our state deferred tax asset valuation allowance attributable to uncertainty associated with certain state net operating loss carryforwards.

In December 2013, we entered into a definitive agreement to sell our 1-800 CONTACTS business and an asset purchase agreement to sell our glasses.com related assets (collectively, 1-800 CONTACTS). The operating results for 1-800 CONTACTS are reported as discontinued operations as a result of the pending divestiture at December 31, 2013. For the year ended December 31, 2013, we recorded a loss from discontinued operations, net of tax, of \$144.6 compared to income from discontinued operations, net of tax, of \$4.5 for the year ended December 31, 2012. Included in the loss from discontinued operations for the year ended December 31, 2013, is a loss on disposal of held for sale assets, net of tax, of \$164.5. The loss on disposal was calculated as the difference between the fair value, as determined by the sales agreements less costs to sell, and the carrying value of the held for sale assets at December 31, 2013. The divestitures were completed on January 31, 2014 and did not result in any material difference to the loss on disposal recognized during the year ended December 31, 2013.

Our net income as a percentage of total revenue decreased 80.0 basis points to 3.5% in 2013 as compared to 2012 as a result of all factors discussed above.

# Year Ended December 31, 2012 Compared to the Year Ended December 31, 2011

Total operating revenue increased \$648.8, or 1.1% to \$60,514.0 in 2012, resulting primarily from higher premium revenue and, to a lesser extent, increased administrative fees. The higher premium revenue was due primarily to membership growth in our Medicare Advantage business, including CareMore, and growth in our Medicaid business, primarily in the California market, as well as revenue from Amerigroup's operations during the post-acquisition period. In addition, premium rate increases in our Local Group and Individual businesses designed to cover overall cost trends and increased reimbursement in our FEP business contributed to the increased premium revenue. These increases were partially offset by fully-insured membership declines in our Local Group business resulting from strategic product portfolio changes in certain states, competitive pressure in certain markets and unfavorable economic conditions. Administrative fees increased primarily as a result of pricing increases for self-funded members in our National Accounts and Local Group businesses, partially offset by membership declines in our self-funded National Accounts business.

Net investment income decreased \$17.6, or 2.5%, to \$686.1 in 2012, primarily due to lower investment yields, partially offset by higher average cash and investment balances resulting from debt issuances in 2012, including the debt issuance related to our acquisition of Amerigroup.

Net realized gains on investments increased \$99.8, or 42.5%, to \$334.9 in 2012, primarily due to increased gains on sales of fixed maturity securities as a result of improved market conditions.

Other-than-temporary impairment losses on investments decreased \$55.5, or 59.5%, to \$37.8 in 2012, primarily due to improved market conditions.

Benefit expense increased \$566.1, or 1.2%, to \$48,213.6 in 2012, primarily due to increases in our Medicare and Medicaid businesses, partially offset by decreases in our Local Group business. The increase in our Medicare business was driven primarily by membership growth in our Medicare Advantage business, including CareMore, while the increase in our Medicaid business was driven by both increased benefit cost trends and membership growth, including membership acquired with the acquisition of Amerigroup. These increases were partially offset by the fully-insured membership declines in our Local Group business as described above, as well as favorable prior year reserve development in 2012 compared to modest reserve strengthening in 2011.

Our benefit expense ratio increased 20 basis points to 85.3% in 2012, primarily due to higher medical costs in our Medicaid business, primarily in California. The benefit expense ratio increase was partially offset by improvements in our

Local Group and Medicare businesses and the favorable prior year reserve development.

Selling, general and administrative expense increased \$244.9, or 2.9%, to \$8,680.5 in 2012, primarily due to additional selling, general and administrative expense related to CareMore, acquisition and integration related expenses associated with Amerigroup and the impairment of certain software assets, partially offset by lower employee incentive compensation costs.

Our selling, general and administrative expense ratio increased 20 basis points to 14.3% in 2012, primarily due to the increased selling, general and administrative expense discussed in the preceding paragraph, partially offset by increased operating revenue.

Other expense increased \$75.1, or 11.2%, to \$744.8 in 2012 primarily due to increased interest expense resulting from higher outstanding debt balances and financing costs associated with our acquisition of Amerigroup.

Income tax expense decreased \$103.9, or 7.9%, to \$1,207.3 in 2012, primarily due to a lower effective tax rate in 2012 and, to a lesser extent, lower income from continuing operations before income tax expense. The effective tax rates in 2012 and 2011 were 31.3% and 33.1%, respectively. The effective tax rate decreased primarily due to the impact from the 2012 settlement with the IRS of items related to not-for-profit conversions and corporate reorganizations in prior years, as well as issues related to certain of our acquired companies incurred prior to our acquisition of those companies. This was partially offset by increases due to the impact of non-tax deductible litigation settlement expenses and an increase in our state deferred tax asset valuation allowance attributable to uncertainty associated with certain state net operating loss carryforwards.

Our net income as a percentage of total revenue decreased 10 basis points to 4.3% in 2012 as compared to 2011 as a result of all factors discussed above.

# Reportable Segments Results of Operations

We use operating gain to evaluate the performance of our reportable segments, which are Commercial and Specialty Business; Government Business; and Other. Operating gain is calculated as total operating revenue less benefit expense and selling, general and administrative expense. It does not include net investment income, net realized gains/losses on investments, other-than-temporary impairment losses recognized in income, interest expense, amortization of other intangible assets, loss on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. For additional information, including a reconciliation of non-GAAP financial measures, see Note 20, "Segment Information," to our audited consolidated financial statements as of and for the year ended December 31, 2013 included in this Form 10-K. The discussion of segment results for the years ended December 31, 2013, 2012 and 2011 presented below are based on operating gain, as described above, and operating margin, which is calculated as operating gain divided by operating revenue. Our definitions of operating gain and operating margin may not be comparable to similarly titled measures reported by other companies.

Our Commercial and Specialty Business, Government Business, and Other segments' summarized results of operations for the years ended December 31, 2013, 2012 and 2011 are as follows:

							ge					
	Ye	ars E	Ended Decemb	er 31	L	2013 vs	. 2012		2012 vs. 2011			
	2013		2012		2011	\$	%		\$	%		
Commercial and Specialty Business												
Operating revenue	\$ 38,790.1	\$	38,852.9	\$	39,961.2	\$ (62.8)	(0.2)%	\$	(1,108.3)	(2.8)%		
Operating gain	\$ 3,093.3	\$	3,339.7	\$	3,344.5	\$ (246.4)	(7.4)%	\$	(4.8)	(0.1)%		
							)					
Operating margin	8.0%		8.6%		8.4%		(60bp			20bp		
<b>Government Business</b>												
Operating revenue	\$ 31,366.7	\$	21,625.7	\$	19,874.0	\$ 9,741.0	45.0 %	\$	1,751.7	8.8 %		
Operating gain	\$ 927.1	\$	341.8	\$	461.6	\$ 585.3	171.2 %	\$	(119.8)	(26.0)%		
										)		
Operating margin	3.0%		1.6%		2.3%		140bp			(70bp		
Other												
Operating revenue <sup>1</sup>	\$ 34.6	\$	35.4	\$	30.0	\$ (0.8)	(2.3)%	\$	5.4	18.0 %		
Operating loss <sup>2</sup>	\$ (19.0)	\$	(61.6)	\$	(24.0)	\$ 42.6	(69.2)%	\$	(37.6)	156.7 %		

Fluctuations not material.

Year Ended December 31, 2013 Compared to the Year Ended December 31, 2012

# **Commercial and Specialty Business**

Operating revenue decreased \$62.8, or 0.2%, to \$38,790.1 in 2013, primarily due to fully-insured membership declines in our Local Group business resulting from strategic product portfolio changes in certain states, competitive pressure in certain markets and, we believe, affordability challenges affecting healthcare consumers in general. This decrease was partially offset by premium rate increases in our Local Group, Individual and National businesses designed to cover overall cost trends, premium rate and membership increases in our Specialty businesses, primarily related to our dental and vision products, as well as increased administrative fees resulting from pricing increases for self-funded members in our Commercial businesses.

Operating gain decreased \$246.4, or 7.4%, to \$3,093.3 in 2013, primarily as a result of higher selling, general and administrative expenses driven by costs incurred in preparation for the implementation of Health Care Reform provisions that become effective in 2014 as well as increases in allocated incentive compensation as a result of consolidated operating performance. The decrease was further attributable to increased benefit costs in our Individual business. These decreases were partially offset by improved results in our Local Group business resulting from lower than anticipated medical cost trends.

The operating margin in 2013 was 8.0%, a 60 basis point decrease over 2012, primarily due to the factors discussed in the preceding two paragraphs.

# **Government Business**

Operating revenue increased \$9,741.0, or 45.0%, to \$31,366.7 in 2013, primarily due to the acquisition of Amerigroup, growth in our FEP business due to premium rate increases designed to cover overall cost trends, and increases in membership in our CareMore and FEP businesses. These increases were partially offset by membership declines in our non-CareMore Medicare Advantage and Medicare Part D businesses related to our product repositioning strategy toward HMO product offerings.

Operating gain increased \$585.3, or 171.2%, to \$927.1 in 2013, primarily due to the acquisition of Amerigroup and

<sup>2</sup> Fluctuations primarily a result of changes in unallocated corporate expenses.

improved operating results in the majority of our other government lines of business.

The operating margin in 2013 was 3.0%, a 140 basis point increase from 2012, primarily due to the factors discussed in the preceding two paragraphs.

#### Year Ended December 31, 2012 Compared to the Year Ended December 31, 2011

# **Commercial and Specialty Business**

Operating revenue decreased \$1,108.3, or 2.8%, to \$38,852.9 in 2012, primarily due to fully-insured membership declines in our Local Group business resulting from strategic product portfolio changes in certain states, competitive pressure in certain markets and unfavorable economic conditions, partially offset by premium rate increases in our Local Group business designed to cover overall cost trends. Partially offsetting the decline in premium revenue was an increase in administrative fees resulting from pricing increases for self-funded members in our National Accounts and Local Group businesses.

Operating gain decreased \$4.8, or 0.1%, to \$3,339.7 in 2012, primarily as a result of declines in our Local Group business due to fully-insured membership losses as a result of strategic product portfolio changes in certain markets, competitive pressure in certain markets and unfavorable economic conditions as well as declines in our Individual business due to higher benefit cost trends. These decreases were partially offset by an improved benefit expense ratio for our Local Group business, including the impact of favorable prior year reserve development in 2012 compared to modest reserve strengthening in 2011.

The operating margin in 2012 was 8.6%, a 20 basis point increase from 2011, primarily due to the factors discussed in the preceding two paragraphs.

#### **Government Business**

Operating revenue increased \$1,751.7, or 8.8%, to \$21,625.7 in 2012, primarily due to membership growth in our Medicare Advantage business, including CareMore, and, to a lesser extent, growth in our Medicaid business resulting from retroactive premium rate increases in the California market as well as premium revenue from Amerigroup's operations during the post-acquisition period. Additionally, growth in our FEP business resulting from premium rate increases designed to cover overall cost trends during 2012 contributed to the increase.

Operating gain decreased \$119.8, or 26.0%, to \$341.8 in 2012, primarily due to declines in our Medicaid business due to higher benefit cost trends and increased general and administrative expense resulting from transaction expenses associated with the Amerigroup acquisition and restructuring activities.

The operating margin in 2012 was 1.6%, a 70 basis point decrease from 2011, primarily due to the factors discussed in the preceding two paragraphs.

#### **Critical Accounting Policies and Estimates**

We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits, which are discussed below. Our other significant accounting policies are summarized in Note 2, "Basis of Presentation and Significant Accounting Policies," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In general, our estimates are based on historical experience, evaluation of current trends, information from third party professionals and various other assumptions that we believe to be reasonable under the known facts and circumstances.

## Medical Claims Payable

The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. At December 31, 2013, this liability was \$6,127.2 and represented 17.6% of our total consolidated liabilities. We record this liability and the corresponding benefit expense for incurred but not paid claims including the estimated costs of processing such claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems, which approximated 95.5%, or \$5,851.0, of our total medical claims liability as of December 31, 2013; and (2) claims reported to us and processed through our systems but not yet paid, which approximated 4.5%, or \$276.2, of the total medical claims payable as of December 31, 2013. The level of claims payable processed through our systems but not yet paid may fluctuate from one period end to the next, from 1% to 5% of our total medical claims liability, due to timing of when claim payments are made.

Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in aggregate, employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into "claim triangles," which compare claim incurred dates to the dates of claim payments. This information is analyzed to create "completion factors" that represent the average percentage of total incurred claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period end date to estimate the ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.

For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical completion and payment patterns; rather they are projected by estimating the claims expense for those months based on recent claims expense levels and health care trend levels, or "trend factors."

Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes. These adjustments are made by our actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed. Circumstances to be considered in developing our best estimate of reserves include changes in utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. A comparison of prior period liabilities to re-estimated claim liabilities based on subsequent claims development is also considered in making the liability determination. In our comparison of prior year, the methods and assumptions are not changed as reserves are recalculated; rather the availability of additional paid claims information drives our changes in the re-estimate of the unpaid claim liability. To the extent appropriate, changes in such development are recorded as a change to current period benefit expense.

We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are significantly different than actual results, our income statement and financial position could be impacted in future periods. Adjustments of prior year estimates may result in additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the considerable variability of health care costs, adjustments to claim liabilities occur each period and are sometimes significant as compared to the net income recorded in that period. Prior period development is recognized immediately upon the actuary's judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is reasonable.

While there are many factors that are used as a part of the estimation of our medical claims payable liability, the two key assumptions having the most significant impact on our incurred but not paid claims liability as of December 31, 2013 were the completion and trend factors. As discussed above, these two key assumptions can be influenced by other operational

variables including system changes, provider submission patterns and business combinations.

There is variation in the reasonable choice of completion factors by duration for durations of three months through twelve months where the completion factors have the most significant impact. As previously discussed, completion factors tend to be less reliable for the most recent months and therefore are not specifically utilized for months one and two. In our analysis for the claim liabilities at December 31, 2013, the variability in months three to five was estimated to be between 40 and 90 basis points, while months six through twelve have much lower variability ranging from 0 to 30 basis points.

The difference in completion factor assumptions, assuming moderately adverse experience, results in variability of 2%, or approximately \$146.0, in the December 31, 2013 incurred but not paid claims liability, depending on the completion factors chosen. It is important to note that the completion factor methodology inherently assumes that historical completion rates will be reflective of the current period. However, it is possible that the actual completion rates for the current period will develop differently from historical patterns and therefore could fall outside the possible variations described herein.

The other major assumption used in the establishment of the December 31, 2013 incurred but not paid claim liability was the trend factors. In our analysis for the period ended December 31, 2013, there was a 310 basis point differential in the high and low trend factors assuming moderately adverse experience. This range of trend factors would imply variability of 5%, or approximately \$279.0, in the incurred but not paid claims liability, depending upon the trend factors used. Because historical trend factors are often not representative of current claim trends, the trend experience for the most recent six to nine months, plus knowledge of recent events likely affecting current trends, have been taken into consideration in establishing the incurred but not paid claims liability at December 31, 2013.

See Note 12, "Medical Claims Payable," to our audited consolidated financial statements as of and for the year ended December 31, 2013 included in this Form 10-K, for a reconciliation of the beginning and ending balance for medical claims payable for the years ended December 31, 2013, 2012 and 2011. Components of the total incurred claims for each year include amounts accrued for current year estimated claims expense as well as adjustments to prior year estimated accruals. In Note 12, "Medical Claims Payable," the line labeled "Net incurred medical claims: Prior years redundancies" accounts for those adjustments made to prior year estimates. The impact of any reduction of "Net incurred medical claims: Prior years redundancies" may be offset as we establish the estimate of "Net incurred medical claims: Current year." Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for our claims. When we recognize a release of the redundancy, we disclose the amount that is not in the ordinary course of business, if material.

The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 89.3% for 2013, 89.1% for 2012 and 88.8% for 2011. The increase in these ratios reflects acceleration in processing claims that occurred over the course of the past three years.

We calculate the percentage of prior years' redundancies in the current year as a percent of prior years' net incurred claims payable less prior years' redundancies in the current year in order to demonstrate the development of the prior years' reserves. This metric was 10.8% for the year ended December 31, 2013, 10.4% for the year ended December 31, 2012 and 4.5% for the year ended December 31, 2011. The years ended December 31, 2013 and 2012 reflect a higher level of targeted reserve for adverse deviation and a resultant higher level of prior years' redundancies than the year ended December 31, 2011.

We calculate the percentage of prior years' redundancies in the current period as a percent of prior years' net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the year ended December 31, 2013, this metric was 1.3%, which was calculated using the redundancy of \$599.1. This metric was 1.1% for 2012 and 0.5% for 2011.

The following table shows the variance between total net incurred medical claims as reported in Note 12, "Medical Claims Payable," to our audited consolidated financial statements as of and for the year ended December 31, 2013 included in this Form 10-K, for each of 2012 and 2011 and the incurred claims for such years had it been determined retrospectively (computed as the difference between "net incurred medical claims – current year" for the year shown and "net incurred medical claims – prior years redundancies" for the immediately following year):

		Years Ended December 31						
			2011					
Total net incurred medical claims, as reported	\$	47,566.5	\$	47,071.9				
Retrospective basis, as described above		47,481.0		46,768.0				
Variance	\$	85.5	\$	303.9				
Variance to total net incurred medical claims, as reported		0.2%		0.6%				

Given that our business is primarily short tailed (which means that medical claims are generally paid within twelve months of the member receiving service from the provider), the variance to total net incurred medical claims, as reported above, is used to assess the reasonableness of our estimate of ultimate incurred medical claims for a given calendar year with the benefit of one year of experience. We expect that substantially all of the development of the 2013 estimate of medical claims payable will be known during 2014.

The 2012 variance to total net incurred medical claims, as reported of 0.2% was smaller in value than the 2011 percentage of 0.6%. The lower 2012 variance was driven by a more consistent level of prior year redundancies in 2013 and 2012 associated with 2012 and 2011 claim payments, respectively. Prior year redundancies in 2011 associated with 2010 claim payments were much lower by comparison, thus creating a higher 2011 variance.

#### Income Taxes

We account for income taxes in accordance with FASB guidance, which requires, among other things, the separate recognition of deferred tax assets and deferred tax liabilities. Such deferred tax assets and deferred tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at tax rates enacted at the time the deferred tax asset or liability is recorded. A valuation allowance must be established for deferred tax assets if it is "more likely than not" that all or a portion may be unrealized. Our judgment is required in determining an appropriate valuation allowance.

At each financial reporting date, we assess the adequacy of the valuation allowance by evaluating each of our deferred tax assets based on the following:

- the types of temporary differences that created the deferred tax asset;
- the amount of taxes paid in prior periods and available for a carry-back claim;
- · the forecasted future taxable income, and therefore, likely future deduction of the deferred tax item; and
- any significant other issues impacting the likely realization of the benefit of the temporary differences.

We, like other companies, frequently face challenges from tax authorities regarding the amount of taxes due. These challenges include questions regarding the timing and amount of deductions that we have taken on our tax returns. In evaluating any additional tax liability associated with various positions taken in our tax return filings, we record additional liabilities for potential adverse tax outcomes. Based on our evaluation of our tax positions, we believe we have appropriately accrued for uncertain tax benefits, as required by the guidance. To the extent we prevail in matters we have accrued for, our future effective tax rate would be reduced and net income would increase. If we are required to pay more than accrued, our future effective tax rate would increase and net income would decrease. Our effective tax rate and net income in any given future period could be materially impacted.

In the ordinary course of business, we are regularly audited by federal and other tax authorities, and from time to time, these audits result in proposed assessments. We believe our tax positions comply with applicable tax law and we intend to defend our positions vigorously through the federal, state and local appeals processes. We believe we have adequately

provided for any reasonable foreseeable outcome related to these matters. Accordingly, although their ultimate resolution may require additional tax payments, we do not anticipate any material impact on our results of operations from these matters.

For additional information, see Note 8, "Income Taxes," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### Goodwill and Other Intangible Assets

Our consolidated goodwill at December 31, 2013 was \$16,917.2 and other intangible assets were \$8,441.0. The sum of goodwill and other intangible assets represented 42.6% of our total consolidated assets and 102.4% of our consolidated shareholders' equity at December 31, 2013.

We follow FASB guidance for business combinations and goodwill and other intangible assets, which specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Under the guidance, goodwill and other intangible assets (with indefinite lives) are not amortized but are tested for impairment at least annually. Furthermore, goodwill and other intangible assets are allocated to reporting units for purposes of the annual impairment test. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, which include goodwill and other intangible assets. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.

We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. These tests involve the use of estimates related to the fair value of goodwill at the reporting unit level and other intangible assets with indefinite lives, and require a significant degree of management judgment and the use of subjective assumptions. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur.

Fair value is estimated using the income and market approaches for goodwill at the reporting unit level and the income approach for our indefinite lived intangible assets. Use of the income and market approaches for our goodwill impairment test reflects our view that both valuation methodologies provide a reasonable estimate of fair value. The income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. These estimated future cash flows are then discounted. Our assumed discount rate is based on our industry's weighted-average cost of capital. Market valuations are based on observed multiples of certain measures including membership, revenue and EBITDA (earnings before interest, taxes, depreciation and amortization) and include market comparisons to publicly traded companies in our industry.

With the exception of the treatment associated with our 1-800 CONTACTS disposal, we did not incur any impairment losses as a result of our 2013 annual impairment tests as the estimated fair values of our reporting units were substantially in excess of the carrying values as of December 31, 2013. Additionally, we do not believe that the estimated fair values of our reporting units are at risk of becoming impaired in the next twelve months. However, as a result of certain provisions of Health Care Reform, along with current economic conditions and continued high unemployment rates, we have experienced lower operating margins in certain lines of business. Those margins could become further compressed if unemployment levels remain high and if results from implementation of Health Care Reform are significantly different than anticipated. As a result, the estimated fair values of certain of our reporting units with goodwill could fall below their carrying values in future periods and if that were to occur, we would be required to record impairment losses at that time.

While we believe we have appropriately allocated the purchase price of our acquisitions, this allocation requires many assumptions to be made regarding the fair value of assets and liabilities acquired. In addition, estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used. If estimated fair values are less than the carrying values of goodwill and other intangibles with indefinite lives in future annual impairment tests, or if significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

For additional information, see Note 3, "Business Acquisitions and Divestitures" and Note 10, "Goodwill and Other Intangible Assets," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### Investments

Current and long-term available-for-sale investment securities were \$19,254.9 at December 31, 2013 and represented 32.3% of our total consolidated assets at December 31, 2013. We classify fixed maturity and equity securities in our investment portfolio as "available-for-sale" or "trading" and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.

We review investment securities to determine if declines in fair value below cost are other-than-temporary. This review is subjective and requires a high degree of judgment. We conduct this review on a quarterly basis, using both qualitative and quantitative factors, to determine whether a decline in value is other-than-temporary. Such factors considered include the length of time and the extent to which a security's market value has been less than its cost, the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors), financial condition and near term prospects of the issuer, including the credit ratings and changes in the credit ratings of the issuer, recommendations of investment advisors, and forecasts of economic, market or industry trends. In addition, for equity securities, we determine whether we have the intent and ability to hold the security for a period of time to allow for a recovery of its fair value above its carrying amount. If any declines of equity securities are determined to be other-than-temporary, we charge the losses to income when that determination is made.

Certain FASB other-than-temporary impairment, or FASB OTTI, guidance applies to fixed maturity securities and provides guidance on the recognition and presentation of other-than-temporary impairments. In addition, this FASB OTTI guidance requires disclosures related to other-than-temporary impairments. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in our consolidated income statements. For impaired fixed maturity securities that we do not intend to sell or it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment losses recognized in income in our consolidated statements of income and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income.

The credit component of an other-than-temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other debt securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings, and estimates regarding timing and amount of recoveries associated with a default.

We have a committee of accounting and investment associates and management that is responsible for managing the impairment review process. The current economic environment and volatility of securities markets increase the difficulty of assessing investment impairment and the same influences tend to increase the risk of potential impairment of these assets.

We believe we have adequately reviewed our investment securities for impairment and that our investment securities are carried at fair value. However, over time, the economic and market environment may provide additional insight regarding the fair value of certain securities, which could change our judgment regarding impairment. This could result in other-than-temporary impairment losses on investments being charged against future income. Given the current market conditions and the significant judgments involved, there is continuing risk that further declines in fair value may occur and additional, material other-than-temporary impairment losses on investments may be recorded in future periods.

In addition to available-for-sale investment securities, we held additional long-term investments of \$1,542.6, or 2.6% of total consolidated assets, at December 31, 2013. These long-term investments consisted primarily of certain other equity

investments, cash surrender value of corporate-owned life insurance policies and real estate. Due to their less liquid nature, these investments are classified as long-term.

Through our investing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity market valuations. We manage the market risks through our investment policy, which establishes credit quality limits and limits on investments in individual issuers. Ineffective management of these risks could have an impact on our future earnings and financial position. Our investment portfolio includes fixed maturity securities with a fair value of \$17,488.1 at December 31, 2013. The weighted-average credit rating of these securities was "A" as of December 31, 2013. Included in this balance are investments in fixed maturity securities of states, municipalities and political subdivisions and mortgage-backed securities of \$1,699.8 and \$9.7, respectively, that are guaranteed by third parties. With the exception of eleven securities with a fair value of \$9.7, these securities are all investment-grade and carry a weighted-average credit rating of "AA" as of December 31, 2013. The securities are guaranteed by a number of different guarantors and we do not have any significant exposure to any single guarantor (neither indirect through the guarantees, nor direct through investment in the guaranter). Further, due to the high underlying credit rating of the issuers, the weighted-average credit rating of these securities without the guarantee was "AA" as of December 31, 2013 for the securities for which such information is available.

Fair values of available-for-sale fixed maturity and equity securities are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs for the determination of fair value in accordance with FASB guidance for fair value measurements and disclosures. We have controls in place to review the third party pricing services' qualifications and procedures used to determine fair values. In addition, we periodically review the third party pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

We obtain only one quoted price for each security from third party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. For securities not actively traded, the third party pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. As we are responsible for the determination of fair value, we perform monthly analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of month-to-month price fluctuations. If unusual fluctuations are noted in this review, we may obtain additional information from other pricing services to validate the quoted price. There were no adjustments to quoted market prices obtained from third party pricing services during the years ended December 31, 2013 and 2012.

In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and therefore, such inputs are estimated internally. Such securities are designated Level III in accordance with FASB guidance. Securities designated Level III at December 31, 2013 totaled \$177.9 and represented less than 1% of our total assets measured at fair value on a recurring basis. Our Level III securities primarily consisted of certain corporate securities, equity securities and structured securities for which observable inputs were not always available and the fair values of these securities were estimated using internal estimates for inputs including, but not limited to, prepayment speeds, credit spreads, default rates and benchmark yields.

For additional information, see Part II, Item 7A "Quantitative and Qualitative Disclosures about Market Risk" in this Form 10-K, and Note 2, "Basis of Presentation and Significant Accounting Policies," Note 5, "Investments," and Note 7, "Fair Value," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

# Retirement Benefits

# **Pension Benefits**

We sponsor defined benefit pension plans for some of our employees. These plans are accounted for in accordance with FASB guidance for retirement benefits, which requires that amounts recognized in financial statements be determined on an actuarial basis. As permitted by the guidance, we calculate the value of plan assets as described below. Further, the difference

between our expected rate of return and the actual performance of plan assets, as well as certain changes in pension liabilities, are amortized over future periods.

An important factor in determining our pension expense is the assumption for expected long-term return on plan assets. As of our December 31, 2013 measurement date, we selected a weighted-average long-term rate of return on plan assets of 7.66%, consistent with our prior year assumption. We use a total portfolio return analysis in the development of our assumption. Factors such as past market performance, the long-term relationship between fixed maturity and equity securities, interest rates, inflation and asset allocations are considered in the assumption. The assumption includes an estimate of the additional return expected from active management of the investment portfolio. Peer data and an average of historical returns are also reviewed for appropriateness of the selected assumption. We believe our assumption of future returns is reasonable. However, if we lower our expected long-term return on plan assets, future contributions to the pension plan and pension expense would likely increase.

This assumed long-term rate of return on assets is applied to a calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years, producing the expected return on plan assets that is included in the determination of pension expense. The difference between this expected return and the actual return on plan assets is deferred and amortized over the average remaining service of the workforce as a component of pension expense. The net deferral of past asset gains or losses affects the calculated value of plan assets and, ultimately, future pension expense.

The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent measurement date, December 31, 2013. The selected weighted-average discount rate was 4.39%, which was developed using a yield curve approach. Using yields available on high-quality fixed maturity securities with various maturity dates, the yield curve approach provides a "customized" rate, which is meant to match the expected cash flows of our specific benefit plans. The net effect of changes in the discount rate, as well as the net effect of other changes in actuarial assumptions and experience, have been deferred and amortized as a component of pension expense in accordance with FASB guidance.

In managing the plan assets, our objective is to be a responsible fiduciary while minimizing financial risk. Plan assets include a diversified mix of investment grade fixed maturity securities, equity securities and alternative investments across a range of sectors and levels of capitalization to maximize the long-term return for a prudent level of risk. In addition to producing a reasonable return, the investment strategy seeks to minimize the volatility in our expense and cash flow.

# **Other Postretirement Benefits**

We provide most associates with certain medical, vision and dental benefits upon retirement. We use various actuarial assumptions, including a discount rate and the expected trend in health care costs, to estimate the costs and benefit obligations for our retiree benefits.

At our December 31, 2013 measurement date, the selected discount rate for all plans was 4.48%, compared to a discount rate of 3.71% at the December 31, 2012 measurement date. We developed this rate using a yield curve approach as described above.

The assumed health care cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December 31, 2013 measurement date was 8.00% for 2014 with a gradual decline to 4.50% by the year 2025. The assumed health care cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2013 measurement date was 6.00% for 2014 with a gradual decline to 4.50% by the year 2021. These estimated trend rates are subject to change in the future. The health care cost trend rate assumption has a significant effect on the amounts reported. For example, an increase in the assumed health care cost trend rate of one percentage point would increase the postretirement benefit obligation as of December 31, 2013 by \$44.2 and would increase service and interest costs by \$1.8. Conversely, a decrease in the assumed health care cost trend rate of one percentage point would decrease the postretirement benefit obligation by \$38.1 as of December 31, 2013 and would decrease service and interest costs by \$1.5.

For additional information regarding our retirement benefits, see Note 11, "Retirement Benefits," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

## New Accounting Pronouncements

For information regarding new accounting pronouncements that were issued or became effective during the year ended December 31, 2013 that had, or are expected to have a material impact on our financial position, results of operations or financial statement disclosures, see the "New Accounting Pronouncements" section of Note 2, "Basis of Presentation and Significant Accounting Policies" to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

## **Liquidity and Capital Resources**

#### Introduction

Our cash receipts result primarily from premiums, administrative fees, investment income, other revenue, proceeds from the sale or maturity of our investment securities, proceeds from borrowings, and proceeds from the exercise of stock options. Cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.

We manage our cash, investments and capital structure so we are able to meet the short and long-term obligations of our business while maintaining financial flexibility and liquidity. We forecast, analyze and monitor our cash flows to enable investment and financing within the overall constraints of our financial strategy.

A substantial portion of the assets held by our regulated subsidiaries are in the form of cash and cash equivalents and investments. After considering expected cash flows from operating activities, we generally invest cash that exceeds our near term obligations in longer term marketable fixed maturity securities to improve our overall investment income returns. Our investment strategy is to make investments consistent with insurance statutes and other regulatory requirements, while preserving our asset base. Our investments are generally available-for-sale to meet liquidity and other needs. Our subsidiaries pay out excess capital annually in the form of dividends to their respective parent companies for general corporate use, as permitted by applicable regulations.

The availability of financing in the form of debt or equity is influenced by many factors including our profitability, operating cash flows, debt levels, debt ratings, contractual restrictions, regulatory requirements and market conditions. The securities and credit markets have in the past experienced higher than normal volatility, although current market conditions are more stable. During recent years, the Federal Government and various governmental agencies have taken a number of steps to restore liquidity in the financial markets and to help relieve the credit crisis and strengthen the regulation of the financial services market. In addition, governments around the world have developed their own plans to provide liquidity and security in the credit markets and to ensure adequate capital in certain financial institutions.

We have a \$2,500.0 commercial paper program. Should commercial paper issuance be unavailable, we intend to use a combination of cash on hand and/or our \$2,000.0 senior revolving credit facility to redeem our commercial paper when it matures. While there is no assurance in the current economic environment, we believe the lenders participating in our credit facility will be willing and able to provide financing in accordance with their legal obligations. In addition to the \$2,000.0 senior revolving credit facility, we estimate that we will receive approximately \$2,100.0 of dividends from our subsidiaries during 2014, which also provides further operating and financial flexibility.

The table below outlines the cash flows provided by or used in operating, investing and financing activities for the years ended December 31, 2013, 2012 and 2011:

	 Years Ended December 31									
	2013	2012			2011					
Cash flows provided by (used in):	 									
Operating activities	\$ 3,052.3	\$	2,744.6	\$	3,374.4					
Investing activities	(2,234.4)		(4,551.6)		(942.0)					
Financing activities	(1,717.8)		2,088.9		(2,019.2)					
Effect of foreign exchange rates on cash and cash equivalents	2.2		1.1		(0.4)					
(Decrease) increase in cash and cash equivalents	\$ (897.7)	\$	283.0	\$	412.8					

# Liquidity—Year Ended December 31, 2013 Compared to Year Ended December 31, 2012

During the year ended December 31, 2013, net cash flow provided by operating activities was \$3,052.3, compared to \$2,744.6 for the year ended December 31, 2012, an increase of \$307.7. This increase was driven primarily by an increase in net income adjusted for non-cash items, primarily due to the loss on disposal of discontinued operations, changes in amortization expense and realized losses on extinguishment of debt. The increase was further attributable to an increase in net cash flow provided by Amerigroup as 2012 included post-acquisition change-in-control payments and transaction costs that did not recur in 2013. Additionally, the increase was due to a net increase in the collection of income tax refunds in 2013.

Net cash flow used in investing activities was \$2,234.4 during the year ended December 31, 2013, compared to \$4,551.6 for the year ended December 31, 2012. The decrease in cash flow used in investing activities of \$2,317.2 primarily resulted from a decrease in cash used for the purchase of subsidiaries, as net cash used in investing activities for 2012 included the acquisitions of Amerigroup and 1-800 CONTACTS, while there were no purchases of subsidiaries in 2013. This decrease was partially offset by the net change in investment activity and changes in securities lending collateral.

Net cash flow used in financing activities was \$1,717.8 during the year ended December 31, 2013, compared to net cash flow provided by financing activities of \$2,088.9 for the year ended December 31, 2012. The change in cash flow from financing activities of \$3,806.7 primarily resulted from an increase in long-term borrowings in 2012 primarily used to fund the acquisition of Amerigroup compared to an increase in net repayments of long-term borrowings in 2013. The change in cash flow from financing activity was further attributable to a decrease in common stock repurchases, changes in securities lending payable, and an increase in proceeds from the issuance of common stock under our employee stock plans.

# Liquidity—Year Ended December 31, 2012 Compared to Year Ended December 31, 2011

During the year ended December 31, 2012, net cash flow provided by operating activities was \$2,744.6, compared to \$3,374.4 for the year ended December 31, 2011, a decrease of \$629.8. This decrease was driven primarily by payments related to the run-out of medical claims for former members, net operating cash outflows by our Amerigroup subsidiary during the post-acquisition period (including claims payments, change-incontrol payments and payments for transaction costs), increased litigation settlement payments and the addition of required minimum MLR rebate payments in 2012 (which were established as liabilities during the year ended December 31, 2011).

Net cash flow used in investing activities was \$4,551.6 during the year ended December 31, 2012, compared to \$942.0 for the year ended December 31, 2011. The increase in cash flow used in investing activities of \$3,609.6 between the two periods primarily resulted from an increase in the purchase of subsidiaries, reflecting the acquisitions of Amerigroup and 1-800 CONTACTS during 2012, and an increase in purchases of property and equipment, partially offset by changes in securities lending collateral and an increase in the net proceeds from the sales of investments.

Net cash flow provided by financing activities was \$2,088.9 during the year ended December 31, 2012, compared to net cash flow used in financing activities of \$2,019.2 for the year ended December 31, 2011. The increase in cash flow provided by financing activities of \$4,108.1 primarily resulted from an increase in net proceeds from long-term borrowings and a decrease in common stock repurchases, partially offset by changes in bank overdrafts, changes in securities lending payable and a decrease in the proceeds from the issuance of common stock under our employee stock plans.

#### Financial Condition

We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments, including long-term investments, of \$22,395.9 at December 31, 2013. Since December 31, 2012, total cash, cash equivalents and investments, including long-term investments, decreased by \$68.7 primarily due to common stock repurchases, purchases of property and equipment, net repayments of borrowings and cash dividends paid to shareholders. These decreases were partially offset by cash generated from operations and proceeds from employee stock option exercises.

Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries' future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.

At December 31, 2013, we held \$2,164.5 of cash and cash equivalents and investments at the parent company, which are available for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.

We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, which we believe assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot exceed. Our targeted range of debt-to-capital ratio is 30% to 35%. Our debt-to-capital ratio is calculated as the sum of debt divided by the sum of debt plus shareholders' equity. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 36.9% and 38.6% as of December 31, 2013 and 2012, respectively. The higher than targeted consolidated debt-to-capital ratios at December 31, 2013 and December 31, 2012 were primarily due to the increased debt we incurred to finance our acquisition of Amerigroup in 2012 and we expect in time to return to targeted levels.

Our senior debt is rated "A-" by Standard & Poor's, "BBB+" by Fitch, Inc., "Baa2" by Moody's Investor Service, Inc. and "bbb+" by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. A significant downgrade in our debt ratings could adversely affect our borrowing capacity and costs.

# Future Sources and Uses of Liquidity

We have a shelf registration statement on file with the Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries and the financing of possible acquisitions or business expansion.

We have a senior credit facility, or the facility, with certain lenders for general corporate purposes. The facility, as amended, provides credit up to \$2,000.0 and matures on September 29, 2016. The interest rate on the facility is based on either (i) the LIBOR rate plus a predetermined percentage rate based on our credit rating at the date of utilization, or (ii) a base rate as defined in the facility agreement plus a predetermined percentage rate based on our credit rating at the date of utilization. Our ability to borrow under the facility is subject to compliance with certain covenants. There were no amounts outstanding under the facility as of December 31, 2013.

We have an authorized commercial paper program of up to \$2,500.0, the proceeds of which may be used for general corporate purposes. At December 31, 2013 and 2012, \$379.2 and \$570.9, respectively, were outstanding under our commercial paper program. Commercial paper borrowings have been classified as long-term debt at December 31, 2013 and 2012 as our practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year and we have the ability to redeem our commercial paper with borrowings under the senior credit facility described above.

We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal Home Loan Bank of Atlanta, collectively, the FHLBs, and as a member we have the

ability to obtain short-term cash advances subject to certain minimum collateral requirements. At December 31, 2013 and 2012, \$400.0 and \$250.0, respectively, were outstanding under our short-term FHLBs borrowings.

On July 30, 2013, we initiated a cash tender offer and consent solicitation to purchase certain of our outstanding 5.875% Notes due 2017, 7.000% Notes due 2019, 5.950% Notes due 2034, 5.850% Notes due 2036, 6.375% Notes due 2037 and 5.800% Notes due 2040 (collectively, the "Tendered Notes"). On August 13, 2013, we repurchased \$700.0 of the Tendered Notes for cash totaling \$837.7. Holders who tendered their notes prior to the early tender date received the principal amounts, applicable premium for early redemption and accrued and unpaid interest to the early tender offer settlement date. Additionally, on September 5, 2013, we redeemed the \$400.0 outstanding principal balance of our 6.000% senior unsecured notes due 2014, plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling \$411.0. In connection with our early redemption and repurchase of the \$1,100.0 aggregate principal amount of outstanding notes, we realized losses on debt extinguishment of \$145.3.

On July 30, 2013, we issued \$650.0 of 2.300% notes due 2018 and \$600.0 of 5.100% notes due 2044 under our shelf registration statement. We used the proceeds from this offering in part to fund the purchase price of the Tendered Notes and the 6.000% senior unsecured notes discussed above, and the balance for general corporate purposes. Interest on the notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing on January 15, 2014. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

As a result of our acquisition of Amerigroup on December 24, 2012, the carrying amount of \$556.9 of Amerigroup's \$475.0 of 7.500% senior unsecured notes due 2019 were included in our consolidated balance sheet as of December 31, 2012. On January 25, 2013, we redeemed the outstanding principal balance of these notes, plus applicable premium for early redemption, for cash totaling \$555.6. The weighted-average redemption price of the notes was approximately 117% of the principal amount outstanding.

While we generally issue senior unsecured notes for long-term borrowing purposes, on October 9, 2012, we issued \$1,500.0 of senior convertible debentures, or the Debentures. The Debentures are governed by an indenture, or the Indenture, dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures bear interest at a rate of 2.750% per year, payable semi-annually in arrears in cash on April 15 and October 15 of each year, and mature on October 15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. We used approximately \$371.0 of the net proceeds from the issuance to repurchase shares of our common stock concurrently with the offering of the Debentures, and the balance was used for general corporate purposes, including but not limited to additional purchases of shares of our common stock pursuant to our share repurchase program and the repayment of debt. For additional information related to the Debentures, including the circumstances under which holders may convert the Debentures into common stock, see Note 13, "Debt" to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

As discussed in "Financial Condition" above, many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid. Based upon these requirements, we are currently estimating approximately \$2,100.0 of dividends to be paid to the parent company during 2014. During 2013, we received \$3,046.5 of dividends from our subsidiaries.

We regularly review the appropriate use of capital, including common stock repurchases, repurchases of debt securities and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt securities are at the discretion of our Board of Directors and depend upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.

A summary of the cash dividend activity for the year ended December 31, 2013 is as follows:

Declaration Date	Record Date	Payment Date	Cash Dividend er Share	<u>.</u>	Γotal
February 20, 2013	March 8, 2013	March 25, 2013	\$ 0.3750	\$	113.4
May 15, 2013	June 10, 2013	June 25, 2013	0.3750		112.7
July 23, 2013	September 10, 2013	September 25, 2013	0.3750		111.4
October 22, 2013	December 9, 2013	December 23, 2013	0.3750		110.5

On January 28, 2014, our Board of Directors declared a quarterly cash dividend of \$0.4375 per share on the outstanding shares of our common stock. This quarterly dividend is payable on March 25, 2014 to shareholders of record as of March 10, 2014.

A summary of common stock repurchases for the period January 1, 2014 through February 7, 2014 (subsequent to December 31, 2013) and for the year ended December 31, 2013 is as follows:

	January 1, 2014 Through February 7, 2014		Year Ended December 31, 2013
Shares repurchased		5.4	20.7
Average price per share	\$	84.96	\$ 78.08
Aggregate cost	\$	457.6	\$ 1,620.1
Authorization remaining at the end of each period	\$	2,633.4	\$ 3,691.0

On February 4, 2014, we entered into an accelerated share repurchase, or ASR, program with a counterparty. The agreement provides for a repurchase of a number of shares, equal to \$600.0, as determined by the dollar volume weighted-average share price during a period up through at least March 14, 2014, but not to exceed March 31, 2014. At the end of the term of the ASR, the initial amount of shares will be adjusted up or down based on the dollar volume weighted-average price during the same period. On February 4, 2014, we repurchased 6.0 shares under this program. These ASR shares are not included in the shares repurchased subsequent to December 31, 2013, shown in the table above as the final shares to be repurchased will not be determined until the completion of the program in March 2014. However, the \$600.0 has been removed from the authorization remaining as of February 7, 2014 in the table above.

On September 25, 2013, the Board of Directors authorized a \$3,500.0 increase to the common stock repurchase program. We expect to utilize unused authorization remaining at December 31, 2013 over a multi-year period, subject to market and industry conditions. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares when we believe it is a prudent use of capital.

Our current retirement benefits funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the year ended December 31, 2013, no material contributions were necessary to meet ERISA required funding levels. However, during the year ended December 31, 2013, we made tax deductible discretionary contributions to the pension benefit plans of \$38.6.

#### **Contractual Obligations and Commitments**

Our estimated contractual obligations and commitments as of December 31, 2013 are as follows:

		Payments Due by Period							
	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 Years
Debt <sup>1</sup>	\$ 23,297.7	\$	1,489.9	\$	2,838.5	\$	3,148.0	\$	15,821.3
Operating lease commitments	769.3		133.0		226.3		188.4		221.6
Projected other postretirement benefits	440.7		43.4		133.2		135.9		128.2
Purchase obligations:									
IBM outsourcing agreements <sup>2</sup>	251.2		200.3		50.9		_		_
Other purchase obligations <sup>3</sup>	2,757.2		1,499.3		780.1		450.0		27.8
Other long-term liabilities <sup>4</sup>	912.2		_		377.6		347.2		187.4
Investment commitments	341.6		148.9		111.7		61.1		19.9
Total contractual obligations and commitments	\$ 28,769.9	\$	3,514.8	\$	4,518.3	\$	4,330.6	\$	16,406.2

- 1 Includes estimated interest expense.
- 2 Relates to agreements with International Business Machines Corporation, or IBM, to provide information technology infrastructure services. See Note 14, "Commitments and Contingences," to the audited consolidated financial statements as of and for the year ended December 31, 2013 included in this Form 10-K for further information.
- 3 Includes obligations related to non-IBM information technology service agreements and telecommunication contracts.
- 4 Estimated future payments for funded pension benefits have been excluded from this table as we had no funding requirements under ERISA at December 31, 2013 as a result of the value of the assets in the plans. In addition, amount includes other obligations resulting from third-party service contracts.

The above table does not contain \$121.5 of gross liabilities for uncertain tax positions and interest for which we cannot reasonably estimate the timing of the resolutions with the respective taxing authorities. See Note 8, "Income Taxes," to the audited consolidated financial statements as of and for the year ended December 31, 2013 included in this Form 10-K for further information.

In addition to the contractual obligations and commitments discussed above, we have a variety of other contractual agreements related to acquiring materials and services used in our operations. However, we do not believe these other agreements contain material noncancelable commitments.

We believe that funds from future operating cash flows, cash and investments and funds available under our senior credit facility or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.

#### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that will require funding in future periods.

#### Risk-Based Capital

Our regulated subsidiaries' states of domicile have statutory risk-based capital, or RBC, requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners, or NAIC, RBC Model Act. These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer's investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company's business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries' respective RBC levels as of December 31, 2013, which was the most recent date for which reporting was required, were in excess of all mandatory RBC thresholds. In addition to exceeding

the RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries.

For additional information, see Note 22, "Statutory Information," to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This document contains certain forward-looking information about us that is intended to be covered by the safe harbor for "forwardlooking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not generally historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," "intend," "estimate," "project" and similar expressions are intended to identify forward-looking statements, which generally are not historical in nature. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in our public filings with the U.S. Securities and Exchange Commission, or SEC; increased government participation in, or regulation or taxation of health benefits and managed care operations, including, but not limited to, the impact of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, or Health Care Reform; trends in health care costs and utilization rates; our ability to secure sufficient premium rates including regulatory approval for and implementation of such rates; our participation in the federal and state health insurance exchanges under Health Care Reform, which have experienced technical difficulties in implementation and which entail uncertainties associated with the mix and volume of business, particularly in our individual and small group markets, that could negatively impact the adequacy of our premium rates and which may not be sufficiently offset by the risk apportionment provisions of Health Care Reform; our ability to contract with providers consistent with past practice; competitor pricing below market trends of increasing costs; reduced enrollment, as well as a negative change in our health care product mix; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon and funding risks with respect to revenue received from participation therein; a downgrade in our financial strength ratings; litigation and investigations targeted at our industry and our ability to resolve litigation and investigations within estimates; medical malpractice or professional liability claims or other risks related to health care services provided by our subsidiaries; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; non-compliance by any party of the Express Scripts, Inc. pharmacy benefit management services agreement, which could result in financial penalties, our inability to meet customer demands, and sanctions imposed by governmental entities, including the Centers for Medicare and Medicaid Services; events that result in negative publicity for us or the health benefits industry; failure to effectively maintain and modernize our information systems and e-business organization and to maintain good relationships with third party vendors for information system resources; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; intense competition to attract and retain employees; unauthorized disclosure of member sensitive or confidential information; changes in the economic and market conditions, as well as regulations that may negatively affect our investment portfolios and liquidity; possible restrictions in the payment of dividends by our subsidiaries and increases in required minimum levels of capital and the potential negative effect from our substantial amount of outstanding indebtedness; general risks associated with mergers and acquisitions; various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations; future public health epidemics and catastrophes; and general economic downturns. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by federal securities law, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in our SEC reports.

#### ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

(In Millions, Except Per Share Data or As Otherwise Stated Herein)

As a result of our investing and borrowing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity market valuations. Potential impacts discussed below are based upon sensitivity analyses performed on our financial position as of December 31, 2013. Actual results could vary from these estimates. Our primary objectives with our investment portfolio are to provide safety and preservation of capital, sufficient liquidity to meet cash flow requirements, the integration of investment strategy with the business operations and an attainment of a competitive after-tax total return.

#### Investments

Our investment portfolio is exposed to three primary sources of risk: credit quality risk, interest rate risk and market valuation risk.

The primary risks associated with our fixed maturity securities are credit quality risk and interest rate risk. Credit quality risk is defined as the risk of a credit event, such as a ratings downgrade or default, to an individual fixed maturity security and the potential loss attributable to that event. Credit quality risk is managed through our investment policy, which establishes credit quality limitations on the overall portfolio as well as diversification and percentage limits on securities of individual issuers. The result is a well-diversified portfolio of fixed maturity securities, with an average credit rating of approximately "A." Interest rate risk is defined as the potential for economic losses on fixed maturity securities due to a change in market interest rates. Our fixed maturity portfolio is invested primarily in U.S. government securities, corporate bonds, asset-backed bonds, mortgage-related securities and municipal bonds, all of which represent an exposure to changes in the level of market interest rates. Interest rate risk is managed by maintaining asset duration within a band based upon our liabilities, operating performance and liquidity needs.

Additionally, we have the capability of holding any security to maturity, which would allow us to realize full par value.

Our available-for-sale investment portfolio includes corporate securities which account for 40.0% of the total portfolio at December 31, 2013 and are subject to credit/default risk. In a declining economic environment, corporate yields will usually increase prompted by concern over the ability of corporations to make interest payments, thus causing a decrease in the price of corporate securities, and the decline in value of the corporate fixed maturity portfolio. We manage this risk through fundamental credit analysis, diversification of issuers and industries and an average credit rating of our corporate fixed maturity portfolio of approximately "BBB."

Our equity portfolio is comprised of large capitalization and small capitalization domestic equities, foreign equities and index mutual funds. Our equity portfolio is subject to the volatility inherent in the stock market, driven by concerns over economic conditions, earnings and sales growth, inflation, and consumer confidence. These systemic risks cannot be managed through diversification alone. However, more routine risks, such as stock/industry specific risks, are managed by investing in a diversified equity portfolio.

As of December 31, 2013, 90.8% of our available-for-sale investments were fixed maturity securities. Market risk is addressed by actively managing the duration, allocation and diversification of our investment portfolio. We have evaluated the impact on the fixed maturity portfolio's fair value considering an immediate 100 basis point change in interest rates. A 100 basis point increase in interest rates would result in an approximate \$783.2 decrease in fair value, whereas a 100 basis point decrease in interest rates would result in an approximate \$807.7 increase in fair value. While we classify our fixed maturity securities as "available-for-sale" for accounting purposes, we believe our cash flows and duration of our portfolio should allow us to hold securities to maturity, thereby avoiding the recognition of losses should interest rates rise significantly.

As of December 31, 2013, 9.2% of our available-for-sale investments were equity securities. An immediate 10% decrease in each equity investment's value, arising from market movement, would result in a fair value decrease of \$176.7. Alternatively, an immediate 10% increase in each equity investment's value, attributable to the same factor, would result in a fair value increase of \$176.7.

For additional information regarding our investments, see Note 5, "Investments", to our audited consolidated financial

statements as of and for the year ended December 31, 2013, and "Investments" within "Critical Accounting Policies and Estimates" in Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this Form 10-K.

#### **Long-Term Debt**

Our total long-term debt at December 31, 2013 was \$14,091.6, and included \$379.2 of commercial paper. The carrying values of the commercial paper approximate fair value as the underlying instruments have variable interest rates at market value. The remainder of the debt includes senior unsecured notes, convertible debentures and subordinated surplus notes by one of our insurance subsidiaries. This debt is subject to interest rate risk as these instruments have fixed interest rates and the fair value is affected by changes in market interest rates. The senior unsecured notes had combined carrying and estimated fair value of \$12,721.5 and \$12,987.0, respectively, at December 31, 2013. The carrying value and estimated fair value of the convertible debentures were \$966.0 and \$2,030.6, respectively, at December 31, 2013. The carrying value and estimated fair value of the surplus notes were \$24.9 and \$27.3, respectively, at December 31, 2013.

Should interest rates increase or decrease in the future, the estimated fair value of our fixed rate debt would decrease or increase accordingly. For additional information regarding our long-term debt, see Note 7, "Fair Value" and Note 13, "Debt" to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K.

#### **Derivatives**

We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through the use of derivative financial instruments. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge (on an economic basis) interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.

Changes in interest rates will affect the estimated fair value of these derivatives. As of December 31, 2013, we recorded a net asset of \$10.2, the estimated fair value of the swaps at that date. We have evaluated the impact on the interest rate swap's fair value considering an immediate 100 basis point change in interest rates. A 100 basis point increase in interest rates would result in an approximate \$52.9 decrease in fair value, whereas a 100 basis point decrease in interest rates would result in an approximate \$52.9 increase in fair value.

We also utilize put and call options on the S&P 500 index to hedge, on an economic basis, the exposure of our equity security portfolio to fluctuations in the equity markets. While the impact of fluctuations in the equity markets on these derivatives are largely offset by changes in the fair values of our equity security portfolio, the change in fair value of the derivatives is recognized immediately in our income statement, whereas the change in fair value of our equity securities is recognized in accumulated other comprehensive income. Accordingly, a decrease in the S&P 500 index of 10% would result in an approximate increase of \$38.3 in the fair value of these derivatives. An increase in the S&P 500 index of 10% would result in an approximate decrease of \$18.8 in the fair value of these derivatives.

For additional information regarding our derivatives, see Note 6, "Derivative Financial Instruments" to our audited consolidated financial statements as of and for the year ended December 31, 2013, included in this Form 10-K. Also for accounting related to securities in our equity portfolio, see "Critical Accounting Policies and Estimates – Investments" within Part II, Item 7 "Management Discussion and Analysis of Financial Condition and Results of Operations" included in this Form 10-K.

### ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

## WELLPOINT, INC.

### CONSOLIDATED FINANCIAL STATEMENTS

## Years ended December 31, 2013, 2012 and 2011

### Contents

Report of Independent Registered Public Accounting Firm	<u>78</u>
Audited Consolidated Financial Statements:	
Consolidated Balance Sheets	<u>79</u>
Consolidated Statements of Income	<u>80</u>
Consolidated Statements of Comprehensive Income	<u>81</u>
Consolidated Statements of Cash Flows	<u>82</u>
Consolidated Statements of Shareholders' Equity	<u>83</u>
Notes to Consolidated Financial Statements	84

### Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of WellPoint, Inc.

We have audited the accompanying consolidated balance sheets of WellPoint, Inc. (the "Company") as of December 31, 2013 and 2012, and the related consolidated statements of income, comprehensive income, shareholders' equity, and cash flows for each of the three years in the period ended December 31, 2013. Our audits also included the financial statement schedule listed in the Index at Item 15(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of WellPoint, Inc. at December 31, 2013 and 2012, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2013, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), WellPoint, Inc.'s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) and our report dated February 20, 2014 expressed an unqualified opinion thereon.

/s/ ERNST & YOUNG LLP

Indianapolis, Indiana February 20, 2014

### WellPoint, Inc. Consolidated Balance Sheets

	December 31, 2013	December 31, 2012		
(In millions, except share data)				
Assets				
Current assets:				
Cash and cash equivalents	\$ 1,582.1	\$ 2,475.3		
Investments available-for-sale, at fair value:				
Fixed maturity securities (amortized cost of \$16,826.7 and \$16,033.1)	17,038.2	16,912.9		
Equity securities (cost of \$1,168.5 and \$869.9)	1,735.5	1,212.4		
Other invested assets, current	16.3	14.8		
Accrued investment income	168.8	162.2		
Premium and self-funded receivables	3,968.7	3,687.4		
Other receivables	1,063.3	927.6		
Income taxes receivable	235.7	228.5		
Securities lending collateral	969.8	564.6		
Deferred tax assets, net	383.0	236.4		
Other current assets	1,677.5	1,827.4		
Assets held for sale	906.9	1,098.0		
Total current assets	29,745.8	29,347.5		
Long-term investments available-for-sale, at fair value:				
Fixed maturity securities (amortized cost of \$455.9 and \$426.0)	449.9	431.5		
Equity securities (cost of \$27.4 and \$27.1)	31.3	30.1		
Other invested assets, long-term	1,542.6	1,387.6		
Property and equipment, net	1,801.5	1,717.3		
Goodwill	16,917.2	16,889.8		
Other intangible assets	8,441.0	8,665.5		
Other noncurrent assets	645.2	486.1		
Total assets	\$ 59,574.5	\$ 58,955.4		
Liabilities and shareholders' equity				
Liabilities				
Current liabilities:				
Policy liabilities:				
Medical claims payable	\$ 6,127.2	\$ 6,174.5		
Reserves for future policy benefits	63.1	61.3		
Other policyholder liabilities	2,073.2	2,345.7		
Total policy liabilities	8,263.5	8,581.5		
Unearned income	822.7	896.8		
Accounts payable and accrued expenses	3,426.3	3,098.7		
Security trades pending payable	95.2	69.3		
Securities lending payable	969.7	564.7		
Short-term borrowings	400.0	250.0		
Current portion of long-term debt	518.0	557.1		
Other current liabilities	1,674.7	1,769.8		
Liabilities held for sale	181.4	207.1		
Total current liabilities	16,351.5	15,995.0		
Long-term debt, less current portion	13,573.6	14,170.8		
Reserves for future policy benefits, noncurrent	723.0	750.8		
Deferred tax liabilities, net	3,325.2	3,222.9		
Other noncurrent liabilities	836.0	1,013.2		
Total liabilities	34,809.3	35,152.7		

Shareholders' equity		
Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none	_	_
Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144	2.9	3.0
Additional paid-in capital	10,765.2	10,853.5
Retained earnings	13,813.9	12,647.1
Accumulated other comprehensive income	183.2	299.1
Total shareholders' equity	24,765.2	23,802.7
Total liabilities and shareholders' equity	\$ 59,574.5	\$ 58,955.4

## WellPoint, Inc. Consolidated Statements of Income

		Ye	ars E	nded Decembe	r 31	
		2013		2012		2011
(In millions, except per share data)						
Revenues						
Premiums	\$	66,119.1	\$	56,496.7	\$	55,969.6
Administrative fees		4,031.9		3,934.1		3,854.6
Other revenue		40.4		83.2		41.0
Total operating revenue		70,191.4		60,514.0		59,865.2
Net investment income		659.1		686.1		703.7
Net realized gains on investments		271.9		334.9		235.1
Other-than-temporary impairment losses on investments:						
Total other-than-temporary impairment losses on investments		(100.6)		(41.2)		(114.7)
Portion of other-than-temporary impairment losses recognized in other comprehensive income		1.7		3.4		21.4
Other-than-temporary impairment losses recognized in income		(98.9)		(37.8)		(93.3)
Total revenues		71,023.5		61,497.2		60,710.7
Expenses						
Benefit expense		56,237.1		48,213.6		47,647.5
Selling, general and administrative expense:						
Selling expense		1,526.9		1,586.9		1,616.8
General and administrative expense		8,426.0		7,093.6		6,818.8
Total selling, general and administrative expense		9,952.9		8,680.5		8,435.6
Interest expense		602.7		511.8		430.3
Amortization of other intangible assets		245.3		233.0		239.4
Loss on extinguishment of debt		145.3		_		_
Total expenses		67,183.3		57,638.9		56,752.8
Income from continuing operations before income tax expense		3,840.2		3,858.3		3,957.9
Income tax expense		1,205.9		1,207.3		1,311.2
Income from continuing operations		2,634.3		2,651.0		2,646.7
(Loss) income from discontinued operations, net of tax		(144.6)		4.5		_
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7
Basic net income (loss) per share:			-			
Basic - continuing operations	\$	8.83	\$	8.25	\$	7.35
Basic - discontinued operations		(0.49)		0.01		_
Basic net income per share	\$	8.34	\$	8.26	\$	7.35
Diluted net income (loss) per share:	<del>_</del> _		Ť		Ť	
Diluted - continuing operations	\$	8.67	\$	8.17	\$	7.25
Diluted - discontinued operations  Diluted - discontinued operations	φ	(0.47)	ψ	0.01	ψ	1.23
Diluted net income per share	\$	8.20	\$	8.18	\$	7.25
	_				_	
Dividends per share	\$	1.50	\$	1.15	\$	1.00

# WellPoint, Inc. Consolidated Statements of Comprehensive Income

	Years Ended December 31					
		2013		2012		2011
(In millions)						
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7
Other comprehensive (loss) income, net of tax:						
Change in net unrealized gains/losses on investments		(294.7)		189.9		20.6
Change in non-credit component of other-than-temporary impairment						
losses on investments		1.7		4.5		(0.7)
Change in net unrealized gains/losses on cash flow hedges		3.0		0.1		(10.0)
Change in net periodic pension and postretirement costs		172.7		(10.9)		(119.8)
Foreign currency translation adjustments		1.4		0.6		0.2
Other comprehensive (loss) income		(115.9)		184.2		(109.7)
Total comprehensive income	\$	2,373.8	\$	2,839.7	\$	2,537.0

## WellPoint, Inc. Consolidated Statements of Cash Flows

		Years Ended December 31			
	2013	2012	2011		
(In millions)					
Operating activities					
Net income	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7		
Adjustments to reconcile net income to net cash provided by operating activities:					
Net realized gains on investments	(271.9)	(334.9)	(235.1		
Other-than-temporary impairment losses recognized in income	98.9	37.8	93.3		
Loss on extinguishment of debt	145.3	_	_		
Loss on disposal from discontinued operations	221.8	_	_		
Loss on disposal of assets	3.9	4.7	3.3		
Deferred income taxes	59.1	127.5	74.3		
Amortization, net of accretion	800.9	633.6	541.5		
Depreciation expense	107.9	107.1	95.7		
Impairment of property and equipment	47.7	66.8	_		
Share-based compensation	146.0	146.5	134.8		
Excess tax benefits from share-based compensation	(30.1)	(28.8)	(42.2		
Changes in operating assets and liabilities, net of effect of business combinations:	,	, ,	`		
Receivables, net	(418.3)	189.9	(401.8		
Other invested assets	(15.1)		(8.9		
Other assets	(33.6)		(259.2		
Policy liabilities	(345.8)		978.0		
Unearned income			35.1		
	(73.8)				
Accounts payable and accrued expenses	303.6	(406.5)	(208.7		
Other liabilities	(154.6)		(13.6		
Income taxes	9.3	(73.9)	(44.6		
Other, net	(38.6)		(14.2		
Net cash provided by operating activities	3,052.3	2,744.6	3,374.4		
Investing activities					
Purchases of fixed maturity securities	(13,704.5)	(15,040.4)	(11,914.8		
Proceeds from fixed maturity securities:					
Sales	10,977.9	13,675.9	10,446.2		
Maturities, calls and redemptions	1,836.8	1,781.5	1,891.3		
Purchases of equity securities	(820.3)	(232.8)	(259.0		
Proceeds from sales of equity securities	721.0	422.7	287.4		
Purchases of other invested assets	(251.5)	(303.7)	(207.9		
Proceeds from sales of other invested assets	127.1	35.5	29.4		
Settlement of non-hedging derivatives	(109.8)	(59.8)	(96.6		
Changes in securities lending collateral	(405.1)	307.9	28.9		
Purchases of subsidiaries, net of cash acquired	_	(4,597.0)	(600.0		
Purchases of property and equipment	(646.5)	(544.9)	(519.5		
Proceeds from sales of property and equipment	39.2	0.4	3.7		
Other, net	1.3	3.1	(31.1		
Net cash used in investing activities	(2,234.4)	(4,551.6)	(942.0		
Financing activities	(,,,,,,,,	( )	, -1.		
Net (repayments of) proceeds from commercial paper borrowings	(191.7)	(229.0)	463.6		
Proceeds from long-term borrowings	1,250.0	6,468.9	1,097.4		
Repayments of long-term borrowings	(1,801.9)		(705.1		
Proceeds from short-term borrowings	1,100.0	642.0	100.0		
Repayments of short-term borrowings	(950.0)		(100.0		
Changes in securities lending payable	405.0	(307.8)	(29.0		

Changes in bank overdrafts	9.9	(17.6)	264.3
Premiums paid on equity options	(25.8)	_	_
Repurchase and retirement of common stock	(1,620.1)	(2,496.8)	(3,039.8)
Cash dividends	(448.0)	(367.1)	(357.8)
Proceeds from issuance of common stock under employee stock plans	524.7	110.8	245.0
Excess tax benefits from share-based compensation	30.1	28.8	42.2
Net cash (used in) provided by financing activities	(1,717.8)	2,088.9	(2,019.2)
Effect of foreign exchange rates on cash and cash equivalents	2.2	1.1	(0.4)
Change in cash and cash equivalents	(897.7)	283.0	412.8
Cash and cash equivalents at beginning of year	2,484.6	2,201.6	1,788.8
Cash and cash equivalents at end of year	1,586.9	2,484.6	2,201.6
Less cash and cash equivalents of discontinued operations at end of year	(4.8)	(9.3)	
Cash and cash equivalents of continuing operations at end of year	\$ 1,582.1	\$ 2,475.3	\$ 2,201.6

# WellPoint, Inc. Consolidated Statements of Shareholders' Equity

	Common Stock			Additional			Accumulated Other			T-4-1	
	Number of Shares		Par Value	A	Paid-in Capital		Retained Earnings	C	omprehensive Income	S	Total Shareholders' Equity
(In millions)											
January 1, 2011	377.7	\$	3.8	\$	12,862.6	\$	10,721.6	\$	224.6	\$	23,812.6
Net income	_		_		_		2,646.7		_		2,646.7
Other comprehensive loss	_				_		_		(109.7)		(109.7)
Repurchase and retirement of common stock	(44.5)		(0.4)		(1,523.2)		(1,516.2)		_		(3,039.8)
Dividends and dividend equivalents	_		_		_		(361.4)				(361.4)
Issuance of common stock under employee stock plans, net of related tax benefits	6.2				339.8						339.8
December 31, 2011	339.4	\$	3.4	\$	11,679.2	\$	11,490.7	\$	114.9	\$	23,288.2
Net income	_		_		_		2,655.5		_		2,655.5
Other comprehensive income	_						_		184.2		184.2
Repurchase and retirement of common stock	(39.7)		(0.4)		(1,368.5)		(1,127.9)		_		(2,496.8)
Dividends and dividend equivalents	_		_		_		(371.2)				(371.2)
Issuance of convertible debentures	_		_		331.5		_		_		331.5
Conversion of stock awards in connection with AMERIGROUP Corporation acquisition	_		_		19.7		_		_		19.7
Issuance of common stock under employee stock plans, net of related tax benefits	5.0				191.6						191.6
December 31, 2012	304.7	\$	3.0	\$	10,853.5	\$	12,647.1	\$	299.1	\$	23,802.7
Net income	_		_		_		2,489.7		_		2,489.7
Other comprehensive loss	_		_		_		_		(115.9)		(115.9)
Premiums paid on equity options	_		_		(7.9)		_		_		(7.9)
Repurchase and retirement of common stock	(20.7)		(0.1)		(749.5)		(870.5)				(1,620.1)
Convertible debentures tax adjustment	_		_		(3.3)		_		_		(3.3)
Dividends and dividend equivalents	_		_		_		(452.4)				(452.4)
Issuance of common stock under employee stock plans, net of related tax benefits	9.3				672.4	_	_				672.4
December 31, 2013	293.3	\$	2.9	\$	10,765.2	\$	13,813.9	\$	183.2	\$	24,765.2

#### WellPoint, Inc.

#### Notes to Consolidated Financial Statements

December 31, 2013

(In Millions, Except Per Share Data or As Otherwise Stated Herein)

### 1. Organization

References to the terms "we", "our", "us", "WellPoint" or the "Company" used throughout these Notes to Consolidated Financial Statements refer to WellPoint, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.

We are one of the largest health benefits companies in terms of medical membership in the United States, serving 35.7 medical members through our affiliated health plans and approximately 67.8 individuals through our subsidiaries as of December 31, 2013. We offer a broad spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid and senior markets. Our managed care plans include: preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; point-of-service, or POS, plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance. We also provide services to the Federal Government in connection with the Federal Employee Program, or FEP, and various Medicare programs. We also sold contact lenses, eyeglasses and other ocular products through our 1-800 CONTACTS, Inc., or 1-800 CONTACTS, business, which was divested on January 31, 2014.

We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for: Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as BCBS in 10 New York City metropolitan and surrounding counties, and as Blue Cross or BCBS in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Georgia, and Empire Blue Cross Blue Shield, or Empire Blue Cross (in our New York service areas). We also conduct business through our AMERIGROUP Corporation, or Amerigroup, subsidiary, in Florida, Georgia, Kansas, Louisiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas and Washington. Amerigroup also provided services in the state of Ohio through June 30, 2013 and in the state of New Mexico through December 31, 2013. We also serve customers throughout the country as HealthLink, UniCare, and in certain Arizona, California, Nevada, New York and Virginia markets through our CareMore Health Group, Inc., or CareMore, subsidiary. We are licensed to conduct insurance operations in all 50 states through our subsidiaries.

### 2. Basis of Presentation and Significant Accounting Policies

**Basis of Presentation:** The accompanying consolidated financial statements include the accounts of WellPoint and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles, or GAAP. All significant intercompany accounts and transactions have been eliminated in consolidation.

Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in "Foreign currency translation adjustments" in our consolidated statements of shareholders' equity.

Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation. The

operating results for 1-800 CONTACTS are reported as discontinued operations as a result of the pending divestiture at December 31, 2013. These results were previously reported in the Commercial and Specialty Business segment. Additionally, the assets and liabilities of 1-800-CONTACTS are reported as held for sale in the consolidated balance sheets. Unless otherwise specified, all financial information presented in the accompanying consolidated financial statements and in the notes to consolidated financial statements relates only to our continuing operations, other than cash flows presented on the consolidated statements of cash flows. In accordance with Financial Accounting Standards Board, or FASB, guidance, we have elected to not separately disclose net cash provided by or used in operating, investing, and financing activities and the net effect of those cash flows on cash and cash equivalents for discontinued operations during the periods presented. Information related to discontinued operations is included in Note 3, "Business Acquisitions and Divestitures," and in some instances, where appropriate, is included as a separate disclosure within the individual footnotes.

*Use of Estimates:* The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash Equivalents: All highly liquid investments with maturities of three months or less when purchased are classified as cash equivalents.

Investments: Certain FASB other-than-temporary impairment, or FASB OTTI, guidance applies to fixed maturity securities and provides guidance on the recognition and presentation of other-than-temporary impairments. In addition, this FASB OTTI guidance requires disclosures related to other-than-temporary impairments. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in our consolidated income statements. For impaired fixed maturity securities that we do not intend to sell or it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment losses recognized in income in our consolidated income statements and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income, or AOCI.

The credit component of an other-than-temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other debt securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings, and estimates regarding timing and amount of recoveries associated with a default.

The unrealized gains or losses on our current and long-term equity securities classified as available-for-sale are included in accumulated other comprehensive income as a separate component of shareholders' equity, unless the decline in value is deemed to be other-than-temporary and we do not have the intent and ability to hold such equity securities until their full cost can be recovered, in which case such equity securities are written down to fair value and the loss is charged to other-than-temporary impairment losses recognized in income.

We maintain various rabbi trusts to account for the assets and liabilities under certain deferred compensation plans. Under these plans, the participants can defer certain types of compensation and elect to receive a return on the deferred amounts based on the changes in fair value of various investment options, primarily a variety of mutual funds. Rabbi trust assets are classified as trading, which are reported in other invested assets, current, in the consolidated balance sheets.

We use the equity method of accounting for investments in companies in which our ownership interest enables us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported with net investment income.

For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments are reported with net investment income.

Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for cash collateral initially equal to at least 102% of the value of the securities on loan and is thereafter maintained at a minimum of 100% of the market value of the securities loaned (calculated as the ratio of initial market value of cash collateral to current market value of the securities on loan). Accordingly, the market value of the securities on loan to each borrower is monitored daily and the borrower is required to deliver additional cash collateral if the market value of the securities on loan exceeds the initial market value of cash collateral delivered. The fair value of the collateral received at the time of the transaction amounted to \$969.7 and \$564.7 at December 31, 2013 and 2012, respectively. The value of the cash collateral delivered represented 102% of the market value of the securities on loan at December 31, 2013 and 2012. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the cash collateral as an asset, which is reported as "securities lending collateral" on our consolidated balance sheets and we record a corresponding liability for the obligation to return the cash collateral to the borrower, which is reported as "securities lending payable." The securities on loan are reported in the applicable investment category on the consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders' equity.

**Premium and Self-Funded Receivables:** Premium and self-funded receivables include the uncollected amounts from fully-insured and self-funded groups, and are reported net of an allowance for doubtful accounts of \$223.6 and \$197.1 at December 31, 2013 and 2012, respectively. The allowance for doubtful accounts is based on historical collection trends and our judgment regarding the ability to collect specific accounts.

Other Receivables: Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance, government programs, proceeds due from brokers on investment trades and other miscellaneous amounts due to us. These receivables are reported net of an allowance for uncollectible amounts of \$115.0 and \$79.0 at December 31, 2013 and 2012, respectively, which is based on historical collection trends and our judgment regarding the ability to collect specific amounts.

Income Taxes: We file a consolidated income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities based on enacted tax rates and laws. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact from amounts initially recorded for business combinations, if any. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.

We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.

**Property and Equipment:** Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from 15 to 39 years for buildings and improvements, three to seven years for data processing equipment, furniture and other equipment, and three to five years for computer software. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized.

Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the acquisition method of accounting and it also specifies the types of acquired intangible assets that are required to be

recognized and reported separately from goodwill. Goodwill represents the excess of cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to subscriber bases, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses, non-compete and other agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.

Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.

FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. We begin our annual tests with quantitative analyses. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used.

Fair value for purposes of the goodwill impairment test is calculated using a blend of a projected income and market valuation approach. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry's weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations are based on observed multiples of certain measures including membership, revenue, EBITDA (earnings before interest, taxes, depreciation and amortization) and net income as well as market capitalization analyses of WellPoint and other comparable companies. A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset's fair value. This determination is made at the reporting unit level and consists of two steps. First, the fair value of a reporting unit is determined and compared to its carrying amount. Second, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation on a business acquisition, at the impairment test date.

The fair value of indefinite-lived intangible assets is estimated and compared to the carrying value. We estimate the fair value of indefinite-lived intangible assets using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

Derivative Financial Instruments: We primarily invest in the following types of derivative financial instruments: interest rate swaps, forward contracts, put and call options, credit default swaps, embedded derivatives, warrants and swaptions. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.

We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-

in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.

All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, as well as the ineffective portion of the gain or loss, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.

From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in income immediately.

Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December 31, 2013, we believe there were no material concentrations of credit risk with any individual counterparty.

Certain of our derivative agreements contain credit support provisions that require us to post collateral if there are declines in the derivative fair value or our credit rating.

Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with current and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.

*Medical Claims Payable:* Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2) claims reported to us and processed through our systems but not yet paid.

Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in aggregate by employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities.

We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If our assumptions regarding cost trends and utilization are significantly different than actual results, our income statement and financial position could be impacted in future periods.

Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established,

premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December 31, 2013 or 2012.

Reserves for Future Policy Benefits: Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.

The current portion of reserves for future policy benefits relates to the portion of such reserves that we expect to pay within one year. We believe that our liabilities for future policy benefits, along with future premiums received are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.

Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves as well as liabilities for minimum medical loss ratio, or MLR, rebates. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with the customers and can vary from period to period based on the specific contractual requirements.

Effective beginning in 2011, we are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and related Health Care and Education Reconciliation Act of 2010, or collectively, Health Care Reform. If we do not meet or exceed the minimum MLR thresholds specified by Health Care Reform, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by applicable line of business (large group, small group and individual) and legal entity in accordance with regulations issued by the Department of Health and Human Services, or HHS. Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.

We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our GAAP basis consolidated financial statements may be reported as a reduction of premiums in accordance with HHS regulations. For example, certain federal and state income taxes and assessments recorded as income tax expense or general and administrative expense, as appropriate, in our consolidated GAAP financial statements are allowed to be included as a reduction of premium revenue in HHS' calculation of minimum MLR. In addition, profit amounts included in our payments to third party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.

**Revenue Recognition:** Premiums for fully-insured contracts are recognized as revenue over the period insurance coverage is provided, net of amounts recognized for minimum MLR rebates, if applicable. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue from retrospectively rated contracts where revenue is based on the estimated ultimate loss experience of the contract. Premium revenue includes an adjustment for retrospectively rated refunds based on an estimate of incurred claims. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state.

Administrative fees include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion of their claims experience. We charge these self-funded groups an administrative fee, which is based on the number of members in a group or the group's claim experience. In addition, administrative fees include amounts received for the administration of Medicare or certain other government programs. Under our self-funded arrangements, revenue is recognized as administrative services are performed. All benefit payments under these programs are excluded from benefit expense.

Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including stock options and restricted stock awards. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. Effective January 1, 2014, the employee stock purchase plan will allow for a purchase price per share

which is 95% of the fair value of a share of common stock on the last trading day of the plan quarter. The employee stock purchase plan discount is not recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in the income statement based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as additional paid-in-capital and are reclassified from operating cash flows to financing cash flows in the consolidated statements of cash flows. Our share-based employee compensation plans and assumptions are described in Note 15, "Capital Stock."

Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for individual and Medicare customers, and for certain Local Group customers with a smaller employee base. Products for National Accounts and Local Group customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer and working with industry specialists from our in-house sales force. In the individual and small group markets we offer on-exchange products through state or federally facilitated marketplaces and off-exchange products. Federal premium subsidies are available only for certain on-exchange products. The cost of advertising and marketing for product promotion is expensed as incurred while advertising and marketing costs associated with corporate image is expensed when first aired. Total advertising and marketing expense was \$350.9, \$285.4 and \$287.8 for the years ended December 31, 2013, 2012 and 2011, respectively.

*Earnings per Share:* Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.

Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share includes the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.

New Accounting Pronouncements: In February 2013, the FASB issued Accounting Standards Update 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, or ASU 2013-02. ASU 2013-02 amends certain portions of Accounting Standards Codification Topic 220, Comprehensive Income, or ASC 220, to improve reporting by requiring the presentation, in one place, of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, cross-references to other disclosures that provide additional detail about those amounts is required. The adoption of ASU 2013-02 in the first quarter of 2013 did not have an impact on our consolidated financial position, results of operations or cash flows.

In July 2011, the FASB issued ASU No. 2011-06, Other Expenses (Topic 720): Fees Paid to the Federal Government by Health Insurers (a consensus of the FASB Emerging Issues Task Force), or ASU 2011-06. Health Care Reform imposes a mandatory annual fee on health insurers that write certain types of health insurance on U.S. risks for each calendar year beginning on or after January 1, 2014. The annual fee will be allocated to health insurers based on the ratio of the amount of an insurer's net premium revenues written during the preceding calendar year to the amount of health insurance for all U.S. health risk for those certain lines of business that is written during the preceding calendar year. ASU 2011-06 addresses how this fee should be recognized and classified in the income statements of health insurers and stipulates that the liability for the fee should be estimated and recorded in full once the insurer provides qualifying health insurance in the applicable calendar year in which the fee is payable, with a corresponding deferred cost that is amortized to expense using a straight-line method of allocation, unless another method better allocates the fee over the calendar year that it is payable. This ASU is effective for calendar years beginning after December 31, 2013, when the fee initially becomes effective. The total amount to be collected from allocations to health insurers in 2014 is \$8,000.0. Our portion of the 2014 fee is currently estimated to be at least \$900.0. This fee is non-deductible for income tax purposes. Accordingly, adoption of this guidance and the enactment of this fee could have a material impact on our financial position, results of operations or cash flows in future periods.

There were no other new accounting pronouncements that were issued or became effective during the year ended

December 31, 2013 that had, or are expected to have, a material impact on our financial position, results of operations or financial statement disclosures

#### 3. Business Acquisitions and Divestitures

#### Amerigroup

In December 2012, we completed our acquisition of Amerigroup, one of the nation's leading managed care companies focused on meeting the health care needs of financially vulnerable Americans. This acquisition furthers our goal of creating better health care quality at more affordable prices for our customers. Amerigroup also advances our capabilities in effectively and efficiently serving the growing Medicaid population, including the expanding dual eligibles, seniors, persons with disabilities and long-term services and support markets.

We paid \$92.00 per share in cash to acquire all of the outstanding shares of Amerigroup for total cash consideration of \$4,755.8. In addition, 0.5 shares of Amerigroup restricted stock converted to 0.7 shares of WellPoint restricted stock, valued at \$17.1, and 0.1 shares underlying Amerigroup stock options converted to 0.2 shares underlying WellPoint stock options, valued at \$2.6. We also incurred \$24.0 of transaction costs, which were recorded to general and administrative expense during the year ended December 31, 2012.

In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the fair value of Amerigroup's assets acquired and liabilities assumed, including identifiable intangible assets. In 2013, we finalized our purchase accounting and made a measurement period adjustment to the fair value of certain assets acquired and liabilities assumed at the date of acquisition. The effect of these adjustments on the preliminary purchase price allocation recorded at December 31, 2012 was an increase to goodwill of \$28.9, an increase in other intangible assets of \$20.0, a decrease in current liabilities of \$1.6, and an increase in noncurrent liabilities of \$50.5. The below table and the accompanying consolidated balance sheets reflect the impact of these adjustments.

The excess of the consideration transferred over the estimated fair value of net assets acquired resulted in non-tax-deductible goodwill of \$3,062.0, all of which was allocated to our Government Business segment. Goodwill recognized from the acquisition of Amerigroup primarily relates to the future economic benefits arising from expected synergies and is consistent with our stated intentions to strengthen our position and expand operations in the government sector to serve Medicaid and Medicare enrollees.

The following table summarizes the estimated fair values of Amerigroup assets acquired and liabilities assumed:

Current assets	\$ 2,7	716.5
Goodwill	3,0	062.0
Other intangible assets	9	975.0
Other noncurrent assets	4	406.1
Total assets acquired	7,1	159.6
Current liabilities	1,4	416.6
Noncurrent liabilities	9	967.5
Total liabilities assumed	2,3	384.1
Net assets acquired	\$ 4,7	775.5

Of the \$975.0 of total other intangible assets acquired, \$65.0 represents finite-lived customer relationships with an amortization period of three years, \$30.0 represents provider and hospital networks with an amortization period of twenty years and \$880.0 represents indefinite-lived state Medicaid contracts and trade names.

The results of operations of Amerigroup for the period following December 24, 2012 are included in our consolidated financial statements within our Government Business segment and represented \$219.0 of our operating revenue and an offset to net income of \$6.1 for the year ended December 31, 2012. The pro-forma effects of this acquisition for periods prior to acquisition were not considered material to our consolidated results of operations.

#### 1-800 CONTACTS

In December 2013, we entered into a definitive agreement to sell our 1-800 CONTACTS business to the private equity firm Thomas H. Lee Partners, L.P. Additionally, we entered into an asset purchase agreement with Luxottica Group to sell our glasses.com related assets (collectively, 1-800 CONTACTS). The operating results for 1-800 CONTACTS are reported as discontinued operations in the accompanying consolidated statements of income. These results were previously reported in the Commercial and Specialty Business segment. Additionally, the assets and liabilities of 1-800-CONTACTS are reported as held for sale in the accompanying consolidated balance sheets. This divestiture will enable us to focus on our core growth opportunities across both our Commercial and Specialty and Government business segments.

Summarized financial information for the 1-800 CONTACTS discontinued operations for the years ended December 31, 2013 and 2012 is as follows:

	2013	2012
Revenues	\$ 434.7	214.5
Income from discontinued operations before tax	17.3	7.2
Income tax (benefit) expense	 (2.6)	2.7
Income from discontinued operations	19.9	4.5
Loss on disposal from discontinued operations, net of tax	(164.5)	
Discontinued operations, net of tax	\$ (144.6)	\$ 4.5

In connection with the sale of 1-800 CONTACTS, we recognized a loss on disposal of \$221.8, net of an income tax benefit of \$57.3 for the year ended December 31, 2013. The loss on disposal was calculated as the difference between the fair value, as determined by the sales agreements less costs to sell, and the carrying value of the held for sale assets at December 31, 2013. The sale was completed on January 31, 2014 and did not result in any material difference to the loss on disposal shown above.

The assets and liabilities of 1-800 CONTACTS are reported as held for sale in the accompanying consolidated balance sheets at December 31, 2013 and 2012 and consist of the following:

	2013	2012
Assets		
Cash and cash equivalents	\$ 4.8	\$ 9.3
Property and equipment	27.6	21.0
Goodwill	409.9	620.7
Other intangibles	415.4	437.3
Other assets	49.2	9.7
Total assets	\$ 906.9	\$ 1,098.0
Liabilities		
Accounts payable and other accrued expenses	\$ 34.2	\$ 33.8
Deferred income taxes	142.5	158.1
Other liabilities	4.7	15.2
Total liabilities	\$ 181.4	\$ 207.1

#### 4. Restructuring Activities

As a result of restructuring activities implemented during 2012 and 2011, we recorded liabilities for employee termination costs and lease and other contract exit costs. The restructuring activities are classified as components of general

and administrative expenses in the consolidated statements of income for the respective period in which they occurred. There were no restructuring activities implemented during 2013.

The 2012 restructuring activities were initiated primarily as a result of personnel changes, organizational realignment to create efficiencies in our business processes and certain integration activities associated with the Amerigroup acquisition. Activity related to these liabilities for the year ended December 31, 2013 and 2012, by segment, is as follows:

	Commercial and Specialty Business		Government Business		Other		,	Γotal
2012 Restructuring Activities								
Employee termination costs:								
Costs incurred in 2012	\$	70.8	\$	64.5	\$	3.5	\$	138.8
2012 payments		(10.8)		(9.8)		(0.6)		(21.2)
Liabilities for employee termination costs ending balance at December 31, 2012		60.0		54.7		2.9		117.6
2013 payments		(34.6)	(	34.6)		(1.7)		(70.9)
Liabilities released in 2013		(12.0)	(	15.9)		(0.6)		(28.5)
Liabilities for employee termination costs ending balance at December 31, 2013		13.4		4.2		0.6		18.2
Lease and other contract exit costs:								
Costs incurred in 2012		8.8		3.0		0.1		11.9
2012 payments		(0.1)		_		_		(0.1)
Liabilities for lease and other contract exit costs ending balance at December 31, 2012		8.7		3.0		0.1		11.8
2013 payments		(5.7)		(2.0)		(0.1)		(7.8)
Liabilities released in 2013		(0.6)		(0.2)				(0.8)
Liabilities for lease and other contract exit costs ending balance at December 31, 2013		2.4		0.8				3.2
Total liabilities for 2012 restructuring activities ending balance at December 31, 2013	\$	15.8	\$	5.0	\$	0.6	\$	21.4

The 2011 restructuring activities were initiated as a result of a change in strategic focus primarily in response to Health Care Reform. At December 31, 2013, our total liabilities for 2011 restructuring activities were \$17.5, of which \$1.9 related to employee termination costs and \$15.6 related to lease and other contract exit costs. Payments for lease and other contract exit costs will continue to occur over the remaining terms of the related contracts.

#### 5. Investments

A summary of current and long-term investments, available-for-sale, at December 31, 2013 and 2012 is as follows:

					Gross Unrealized Losses						C	Non-Credit omponent of Other-Than- Temporary
	A	Cost or mortized Cost	U	Gross nrealized Gains		Less than 12 Months		2 Months or Greater		Estimated air Value		mpairments ecognized in AOCI
December 31, 2013:												
Fixed maturity securities:												
United States Government securities	\$	300.8	\$	2.5	\$	(3.4)	\$	_	\$	299.9	\$	_
Government sponsored securities		174.4		0.4		(1.3)		_		173.5		_
States, municipalities and political subdivisions, tax-exempt		5,899.5		202.9		(90.1)		(9.6)		6,002.7		(0.6)
Corporate securities		7,614.1		205.2		(95.2)		(15.5)		7,708.6		(0.1)
Options embedded in convertible securities		89.2		_		_		_		89.2		_
Residential mortgage-backed securities		2,269.4		48.0		(41.4)		(7.1)		2,268.9		_
Commercial mortgage-backed securities		479.0		10.5		(2.6)		(0.3)		486.6		_
Other debt securities		456.2		5.8		(2.5)		(0.8)		458.7		(0.1)
Total fixed maturity securities		17,282.6		475.3		(236.5)		(33.3)		17,488.1	\$	(0.8)
Equity securities		1,195.9		578.9		(8.0)		_		1,766.8		
Total investments, available-for-sale	\$	18,478.5	\$	1,054.2	\$	(244.5)	\$	(33.3)	\$	19,254.9		
December 31, 2012												
Fixed maturity securities:												
United States Government securities	\$	330.3	\$	13.1	\$	(0.2)	\$	_	\$	343.2	\$	_
Government sponsored securities		153.6		2.6		_		_		156.2		_
States, municipalities and political subdivisions, tax-exempt		5,501.3		388.2		(5.7)		(1.6)		5,882.2		<u> </u>
Corporate securities		7,642.0		387.0		(17.0)		(8.0)		8,004.0		(1.7)
Options embedded in convertible securities		67.2		_		_		_		67.2		_
Residential mortgage-backed securities		2,204.7		103.1		(1.1)		(1.9)		2,304.8		(0.4)
Commercial mortgage-backed securities		323.2		22.5		_		_		345.7		_
Other debt securities		236.8		7.6		(0.2)		(3.1)		241.1		(1.3)
Total fixed maturity securities		16,459.1		924.1		(24.2)		(14.6)		17,344.4	\$	(3.4)
Equity securities		897.0		358.0		(12.5)		_		1,242.5		
Total investments, available-for-sale	\$	17,356.1	\$	1,282.1	\$	(36.7)	\$	(14.6)	\$	18,586.9		

At December 31, 2013, we owned \$2,755.5 of mortgage-backed securities and \$423.8 of asset-backed securities out of a total available-for-sale investment portfolio of \$19,254.9. These securities included sub-prime and Alt-A securities with fair values of \$32.2 and \$102.4, respectively. These sub-prime and Alt-A securities had accumulated net unrealized gains of \$1.7 and \$6.4, respectively. The average credit rating of the sub-prime and Alt-A securities was "BB" and "CCC", respectively.

The following tables summarize for fixed maturity securities and equity securities in an unrealized loss position at December 31, 2013 and 2012, the aggregate fair value and gross unrealized loss by length of time those securities have been continuously in an unrealized loss position.

	Less than 12 Months					12 Months or Greater					
	Number of Securities		Estimated Fair Value	U	Gross nrealized Loss	Number of Securities		stimated air Value	Uı	Gross prealized Loss	
(Securities are whole amounts)											
December 31, 2013:											
Fixed maturity securities:											
United States Government securities	27	\$	179.2	\$	(3.4)		\$	_	\$		
Government sponsored securities	22		73.4		(1.3)	_		_		_	
States, municipalities and political subdivisions, tax-exempt	806		2,070.9		(90.1)	42		82.4		(9.6)	
Corporate securities	1,448		2,586.6		(95.2)	107		81.3		(15.5)	
Residential mortgage-backed securities	605		1,243.0		(41.4)	80		116.2		(7.1)	
Commercial mortgage-backed securities	52		177.7		(2.6)	4		5.6		(0.3)	
Other debt securities	65		185.3		(2.5)	17		16.2		(0.8)	
Total fixed maturity securities	3,025		6,516.1		(236.5)	250		301.7		(33.3)	
Equity securities	426		120.8		(8.0)			_		_	
Total fixed maturity and equity securities	3,451	\$	6,636.9	\$	(244.5)	250	\$	301.7	\$	(33.3)	
December 31, 2012											
Fixed maturity securities:											
United States Government securities	17	\$	48.5	\$	(0.2)	_	\$	_	\$	_	
States, municipalities and political subdivisions, tax-exempt	184		420.1		(5.7)	1		46.9		(1.6)	
Corporate securities	457		1,066.5		(17.0)	74		52.6		(8.0)	
Residential mortgage-backed securities	79		211.0		(1.1)	44		25.5		(1.9)	
Commercial mortgage-backed securities	4		10.1		_	3		4.1		_	
Other debt securities	7		5.4		(0.2)	21		28.9		(3.1)	
Total fixed maturity securities	748		1,761.6		(24.2)	143		158.0		(14.6)	
Equity securities	961		149.6		(12.5)	_		_		_	
Total fixed maturity and equity securities	1,709	\$	1,911.2	\$	(36.7)	143	\$	158.0	\$	(14.6)	

The amortized cost and fair value of fixed maturity securities at December 31, 2013, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.

	 Amortized Cost	Estimated Fair Value
Due in one year or less	\$ 423.9	\$ 426.3
Due after one year through five years	4,580.5	4,712.1
Due after five years through ten years	5,105.4	5,196.6
Due after ten years	4,424.4	4,397.6
Mortgage-backed securities	2,748.4	2,755.5
Total available-for-sale fixed maturity securities	\$ 17,282.6	\$ 17,488.1

The major categories of net investment income for the years ended December 31 are as follows:

	2	013	 2012	 2011
Fixed maturity securities	\$	638.9	\$ 671.2	\$ 692.4
Equity securities		45.9	38.4	34.0
Cash and cash equivalents		1.0	2.5	3.7
Other		19.8	 16.2	2.4
Investment income		705.6	728.3	732.5
Investment expense		(46.5)	(42.2)	(28.8)
Net investment income	\$	659.1	\$ 686.1	\$ 703.7

Net realized investment gains/losses and net change in unrealized appreciation/depreciation in investments for the years ended December 31 are as follows:

	 2013	 2012	 2011
Net realized gains (losses) on investments:			
Fixed maturity securities:			
Gross realized gains from sales	\$ 225.9	\$ 401.0	\$ 289.2
Gross realized losses from sales	 (125.7)	 (54.8)	 (65.1)
Net realized gains from sales of fixed maturity securities	100.2	346.2	224.1
Equity securities:			
Gross realized gains from sales	224.1	82.0	75.4
Gross realized losses from sales	(100.5)	(93.8)	(68.0)
Net realized gains (losses) from sales of equity securities	123.6	(11.8)	7.4
Other realized gains on investments	48.1	0.5	3.6
Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in income:			
Fixed maturity securities	(42.5)	(11.8)	(24.2)
Equity securities	(13.9)	(17.5)	(27.9)
Other invested assets, long-term	 (42.5)	(8.5)	(41.2)
Other-than-temporary impairment losses recognized in income	 (98.9)	 (37.8)	 (93.3)
Character and a second			
Change in net unrealized (losses) gains on investments:	(670.0)	100.0	155.0
Fixed maturity securities	(679.8)	199.8	155.9
Equity securities	 225.4	 94.7	(124.6)
Total change in net unrealized (losses) gains on investments	(454.4)	294.5	31.3
Deferred income tax benefit (expense)	 159.7	 (104.6)	(10.7)
Net change in net unrealized (losses) gains on investments	 (294.7)	 189.9	 20.6
Net realized gains on investments, other-than-temporary impairment losses recognized in income and net change in net unrealized (losses) gains on			
investments	\$ (121.7)	\$ 487.0	\$ 162.4

A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market

conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.

Proceeds from fixed maturity securities, equity securities and other invested assets and the related gross realized gains and gross realized losses for the years ended December 31 are as follows:

		2013		2013 2012		2011	
Proceeds	\$	13,662.8	\$	15,915.6	\$	12,654.3	
Gross realized gains		498.1		483.5		368.2	
Gross realized losses		(226.2)		(148.6)		(133.1)	

A significant judgment in the valuation of investments is the determination of when an other-than-temporary decline in value has occurred. We follow a consistent and systematic process for recognizing impairments on securities that sustain other-than-temporary declines in value. We have established a committee responsible for the impairment review process. The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but not limited to: (i) the length of time and the extent to which the fair value has been less than book value, (ii) the financial condition and near term prospects of the issuer, (iii) our intent and ability to retain impaired equity security investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv) our intent to sell or the likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v) whether the debtor is current on interest and principal payments, (vi) the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors) and (vii) general market conditions and industry or sector specific factors. For securities that are deemed to be other-than-temporarily impaired, the security is adjusted to fair value and the resulting losses are recognized in the consolidated statements of income. The new cost basis of the impaired securities is not increased for future recoveries in fair value.

Other-than-temporary impairments recorded in 2013, 2012 and 2011 were primarily the result of the continued credit deterioration on specific issuers in the bond markets and certain equity securities' fair values remaining below cost for an extended period of time. There were no individually significant other-than-temporary impairment losses on investments by issuer during 2013, 2012 or 2011.

Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have an adverse material impact on our results of operations or shareholders' equity.

The changes in the amount of the credit component of other-than-temporary impairment losses on fixed maturity securities recognized in income, for which a portion of the other-than-temporary impairment losses was recognized in other comprehensive income, was not material for the years ended December 31, 2013, 2012 or 2011.

At December 31, 2013 and 2012, no investments exceeded 10% of shareholders' equity.

As of December 31, 2013 we did not hold any fixed maturity investments that did not produce income during 2013. The carrying value of fixed maturity investments that did not produce income during 2012 was \$1.8 at December 31, 2012.

As of December 31, 2013 we had committed approximately \$341.6 to future capital calls from various third-party investments in exchange for an ownership interest in the related entity.

At December 31, 2013 and 2012, securities with carrying values of approximately \$449.9 and \$431.5, respectively, were deposited by our insurance subsidiaries under requirements of regulatory authorities.

### **6. Derivative Financial Instruments**

A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December 31, 2013 and 2012 is as follows:

		ontractual/ Notional		Estimat Va			air 
	_	Amount	<b>Balance Sheet Location</b>		Asset	(L	iability)
December 31, 2013							
<b>Hedging instruments</b>							
Interest rate swaps	\$	1,660.0	Other assets/other liabilities	\$	30.9	\$	(20.7)
Non-hedging instruments							
Derivatives embedded in convertible securities		295.0	Fixed maturity securities		89.2		_
Interest rate swaps		72.6	Equity securities		1.8		(2.5)
Options		7,891.6	Equity securities/other assets		776.5		(787.7)
Futures			Equity securities		3.5		(1.6)
Subtotal non-hedging		8,259.2	Subtotal non-hedging		871.0		(791.8)
Total derivatives	\$	9,919.2	Total derivatives		901.9		(812.5)
			Amounts netted		(791.8)		791.8
			Net derivatives	\$	110.1	\$	(20.7)
December 31, 2012							
Hedging instruments							
Interest rate swaps	\$	1,650.0	Other assets/other liabilities	\$	58.6	\$	(0.1)
Non-hedging instruments							
Derivatives embedded in convertible securities		278.8	Fixed maturity securities		67.2		_
Credit default and interest rate swaps		95.9	Equity securities		_		(7.3)
Options		6,271.8	Equity securities		385.6		(411.2)
Futures		_	Equity securities		2.1		(0.4)
Subtotal non-hedging		6,646.5	Subtotal non-hedging		454.9		(418.9)
Total derivatives	\$	8,296.5	Total derivatives		513.5		(419.0)
			Amounts netted		(418.9)		418.9
			Net derivatives	\$	94.6	\$	(0.1)

### Fair Value Hedges

We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to LIBOR. A summary of our outstanding fair value hedges at December 31, 2013 and 2012 is as follows:

	Year Entered	Outstanding Notional Amount			ıl Amount	Interest Rate	
Type of Fair Value Hedges	Into		2013		2012	Received	<b>Expiration Date</b>
Interest rate swap	2013	\$	10.0	\$	_	4.350 %	August 15, 2020
Interest rate swap	2012		200.0		200.0	4.350	August 15, 2020
Interest rate swap	2012		625.0		625.0	1.875	January 15, 2018
Interest rate swap	2012		200.0		200.0	2.375	February 15, 2017
Interest rate swap	2011		200.0		200.0	5.250	January 15, 2016
Interest rate swap	2010		25.0		25.0	5.250	January 15, 2016
Interest rate swap	2006		200.0		200.0	5.000	December 15, 2014
Interest rate swap	2005		200.0		200.0	5.000	December 15, 2014
Total notional amount outstanding		\$	1,660.0	\$	1,650.0		

A summary of the effect of fair value hedges on our income statement for the years ended December 31, 2013, 2012 and 2011 is as follows:

Type of Fair Value Hedges	Income Statement Location of Hedge Gain	Hedge Gain Recognized	Hedged Item	Income Statement Location of Hedged Item Loss	Hedged Item Loss Recognized
Year ended December 31, 2013					
Interest rate swaps	Interest expense	\$ 31.5	Fixed rate debt	Interest expense	\$ (31.5)
Year ended December 31, 2012					
Interest rate swaps	Interest expense	\$ 38.2	Fixed rate debt	Interest expense	\$ (38.2)
Year ended December 31, 2011					
Interest rate swaps	Interest expense	\$ 45.1	Fixed rate debt	Interest expense	\$ (45.1)

### Cash Flow Hedges

We have historically entered into forward starting pay fixed interest rate swaps, with the objective of eliminating the variability of cash flows in the interest payments on various debt issuances. These swaps have all terminated and no amounts were outstanding at December 31, 2013 or 2012. The unrecognized loss for all terminated cash flow hedges included in accumulated other comprehensive income was \$32.3 and \$35.3 at December 31, 2013 and 2012. As of December 31, 2013, the total amount of amortization over the next twelve months for all cash flow hedges will increase interest expense by approximately \$5.0.

A summary of the effect of cash flow hedges on our financial statements for the years ended December 31, 2013, 2012 and 2011 is as follows:

			Effective Portion						
			Income Statement Location of	Hedge Loss	Ineffective Portion				
Type of Cash Flow Hedge	Pretax Hedge Loss Recognized in Other Comprehensive (Loss) Income		Loss Reclassification from Accumulated Other Comprehensive Income	Reclassified from Accumulated Other Comprehensive Income	Income Statement Location of Loss Recognized	Hedge Loss Recognized			
Year ended December 31, 2013									
Forward starting pay fixed swaps	\$		Interest expense	\$ (4.6)	None	\$			
Year ended December 31, 2012									
Forward starting pay fixed swaps  Year ended December 31, 2011	\$	(4.0)	Interest expense	\$ (4.2)	Interest expense	\$	(0.1)		
Forward starting pay fixed swaps	\$	(18.2)	Interest expense	\$ (1.8)	None	\$	_		

We test for cash flow hedge effectiveness at hedge inception and re-assess at the end of each reporting period. No amounts were excluded from the assessment of hedge effectiveness.

#### Non-Hedging Derivatives

A summary of the effect of non-hedging derivatives on our income statement for the years ended December 31, 2013, 2012 and 2011 is as follows:

Type of Non-hedging Derivatives	Income Statement Location of Gain (Loss) Recognized	Ga	rivative n (Loss) cognized	
Year ended December 31, 2013				
Derivatives embedded in convertible securities	Net realized gains on investments	\$	31.5	
Interest rate swaps	Net realized gains on investments		2.2	
Options	Net realized gains on investments		(111.7)	
Futures	Net realized gains on investments		22.3	
Swaptions	Net realized gains on investments	\$	3.0	
Total		\$	(52.7)	
Year ended December 31, 2012				
Derivatives embedded in convertible securities	Net realized gains on investments	\$	(2.4)	
Credit default and interest rate swaps	Net realized gains on investments		(3.9)	
Options	Net realized gains on investments		(66.0)	
Futures	Net realized gains on investments		(6.7)	
Total		\$	(79.0)	
Year ended December 31, 2011				
Derivatives embedded in convertible securities	Net realized gains on investments	\$	(7.6)	
Credit default and interest rate swaps	Net realized gains on investments		(53.3)	
Options	Net realized gains on investments		9.6	
Futures	Net realized gains on investments		(5.9)	
Total		\$	(57.2)	

#### 7. Fair Value

Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:

Level Input:	Input Definition:
Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II	Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:

Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.

Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. United States Government securities represent Level I securities, while Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions and mortgage-backed securities. For securities not actively traded, the third party pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the third party pricing services' qualifications and procedures used to determine fair values. In addition, we periodically review the third party pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

Equity securities, available-for-sale: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security's current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, or EBITDA, and/or revenue multiples that are not observable in the markets.

Other invested assets, current: Other invested assets, current include securities held in rabbi trusts that are classified as trading. Fair values are based on quoted market prices.

Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.

*Derivatives:* Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate

market observable inputs for similar derivative transactions.

In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan assets not defined above (see Note 11, "Retirement Benefits," for fair values of benefit plan assets):

Mutual funds: Fair values are based on quoted market prices, which represent the net asset value, or NAV, of shares held.

Common and collective trusts: Fair values of common/collective trusts that replicate traded money market funds are based on cost, which approximates fair value. Fair values of common/collective trusts that invest in securities are valued at the NAV of the shares held, where the trust applies fair value measurements to the underlying investments to determine the NAV.

*Partnership interests*: Fair values are estimated based on the plan's proportionate share of the undistributed partners' capital as reported in audited financial statements of the partnership.

Contract with insurance company: Fair value of the contract in the insurance company general investment account is determined by the insurance company based on the fair value of the underlying investments of the account.

*Investment in DOL 103-12 trust:* Fair value is based on the plan's proportionate share of the fair value of investments held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity, or DOL 103-12 trust, as reported in audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of the trust.

Life insurance contracts: Fair value is based on the cash surrender value of the policies as reported by the insurer.

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December 31, 2013 and 2012 is as follows:

		Level I		Level II	I	evel III		Total
December 31, 2013								
Assets:								
Cash equivalents	\$	632.3	\$	_	\$	_	\$	632.3
Investments available-for-sale:								
Fixed maturity securities:								
United States Government securities		299.9		_		_		299.9
Government sponsored securities		_		173.5		_		173.5
States, municipalities and political subdivisions, tax-exempt				6,002.7		_		6,002.7
Corporate securities		_		7,593.4		115.2		7,708.6
Options embedded in convertible securities				89.2		_		89.2
Residential mortgage-backed securities		_		2,268.9		_		2,268.9
Commercial mortgage-backed securities		_		480.1		6.5		486.6
Other debt securities		35.6		408.3		14.8		458.7
Total fixed maturity securities		335.5		17,016.1		136.5		17,488.1
Equity securities		1,475.7		249.7		41.4		1,766.8
Other invested assets, current		16.3		_		_		16.3
Securities lending collateral		408.5		561.3		_		969.8
Derivatives excluding embedded options (reported with other assets)				58.4				58.4
Total assets	\$	2,868.3	\$	17,885.5	\$	177.9	\$	20,931.7
Liabilities:								
Derivatives excluding embedded options (reported with other liabilities)	\$	_	\$	(20.7)	\$	_	\$	(20.7)
Total liabilities	\$		\$	(20.7)	\$		\$	(20.7)
	_		_	<u> </u>	_			<u> </u>
December 31, 2012:								
Assets:								
Cash equivalents	\$	728.3	\$	_	\$	_	\$	728.3
Investments available-for-sale:	Ψ	, 20.0	Ψ		Ψ		Ψ.	72010
Fixed maturity securities:								
United States Government securities		343.2		_		_		343.2
Government sponsored securities				156.2		_		156.2
States, municipalities and political subdivisions, tax-exempt		_		5,882.2		_		5,882.2
Corporate securities				7,882.9		121.1		8,004.0
Options embedded in convertible securities		_		67.2				67.2
Residential mortgage-backed securities		_		2,300.5		4.3		2,304.8
Commercial mortgage-backed securities		_		345.7		_		345.7
Other debt securities		33.8		203.4		3.9		241.1
Total fixed maturity securities	_	377.0		16,838.1	_	129.3	_	17,344.4
Equity securities		1,103.1		113.2		26.2		1,242.5
Other invested assets, current		14.8		113.2				14.8
Securities lending collateral		231.7		332.9		_		564.6
Derivatives excluding embedded options (reported with other assets)		231.7		58.6				58.6
Total assets	\$	2,454.9	\$	17,342.8	\$	155.5	\$	19,953.2
	φ	۷,٦٥٩.۶	φ	11,542.0	φ	133.3	φ	17,733.2
Liabilities:	ф		Ф	(0.1)	¢.		Ф	(0.1)
Derivatives excluding embedded options (reported with other liabilities)	\$	<del>-</del>	\$	(0.1)	\$		\$	(0.1)
Total liabilities	\$		\$	(0.1)	\$		\$	(0.1)

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December 31, 2013, 2012 and 2011 is as follows:

	Corporate Securities		Residential Mortgage- backed Securities		Commercial Mortgage- backed Securities		Other Debt Securities		Equity Securities		Total	
Year Ended December 31, 2013:												
Beginning balance at January 1, 2013	\$	121.1	\$ 4.3	\$	_	\$	3.9	\$	26.2	\$	155.5	
Total gains (losses):												
Recognized in net income		(30.3)	_		_		(0.1)		(4.8)		(35.2)	
Recognized in accumulated other comprehensive income		(3.5)	_		_		0.6		9.5		6.6	
Purchases		51.9	_		_		1.6		17.6		71.1	
Sales		(4.8)	_		_		_		(7.1)		(11.9)	
Settlements		(15.5)	(1.9)		(6.1)		(0.7)		_		(24.2)	
Transfers into Level III		3.0	13.1		12.6		9.8		_		38.5	
Transfers out of Level III		(6.7)	(15.5)		_		(0.3)		_		(22.5)	
Ending balance at December 31, 2013	\$	115.2	\$ _	\$	6.5	\$	14.8	\$	41.4	\$	177.9	
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2013	\$	(30.8)	\$ _	\$	_	\$	(0.1)	\$	(6.5)	\$	(37.4)	
Year Ended December 31, 2012:												
Beginning balance at January 1, 2012	\$	195.1	\$ _	\$	6.3	\$	59.0	\$	24.4	\$	284.8	
Total gains (losses):												
Recognized in net income		15.2	_		_		0.1		(0.9)		14.4	
Recognized in accumulated other comprehensive income		(19.7)	_		0.1		0.7		(14.2)		(33.1)	
Purchases		77.8	3.0		3.4		_		4.9		89.1	
Business combinations		2.6	_		_		_		_		2.6	
Sales		(29.8)	_		_		(16.6)		(0.5)		(46.9)	
Settlements		(67.8)	(0.1)		(0.1)		(1.3)		_		(69.3)	
Transfers into Level III		2.9	1.4		1.9		12.0		12.5		30.7	
Transfers out of Level III		(55.2)			(11.6)		(50.0)				(116.8)	
Ending balance at December 31, 2012	\$	121.1	\$ 4.3	\$		\$	3.9	\$	26.2	\$	155.5	
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2012	\$		\$ 	\$		\$		\$	(0.7)	\$	(0.7)	
Year Ended December 31, 2011:												
Beginning balance at January 1, 2011	\$	278.4	\$ 3.8	\$	7.8	\$	81.4	\$	17.3	\$	388.7	
Total gains (losses):												
Recognized in net income		5.2	_		_		(1.7)		(7.0)		(3.5)	
Recognized in accumulated other comprehensive income		(3.0)	0.1		0.1		_		4.1		1.3	
Purchases		31.2	2.8		2.6		12.2		10.2		59.0	
Sales		(27.6)	(9.1)		(8.2)		(22.9)		(0.4)		(68.2)	
Settlements		(130.5)	(0.8)		(1.4)		(17.7)		_		(150.4)	
Transfers into Level III		41.4	9.7		5.4		7.8		0.2		64.5	
Transfers out of Level III			(6.5)				(0.1)			_	(6.6)	
Ending balance at December 31, 2011	\$	195.1	\$ _	\$	6.3	\$	59.0	\$	24.4	\$	284.8	
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2011	\$	(0.6)	\$ 	\$		\$	(1.2)	\$	(7.0)	\$	(8.8)	

Transfers between levels, if any, are recorded as of the beginning of the reporting period. There were no material transfers into or out of Level III during the years ended December 31, 2013 or 2011 and no material transfers into Level III during the year ended December 31, 2012. During the year ended December 31, 2012, the transfers out of Level III of

-104-

corporate securities were for certain sub-prime securities transferred from Level III to Level II as a result of inputs that were previously unobservable becoming observable due to increased volume and level of trading in active markets. In addition, the transfers out of Level III of other debt securities were for certain inverse floating rate securities transferred from Level III to Level II as a result of those securities' impending maturity and settlement and recent trading activity of similar securities in observable markets.

During the years ended December 31, 2013, 2012 or 2011, there were no material transfers from Level I to Level II or from Level II to Level II.

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, "Business Acquisitions and Divestitures", we completed our acquisition of Amerigroup on December 24, 2012. The values of net assets acquired in our acquisition of Amerigroup and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of Amerigroup's assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Amerigroup were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets can be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Refer to Note 13, "Debt," for additional disclosure regarding the Amerigroup senior unsecured notes recorded at their acquisition date fair value during 2012 (nonrecurring fair value measurement). Other than the assets acquired and liabilities assumed in our acquisition of Amerigroup described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2013 and 2012.

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain only one quoted price for each security from third party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. When broker quotes are used, we generally obtain only one broker quote per security. As we are responsible for the determination of fair value, we perform monthly analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the third party pricing services engaged and the valuation techniques and inputs used. Our analysis includes a review of month-to-month price fluctuations. If unusual fluctuations are noted in this review, we may obtain additional information from other pricing services to validate the quoted price. There were no adjustments to quoted market prices obtained from third party pricing services during the years ended December 31, 2013, 2012 or 2011.

In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.

Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.

The carrying amounts reported in the consolidated balance sheets for cash, accrued investment income, premium and self-funded receivables, other receivables, income taxes receivable, unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and certain other current liabilities approximate fair value because of the short term nature of these items. These assets and liabilities are not listed in the table below.

The following methods and assumptions were used to estimate the fair value of each class of financial instrument:

Other invested assets, long-term: Other invested assets, long-term include primarily our investments in limited

partnerships, joint ventures and other non-controlled corporations, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities' undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.

Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.

Long-term debt - commercial paper: The carrying amount for commercial paper approximates fair value as the underlying instruments have variable interest rates at market value.

Long-term debt - notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.

Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.

A summary of the carrying value and fair value by level of financial instruments not recorded at fair value on our consolidated balance sheets at December 31, 2013 and 2012 are as follows:

	Carrying										
	Value		Level I		Level II		Level III		Total		
December 31, 2013											
Assets:											
Other invested assets, long-term	\$ 1,542.6	5 \$	_	\$	_	\$	1,542.6	\$	1,542.6		
Liabilities:											
Debt:											
Short-term borrowings	400.0	)	_		400.0		_		400.0		
Commercial paper	379.2	2	_		379.2		_		379.2		
Notes	12,746.4	ļ	_		13,014.3		_		13,014.3		
Convertible debentures	966.0	)	_		2,030.6		_		2,030.6		
December 31, 2012											
Assets:											
Other invested assets, long-term	\$ 1,387.7	\$	_	\$	_	\$	1,387.7	\$	1,387.7		
Liabilities:											
Debt:											
Short-term borrowings	250.0	)	_		250.0		_		250.0		
Commercial paper	570.9	)	_		570.9		_		570.9		
Notes	13,198.9	)	_		14,407.1		_		14,407.1		
Convertible debentures	958.1		_		1,613.4		_		1,613.4		

### 8. Income Taxes

The components of deferred income taxes at December 31 are as follows:

	2	2013	2012
Deferred tax assets relating to:			
Retirement benefits	\$	287.8	\$ 405.3
Accrued expenses		342.8	431.2
Insurance reserves		213.1	221.2
Net operating loss carryforwards		17.2	19.2
Bad debt reserves		124.8	108.2
State income tax		32.9	79.3
Deferred compensation		52.0	55.7
Investment basis difference		166.3	138.2
Other		84.0	47.0
Total deferred tax assets		1,320.9	1,505.3
Valuation allowance		(24.1)	(18.1)
Total deferred tax assets, net of valuation allowance		1,296.8	1,487.2
Deferred tax liabilities relating to:			
Unrealized gains on securities		266.5	431.0
Acquisition related:			
Trademarks and other non-amortizable intangible assets		2,200.5	2,200.5
Subscriber base, provider and hospital networks		370.9	447.7
Internally developed software and other amortization differences		703.9	599.3
Retirement benefits		231.5	214.1
Debt discount		186.9	189.7
State deferred tax		55.3	165.9
Depreciation and amortization		33.1	73.9
Other		190.4	151.6
Total deferred tax liabilities		4,239.0	4,473.7
Net deferred tax liability	\$	(2,942.2)	\$ (2,986.5)
Deferred tax asset-current	\$	383.0	\$ 236.4
Deferred tax liability-noncurrent		(3,325.2)	(3,222.9)
Net deferred tax liability	\$	(2,942.2)	\$ (2,986.5)
		<del></del>	,

Changes in the valuation allowance during 2013 included an increase of \$12.1 impacting tax expense related to additional state operating losses and a reduction of \$6.1 impacting goodwill related to acquisition goodwill adjustments for a net increase of \$6.0.

Changes in the valuation allowance during 2012 included an \$11.0 release related to federal credits and loss carryforwards as tax settlements were completed and establishment of an \$18.1 allowance related to state net operating losses net of the federal benefit.

Significant components of the provision for income taxes for the years ended December 31 consist of the following:

	2013	 2012	 2011
Current tax expense (benefit):			
Federal	\$ 1,226.4	\$ 1,060.2	\$ 1,150.4
State and local	(42.6)	 95.7	21.6
Total current tax expense	1,183.8	1,155.9	1,172.0
Deferred tax expense	22.1	51.4	139.2
Total income tax expense	\$ 1,205.9	\$ 1,207.3	\$ 1,311.2

State and local current tax expense is reported gross of federal benefit, and includes amounts related to true up of prior years' tax, audit settlements, uncertain tax positions and state tax credits. Such items are included in multiple lines in the following rate reconciliation table on a net of federal tax basis.

A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December 31, is as follows:

	2013				20	012	2011				
	Amount		Percent		Amount	Percent		ıt Percent		Amount	Percent
Amount at statutory rate	\$	1,344.1	35.0 %	\$	1,350.4	35.0 %	\$	1,385.3	35.0 %		
State and local income taxes net of federal tax benefit		24.4	0.6		25.5	0.6		42.3	1.1		
Tax exempt interest and dividends received deduction		(64.9)	(1.7)		(59.3)	(1.5)		(58.6)	(1.5)		
Audit settlements		_			(200.5)	(5.2)		(49.7)	(1.3)		
Other, net		(97.7)	(2.5)		91.2	2.4		(8.1)	(0.2)		
Total income tax expense	\$	1,205.9	31.4 %	\$	1,207.3	31.3 %	\$	1,311.2	33.1 %		

During the year ended December 31, 2013 we recognized income tax benefits of \$65.0, or \$0.21 per diluted share, resulting from a favorable tax election made subsequent to the Amerigroup acquisition. This benefit is included in Other, net above.

During the year ended December 31, 2012, we recognized income tax benefits of \$200.5, or \$0.62 per diluted share, for settlement of certain of our open tax issues with the Internal Revenue Service, or IRS, following approval by the Joint Committee on Taxation. This included amounts related to not-for-profit conversion and corporate reorganizations in prior years, as well as amounts associated with issues related to certain of our acquired companies. This income tax benefit includes the release of gross unrecognized tax benefits from uncertain tax positions, discussed below, release of a valuation allowance, discussed above, and recognition of interest income. This income tax benefit, and resulting decrease in the effective tax rate, was partially offset due to the non-tax deductibility of litigation settlement expenses associated with the settlement of a class action lawsuit in June 2012 and an increase in our state deferred tax asset valuation allowance attributable to the uncertainty associated with some of our state net operating loss carryforwards.

During the year ended December 31, 2011, following approval by the Joint Committee on Taxation, we settled the audit of our 2003 and 2004 (short year) federal tax returns, which had been in the appeals process with the IRS. This resulted in a tax benefit of \$39.3. In addition, during the year ended December 31, 2011, we completed a state tax examination, resulting in additional tax benefits for audit settlements of \$10.4.

The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December 31, is as follows:

	2013	2012
Balance at January 1	\$ 143.5	\$ 229.1
Additions for tax positions related to:		
Current year	5.0	50.1
Prior years	_	13.0
Reductions related to:		
Tax positions of prior years	(45.3)	_
Settlements with taxing authorities	 	(148.7)
Balance at December 31	\$ 103.2	\$ 143.5

The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is included in the amounts described in the following paragraph.

As of December 31, 2013, \$61.7 of unrecognized tax benefits would impact our effective tax rate in future periods, if recognized. Also included in the table above is \$10.9 that would be recognized as an adjustment to additional paid-in capital and \$5.7 that would be recognized as an adjustment to goodwill, neither of which would affect our effective tax rate. The December 31, 2013 balance also includes \$0.8 of tax positions for which ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. Excluding the impact of interest and penalties, the disallowance of the shorter deductibility period would not affect our effective tax rate, but would accelerate the payment of cash to the taxing authority to an earlier period.

For the years ended December 31, 2013, 2012 and 2011, we recognized approximately \$2.6, \$(9.0) and \$(0.1) in interest, respectively. We had accrued approximately \$18.3 and \$15.7 for the payment of interest at December 31, 2013 and 2012, respectively.

As of December 31, 2013, as further described below, certain tax years remain open to examination by the IRS and various state and local authorities. In addition, we continue to discuss certain industry issues with the IRS. As a result of these examinations and discussions, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could change within a range of approximately \$8.3 to \$(84.8).

We are a member of the IRS Compliance Assurance Process, or CAP. The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.

As of December 31, 2013, the examinations of our 2013 through 2010 tax years continue to be in process. The issues in 2010 have been resolved, but still require final approval from the Joint Committee on Taxation before they can be finalized. The 2011 tax year is at IRS Appeals, but at this time no hearing date has been established. The other years are being discussed with the IRS.

In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported with general and administrative expense.

At December 31, 2013, we had unused federal tax net operating loss carryforwards of approximately \$44.8 to offset future taxable income. The loss carryforwards expire in the years 2017 through 2024. During 2013, 2012 and 2011 federal income taxes paid totaled \$1,172.0, \$1,188.2 and \$1,153.9, respectively.

#### 9. Property and Equipment

A summary of property and equipment at December 31 is as follows:

	2013		 2012
Land and improvements	\$ 3	5.4	\$ 45.9
Building and components	38	4.0	406.0
Data processing equipment, furniture and other equipment	86	1.5	783.3
Computer software, purchased and internally developed	1,87	9.0	1,656.5
Leasehold improvements	32	5.1	 303.1
Property and equipment, gross	3,48	5.0	3,194.8
Accumulated depreciation and amortization	(1,68	3.5)	 (1,477.5)
Property and equipment, net	\$ 1,80	1.5	\$ 1,717.3

Depreciation expense for 2013, 2012 and 2011 was \$105.3, \$102.9 and \$95.7, respectively. Amortization expense on computer software and leasehold improvements for 2013, 2012 and 2011 was \$351.8, \$260.6 and \$204.6, respectively, which includes amortization expense on computer software, both purchased and internally developed, for 2013, 2012 and 2011 of \$313.6, \$239.5 and \$183.9, respectively. Capitalized costs related to the internal development of software of \$1,561.0 and \$1,316.8 at December 31, 2013 and 2012, respectively, are reported with computer software.

During the years ended December 31, 2013 and 2012, we recognized \$47.7 and \$66.8, respectively, of impairments related to computer software (primarily internally developed) due to project cancellation or asset replacement, some of which resulted from a change in strategic focus needed to effectively manage business operations in a post-Health Care Reform environment.

#### 10. Goodwill and Other Intangible Assets

A summary of the change in the carrying amount of goodwill by reportable segment (see Note 20, "Segment Information") for 2013 and 2012 is as follows:

	and	mmercial d Specialty Business	 overnment Business	Other	Total
Balance as of January 1, 2012	\$	11,555.6	\$ 2,303.1	\$ _	\$ 13,858.7
Amerigroup acquisition		_	3,033.1	_	3,033.1
Measurement period adjustments		(0.3)	 (1.7)	 	 (2.0)
Balance as of December 31, 2012	\$	11,555.3	\$ 5,334.5	_	\$ 16,889.8
Measurement period adjustments		(1.3)	 28.7		 27.4
Balance as of December 31, 2013	\$	11,554.0	\$ 5,363.2	 	\$ 16,917.2
Accumulated impairment as of December 31, 2013	\$	(41.0)	\$		\$ (41.0)

Goodwill adjustments incurred during 2013 and 2012 included a reduction of \$1.5 and \$0.4, respectively, related to the tax benefit on the exercise of stock options issued as part of various acquisitions and an increase of \$28.9 and a decrease of \$1.6, respectively, related to other measurement period adjustments.

As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2013, 2012 and 2011. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a significant degree of management judgment and the use of subjective assumptions. The fair values were estimated using the income and market value valuation methods, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections, income projections, cash flows and discount rates. We did not incur any impairment losses in 2013,

2012 or 2011 as the estimated fair values of our reporting units were substantially in excess of their carrying values.

The components of other intangible assets as of December 31 are as follows:

		2013																														
	Gross Carrying Amount	ccumulated nortization			Carrying		Carrying		Carrying		Carrying		Carrying		Carrying		Gross Carrying Amount		Carrying			ccumulated nortization		Net Carrying Amount								
Intangible assets with finite lives:																																
Customer relationships	\$ 3,308.9	\$ (2,264.2)	\$	1,044.7	\$	3,334.8	\$	(2,058.0)	\$	1,276.8																						
Provider and hospital relationships	140.5	(44.7)		95.8		140.5		(38.1)		102.4																						
Other	61.7	(28.3)		33.4		66.1		(26.9)		39.2																						
Total	3,511.1	(2,337.2)		1,173.9		3,541.4		(2,123.0)		1,418.4																						
Intangible assets with indefinite lives:																																
Blue Cross and Blue Shield and other trademarks	6,298.7	_		6,298.7		6,298.7		_		6,298.7																						
Provider network	271.8	_		271.8		271.8		_		271.8																						
State Medicaid contracts	696.6	_		696.6		676.6		_		676.6																						
Total	7,267.1	_		7,267.1		7,247.1				7,247.1																						
Other intangible assets	\$ 10,778.2	\$ (2,337.2)	\$	8,441.0	\$	10,788.5	\$	(2,123.0)	\$	8,665.5																						

As of December 31, 2013, the estimated amortization expense for each of the five succeeding years is as follows: 2014, \$213.3; 2015, \$182.1; 2016, \$151.4; 2017, \$131.5; and 2018, \$111.7.

#### 11. Retirement Benefits

We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.

The WellPoint Cash Balance Pension Plan, or the WellPoint Plan, is a cash balance pension plan covering certain eligible employees of the affiliated companies that participate in the WellPoint Plan. Effective January 1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules continue to accrue benefits. Several pension plans acquired through various corporate mergers and acquisitions have been merged into the WellPoint Plan. Effective January 1, 2011, we split the WellPoint Plan, with no change in benefits for any participant. Current employees who are still receiving credits and/or benefit accruals were placed into a new plan, the WellPoint Cash Balance Pension Plan B. All other participants remain in the WellPoint Plan. Effective January 1, 2012, the WellPoint Plan was renamed the WellPoint Cash Balance Pension Plan A.

The UGS Pension Plan is a defined benefit pension plan with a cash balance component. The UGS Pension Plan covers eligible employees of the affiliated companies that participate in the UGS Pension Plan. Effective January 1, 2004, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits previously accrued. Certain employees subject to collective bargaining and certain other employees who met grandfathering rules continue to accrue benefits.

The Employees' Retirement Plan of Blue Cross of California, or the BCC Plan, is a defined benefit pension plan that covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective January 1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired or rehired after December 31, 2006 are eligible to participate in the BCC Plan.

All of the plans' assets consist primarily of common stocks, fixed maturity securities, investment funds and short-term investments. The funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended, or ERISA, including amendment by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to provide assets sufficient to meet the benefits to be paid to plan participants.

We use a December 31 measurement date for determining benefit obligations and fair value of plan assets.

The following tables disclose consolidated "pension benefits," which include the defined benefit pension plans described above, and consolidated "other benefits," which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were computed using assumptions at the December 31 measurement dates.

The reconciliation of the benefit obligation is as follows:

		Pension	Ben	efits	 Other Benefits				
	2013 2012				2013		2012		
Benefit obligation at beginning of year	\$	1,948.5	\$	1,851.3	\$ 623.0	\$	651.3		
Service cost		14.2		16.4	6.7		6.8		
Interest cost		67.8		76.4	22.4		27.5		
Actuarial (gain) loss		(129.9)		129.6	4.8		(28.4)		
Benefits paid		(135.9)		(125.2)	(49.4)		(34.2)		
Benefit obligation at end of year	\$	1,764.7	\$	1,948.5	\$ 607.5	\$	623.0		

The changes in the fair value of plan assets are as follows:

	 Pension	Ber	efits	 Other	Bene	fits
	2013		2012	2013		2012
Fair value of plan assets at beginning of year	\$ 1,817.9	\$	1,721.8	\$ 320.3	\$	301.1
Actual return on plan assets	223.4		186.8	37.0		21.9
Employer contributions	38.6		34.5	31.3		38.4
Benefits paid	(135.9)		(125.2)	(38.8)		(41.1)
Fair value of plan assets at end of year	\$ 1,944.0	\$	1,817.9	\$ 349.8	\$	320.3

The net amount included in the consolidated balance sheets is as follows:

	Pension	Ben	efits	 Other	Bene	fits
	2013		2012	2013		2012
Noncurrent assets	\$ 240.8	\$	3.0	\$ 	\$	_
Current liabilities	(3.5)		(11.5)	_		_
Noncurrent liabilities	(58.0)		(122.1)	(257.7)		(302.7)
Net amount at December 31	\$ 179.3	\$	(130.6)	\$ (257.7)	\$	(302.7)

The net amounts included in accumulated other comprehensive loss (income) that have not been recognized as components of net periodic benefit costs are as follows:

		Pension	Ben	efits	Other Ben			nefits			
	2013			2013 2		2012		2013			2012
Net actuarial loss	\$	427.2	\$	686.8	\$	169.6	\$	191.0			
Prior service credit		(3.0)		(3.9)		(102.4)		(103.0)			
Net amount before tax at December 31	\$	424.2	\$	682.9	\$	67.2	\$	88.0			

The estimated net actuarial loss and prior service credit for the defined benefit pension plans that will be reclassified from accumulated other comprehensive loss into net periodic benefit costs over the next year are \$18.8 and \$0.8, respectively. The estimated net actuarial loss and prior service credit for postretirement benefit plans that will be reclassified from accumulated other comprehensive loss into net periodic benefit costs over the next year are \$9.4 and \$14.5, respectively.

The accumulated benefit obligation for the defined benefit pension plans was \$1,758.2 and \$1,941.8 at December 31, 2013 and 2012, respectively.

As of December 31, 2013, certain pension plans had accumulated benefit obligations in excess of plan assets. For those same plans, the projected benefit obligation was also in excess of plan assets. Such plans had a combined projected benefit obligation, accumulated benefit obligation and fair value of plan assets of \$60.7, \$60.7 and \$0.0, respectively.

The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:

	Pension B	enefits	Other Be	nefits
	2013	2012	2013	2012
Discount rate	4.39%	3.60%	4.48%	3.71%
Rate of compensation increase	3.00%	3.50%	3.00%	3.50%
Expected rate of return on plan assets	7.66%	7.66%	7.00%	7.00%

The components of net periodic benefit cost included in the consolidated statements of income are as follows:

	2013	2012	2011
Pension Benefits			
Service cost	\$ 14.2	\$ 16.4	\$ 17.3
Interest cost	67.8	76.4	84.7
Expected return on assets	(133.1)	(134.7)	(128.2)
Recognized actuarial loss	28.3	30.5	26.4
Amortization of prior service credit	(0.8)	(0.8)	(0.8)
Settlement loss	 11.0	 13.8	21.3
Net periodic benefit cost	\$ (12.6)	\$ 1.6	\$ 20.7
Other Benefits			
Service cost	\$ 6.7	\$ 6.8	\$ 6.3
Interest cost	22.4	27.5	31.4
Expected return on assets	(22.1)	(21.0)	(17.3)
Recognized actuarial loss	11.2	14.1	10.2
Amortization of prior service credit	(13.3)	(13.3)	(12.0)
Net periodic benefit cost	\$ 4.9	\$ 14.1	\$ 18.6

During the years ended December 31, 2013, 2012 and 2011 we incurred total settlement losses of \$11.0, \$13.8 and \$21.3, respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.

The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:

	2013	2012	2011
Pension Benefits			
Discount rate	3.60%	4.29%	5.15%
Rate of compensation increase	3.50%	3.50%	3.75%
Expected rate of return on plan assets	7.91%	8.00%	8.00%
Other Benefits			
Discount rate	3.71%	4.36%	5.24%
Rate of compensation increase	3.50%	3.50%	3.75%
Expected rate of return on plan assets	7.00%	7.00%	6.75%

The assumed health care cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December 31, 2013 measurement date was 8.00% for 2014 with a gradual decline to 4.50% by the year 2025. The assumed health care cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2013 measurement date was 6.00% for 2014 with a gradual decline to 4.50% by the year 2021. These estimated trend rates are subject to change in the future. The health care cost trend rate assumption has a significant effect on the amounts reported. For example, an increase in the assumed health care cost trend rate of one percentage point would increase the postretirement benefit obligation as of December 31, 2013 by \$44.2 and would increase service and interest costs by \$1.8. Conversely, a decrease in the assumed health care cost trend rate of one percentage point would decrease the postretirement benefit obligation by \$38.1 as of December 31, 2013 and would decrease service and interest costs by \$1.5.

Plan assets include a diversified mix of investment grade fixed maturity securities, equity securities and alternative investments across a range of sectors and levels of capitalization to maximize the long-term return for a prudent level of risk. The weighted-average target allocation for pension benefit plan assets is 45% equity securities, 46% fixed maturity securities, and 9% to all other types of investments. Equity securities primarily include a mix of domestic securities, foreign securities and mutual funds invested in equities. Fixed maturity securities primarily include treasury securities, corporate bonds, and asset-backed investments issued by corporations and the U.S. government. Other types of investments include partnership interests, collective trusts that replicate money market funds and insurance contracts designed specifically for employee benefit plans. As of December 31, 2013, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were invested in WellPoint common stock.

Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value.

The fair values of our pension benefit assets and other benefit assets at December 31, 2013, excluding \$3.9 of cash, investment income receivable and amounts due to/from brokers, by asset category and level inputs, as defined by FASB guidance regarding fair value measurements and disclosures (see Note 7, "Fair Value," for additional information regarding the definition of level inputs), are as follows:

	 Level I	 Level II		Level III	Total
December 31, 2013:					
Pension Benefit Assets:					
Equity securities:					
U.S. securities	\$ 613.8	\$ 	\$	_	\$ 613.8
Foreign securities	296.8	_		_	296.8
Mutual funds	37.4			_	37.4
Fixed maturity securities:					
Government securities	177.9	11.5		_	189.4
Corporate securities	_	272.1		_	272.1
Asset-backed securities	_	127.0		_	127.0
Other types of investments:					
Common and collective trusts	_	46.6		_	46.6
Partnership interests	_	_		159.1	159.1
Insurance company contracts	_	_		197.4	197.4
Treasury futures contracts	0.7	_		_	0.7
Total pension benefit assets	\$ 1,126.6	\$ 457.2	\$	356.5	\$ 1,940.3
Other Benefit Assets:					
Equity securities:					
U.S. securities	\$ 39.0	\$ _	\$	_	\$ 39.0
Foreign securities	18.6	_		_	18.6
Mutual funds	4.7	_		_	4.7
Fixed maturity securities:					
Government securities	14.3			_	14.3
Corporate securities	4.3	9.9		_	14.2
Asset-backed securities	_	11.2		_	11.2
Other types of investments:					
Common and collective trusts	_	2.2		_	2.2
Partnership interests	_	_		1.2	1.2
Life insurance contracts	_	_		230.0	230.0
Investment in DOL 103-12 trust	_	14.2		_	14.2
Total other benefit assets	\$ 80.9	\$ 37.5	\$	231.2	\$ 349.6

The fair values of our pension benefit assets and other benefit assets at December 31, 2012, excluding \$3.2 of cash, investment income receivable and amounts due to/from brokers, by asset category and level inputs, as defined by FASB guidance regarding fair value measurements and disclosures (see Note 7, "Fair Value," for additional information regarding the definition of level inputs) are as follows:

	Level I		Level II		evel II L		Total
December 31, 2012:							
Pension Benefit Assets:							
Equity securities:							
U.S. securities	\$	514.3	\$	_	\$	_	\$ 514.3
Foreign securities		272.5		_		_	272.5
Mutual funds		30.9		_		_	30.9
Fixed maturity securities:							
Government securities		192.1		18.0		_	210.1
Corporate securities		_		240.5		_	240.5
Asset-backed securities		_		138.7		_	138.7
Other types of investments:							
Common and collective trusts		_		28.9		_	28.9
Partnership interests		_		_		176.5	176.5
Insurance company contracts		_		_		202.5	202.5
Treasury futures contracts		(0.2)					(0.2)
Total pension benefit assets	\$	1,009.6	\$	426.1	\$	379.0	\$ 1,814.7
Other Benefit Assets:							
Equity securities:							
U.S. securities	\$	23.2	\$	_	\$	_	\$ 23.2
Foreign securities		11.6		_		_	11.6
Mutual funds		36.1		_		_	36.1
Fixed maturity securities:							
Government securities		4.3		_		_	4.3
Corporate securities		_		9.2		_	9.2
Asset-backed securities		_		13.8		_	13.8
Other types of investments:							
Common and collective trusts		_		2.1		_	2.1
Partnership interests		_		_		1.2	1.2
Life insurance contracts		_				203.7	203.7
Investment in DOL 103-12 trust				15.1			15.1
Total other benefit assets	\$	75.2	\$	40.2	\$	204.9	\$ 320.3

A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December 31, 2013, 2012 and 2011 is as follows:

		Equity urities	Partnership Interests		-						Insurance Company Contracts			Life surance ontracts		Total
Year Ended December 31, 2013:																
Beginning balance at January 1, 2013	\$	_	\$	177.7	\$	202.5	\$	203.7	\$	583.9						
Actual return on plan assets:																
Relating to assets still held at the reporting date				2.2		(5.6)		26.3		22.9						
Purchases		_		15.6		9.5		_		25.1						
Sales				(35.2)		(9.0)		_		(44.2)						
Ending balance at December 31, 2013	\$		\$	160.3	\$	197.4	\$	230.0	\$	587.7						
Year Ended December 31, 2012:																
·	\$	317.6	\$	166.1	\$	195.5	\$	95.7	\$	774.9						
Beginning balance at January 1, 2012 Actual return on plan assets:	Ф	317.0	Ф	100.1	Ф	193.3	Ф	93.7	Ф	114.9						
Relating to assets still held at the reporting date				4.5		5.5		13.2		23.2						
Purchases		<del></del>		14.1		8.8		94.8		117.7						
Sales		(317.6)		(7.0)		(7.3)		<del></del>		(331.9)						
Ending balance at December 31, 2012	\$	(317.0)	\$	177.7	\$	202.5	\$	203.7	\$	583.9						
	<u> </u>		<u> </u>		÷		Ė									
Year Ended December 31, 2011:																
Beginning balance at January 1, 2011	\$	429.8	\$	153.1	\$	188.8	\$	_	\$	771.7						
Actual return on plan assets:																
Relating to assets still held at the reporting date		4.8		5.8		2.7		1.0		14.3						
Purchases		_		7.6		11.6		94.7		113.9						
Sales		(117.0)		(0.4)		(7.6)		_		(125.0)						
Ending balance at December 31, 2011	\$	317.6	\$	166.1	\$	195.5	\$	95.7	\$	774.9						

There were no transfers between Levels I, II and III during the years ended December 31, 2013, 2012 and 2011. The significant decline in plan assets measured using Level III inputs as of December 31, 2012 was primarily due to the sale of an equity partnership.

Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended December 31, 2013, 2012 and 2011, no material contributions were necessary to meet ERISA required funding levels. However, during the years ended December 31, 2013, 2012 and 2011, we made tax deductible discretionary contributions to the pension benefit plans of \$38.6, \$34.5 and \$57.7, respectively. Additionally, during the year ended December 31, 2011, we made tax deductible discretionary contributions to other benefit plans of \$30.0. Employer contributions to other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.

Our estimated future payments for pension benefits and postretirement benefits, which reflect expected future service, as appropriate, are as follows:

	Pension Benefits	Other Benefits
2014	\$ 138.2	\$ 43.4
2015	147.9	43.5
2016	141.0	43.9
2017	145.6	44.7
2018	148.3	45.4
2019 – 2023	656.5	225.8

In addition to the defined benefit plans, we maintain the WellPoint 401(k) Retirement Savings Plan, CareMore 401(k) Pension Plan and the Amerigroup Retirement Savings Plan which are qualified defined contribution plans covering substantially all employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled \$102.5, \$91.0 and \$87.8 during 2013, 2012 and 2011, respectively.

### 12. Medical Claims Payable

A reconciliation of the beginning and ending balances for medical claims payable for the years ended December 31 is as follows:

	 Years Ended December 31						
	2013		2012		2011		
Gross medical claims payable, beginning of year	\$ 6,174.5	\$	5,489.0	\$	4,852.4		
Ceded medical claims payable, beginning of year	 (27.2)		(16.4)		(32.9)		
Net medical claims payable, beginning of year	6,147.3		5,472.6		4,819.5		
Business combinations and purchase adjustments	_		804.4		100.9		
Net incurred medical claims:							
Current year	55,894.3		48,080.1		47,281.6		
Prior years redundancies	(599.1)		(513.6)		(209.7)		
Total net incurred medical claims	55,295.2		47,566.5		47,071.9		
Net payments attributable to:							
Current year medical claims	49,887.2		42,832.4		41,999.0		
Prior years medical claims	5,451.5		4,863.8		4,520.7		
Total net payments	55,338.7		47,696.2		46,519.7		
Net medical claims payable, end of year	 6,103.8		6,147.3		5,472.6		
Ceded medical claims payable, end of year	23.4		27.2		16.4		
Gross medical claims payable, end of year	\$ 6,127.2	\$	6,174.5	\$	5,489.0		

Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated. The prior year redundancy of \$599.1 shown above for the year ended December 31, 2013 represents an estimate based on paid claim activity from January 1, 2013 to December 31, 2013. Medical claim liabilities are usually described as having a "short tail," which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the \$599.1 redundancy relates to claims incurred in calendar year 2012.

The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December 31, 2013, 2012 and 2011, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.

	 by Changes in Key Assumptions							
	2013 2012				2011			
Assumed trend factors	\$ (428.4)	\$	(394.4)	\$	(264.8)			
Assumed completion factors	(170.7)		(119.2)		55.1			
Total	\$ (599.1)	\$	(513.6)	\$	(209.7)			

(Favorable) Unfavorable Developments

The favorable development recognized in 2013 resulted primarily from trend factors in late 2012 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development. The favorable development recognized in 2012 resulted primarily from trend factors in late 2011 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development. The favorable development recognized in 2011 was driven by trend factors in late 2010 developing more favorably than originally expected. This impact was partially offset by completion factors developing unfavorably due to slight increases in payment cycle times.

### 13. Debt

### Short-term Borrowings

We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal Home Bank of Atlanta, collectively, the FHLBs, and as a member we have the ability to obtain short-term cash advances subject to certain minimum collateral requirements. At December 31, 2013 and 2012, \$400.0 and \$250.0, respectively, were outstanding under our short-term FHLBs borrowings. These outstanding short-term FHLBs borrowings at December 31, 2013 and 2012 had fixed interest rates of 0.170% and 0.206%, respectively.

### Long-term Debt

The carrying value of long-term debt at December 31 consists of the following:

	2013	2012
Senior unsecured notes:		
6.000%, due 2014	\$ — 9	399.8
5.000%, due 2014	518.0	535.9
1.250%, due 2015	624.9	624.8
5.250%, due 2016	1,109.6	1,114.0
2.375%, due 2017	399.6	401.5
5.875%, due 2017	545.1	697.4
1.875%, due 2018	614.5	625.2
2.300%, due 2018	647.5	_
7.500%, due 2019	_	556.9
7.000%, due 2019	452.9	599.3
4.350%, due 2020	688.9	701.0
3.700%, due 2021	699.4	699.3
3.125%, due 2022	846.3	845.9
3.300%, due 2023	996.9	996.7
5.950%, due 2034	447.3	498.8
5.850%, due 2036	775.6	895.7
6.375%, due 2037	651.4	796.7
5.800%, due 2040	216.2	296.8
4.625%, due 2042	893.9	893.7
4.650%, due 2043	994.4	994.2
5.100%, due 2044	599.1	_
Senior convertible debentures:		
2.750%, due 2042	966.0	958.1
Surplus notes:		
9.000%, due 2027	24.9	25.0
Variable rate debt:		
Commercial paper program	379.2	570.9
Capital leases	_	0.3
Total long-term debt	14,091.6	14,727.9
Current portion of long-term debt	(518.0)	(557.1)
Long-term debt, less current portion	\$ 13,573.6	14,170.8

All long-term debt shown above is a direct obligation of WellPoint, Inc., except for the Amerigroup debt described below, the surplus notes and capital leases.

On September 5, 2013, we redeemed the \$400.0 outstanding principal balance of our 6.000% senior unsecured notes due 2014, plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling \$411.0. We recognized a loss on extinguishment of debt of \$10.0 for the redemption of these notes.

On July 30, 2013, we initiated a cash tender offer and consent solicitation to purchase up to \$300.0 aggregate principal amount of our outstanding 5.875% notes due 2017 and 7.000% notes due 2019 (the "First Tranche Offer") and to purchase up

to \$300.0 aggregate principal amount of our outstanding 5.950% notes due 2034, 5.850% notes due 2036, 6.375% notes due 2037 and 5.800% notes due 2040 (the "Second Tranche Offer"), collectively, the "Tender Offers". The Tender Offers were each subject to increase up to an additional \$100.0 at our election. On August 12, 2013, we increased the Second Tranche Offer to \$400.0 and on August 13, 2013 we repurchased \$300.0 of the First Tranche Offer notes and \$400.0 of the Second Tranche Offer notes for cash totaling \$837.7. Holders who tendered their notes prior to the early tender date received the principal amounts, applicable premium for early redemption and accrued and unpaid interest to the early tender offer settlement date. We recognized a loss on extinguishment of debt of \$135.3 for the repurchase of these notes.

On July 30, 2013, we issued \$650.0 of 2.300% notes due 2018 and \$600.0 of 5.100% notes due 2044 under our shelf registration statement. We used the proceeds from this offering in part to fund the purchase price of the 6.000% senior unsecured notes and the Tender Offers, discussed above, and the balance for general corporate purposes. Interest on the notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing on January 15, 2014. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

As a result of our acquisition of Amerigroup on December 24, 2012, the carrying amount of Amerigroup's \$475.0 of 7.500% senior unsecured notes due 2019 were included in our consolidated balance sheet as of December 31, 2012. In accordance with FASB accounting guidance for business combinations, the notes were recorded at their estimated fair value of \$556.9 on the date of acquisition. The fair value of the notes was estimated based on the most recent quoted market price for the notes, which we consider to be a Level II input in accordance with FASB guidance for fair value measurements. On January 25, 2013, we redeemed the outstanding principal balance of these notes, plus applicable premium for early redemption, for cash totaling \$555.6. The weighted-average redemption price of the notes was approximately 117% of the principal amount outstanding.

On September 10, 2012, we issued \$625.0 of 1.250% notes due 2015, \$625.0 of 1.875% notes due 2018, \$1,000.0 of 3.300% notes due 2023 and \$1,000.0 of 4.650% notes due 2043 under our shelf registration statement. We used the net proceeds of this offering to pay a portion of the consideration for our acquisition of Amerigroup and the balance for general corporate purposes. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

At maturity on August 1, 2012, we repaid the \$800.0 outstanding balance of our 6.800% senior unsecured notes.

On May 7, 2012, we issued \$850.0 of 3.125% notes due 2022 and \$900.0 of 4.625% notes due 2042 under our shelf registration statement. We used the proceeds from this offering for working capital and for general corporate purposes, including, but not limited to, repayment of short-term and long-term debt. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

At maturity on January 17, 2012, we repaid the \$350.0 outstanding balance of our 6.375% senior unsecured notes.

Surplus notes are unsecured obligations of Anthem Insurance Companies, Inc., or Anthem Insurance, a wholly owned subsidiary, and are subordinate in right of payment to all of Anthem Insurance's existing and future indebtedness. Any payment of interest or principal on the surplus notes may be made only with the prior approval of the Indiana Department of Insurance, or IDOI, and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana insurance laws.

We have a senior credit facility, or the facility, with certain lenders for general corporate purposes. The facility, as amended, provides credit up to \$2,000.0 and matures on September 29, 2016. The interest rate on the facility is based on either, (i) the LIBOR rate plus a predetermined percentage rate based on our credit rating at the date of utilization, or (ii) a base rate as defined in the facility agreement plus a predetermined percentage rate based on our credit rating at the date of utilization. Our ability to borrow under the facility is subject to compliance with certain covenants. There were no amounts outstanding under the facility at December 31, 2013 or 2012.

We have an authorized commercial paper program of up to \$2,500.0, the proceeds of which may be used for general

corporate purposes. The weighted-average interest rate on commercial paper borrowings at December 31, 2013 and 2012 was 0.420% and 0.396%, respectively. Commercial paper borrowings have been classified as long-term debt as our practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year and we have the ability to redeem our commercial paper with borrowings under the senior credit facility described above.

#### Convertible Debentures

On October 9, 2012, we issued \$1,500.0 of senior convertible debentures, or the Debentures. The Debentures are governed by an indenture, or the Indenture, dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures bear interest at a rate of 2.750% per year, payable semi-annually in arrears in cash on April 15 and October 15 of each year, and mature on October 15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. The Debentures also have a contingent interest feature that will require us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October 15, 2022.

Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April 15, 2042, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ended December 31, 2012, if the last reported sale price of our common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2) during the five business day period after any 10 consecutive trading day period, or the measurement period, in which the trading price per \$1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the applicable conversion rate on each such day; (3) if we call any or all of the Debentures for redemption, at any time prior to the close of business on the third scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events, as defined in the Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately preceding the Debentures' maturity date of October 15, 2042, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.

Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock or a combination of cash and shares of common stock based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures will be 13.2319 shares of our common stock per \$1,000 (whole dollars) of principal amount of Debentures, which represents a 25.0% conversion premium based on the closing price of \$60.46 per share of our common stock on October 2, 2012 (the date the Debentures' terms were finalized) and is equivalent to an initial conversion price of \$75.575 per share of our common stock. As of December 31, 2013, our common stock was last traded at a price of \$92.39 per share. If the Debentures had been converted or matured at December 31, 2013, we would be obligated to pay the principal of the Debentures plus an amount in cash or shares equal to \$342.0. The Debentures and underlying shares of our common stock have not been and will not be registered under the Securities Act of 1933, as amended, or the Securities Act, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act; the restrictions for which expired in October 2013. We used approximately \$371.0 of the net proceeds from the issuance to repurchase shares of our common stock concurrently with the offering of the Debentures, and the remaining balance was used for general corporate purposes, including but not limited to additional purchases of shares of our common stock pursuant to our share repurchase program and the repayment of short-term and/or long-term debt.

We have accounted for the Debentures in accordance with the cash conversion guidance in FASB guidance for debt with conversion and other options. As a result, the value of the embedded conversion option has been bifurcated from its debt host and recorded as a component of "additional paid-in capital" (net of deferred taxes and equity issuance costs) in our consolidated balance sheet.

The following table summarizes at December 31, 2013 the related balances, conversion rate and conversion price of the Debentures:

Outstanding principal amount	\$ 1,500.0
Unamortized debt discount	534.0
Net debt carrying amount	966.0
Equity component carrying amount	543.6
Conversion rate (shares of common stock per \$1,000 of principal amount)	13.2917
Effective conversion price (per \$1,000 of principal amount)	75.2345

The remaining amortization period of the unamortized debt discount as of December 31, 2013 is approximately 29 years. The unamortized discount will be amortized into interest expense using the effective interest method based on an effective interest rate of 5.130%, which represents the market interest rate for a comparable debt instrument that does not have a conversion feature. During the year ended December 31, 2013, we recognized \$49.2 of interest expense related to the Debentures, of which \$41.3 represented interest expense recognized at the stated interest rate of 2.750% and \$7.9 represented interest expense resulting from amortization of the debt discount.

Total interest paid during 2013, 2012 and 2011 was \$597.2, \$479.1, and \$432.9, respectively.

We were in compliance with all applicable covenants under all of our outstanding debt agreements at December 31, 2013.

Future maturities of all long-term debt outstanding at December 31, 2013 are as follows: 2014, \$897.2; 2015, \$624.9; 2016, \$1,109.6; 2017, \$944.7; 2018, \$1,262.0 and thereafter, \$9,253.2.

### 14. Commitments and Contingencies

#### Litigation

In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.

In the Los Angeles County Superior Court, we defended a lawsuit filed by the Los Angeles City Attorney alleging the wrongful rescission of individual insurance policies and representations made concerning rescission practices and policies. The suit named WellPoint as well as Blue Cross of California, or BCC, and BC Life & Health Insurance Company, or BCL&H (which name changed to Anthem Blue Cross Life and Health Insurance Company in July 2007), both WellPoint subsidiaries. The lawsuit generally alleged unfair business practices and a purported practice of rescinding new individual members following the submission of large claims. The Los Angeles City Attorney filed an amended complaint in October 2010, adding claims of misrepresentation arising from several public statements made by the Company during 2010. The Los Angeles City Attorney requested two thousand five hundred dollars (\$2,500) per alleged violation of the California Business and Professions Code. The lawsuit was recently settled for \$6.0. The court entered final approval of the settlement and judgment on July 10, 2013.

We are defending a certified class action filed as a result of the 2001 demutualization of Anthem Insurance Companies, Inc., or AICI. The lawsuit names AICI as well as Anthem, Inc., or Anthem, n/k/a WellPoint, Inc., and is captioned *Ronald Gold, et al. v. Anthem, Inc. et al.* AICI's 2001 Plan of Conversion, or the Plan, provided for the conversion of AICI from a mutual insurance company into a stock insurance company pursuant to Indiana law. Under the Plan, AICI distributed the fair value of the company at the time of conversion to its Eligible Statutory Members, or ESMs, in the form of cash or Anthem common stock in exchange for their membership interests in the mutual company. Plaintiffs in *Gold* allege that AICI distributed value to the wrong ESMs. Cross motions for summary judgment were granted in part and denied in part on July 26, 2006 with regard to the issue of sovereign immunity asserted by co-defendant, the state of Connecticut, or the State.

The court also denied our motion for summary judgment as to plaintiffs' claims on January 10, 2005. The State appealed the denial of its motion to the Connecticut Supreme Court. We filed a cross-appeal on the sovereign immunity issue. On May 11, 2010, the Court reversed the judgment of the trial court denying the State's motion to dismiss the plaintiff's claims under sovereign immunity and dismissed our cross-appeal. The case was remanded to the trial court for further proceedings. Plaintiffs' motion for class certification was granted on December 15, 2011. We and the plaintiffs filed renewed cross-motions for summary judgment on January 24, 2013. Argument on the renewed motions was held on April 19, 2013. On August 19, 2013, the court denied plaintiffs' motion for summary judgment. The court deferred a final ruling on our motion for summary judgment, instead requesting supplemental argument which occurred on November 7, 2013. The matter was taken under advisement. We intend to vigorously defend the *Gold* lawsuit; however, its ultimate outcome cannot be presently determined.

We are currently a defendant in eleven putative class actions relating to out-of-network, or OON, reimbursement that were consolidated into a single multi-district lawsuit called In re WellPoint, Inc. Out-of-Network "UCR" Rates Litigation that is pending in the United States District Court for the Central District of California. The lawsuits were filed in 2009. The plaintiffs include current and former members on behalf of a putative class of members who received OON services for which the defendants paid less than billed charges, the American Medical Association, four state medical associations, OON physicians, chiropractors, clinical psychologists, podiatrists, psychotherapists, the American Podiatric Association, California Chiropractic Association and the California Psychological Association on behalf of a putative class of all physicians and all nonphysician health care providers. The plaintiffs have filed several amended complaints alleging that the defendants violated the Racketeer Influenced and Corrupt Organizations Act, or RICO, the Sherman Antitrust Act, ERISA, federal regulations, and state law by using an OON reimbursement database called Ingenix and in our use of non-Ingenix OON reimbursement methodologies. We have filed motions to dismiss in response to each of those amended complaints. Our motions to dismiss have been granted in part and denied in part by the Court. The most recent pleading filed by the plaintiffs is a Fourth Amended Complaint to which we filed a motion to dismiss most, but not all, of the claims, In July 2013 the court issued an order granting in part and denying in part our motion. The court held that the state and federal anti-trust claims along with the RICO claims should be dismissed in their entirety with prejudice. The court further found that the ERISA claims, to the extent they involved non-Ingenix methodologies, along with those that involved our alleged non-disclosures should be dismissed with prejudice. The court also dismissed most of the plaintiffs' state law claims with prejudice. The only claims that remain after the court's decision are an ERISA benefits claim relating to claims priced based on Ingenix, a breach of contract claim on behalf of one subscriber plaintiff, a breach of implied covenant claim on behalf of one plaintiff, and one subscriber plaintiff's claim under the California Unfair Competition Law. The plaintiffs filed a motion for reconsideration of the motion to dismiss order, which the court granted in part and denied in part. The court ruled that the plaintiffs adequately allege that one Georgia provider plaintiff is deemed to have exhausted administrative remedies regarding non-Ingenix methodologies based on the facts alleged regarding that plaintiff so those claims are back in the case. Fact discovery is complete. The plaintiffs filed a motion for class certification in November 2013. The plaintiffs seek the following classes: (1) a subscriber ERISA class as to OON claims processed using the Ingenix database as the pricing methodology; (2) a physician provider class as to OON claims processed using Ingenix; (3) a non-physician provider class as to OON claims processed using Ingenix; (3) a provider ERISA class as to OON claims processed using non-Ingenix pricing methodologies; (4) a California subscriber breach of contract/unfair competition class; and (5) a subscriber breach of implied covenant class for all WellPoint states except California. We deposed all of the plaintiffs' class certification experts. Our response to the class certification is due in February 2014. Earlier in the case, in 2009, we filed a motion in the United States District Court for the Southern District of Florida, or the Florida Court, to enjoin the claims brought by the medical doctors and doctors of osteopathy and certain medical associations based on prior litigation releases, which was granted in 2011. The Florida Court ordered the plaintiffs to dismiss their claims that are barred by the release. The plaintiffs then filed a petition for declaratory judgment asking the court to find that these claims are not barred by the releases from the prior litigation. We filed a motion to dismiss the declaratory judgment action, which was granted. The plaintiffs appealed the dismissal of the declaratory judgment to the United States Court of Appeals for the Eleventh Circuit, but the dismissal was upheld. The enjoined physicians have not yet dismissed their claims. The Florida Court found the enjoined physicians in contempt and sanctioned them in July 2012. The barred physicians are paying the sanctions and have appealed the Florida Court's sanctions order to the United States Court of Appeals for the Eleventh Circuit. Oral argument on that appeal occurred in October 2013. We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.

Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to

income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.

With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves, for all of those proceedings is from \$0 to approximately \$250.0 at December 31, 2013. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.

#### Other Contingencies

From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like HMOs and health insurers generally, exclude certain health care and other services from coverage under our HMO, PPO and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable settlements of coverage claims.

In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.

The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary organization consisting of the state life and health insurance guaranty associations located throughout the U.S. State life and health insurance guaranty associations, working together with NOLHGA, provide a safety net for their state's policyholders, ensuring that they continue to receive coverage even if their insurer is declared insolvent. We are aware that the Pennsylvania Insurance Commissioner, or Insurance Commissioner, has placed Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, or collectively Penn Treaty, in rehabilitation, an intermediate action before insolvency. The state court denied the Insurance Commissioner's petition for the liquidation of Penn Treaty and ordered the Insurance Commissioner to file an updated plan of rehabilitation, which proposed plan was filed on April 30, 2013. The state court has ordered a hearing on the proposed plan for which a date has not yet been set. The Insurance Commissioner has filed a Notice of Appeal asking the Pennsylvania Supreme Court to reverse the order denying the liquidation petition. The Supreme Court has probable jurisdiction over the appeal and issued a schedule for filing briefs. In the event rehabilitation of Penn Treaty is unsuccessful and Penn Treaty is declared insolvent and placed in liquidation, we and other insurers may be required to pay a portion of their policyholder claims through state guaranty association assessments in future periods. Given the uncertainty around whether Penn Treaty will ultimately be declared insolvent and, if so, the amount of the insolvency, the amount and timing of any associated future guaranty fund assessments and the availability and amount of any potential premium tax and other offsets, we currently cannot estimate our net exposure, if any, to this potential insolvency. We will continue to monitor the situation and may record a liability and expense in future repo

#### **Contractual Obligations and Commitments**

We are a party to an agreement with Express Scripts, Inc., or Express Scripts, to provide pharmacy benefit management, or PBM, services for our plans, excluding Amerigroup and certain self-insured members, which have exclusive agreements with different PBM services providers, provided however that Amerigroup will be transitioning to the Express Scripts agreement during 2014. The initial term of this agreement expires on December 31, 2019. Under this agreement, Express Scripts is the exclusive provider of certain specified PBM services, such as pharmacy network management, home delivery, pharmacy customer service, claims processing, rebate management, drug utilization and specialty pharmaceutical management services. Accordingly, the agreement contains certain financial and operational requirements obligating both Express Scripts and us. Express Scripts' primary obligations relate to the performance of such services and meeting certain pricing guarantees and performance standards. Our primary obligations relate to oversight, provision of data, payment for services and certain minimum volume requirements. The failure by either party to meet the respective requirements could potentially serve as a basis for financial penalties or early termination of the contract. We believe we have appropriately recognized all rights and obligations under this contract at December 31, 2013.

During the first quarter of 2010, we entered into a new agreement with International Business Machines Corporation to provide information technology infrastructure services. This new agreement supersedes certain prior agreements and also includes provisions for additional services. Our remaining commitment under this agreement at December 31, 2013 was \$251.2 through March 31, 2015. We have the ability to terminate this agreement upon the occurrence of certain events, subject to early termination fees.

On March 31, 2009, we entered into an agreement with Affiliated Computer Services, Inc. to provide certain print and mailroom services that were previously performed in-house. Our remaining commitment under this agreement at December 31, 2013 was \$141.4 through March 31, 2016. We have the ability to terminate this agreement upon the occurrence of certain events, subject to early termination fees.

### **Vulnerability from Concentrations**

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the geographic regions in which we conduct business. As of December 31, 2013, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.

#### 15. Capital Stock

#### Stock Incentive Plans

On March 15, 2006, our Board of Directors adopted the WellPoint 2006 Incentive Compensation Plan, or the 2006 Plan, which was approved by our shareholders on May 16, 2006. On March 4, 2009, our Board of Directors approved an amendment and restatement of the 2006 Plan to increase the number of shares available by 33.0 shares, to rename the plan as the WellPoint Incentive Compensation Plan, or Incentive Plan, and to extend the term of the Incentive Plan such that no awards may be granted on or after May 20, 2019, which was approved by our shareholders on May 20, 2009.

The Incentive Plan gives authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The Incentive Plan, as amended and restated, increases the number of available shares for issuance to 60.1 shares, subject to adjustment as set forth in the Incentive Plan.

Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest over three years in equal semi-annual installments and generally have a term of seven years from the grant date.

Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination

due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.

Restricted stock awards are issued at the fair value of the stock on the grant date and may also include one or more performance measures that must be met for the restricted stock award to vest. The restrictions lapse in three equal annual installments.

For the years ended December 31, 2013, 2012 and 2011, we recognized share-based compensation cost of \$146.0, \$146.5 and \$134.8, respectively, as well as related tax benefits of \$52.6, \$52.0 and \$48.6, respectively.

A summary of stock option activity for the year ended December 31, 2013 is as follows:

	Number of Shares	Veighted-Average Option Price per Share	Weighted-Average Remaining Contractual Life (Years)	Iì	ggregate itrinsic Value
Outstanding at January 1, 2013	17.8	\$ 64.67			
Granted	2.0	62.55			
Exercised	(8.4)	62.34			
Forfeited or expired	(1.4)	70.77			
Outstanding at December 31, 2013	10.0	65.38	3.3	\$	270.9
Exercisable at December 31, 2013	7.6	66.04	2.6	\$	199.9

The intrinsic value of options exercised during the years ended December 31, 2013, 2012 and 2011 amounted to \$176.0, \$65.4 and \$115.8, respectively. We recognized tax benefits of \$56.8, \$22.9 and \$42.9 in 2013, 2012 and 2011, respectively, from option exercises and disqualifying dispositions. During the years ended December 31, 2013, 2012 and 2011 we received cash of \$524.7, \$110.8 and \$245.0, respectively, from exercises of stock options.

The total fair value of restricted stock awards that vested during the years ended December 31, 2013, 2012 and 2011 was \$46.7, \$222.3 and \$120.2, respectively.

A summary of the status of nonvested restricted stock activity, including restricted stock units, for the year ended December 31, 2013 is as follows:

	Restricted Stock Shares and Units	ghted-Average Grant Date Fair Value per Share
Nonvested at January 1, 2013	2.6	\$ 63.87
Granted	2.7	63.06
Vested	(0.6)	59.95
Forfeited	(0.5)	64.84
Nonvested at December 31, 2013	4.2	63.83

\*\*\* \* 1 4 1 4

During the year ended December 31, 2013, we granted approximately 0.9 restricted stock units under the Incentive Plan that were contingent upon us achieving specified operating gain targets for 2013. We expect to issue approximately 1.2 restricted stock units under this performance plan as certain performance targets were exceeded. These restricted stock units have been included in the activity shown above.

As of December 31, 2013, the total remaining unrecognized compensation cost related to nonvested stock options and restricted stock amounted to \$10.5 and \$88.1, respectively, which will be amortized over the weighted-average remaining requisite service periods of 11 months and 12 months, respectively.

As of December 31, 2013, there were approximately 24.9 shares of common stock available for future grants under the Incentive Plan.

#### Fair Value

We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice model are based on an analysis of implied volatilities of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the "multiple-grant" approach for recognizing compensation expense associated with each separately vesting portion of the share-based award.

The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December 31:

	2013	2012	2011
Risk-free interest rate	1.25%	1.41%	2.84%
Volatility factor	35.00%	34.00%	34.00%
Dividend yield (annual)	2.40%	1.60%	1.50%
Weighted-average expected life (years)	4.0	4.1	4.0

The following weighted-average fair values were determined for the years ending December 31:

	2013 20		2012	2011
Options granted during the year	\$ 14.64	\$	16.50	\$ 17.84
Restricted stock and stock awards granted during the year	63.06		65.91	66.16

The binomial lattice option-pricing model requires the input of highly subjective assumptions including the expected stock price volatility. Because our stock option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.

#### Employee Stock Purchase Plan

We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan, or the Stock Purchase Plan, which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in WellPoint. The Stock Purchase Plan was suspended effective January 1, 2011, and no shares were issued during 2013, 2012 or 2011. Effective January 1, 2014, the Stock Purchase Plan is being reinstated. Pursuant to terms of the Stock Purchase Plan, an employee is permitted to purchase no more than \$23,750 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter. Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the employee's investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a price per share of 95% of the fair value of a share of common stock on the last trading day of the plan quarter. As of December 31, 2013, 6.1 shares were available for issuance under the Stock Purchase Plan.

#### Use of Capital and Stock Repurchase Program

We regularly review the appropriate use of capital, including common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt are at the discretion of our Board of Directors and depend upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. Historically our common stock repurchase program, discussed below, has been our primary use of capital. Beginning in 2011, our Board of Directors established a quarterly dividend to shareholders.

A summary of the cash dividend activity for the years ended December 31, 2013 and 2012 is as follows:

			h Dividend per			
<b>Declaration Date</b>	Record Date	Payment Date		Share	Total	
Year Ended December 31, 2013						
February 20, 2013	March 8, 2013	March 25, 2013	\$	0.3750	\$	113.4
May 15, 2013	June 10, 2013	June 25, 2013		0.3750		112.7
July 23, 2013	September 10, 2013	September 10, 2013 September 25, 2013		0.3750		111.4
October 22, 2013	December 9, 2013	December 23, 2013		0.3750		110.5
Year Ended December 31, 2012						
January 24, 2012	March 9, 2012	March 23, 2012	\$	0.2875	\$	95.8
May 16, 2012	June 8, 2012	June 25, 2012		0.2875		93.5
July 24, 2012	September 10, 2012	September 25, 2012		0.2875		90.7
November 6, 2012	December 7, 2012	December 21, 2012		0.2875		87.1

On January 28, 2014, the Board of Directors declared a quarterly cash dividend to shareholders of \$0.4375 per share on the outstanding shares of our common stock. This quarterly dividend will be paid on March 25, 2014 to the shareholders of record as of March 10, 2014.

Under our Board of Directors' authorization, we maintain a common stock repurchase program. On September 25, 2013, the Board of Directors authorized a \$3,500.0 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.

A summary of common stock repurchases for the period January 1, 2014 through February 7, 2014 (subsequent to December 31, 2013) and for the years ended December 31, 2013 and 2012 is as follows:

		January 1, 2014 through	 Years Ended	Dec	ember 31
	_	February 7, 2014	2013		2012
Shares repurchased		5.4	20.7		39.7
Average price per share		\$ 84.96	\$ 78.08	\$	62.96
Aggregate cost		\$ 457.6	\$ 1,620.1	\$	2,496.8
Authorization remaining at the end of each period		\$ 2,633.4	\$ 3,691.0	\$	1,836.9

During 2013, we purchased call options on 3.0 shares of our common stock. The call options allow us to repurchase shares at a predetermined strike price up through the expiration dates. The purpose of the call options is to reduce share price volatility on potential future common stock repurchases. The aggregate premium paid was \$25.8, of which \$7.9 was recorded as a reduction of shareholders' equity and the remaining \$17.9 was recorded as a derivative asset based on FASB guidance. The aggregate premium is reported in financing activities in our consolidated statements of cash flow. The call options had strike prices ranging from \$77.50 to \$83.10 per share. The aggregate fair value of the call options reported as a derivative asset was \$27.5 at December 31, 2013. The call options were exercised on various dates throughout January and February 2014.

On February 4, 2014, we entered into an accelerated share repurchase, or ASR, program with a counterparty. The agreement provides for a repurchase of a number of shares, equal to \$600.0, as determined by the dollar volume weighted-average share price during a period up through at least March 14, 2014, but not to exceed March 31, 2014. At the end of the

term of the ASR, the initial amount of shares will be adjusted up or down based on the dollar volume weighted-average price during the same period. On February 4, 2014, we repurchased 6.0 shares under this program. These ASR shares are not included in the shares repurchased subsequent to December 31, 2013 shown in the table above as the final shares to be repurchased will not be determined until the completion of the program in March 2014. However the \$600.0 has been removed from the authorization remaining as of February 7, 2014 in the table above.

### 16. Accumulated Other Comprehensive Income (Loss)

A reconciliation of the components of accumulated other comprehensive income at December 31 is as follows:

	20	13	2012		
Investments:					
Gross unrealized gains	\$	1,054.2	\$	1,282.1	
Gross unrealized losses		(277.8)		(51.3)	
Net pretax unrealized gains		776.4		1,230.8	
Deferred tax liability		(267.4)		(427.1)	
Net unrealized gains on investments		509.0		803.7	
Non-credit components of OTTI on investments:					
Unrealized losses		(0.8)		(3.4)	
Deferred tax asset		0.3		1.2	
Net unrealized non-credit component of OTTI on investments		(0.5)		(2.2)	
Cash flow hedges:					
Gross unrealized losses		(49.7)		(54.3)	
Deferred tax asset		17.4		19.0	
Net unrealized losses on cash flow hedges		(32.3)		(35.3)	
Defined benefit pension plans:					
Deferred net actuarial loss		(427.2)		(686.8)	
Deferred prior service credits		3.0		3.9	
Deferred tax asset		169.9		269.1	
Net unrecognized periodic benefit costs for defined benefit pension plans		(254.3)		(413.8)	
Postretirement benefit plans:					
Deferred net actuarial loss		(169.6)		(191.0)	
Deferred prior service credits		102.4		103.0	
Deferred tax asset		27.0		34.6	
Net unrecognized periodic benefit costs for postretirement benefit plans		(40.2)		(53.4)	
Foreign currency translation adjustments:					
Gross unrealized gains		2.2		0.2	
Deferred tax liability		(0.7)		(0.1)	
Net unrealized gains on foreign currency translation adjustments		1.5		0.1	
Accumulated other comprehensive income	\$	183.2	\$	299.1	

Other comprehensive income (loss) reclassification adjustments for the years ended December 31 are as follows:

	2013		2012		2011
Investments:					
Net holding loss on investment securities arising during the period, net of tax benefit of \$223.6, \$5.4 and \$38.2, respectively	\$	(407.2)	\$	(3.2)	\$ (71.6)
Reclassification adjustment for net realized gain on investment securities, net of tax expense of (\$60.6), (\$104.0) and (\$49.6), respectively		112.5		193.1	 92.2
Total reclassification adjustment on investments		(294.7)		189.9	20.6
Non-credit component of OTTI on investments:					
Non-credit component of OTTI on investments, net of tax (expense) benefit of (\$0.9), (\$2.4) and \$0.5, respectively		1.7		4.5	(0.7)
Cash flow hedges:					
Holding gain (loss), net of tax (expense) benefit of (\$1.6), (\$0.1) and \$5.3, respectively		3.0		0.1	(10.0)
Other:					
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax (expense) benefit of (\$106.8), (\$7.1) and \$81.7, respectively		172.7		(10.9)	(119.8)
Foreign currency translation adjustment, net of tax expense of (\$0.6), (\$0.3) and (\$0.2), respectively		1.4		0.6	0.2
Net (loss) gain recognized in other comprehensive income, net of tax benefit (expense) of \$53.1, (\$108.5) and \$75.9, respectively	\$	(115.9)	\$	184.2	\$ (109.7)

### 17. Reinsurance

We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations.

We evaluate the financial condition of our reinsurers and monitor concentrations of credit risk arising from similar geographic regions, activities, or economic characteristics of the reinsurers to minimize our exposure to significant losses from reinsurer insolvencies.

A summary of direct, assumed and ceded premiums written and earned for the years ended December 31 is as follows:

	2013				2012				2011			
		Written	Earned		Written		Earned		Written			Earned
Direct	\$	65,939.1	\$	66,038.9	\$	56,443.6	\$	56,373.6	\$	56,190.3	\$	55,875.8
Assumed		174.3		174.0		197.0		196.4		179.9		178.5
Ceded		(92.6)		(93.8)		(73.2)		(73.3)		(84.2)		(84.7)
Net premiums	\$	66,020.8	\$	66,119.1	\$	56,567.4	\$	56,496.7	\$	56,286.0	\$	55,969.6
Percentage—assumed to net premiums		0.3%		0.3%		0.3%		0.3%		0.3%		0.3%

A summary of net premiums written and earned by segment (see Note 20, "Segment Information") for the years ended December 31 is as follows:

	2013			 2012				2011			
	Written	Written Earned		 Written Earned				Written		Earned	
Reportable segments:											
Commercial and Specialty Business	\$ 35,126.0	\$	35,159.8	\$ 35,352.1	\$	35,251.9	\$	36,476.3	\$	36,436.7	
Government Business	30,894.8		30,959.3	21,215.3		21,244.8		19,809.7		19,532.9	
Other	_		_	_		_		_		_	
Net premiums	\$ 66,020.8	\$	66,119.1	\$ 56,567.4	\$	56,496.7	\$	56,286.0	\$	55,969.6	

The effect of reinsurance on benefit expense for the years ended December 31 is as follows:

	2013 2012			2011		
Direct	\$ 56,185.2	\$	48,135.1	\$	47,569.8	
Assumed	155.6		173.0		165.0	
Ceded	(103.7)		(94.5)		(87.3)	
Net benefit expense	\$ 56,237.1	\$	48,213.6	\$	47,647.5	

The effect of reinsurance on certain assets and liabilities at December 31 is as follows:

	:	2013	2012
Policy liabilities, assumed	\$	55.4	\$ 62.4
Unearned income, assumed		0.4	0.5
Premiums payable, ceded		17.1	18.1
Premiums receivable, assumed		14.1	16.6

### 18. Leases

We lease office space and certain computer and related equipment using noncancelable operating leases. At December 31, 2013, future lease payments for operating leases with initial or remaining noncancelable terms of one year or more consist of the following:

2014	\$ 133.0
2015	126.7
2016	99.6
2017	97.3
2018	91.1
Thereafter	221.6
Total minimum payments required	\$ 769.3

We have certain lease agreements that contain contingent payment provisions. Under these provisions, we pay contingent amounts in addition to base rent, primarily based upon annual changes in the consumer price index. The schedule above contains estimated amounts for potential future increases in lease payments based on the contingent payment provisions.

Lease expense for 2013, 2012 and 2011 was \$185.9, \$153.3 and \$148.6, respectively.

### 19. Earnings per Share

The denominator for basic and diluted earnings per share at December 31 is as follows:

	2013	2012	2011
Denominator for basic earnings per share—weighted-average shares	298.5	321.5	360.2
Effect of dilutive securities—employee stock options, non-vested restricted stock awards and convertible debentures	5.3	3.3	4.9
Denominator for diluted earnings per share	303.8	324.8	365.1

During the years ended December 31, 2013, 2012 and 2011, weighted-average shares related to certain stock options of 4.2, 12.6 and 10.5, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive.

### 20. Segment Information

On May 20, 2013, we announced certain organizational and executive leadership changes to align with how our new Chief Executive Officer is managing our operations. Beginning with the three months ended June 30, 2013, our organizational structure is comprised of three reportable segments: Commercial and Specialty Business; Government Business; and Other.

Our Commercial and Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the Commercial and Specialty Business segment offer fully-insured products; provide a broad array of managed care services to self-funded customers including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services; and provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance.

Our Government Business segment includes Medicare and Medicaid businesses, National Government Services and services provided to the Federal Government in connection with FEP. Our Medicare business includes services such as Medicare Advantage, Medicare Part D, and Medicare Supplement, while our Medicaid business includes our managed care alternatives through publicly funded health care programs, including Medicaid, state Children's Health Insurance Programs and Medicaid expansion programs. National Government Services acts as a Medicare contractor in several regions across the nation.

Our Other segment includes other businesses that do not meet the quantitative thresholds for an operating segment as defined by FASB guidance, as well as corporate expenses not allocated to the other reportable segments.

We define operating revenues to include premium income, administrative fees and other revenues. Operating revenues are derived from premiums and fees received primarily from the sale and administration of health benefit products. Operating gain is calculated as total operating revenue less benefit expense and selling, general and administrative expense.

Through our participation in various federal government programs, we generated approximately 20.3%, 23.7% and 23.5% of our total consolidated revenues from agencies of the U.S. government for the years ended December 31, 2013, 2012, and 2011, respectively. These revenues are contained in the Government Business segment.

The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, "Basis of Presentation and Significant Accounting Policies," except that certain shared administrative expenses for each segment are recognized on a pro rata allocated basis, which in aggregate approximates the consolidated expense. Any difference between the allocated expenses and actual consolidated expense is included in other expenses not allocated to reportable segments. Intersegment sales and expenses are recorded at cost and eliminated in the consolidated financial statements. We evaluate performance of the reportable segments based on operating gain or loss as defined above. We evaluate investment income, net realized gains on investments, other-than-temporary impairment losses recognized in income, interest expense, amortization expense, loss on extinguishment of debt and income taxes, and asset and liability

details on a consolidated basis as these items are managed in a corporate shared service environment and are not the responsibility of segment operating management.

Financial data by reportable segment for the years ended December 31 is as follows:

	and	mmercial I Specialty Business	_	overnment Business	Other		Total
Year ended December 31, 2013							
Operating revenue	\$	38,790.1	\$	31,366.7	\$	34.6	\$ 70,191.4
Operating gain (loss)		3,093.3		927.1		(19.0)	4,001.4
Depreciation and amortization of property and equipment						457.1	457.1
Year ended December 31, 2012							
Operating revenue	\$	38,852.9	\$	21,625.7	\$	35.4	\$ 60,514.0
Operating gain (loss)		3,339.7		341.8		(61.6)	3,619.9
Depreciation and amortization of property and equipment						363.5	363.5
Year ended December 31, 2011							
Operating revenue	\$	39,961.2	\$	19,874.0	\$	30.0	\$ 59,865.2
Operating gain (loss)		3,344.5		461.6		(24.0)	3,782.1
Depreciation and amortization of property and equipment		=		_		300.3	300.3

The major product revenues for each of the reportable segments for the years ended December 31, are as follows:

	2013		2012		2011
Commercial and Specialty Business					
Managed care products	\$	33,903.6	\$	34,091.5	\$ 35,387.8
Managed care services		3,472.1		3,444.8	3,374.5
Dental/Vision products and services		952.5		903.9	826.8
Other		461.9		412.7	372.1
Total Commercial and Specialty Business		38,790.1		38,852.9	39,961.2
Government Business					
Managed care products		30,959.3		21,244.7	19,533.0
Managed care services		407.4		381.0	 341.0
Total Government Business		31,366.7		21,625.7	19,874.0
Other					
Other		34.6		35.4	30.0
Total product revenues	\$	70,191.4	\$	60,514.0	\$ 59,865.2

The classification between managed care products and managed care services in the above table primarily distinguishes between the level of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.

Asset and equity details by reportable segment have not been disclosed, as we do not internally report such information.

A reconciliation of reportable segment operating revenues to the amounts of total revenues included in the consolidated statements of income for the years ended December 31 is as follows:

	2013		2012		2011
Reportable segments operating revenues	\$	70,191.4	\$	60,514.0	\$ 59,865.2
Net investment income		659.1		686.1	703.7
Net realized gains on investments		271.9		334.9	235.1
Other-than-temporary impairment losses recognized in income		(98.9)		(37.8)	(93.3)
Total revenues	\$	71,023.5	\$	61,497.2	\$ 60,710.7

A reconciliation of reportable segment operating gain to income from continuing operations before income taxes included in the consolidated statements of income for the years ended December 31 is as follows:

	2013 2012 201			2011		
Reportable segments operating gain	\$	4,001.4	\$	3,619.9	\$	3,782.1
Net investment income		659.1		686.1		703.7
Net realized gains on investments		271.9		334.9		235.1
Other-than-temporary impairment losses recognized in income		(98.9)		(37.8)		(93.3)
Interest expense		(602.7)		(511.8)		(430.3)
Amortization of other intangible assets		(245.3)		(233.0)		(239.4)
Loss on extinguishment of debt		(145.3)		_		_
Income from continuing operations before income tax expense	\$	3,840.2	\$	3,858.3	\$	3,957.9

#### 21. Related Party Transactions

WellPoint Foundation, Inc., or the Foundation, is an Indiana non-profit organization exempt from federal taxation under Section 501(c)(3) of the Internal Revenue Code. The Foundation was formed to conduct, support and assist charitable, health-related, educational, and other community-based programs and projects. The officers and directors of the Foundation are also our officers. These officers and directors receive no compensation from the Foundation for the management services performed for the Foundation but may be reimbursed by the Foundation for any cash expenditures incurred on behalf of the Foundation. During the years ended December 31, 2013, 2012 and 2011, we received \$0.7, \$0.6 and \$0.6, respectively, from the Foundation for administrative services provided by our associates. We contributed \$10.0 to the Foundation during the year ended December 31, 2013. We made no contributions to the Foundation during the years ended December 31, 2012 and 2011. The Foundation is not a subsidiary of ours and the financial results of the Foundation are not consolidated with our financial statements. We have no current legal obligations for future commitments to the Foundation.

### 22. Statutory Information

The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance regulatory authorities, or statutory, which vary in certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care, or DMHC, and report their accounts in conformity with GAAP (these entities are collectively referred to as the "DMHC regulated entities"). Typical differences of GAAP reporting as compared to statutory reporting are the inclusion of unrealized gains or losses relating to fixed maturity securities in shareholders' equity, recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of Insurance Commissioners, or NAIC, developed a codified version of the statutory accounting principles, designed to foster more consistency among the states for accounting guidelines and reporting.

Our insurance and HMO subsidiaries that are subject to statutory reporting are domiciled in various jurisdictions. These subsidiaries prepare statutory financial statements in accordance with accounting practices prescribed or permitted by the respective jurisdictions' insurance regulators. Prescribed statutory accounting practices are set forth in a variety of

publications of the NAIC as well as state laws, regulations and general administrative rules.

Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary's domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC.

Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital requirements. Risk-based capital is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining the amount of risk-based capital specifies various factors, weighted based on the perceived degree of risk, which are applied to certain financial balances and financial activity. Below minimum risk-based capital requirements are classified within certain levels, each of which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December 31, 2013 and 2012, all of our regulated subsidiaries exceeded the minimum risk-based capital requirements and/or capital and solvency requirements of their applicable governmental regulator. The statutory risk-based capital necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately \$3,500.0 and \$3,400.0 as of December 31, 2013 and 2012, respectively. The tangible net equity required for the DMHC regulated entities was approximately \$450.0 as of December 31, 2013 and 2012.

Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC regulated entities, was \$10,003.0 and \$9,967.7 at December 31, 2013 and 2012, respectively. Statutory-basis net income of our insurance and HMO subsidiaries and net income of our other regulated subsidiaries, excluding the DMHC regulated entities, was \$2,594.8, \$2,800.0 and \$2,402.5 for 2013, 2012 and 2011, respectively. GAAP equity of the DMHC regulated entities was \$1,449.2 and \$1,312.5 at December 31, 2013 and 2012, respectively. GAAP net income of the DMHC regulated entities was \$487.7, \$469.7 and \$524.3 for the years ended December 31, 2013, 2012 and 2011, respectively.

### 23. Selected Quarterly Financial Data (Unaudited)

Selected quarterly financial data is as follows:

		For the Quarter Ended						
		March 31		June 30		September 30		ecember 31
2013								
Total revenues	\$	17,576.0	\$	17,690.3	\$	17,855.5	\$	17,901.7
Income from continuing operations before income taxes		1,282.5		1,208.1		879.7		469.9
Income from continuing operations		872.3		799.3		653.8		308.9
Income (loss) from discontinued operations		12.9		0.8		2.4		(160.7)
Net income		885.2		800.1		656.2		148.2
Basic net income per share - continuing operations	\$	2.88	\$	2.67	\$	2.20	\$	1.05
Basic net income (loss) per share - discontinued operations		0.04		_		0.01		(0.55)
Basic net income per share		2.92		2.67		2.21		0.50
Diluted net income per share - continuing operations	\$	2.85	\$	2.64	\$	2.15	\$	1.02
Diluted net income (loss) per share - discontinued operations		0.04		_		0.01		(0.53)
Diluted net income per share		2.89		2.64		2.16		0.49
2012								
Total revenues	\$	15,415.2	\$	15,396.3	\$	15,247.4	\$	15,438.3
Income from continuing operations before income taxes		1,309.8		1,048.7		1,019.6		480.2
Income from continuing operations		856.5		643.6		687.5		463.4
Income from discontinued operations		_		_		3.7		0.8
Net income		856.5		643.6		691.2		464.2
Basic net income per share - continuing operations	\$	2.56	\$	1.96	\$	2.16	\$	1.52
Basic net income per share - discontinued operations				_		0.01		_
Basic net income per share		2.56		1.96		2.17		1.52
Diluted net income per share - continuing operations	\$	2.53	\$	1.94	\$	2.14	\$	1.51
Diluted net income per share - continuing operations  Diluted net income per share - discontinued operations	Ψ	2.33	Ψ	1.74	Ψ	0.01	Ψ	
Diluted net income per share - discontinued operations  Diluted net income per share		2.53		1.94		2.15		1.51
Diffused net income per snare		2.33		1.94		2.13		1.31

### ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

There have been no changes in or disagreements with our independent registered public accounting firm on accounting or financial disclosures.

### ITEM 9A. CONTROLS AND PROCEDURES

### **Evaluation of Disclosure Controls and Procedures**

We carried out an evaluation as of December 31, 2013, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to

us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

### Management's Report on Internal Control Over Financial Reporting

Management, under the supervision and with the participation of the principal executive officer and principal financial officer, of WellPoint, Inc., or the Company, is responsible for establishing and maintaining effective internal control over financial reporting, or Internal Control, as such term is defined in the Exchange Act. The Company's Internal Control is designed to provide reasonable assurance regarding the reliability of the Company's financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles, or GAAP. The Company's Internal Control includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

Because of inherent limitations in any Internal Control, no matter how well designed, misstatements due to error or fraud may occur and not be detected. Accordingly, even effective Internal Control can provide only reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

Management, under the supervision and with the participation of the principal executive officer and principal financial officer, assessed the effectiveness of the Company's Internal Control as of December 31, 2013. Management's assessment was based on criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Based on management's assessment, management has concluded that the Company's Internal Control was effective as of December 31, 2013 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP.

Ernst & Young LLP, the Company's independent registered public accounting firm, has audited the consolidated financial statements of the Company for the year ended December 31, 2013, and has also issued an audit report dated February 20, 2014, on the effectiveness of the Company's internal control over financial reporting as of December 31, 2013, which is included in this Annual Report on Form 10-K.

/S/ JOSEPH R. SWEDISH Chief Executive Officer /S/ WAYNE S. DEVEYDT
Executive Vice President and
Chief Financial Officer

#### **Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of WellPoint, Inc.

We have audited WellPoint, Inc.'s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control–Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) (the COSO criteria). WellPoint, Inc.'s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, WellPoint, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of WellPoint, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of income, comprehensive income, shareholders' equity, and cash flows for each of the three years in the period ended December 31, 2013 of WellPoint, Inc. and our report dated February 20, 2014 expressed an unqualified opinion thereon.

/s/ ERNST & YOUNG LLP

Indianapolis, Indiana February 20, 2014

#### ITEM 9B. OTHER INFORMATION

None.

#### PART III

#### ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item concerning our Executive Officers, Directors and nominees for Director, Audit Committee members and financial expert(s) and concerning disclosure of delinquent filers under Section 16(a) of the Exchange Act and our Standards of Business Conduct is incorporated herein by reference from our definitive Proxy Statement for our 2014 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

#### ITEM 11. EXECUTIVE COMPENSATION

The information required by this Item concerning remuneration of our Executive Officers and Directors, material transactions involving such Executive Officers and Directors and Compensation Committee interlocks, as well as the Compensation Committee Report, are incorporated herein by reference from our definitive Proxy Statement for our 2014 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

## ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item concerning the stock ownership of management and five percent beneficial owners and securities authorized for issuance under equity compensation plans is incorporated herein by reference from our definitive Proxy Statement for our 2014 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

#### ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this Item concerning certain relationships and related person transactions and director independence is incorporated herein by reference from our definitive Proxy Statement for our 2014 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

#### ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item concerning principal accounting fees and services is incorporated herein by reference from our definitive Proxy Statement for our 2014 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last fiscal year.

#### PART IV

#### ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

#### (a) 1. Financial Statements:

The following consolidated financial statements of the Company are set forth in Part II, Item 8

Report of Independent Registered Public Accounting Firm

Consolidated Balance Sheets as of December 31, 2013 and 2012

Consolidated Statements of Income for the years ended December 31, 2013, 2012, and 2011

Consolidated Statements of Comprehensive Income for the years ended December 31, 2013, 2012, and 2011

Consolidated Statements of Shareholders' Equity for the years ended December 31, 2013, 2012 and 2011

Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 and 2011

Notes to Consolidated Financial Statements

#### 2. Financial Statement Schedule:

The following financial statement schedule of the Company is included in Item 15(c):

Schedule II—Condensed Financial Information of Registrant (Parent Company Only).

All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are inapplicable, or the required information is included in the consolidated financial statements, and therefore, have been omitted.

#### 3. Exhibits:

A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which immediately precedes such exhibits, and is incorporated herein by reference.

#### (b) Exhibits

The response to this portion of Item 15 is submitted as a separate section of this report.

#### (c) Financial Statement Schedule

Schedule II—Condensed Financial Information of Registrant (Parent Company Only).

### Schedule II—Condensed Financial Information of Registrant

# WellPoint, Inc. (Parent Company Only) Balance Sheets

Prices mentin savilable-for-sale, aftir value:   Fixed manurity securities (annotized cost of \$897.4 and \$1,415.5)   900.4   1.455.5     Equity securities (cost of \$522.6 and \$26.7)   1.0   1.0     Other invested assets, current   1.9   1.0     Other cecivables   1.5   1.5   1.0     Other cerivate assets, net   1.5   1.5     Other current assets   1.5   1.5     Other current assets   1.5   1.5     Other current assets   1.5   1.5     Other invested assets, forst of \$6.7 and \$6.8)   1.5     Other invested assets, forst of \$6.7 and \$6.8)   1.5     Other invested assets, forst of \$6.7 and \$6.8)   1.5     Other invested assets, forst of \$6.7 and \$6.8)   1.5     Other invested assets, forst of \$6.7 and \$6.8)   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other invested assets, forst of \$6.7 and \$6.8   1.5     Other investe	(In millions, except share data)	December 31, 2013		December 31, 2012		
Clash and ceath equivalents         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,000,000         \$ 1,00	Assets					
Prise   Pris   Prise   Prise   Prise   Prise   Prise   Prise   Prise   Prise	Current assets:					
Fixed manurity securities (control \$807.4 and \$1,415.5)         900.4         1,425.           Equity securities (cost of \$52.6 and \$26.7)         89.6         15.           Other invesced assets, current         1.0         1.0           Other receivables         35.6         37.           Income takes receivable         154.6         229.           Securities lending collateral         66.2         29.           Deferred tax assets, net         118.8         7.           Other current assets         3,409.9         2,478.           Total current assets         3,409.9         2,478.           Total current assets         61.7         56.           Other invested assets, long-term         2.0         3.3           Investment in subsidiaries         3.5         3.2         18.           Total current takes         3.5         3.2         2.           Total curr	Cash and cash equivalents	\$	1,174.5	\$	588.1	
Equity securities (cost of \$3.2.6 and \$2.6.7)         1.5         1.5           Other invested assets, current         1.9         1.5           Other receivables         3.56         3.5           Income taxes receivable         1.94         2.27           Not from subsidiaries         8.93         2.27           Securities Income taxes         3.04         2.28           Sceurities Income taxes         3.10         3.15           Other current assets         4.18         3.17           Other current assets         4.18         3.18           Total current assets         6.7         5.6           Collective Investing the south for Scale at fair value:         2.27         2.2           Use of the invested assets, long-term for seal at fair value:         6.15         5.96           Other invested assets, long-term for seal at fair value:         4.10         5.96           Other stream of a south for seal at fair value:         4.10         5.96           Other stream for seal south for seal at fair value:         5.96         5.96           Other stream for seal south for seal at fair value:         4.10         5.96           Other stream for seal south for seal at fair value:         5.96         5.96         5.96           Other stream for s	Investments available-for-sale, at fair value:					
Other invested assets, current         1.9         1.1           Other receivables         3.5.6         3.5.1         2.27           Net due from subsidiaries         89.34         2.27           Net due from subsidiaries         89.34         2.27           Securities lending collateral         46.2         2.9           Oberferred tax sests, net         11.8         7.2           Under current assets         18.3         1.45           Other current assets         18.3         1.45           Understern investments available-for-sale, at fair value:         2.0         6.0           Understern investments available-for-sale, at fair value:         46.7         5.0           Understern day acquipment, net         16.5         5.0         6.0           Other invested assets, one         18.3         11.0         1.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0         2.0 <t< td=""><td>Fixed maturity securities (amortized cost of \$897.4 and \$1,415.5)</td><td></td><td>900.4</td><td></td><td>1,425.9</td></t<>	Fixed maturity securities (amortized cost of \$897.4 and \$1,415.5)		900.4		1,425.9	
Other receivables         35.6         37.7           Incone taxes receivable         15.4         22.7           Nex due from subsidiaries         803.4         2.7           Securities lending collateral         46.2         2.9           Deferred tax assers, net         11.8         17.2           Other current assers         3,400         2,478           Long-term investments available-for-sale, at fair value:         3,400         2,478           Cherring securities (cost of 56.7 and \$6.8)         6.6         6.           Other invested assers, long-term         6.5         5.0           Property and equipment, net         148.3         110.0           Deferred tax assets, net         2.9         2.3           Property and equipment, net         148.3         110.0           Deferred tax assets, net         2.9         2.3           Property and equipment, net         18.3         110.0           Deferred tax assets, net         2.9         2.1           Property and equipment, net         18.3         10.0           Incomplete tax assets, net         1.0         2.0           Property and equipment, net         18.3         2.0           Property and equipment, net         1.2         2.2	Equity securities (cost of \$52.6 and \$26.7)		89.6		15.0	
Roome taxes receivable	Other invested assets, current		1.9		1.6	
Net due from subsidiaries         893.4         —           Securities lending collateral         46.2         29.           Deferred tax assets, net         11.8         7.7           Other current assets         3,90.9         2,788.           Congressiant savilable-for-sale, at fair value:         3,90.9         2,788.           Ungestern investments available-for-sale, at fair value:         615.7         506.           Properly and equipment, net         615.7         506.           Deferred tax assets, net         2.9         23.           Investments in subsidiaries         35.16.2         35.40.2           Other noncurrent assets         35.50.2         35.40.2           Deferred tax assets, net         2.9         23.           Investments in subsidiaries         35.50.2         35.40.2           Other onneutrent assets         35.50.2         35.00.2           Total assets         39.33.3         38.00.2           Easterity tradispart         45.2         21.8           Contral assets         2.9         1.7           Accounts payable and accrued expenses         2.9         1.7           Security tradispending payable         2.9         1.2           Current portion of long-term debt <td< td=""><td>Other receivables</td><td></td><td>35.6</td><td></td><td>37.7</td></td<>	Other receivables		35.6		37.7	
Sceutities lending collateral         46.2         20.2           Defered tax assets, net         11.3         7.2           Other current assets         18.13.1         14.55           Total current assets         3,490.9         2,478.8           Long-term investments available-for-sale, at fair value:         8.6         6.0           Other investoed assets, long-terms         15.5         5.6           Other investoed assets, long-terms         15.1         5.0           Poperty and equipment, net         148.3         110.0           Deferred tax assets, net         2.9         2.2           Investments in subsidiaries         35.16 c.         5.54.6           Other noncurrent assets         15.2         2.8           Other noncurrent assets         15.2         2.8           Total asset         5.93.03         5.38.6           Testilities         3.93.03         5.38.6           Unitable steet         15.2         2.8           Scenities and sharcholders' equity         2.8         1.7           Scenities and sharcholders' equity         2.8         1.7           Scenities and sharcholders' equity         2.8         1.2           Scenities lending payable         2.8         1.2	Income taxes receivable		154.4		227.0	
Deferred tax assets, net         11.8         7.7           Other current assets         18.1         14.5           Total current assets         3,490.9         2,478.8           Lang-term investments available-for-sale, at fair value:         2.7         6.6           Other invested assets, long-term         6.15.7         5.6         6.           Other property and equipment, net         18.1         11.0         6.         6.         7.         6.         6.         7.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.         6.	Net due from subsidiaries		893.4		_	
Other current assets         183.         145.           Total current assets         3,490.         2,478.           Long-term investments available-for-sale, affair value:         8.67.         6.6.           Tenging securities (cost of \$6.7 and \$6.8)         6.7.         6.6.           Other invested assets, long-term         6.15.         5.96.           Property and equipment, net         18.3.         110.           Deferred tax assets, net         2.9.         2.3.           Investments in subsidiaries         35,16.2         35,46.2           Other noncurrent assets         15.2.         218.           Total assets         15.2.         218.           Total subsidiaries         15.2.         218.           Securities Householders' equit         2.8.         17.           Securities Individual accruel expenses         2.9.         4.0.           Securities Individual payable         4.6.         2.9.           Outer current profice of one-term debt         5.18.         2.1           Guerrita profice Individual	Securities lending collateral		46.2		29.1	
Total current assets         3,490 s.         2,478 s.           Long-tern investments available-for-sale, at fair value:         Security securities (cost of \$67, and \$6.8)         6.6           Other invested assets, long-term         6.15.7         5.96.           Other progray and equipment, net         148.3         110.0           Defer dax assets, net         2.9         2.3           Other mourant assets         35.16.2         35.66.2           Other mourant assets         15.2         3.93.03         3.89.60.2           Total assets         3.93.93         3.89.60.2         3.89.60.2           Labilities           Total assets         5.92.1         \$ 402.         3.89.60.2           Labilities         2.89.2         \$ 5.92.1         \$ 402.         3.89.60.2         1.79.         \$ 402.         3.89.60.2         1.79.         \$ 402.         3.89.60.2         1.79.         \$ 402.         3.89.60.2         1.79.         \$ 402.         3.89.60.2         1.79.         \$ 402.         3.89.60.2         1.79.         \$ 402.         3.89.60.2         1.79.         4.00.2         3.89.60.2         1.79.         4.00.2         3.99.60.2         1.79.         4.00.2         4.00.2         4.00.2         4.00.2	Deferred tax assets, net		11.8		7.9	
Legity securities (cost of \$6.7 and \$6.8)         6.7         6.6           Other invested assets, long-term         615.7         59.6           Other property and equipment, net         148.3         110.0           Deferred tax assets, net         2.9         23.           Investments in subsidiaries         35,516.2         35,462.           Other noncurrent assets         \$39,930.3         \$38,806.           Etabilities and shareholders' equity         ****         ****           Liabilities and shareholders' equity           ****         ****         \$39,930.3         \$38,806.           ****         ****         ****         ****         ****         ****         ****         ***         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         ****         **** <td< td=""><td>Other current assets</td><td></td><td>183.1</td><td></td><td>145.7</td></td<>	Other current assets		183.1		145.7	
Equity securities (cost of \$6.7 and \$6.8)         6.6           Other invested assets, long-term         61.5         59.6           Property and equipment, net         148.3         110.           Deferred tax assets, net         2.9         2.3           Investments in subsidiaries         35,516.2         35,402.           Other noncurrent assets         152.3         21.8           Total assets         5 39,933.0         \$ 38,906.           Liabilities         8         39,933.0         \$ 38,906.           Liabilities         8         592.1         \$ 402.           Current liabilities           Current postion of payable         2.8         9.17.           Security trades pending payable         2.8         9.2         1.7           Security trades pending payable         2.8         1.7         2.2         2.2           Net due to subsidiaries         1.6         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2         2.2 </td <td>Total current assets</td> <td></td> <td>3,490.9</td> <td></td> <td>2,478.0</td>	Total current assets		3,490.9		2,478.0	
Other invested assets, long-term         615.7         596.6           Property and equipment, net         148.3         110.           Deferred tax assets, net         2.9         23.           Investments in subsidiaries         35,516.2         55,462.           Other noncurrent assets         152.3         218.8           Total assets         39,933.0         \$ 38,986.           Libilities methoders' equity           Use of the property of the property of the property of the color of the property of the property of the color of the property of the property of the property of the color of the property of the	Long-term investments available-for-sale, at fair value:					
Property and equipment net         148.3         110.0           Deferred tax assets, net         2.9         2.3           Investments in subsidiaries         35.16.2         35.46.2           Other noncurrent assets         15.23         218.8           Total asset         3.93.30         38.896.2           Liabilities           Total subsidiaries         5.92.1         8.00.2           Security rades pending payable         28.9         17.           Security trades pending payable         46.2         29.           Net due to subsidiaries         4.0         29.           Net due to subsidiaries         5.18.0         -           Current portion of long-term debt         5.18.0         -           Other current liabilities         13.98.6         753.           Coll querrent liabilities         13.98.6         753.           Long-term debt, less current portion         13.54.8         14.14.5           Other noncurrent liabilities         15.16.9         15.03.0           Total labilities         2.0         19.0           Total current liabilities         2.0         19.0           Total current liabilities         2.0         15.16.3         15.0	Equity securities (cost of \$6.7 and \$6.8)		6.7		6.8	
Defered tax assets, net         2.9         2.3           Investments in subsidiaries         35,516.2         35,462.           Other noncurrents assets         \$193.30         38,896.           Total assets         \$39,303         38,896.           Liabilities and sharcholders' equity <td of="" rowspace="" state="" state<="" td="" the="" to=""><td>Other invested assets, long-term</td><td></td><td>615.7</td><td></td><td>596.4</td></td>	<td>Other invested assets, long-term</td> <td></td> <td>615.7</td> <td></td> <td>596.4</td>	Other invested assets, long-term		615.7		596.4
Investments in subsidiaries         35,516.2         33,620.2           Other noncurrent assets         152.3         218.2           Total assets         \$39,930.2         \$38,986.2           Liabilities and shareholders' equity           Use of the installibilities           Current liabilities           Current liabilities         \$592.1         \$ 402.2           Security trades pending payable         \$592.1         \$ 402.2           Security lending payable         \$592.1         \$ 80.2           Current portion of long-term debt         \$18.0         \$ 2.2           Current portion of long-term debt         \$18.0         \$ 75.3           Long-term debt, less current portion         \$1,398.6         \$ 13,486.3           Other current liabilities         \$1,398.6         \$ 13,486.3         \$ 14,455.3           Long-term debt, less current portion         \$1,509.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2         \$ 15,009.2	Property and equipment, net		148.3		110.2	
Other noncurrent assets         15.23         21.81           Total assets         3.93,930         \$ 38,986           Liabilities           Liabilities           Counts payable and accrued expenses         \$ 592.1         \$ 402.           Security trades pending payable         2.89         5.92.1         \$ 80.           Scurity trades pending payable         46.2         29.           Net due to subsidiaries         - 6.2         89.           Current portion of long-term debt         518.0         - 6.           Other current liabilities         13.98.6         75.3           Long-term debt, less current portion         13.98.6         75.3           Long-term debt, less current portion         13.98.6         15.14.5           Other noncurrent liabilities         20.0         194.           Total liabilities         15.10.7         15.00.2           Total liabilities         20.0         194.           Total liabilities         15.10.8         15.00.2           Total liabilities         20.0         194.           Total liabilities         20.0         194.           Total liabilities         20.0         194.           Total liabilities         2	Deferred tax assets, net		2.9		23.8	
Total assets         \$ 39,930         \$ 38,806.           Liabilities           Current liabilities:           Accounts payable and accrued expenses         \$ 592.1         \$ 402.           Security trades pending payable         28.9         17.           Security trades pending payable         46.2         29.           Net due to subsidiaries         -         89.           Current portion of long-term debt         518.0         -           Other current liabilities         13,98.6         753.           Long-term debt, less current portion         13,546.5         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         220.6         194.           Total liabilities         25.0         194.           Commitments and contingencies—Note 5         5         19.3           Sharefuelders' equity           Peferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         -         -         -           Commitments and contingencies—Note 5         2.         3.         3.         3.           Actional paid-in capital         10,765.2         3.         3.         3.         3.	Investments in subsidiaries		35,516.2		35,462.2	
Liabilities and shareholders' equity           Current liabilities:           Accounts payable and accrued expenses         \$ 592.1         \$ 402.           Security trades pending payable         28.9         17.           Securities lending payable         46.2         29.           Net due to subsidiaries         -         89.           Current portion of long-term debt         518.0         -           Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         5         15,167.8         15,093.           Total liabilities         5,167.8         15,093.         15,093.           Commitments and contingencies—Note 5         5         15,167.8         15,093.           Commitments and contingencies—Note 5         5         15,167.8         15,093.           Additional paid-in capital         2,9         3.           Additional paid-in capital         10,765.2         10,853. <tr< td=""><td>Other noncurrent assets</td><td></td><td>152.3</td><td></td><td>218.9</td></tr<>	Other noncurrent assets		152.3		218.9	
Liabilities           Current liabilities:         \$ 592.1         \$ 402.           Security trades pending payable         28.9         17.           Securities lending payable         46.2         29.           Net due to subsidiaries         -         89.           Current portion of long-term debt         518.0         -           Other current liabilities         213.4         214.           Total current liabilities         13,98.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         220.6         194.           Commitments and contingencies—Note 5         5         15,167.8         15,093.           Total liabilities         15,167.8         15,093.         15,093.           Commitments and contingencies—Note 5         5         15,167.8         15,093.           Total liabilities         15,167.8         15,093.         15,093.           Commitments and contingencies—Note 5         5         15,167.8         15,093.           Additional paid-ri capital         2         2         3           Additional paid-in capital         10,765.2	Total assets	\$	39,933.0	\$	38,896.3	
Current liabilities:         Accounts payable and accrued expenses       \$ 592.1       \$ 402.         Security trades pending payable       28.9       17.         Securities lending payable       46.2       29.         Net due to subsidiaries       —       89.         Current portion of long-term debt       518.0       —         Other current liabilities       213.4       214.         Total current liabilities       1,398.6       753.         Long-term debt, less current portion       13,548.6       14,145.         Other noncurrent liabilities       220.6       194.         Total liabilities       220.6       194.         Commitments and contingencies—Note 5       5       5         Shareholders' equity       —       —         Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none       —       —         Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144       2.9       3.0         Additional paid-in capital       10,765.2       10,853.         Retained earnings       13,813.9       12,647.         Accumulated other comprehensive income       183.2       299.         Total shareholders' equity <td>Liabilities and shareholders' equity</td> <td></td> <td></td> <td></td> <td></td>	Liabilities and shareholders' equity					
Accounts payable and accrued expenses         \$ 592.1         \$ 402.           Security trades pending payable         28.9         17.           Securities lending payable         46.2         29.           Net due to subsidiaries         —         89.           Current portion of long-term debt         518.0         —           Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         220.6         194.           Commitments and contingencies—Note 5         5         5           Shareholders' equity         —         —           Common stock, par value \$0.01, shares authorized—100,000,000; shares issued and outstanding—none         —         —           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,80 and 304,715,144         2.9         3.0           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total sh	Liabilities					
Security trades pending payable         28.9         17.           Securities lending payable         46.2         29.           Net due to subsidiaries         —         89.           Current portion of long-term debt         518.0         —           Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         5         5           Shareholders' equity         —         —           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         —         —           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.	Current liabilities:					
Security trades pending payable         28.9         17.           Securities lending payable         46.2         29.           Net due to subsidiaries         —         89.           Current portion of long-term debt         518.0         —           Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         5         5           Shareholders' equity         —         —           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         —         —           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.	Accounts payable and accrued expenses	\$	592.1	\$	402.1	
Securities lending payable         46.2         29.           Net due to subsidiaries         —         89.           Current portion of long-term debt         518.0         —           Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         Starcholders' equity         —           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         —         —           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2,9         3.           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.			28.9		17.7	
Net due to subsidiaries         —         89.           Current portion of long-term debt         518.0         —           Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         Shareholders' equity         —         —           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         —         —         —           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.			46.2		29.1	
Other current liabilities         213.4         214.4           Total current liabilities         1,398.6         753.2           Long-term debt, less current portion         13,548.6         14,145.2           Other noncurrent liabilities         220.6         194.2           Total liabilities         15,167.8         15,093.2           Commitments and contingencies—Note 5         Shareholders' equity         -         -           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         -         -         -           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.0           Additional paid-in capital         10,765.2         10,853.2           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.2			_		89.7	
Other current liabilities         213.4         214.           Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         Shareholders' equity         -         -           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         -         -         -           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.0           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.	Current portion of long-term debt		518.0		_	
Total current liabilities         1,398.6         753.           Long-term debt, less current portion         13,548.6         14,145.           Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         Shareholders' equity         -         -           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         -         -         -           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.0           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.	·		213.4		214.6	
Long-term debt, less current portion       13,548.6       14,145.         Other noncurrent liabilities       220.6       194.         Total liabilities       15,167.8       15,093.         Commitments and contingencies—Note 5					753.2	
Other noncurrent liabilities         220.6         194.           Total liabilities         15,167.8         15,093.           Commitments and contingencies—Note 5         Shareholders' equity           Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none         —         —           Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144         2.9         3.4           Additional paid-in capital         10,765.2         10,853.           Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.						
Total liabilities  Commitments and contingencies—Note 5  Shareholders' equity  Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none  Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144  Additional paid-in capital  Additional paid-in capital  Retained earnings  10,765.2  10,853.  Retained earnings  13,813.9  12,647.  Accumulated other comprehensive income  183.2  299.  Total shareholders' equity					194.5	
Commitments and contingencies—Note 5  Shareholders' equity  Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none  Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144  Additional paid-in capital  Retained earnings  10,765.2  10,853.  Retained earnings  13,813.9  12,647.  Accumulated other comprehensive income  183.2  299.  Total shareholders' equity  24,765.2  23,802.						
Shareholders' equity  Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none  Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144  Additional paid-in capital  Retained earnings  10,765.2  10,853.  Retained earnings  13,813.9  12,647.  Accumulated other comprehensive income  183.2  299.  Total shareholders' equity  24,765.2  23,802.			13,107.0		13,073.0	
Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none  Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144  Additional paid-in capital  Retained earnings  10,765.2  10,853.  Retained earnings  13,813.9  12,647.  Accumulated other comprehensive income  183.2  299.  Total shareholders' equity  24,765.2  23,802.						
Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144       2.9       3.0         Additional paid-in capital       10,765.2       10,853.         Retained earnings       13,813.9       12,647.         Accumulated other comprehensive income       183.2       299.         Total shareholders' equity       24,765.2       23,802.	• •		_		_	
Additional paid-in capital       10,765.2       10,853.         Retained earnings       13,813.9       12,647.         Accumulated other comprehensive income       183.2       299.         Total shareholders' equity       24,765.2       23,802.	Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and		2.9		3.0	
Retained earnings         13,813.9         12,647.           Accumulated other comprehensive income         183.2         299.           Total shareholders' equity         24,765.2         23,802.					10,853.5	
Accumulated other comprehensive income 183.2 299.  Total shareholders' equity 24,765.2 23,802.					12,647.1	
Total shareholders' equity         24,765.2         23,802.	-				299.1	
					23,802.7	
	Total liabilities and shareholders' equity	\$	39,933.0	\$	38,896.3	

# WellPoint, Inc. (Parent Company Only) Statements of Income

	Years ended December 31					
(In millions)		2013 2012		2012	2011	
Revenues						
Net investment income	\$	61.2	\$	95.3	\$	116.6
Net realized losses on investments		(83.2)		(28.5)		(17.9)
Other-than-temporary impairment losses on investments:						
Total other-than-temporary impairment losses on investments		(51.6)		(15.3)		(18.3)
Portion of other-than-temporary impairment losses recognized in other comprehensive income		0.2		1.3		0.3
Other-than-temporary impairment losses recognized in income		(51.4)		(14.0)		(18.0)
Other revenue		4.4		3.5		3.1
Total revenues		(69.0)		56.3		83.8
Expenses						
General and administrative expense		196.6		211.9		53.4
Interest expense		598.4		507.0		407.3
Loss on extinguishment of debt		145.3		_		_
Total expenses		940.3		718.9		460.7
Loss before income tax credits and equity in net income of subsidiaries		(1,009.3)		(662.6)		(376.9)
Income tax credits		(369.7)		(172.1)		(207.0)
Equity in net income of subsidiaries		3,129.3		3,146.0		2,816.6
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7

# WellPoint, Inc. (Parent Company Only) Statements of Comprehensive Income

(in millions)	Years ended December 31					
		2013		2012		2011
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7
Other comprehensive (loss) income, net of tax:						
Change in net unrealized gains/losses on investments		(294.7)		189.9		20.6
Change in non-credit component of other-than-temporary impairment losses on						
investments		1.7		4.5		(0.7)
Change in net unrealized gains/losses on cash flow hedges		3.0		0.1		(10.0)
Change in net periodic pension and postretirement costs		172.7		(10.9)		(119.8)
Foreign currency translation adjustments		1.4		0.6		0.2
Other comprehensive (loss) income		(115.9)		184.2		(109.7)
Total comprehensive income	\$	2,373.8	\$	2,839.7	\$	2,537.0

# WellPoint, Inc. (Parent Company Only) Statements of Cash Flows

(In millions)		Years ended December 31					
		2013	2012			2011	
Operating activities							
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7	
Adjustments to reconcile net income to net cash provided by operating activities:							
(Undistributed) distributed earnings of subsidiaries		(78.5)		(432.0)		399.3	
Net realized losses on investments		83.2		28.5		17.9	
Other-than-temporary impairment losses recognized in income		51.4		14.0		18.0	
Loss on extinguishment of debt		145.3		_		_	
Loss on disposal of assets		3.6		_		_	
Deferred income taxes		(4.5)		49.2		95.3	
Amortization, net of accretion		25.2		23.2		3.1	
Depreciation		45.7		13.1		0.3	
Share-based compensation		146.0		146.5		134.8	
Excess tax benefits from share-based compensation		(30.1)		(28.8)		(42.2	
Changes in operating assets and liabilities, net of effect of business combinations:							
Receivables, net		3.5		9.6		13.5	
Other invested assets, current		(0.3)		0.2		4.6	
Other assets		42.3		(31.7)		(52.0	
Amounts due (from) to subsidiaries		(983.1)		754.7		(497.2	
Accounts payable and accrued expenses		111.8		(34.5)		1.5	
Other liabilities		(18.6)		8.9		(0.9	
Income taxes		83.9		(204.0)		35.3	
Net cash provided by operating activities		2,116.5		2,972.4		2,778.0	
Investing activities							
Purchases of investments		(1,964.3)		(5,383.2)		(2,681.7	
Proceeds from sales, maturities, calls and redemptions of investments		2,443.3		5,554.5		3,689.6	
Settlement of non-hedging derivatives		(109.8)		(59.8)		(96.6	
Capitalization of subsidiaries		(121.2)		(6,085.1)		(832.1	
Changes in securities lending collateral		(17.0)		73.8		17.3	
(Purchases) sales of property and equipment, net		(87.4)		(117.1)		2.3	
Other, net		(18.9)		(114.4)		(49.6	
Net cash provided by (used in) investing activities		124.7		(6,131.3)		49.2	
Financing activities							
Net (repayments of) proceeds from commercial paper borrowings		(191.7)		(229.0)		463.7	
Proceeds from long-term borrowings		1,250.0		6,468.9		1,097.4	
Repayments of long-term borrowings		(1,245.0)		(800.0)		(700.0	
Changes in securities lending payable		17.1		(72.7)		(17.3	
Changes in bank overdrafts		71.8		30.5		(66.9	
Premiums paid on equity options		(25.8)		_			
Repurchase and retirement of common stock		(1,620.1)		(2,496.8)		(3,039.8	
Cash dividends		(465.9)		(380.9)		(369.8	
Proceeds from issuance of common stock under employee stock plans		524.7		110.8		245.0	
Excess tax benefits from share-based compensation		30.1		28.8		42.2	
Net cash (used in) provided by financing activities		(1,654.8)		2,659.6		(2,345.5	
Change in cash and cash equivalents		586.4		(499.3)		481.7	
Cash and cash equivalents at beginning of year		588.1		1,087.4		605.7	
Cash and cash equivalents at end of year	\$	1,174.5	\$	588.1	\$	1,087.4	

# WellPoint, Inc. (Parent Company Only) Notes to Condensed Financial Statements

December 31, 2013 (In Millions, Except Per Share Data)

#### 1. Basis of Presentation and Significant Accounting Policies

In the parent company only financial statements of WellPoint, Inc., or WellPoint, WellPoint's investment in subsidiaries is stated at cost plus equity in undistributed earnings of the subsidiaries. WellPoint's share of net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.

Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of WellPoint.

Certain prior year amounts have been reclassified to conform to the current year presentation.

WellPoint's parent company only financial statements should be read in conjunction with WellPoint's audited consolidated financial statements and the accompanying notes included in this Form 10-K.

#### 2. Subsidiary Transactions

#### Dividends from Subsidiaries

WellPoint received cash dividends from subsidiaries of \$3,046.5, \$2,935.1 and \$2,915.9 during 2013, 2012 and 2011, respectively.

#### Dividends to Subsidiaries

Certain subsidiaries of WellPoint own shares of WellPoint common stock. WellPoint paid cash dividends to subsidiaries related to these shares of common stock in the amount of \$17.9, \$13.8 and \$12.0 during 2013, 2012 and 2011, respectively.

#### Investments in Subsidiaries

Capital contributions to subsidiaries were \$121.2, \$6,085.1 and \$832.1 during 2013, 2012 and 2011, respectively.

#### Amounts Due to and From Subsidiaries

At December 31, 2013 and 2012, WellPoint reported \$893.4 due from subsidiaries and \$89.7 payable to subsidiaries, respectively. The amounts due to or from subsidiaries primarily include amounts for allocated administrative expenses or cash held overnight at the parent level resulting from daily cash management activities. These items are routinely settled, and as such, are classified as current assets or liabilities.

#### 3. Derivative Financial Instruments

The information regarding derivative financial instruments contained in Note 6, "Derivative Financial Instruments," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### 4. Long-Term Debt

The information regarding long-term debt contained in Note 13, "Debt," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### 5. Commitments and Contingencies

The information regarding commitments and contingencies contained in Note 14, "Commitments and Contingencies," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

### 6. Capital Stock

The information regarding capital stock contained in Note 15, "Capital Stock," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### **SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WELLPOINT, INC.		
By:	/S/	JOSEPH R. SWEDISH

Joseph R. Swedish Chief Executive Officer and Director

Dated: February 20, 2014

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
/S/ JOSEPH R. SWEDISH	Chief Executive Officer and Director (Principal Executive Officer)	February 20, 2014
Joseph R. Swedish		
/s/ WAYNE S. DEVEYDT	Executive Vice President and Chief Financial Officer (Principal Financial Officer)	February 20, 2014
Wayne S. DeVeydt		
/s/ JOHN E. GALLINA	Senior Vice President and Chief Accounting Officer (Principal Accounting Officer)	February 20, 2014
John E. Gallina		
/s/ GEORGE A. SCHAEFER, JR.	Chair of the Board	February 20, 2014
George A. Schaefer, Jr.		
/s/ ROBERT L. DIXON, JR.	Director	February 20, 2014
Robert L. Dixon, Jr.		
/s/ LEWIS HAY III	Director	February 20, 2014
Lewis Hay III		
/s/ JULIE A. HILL	Director	February 20, 2014
Julie A. Hill		
/s/ WARREN Y. JOBE	Director	February 20, 2014
Warren Y. Jobe		
/s/ RAMIRO G. PERU	Director	February 20, 2014
Ramiro G. Peru		
/s/ WILLIAM J. RYAN	Director	February 20, 2014
William J. Ryan		
/s/ JOHN H. SHORT	Director	February 20, 2014
John H. Short		
/s/ ELIZABETH E. TALLETT	Director	February 20, 2014
Elizabeth E. Tallett		

#### INDEX TO EXHIBITS

Exhibit
Number Exhibit

- 2.1 Stock and Interest Purchase Agreement dated April 9, 2009, by and between the Company and Express Scripts, Inc., incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K filed on April 13, 2009.
- 2.2 Agreement and Plan of Merger, dated as of July 9, 2012 by and among WellPoint, Inc., WellPoint Merger Sub, Inc. and AMERIGROUP Corporation, incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on July 10, 2012.
  - (a) Amendment No. 1 to Agreement and Plan of Merger, dated as of October 2, 2012, by and among WellPoint, Inc., WellPoint Merger Sub, Inc. and AMERIGROUP Corporation, incorporated by reference to Exhibit 2.1(a) to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.
- 3.1 Articles of Incorporation of the Company, as amended effective May 17, 2011, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 20, 2011.
- 3.2 By-laws of the Company, as amended effective October 22, 2013, incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
- 4.1 Articles of Incorporation of the Company, as amended effective May 17, 2011 (Included in Exhibit 3.1).
- 4.2 By-laws of the Company, as amended effective October 22, 2013 (Included in Exhibit 3.2).
- 4.3 Specimen of Certificate of the Company's common stock, \$0.01 par value per share, incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-8 filed on December 28, 2005 (Registration No. 333-130743).
- 4.4 Indenture, dated as of December 9, 2004, between the Company and The Bank of New York Trust Company, N.A., as trustee, incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 15, 2004, SEC File No. 001-16751.
  - (a) Form of the Company's 5.000% Notes due 2014 (included in Exhibit 4.4).
  - (b) Form of the Company's 5.950% Notes due 2034 (included in Exhibit 4.4).
- 4.5 Indenture, dated as of January 10, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.), as trustee, incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on January 11, 2006, SEC File No. 001-16751.
  - (a) Form of 5.25% Notes due 2016, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on January 11, 2006, SEC File No. 001-16751.
  - (b) Form of 5.85% Notes due 2036, incorporated by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on January 11, 2006, SEC File No. 001-16751.
  - (c) Form of 5.875% Notes due 2017, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on June 8, 2007, SEC File No. 001-16751.
  - (d) Form of 6.375% Notes due 2037, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on June 8, 2007, SEC File No. 001-16751.
  - (e) Form of 7.000% Notes due 2019, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on February 5, 2009.
  - (f) Form of 4.350% Notes due 2020, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on August 12, 2010.
  - (g) Form of 5.800% Notes due 2040, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on August 12, 2010.

#### **Exhibit**

- (h) Form of 2.375% Notes due 2017, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on August 15, 2011.
- (i) Form of 3.700% Notes due 2021, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on August 15, 2011.
- (j) Form of 3.125% Notes due 2022, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on May 7, 2012.
- (k) Form of 4.625% Notes due 2042, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on May 7, 2012.
- (l) Form of 1.250% Notes due 2015, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on September 10, 2012.
- (m) Form of 1.875% Notes due 2018, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on September 10, 2012.
- (n) Form of 3.300% Notes due 2023, incorporated by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on September 10, 2012.
- (o) Form of 4.650% Notes due 2043, incorporated by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on September 10, 2012.
- (p) Form of 2.300% Notes due 2018, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on July 31, 2013.
- (q) Form of 5.100% Notes due 2044, incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on July 31, 2013.
- 4.6 Indenture dated as of October 9, 2012 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee, incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on October 9, 2012.
  - (a) Form of the 2.750% Senior Convertible Debentures due 2042 (included in Exhibit 4.6).
- 4.7 Upon the request of the Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
- 10.1 \* Anthem 2001 Stock Incentive Plan, amended and restated as of January 1, 2003, incorporated by reference to Exhibit 10.1(iii) to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2003, SEC File No. 001-16751.
  - (a) Form of Stock Incentive Plan General Stock Option Grant Agreement as of March 1, 2006, incorporated by reference to Exhibit 10.1(b) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2006, SEC File No. 001-16751.
- 10.2 \* WellPoint Incentive Compensation Plan as amended and restated effective May 20, 2009, incorporated by reference to Exhibit 99 to the Company's Registration Statement on Form S-8 filed June 8, 2009.
  - (a) First Amendment to WellPoint Incentive Compensation Plan effective December 8, 2010, incorporated by reference to Exhibit 10.2(a) to the Company's Annual Report on Form 10-K for the year ended December 31, 2010.
  - (b) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement under the 2006 Incentive Compensation Plan, incorporated by reference to Exhibit 10.2(j) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, SEC File No. 001-16751.
  - (c) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2008 under the 2006 Incentive Compensation Plan, incorporated by reference to Exhibit 10.2(k) to the Company's Annual Report on Form 10-K for the year ended December 31, 2007, SEC File No. 001-16751.

#### Exhibit Number

#### Exhibit

- (d) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2009 under the 2006 Incentive Compensation Plan, incorporated by reference to Exhibit 10.2(m) to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, SEC File No. 001-16751.
- (e) Form of Incentive Compensation Plan Non-Qualified Stock Option Award Agreement, incorporated by reference to Exhibit 10.2(o) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
- (f) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement, incorporated by reference to Exhibit 10.2(p) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
- (g) Form of Incentive Compensation Plan Performance Share Award Agreement, incorporated by reference to Exhibit 10.2(q) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
- (h) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement, incorporated by reference to Exhibit 10.2(r) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.
- (i) Form of Incentive Compensation Plan Performance Share Award Agreement, incorporated by reference to Exhibit 10.2(s) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.
- (j) Form of Incentive Compensation Plan Performance Share Award Agreement, Grant A for 2012, incorporated by reference to Exhibit 10.2(p) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.
- (k) Form of Incentive Compensation Plan Performance Share Award Agreement, Grant B for 2012, incorporated by reference to Exhibit 10.2(q) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.
- (l) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement, incorporated by reference to Exhibit 10.2(t) to the Company's Current Report on Form 8-K filed on September 14, 2012.
- (m) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2013, incorporated by reference to Exhibit 10.2(s) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.
- (n) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2013, incorporated by reference to Exhibit 10.2(t) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.
- (o) Form of Incentive Compensation Plan Performance Share Award Agreement for 2013, incorporated by reference to Exhibit 10.2(u) to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.
- \* WellPoint, Inc. Comprehensive Non-Qualified Deferred Compensation Plan, as amended and restated effective January 1, 2014, incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.
- 10.4 \* WellPoint, Inc. Executive Agreement Plan, amended and restated effective January 1, 2009, incorporated by reference to Exhibit 10.4 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008.
  - (a) Amendment to the WellPoint, Inc. Executive Agreement Plan effective as of April 1, 2009, incorporated by reference to Exhibit 10.4(a) of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009.
  - (b) Second Amendment to the WellPoint, Inc. Executive Agreement Plan effective as of March 1, 2011, incorporated by reference to Exhibit 10.4(b) to the Company's Current Report on Form 8-K filed on March 10, 2011.
  - (c) Third Amendment to the WellPoint, Inc. Executive Agreement Plan effective as of August 6, 2013, incorporated by reference to Exhibit 10.4(c) to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.

Exhibit <u>Number</u>

Exhibit

- 10.5 \* WellPoint, Inc. Executive Salary Continuation Plan effective January 1, 2006, incorporated by reference to Exhibit 10.59 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006, SEC File No. 001-016751.
- 10.6 \* WellPoint Directed Executive Compensation Plan amended effective January 1, 2014, incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.
- 10.7 \* WellPoint, Inc. Board of Directors Compensation Program, as amended effective May 15, 2013, incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.
- 10.8 \* WellPoint Board of Directors' Deferred Compensation Plan, as amended and restated effective January 1, 2009, incorporated by reference to Exhibit 10.8 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, SEC File No. 001-16751.
- 10.9 \* Amerigroup Corporation 2009 Equity Incentive Plan effective May 7, 2009, incorporated by reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 filed on December 26, 2012 (Registration No. 333-185675).
- 10.10 \* Employment Agreement between Anthem Insurance Companies, Inc. and Samuel R. Nussbaum, M.D., dated as of January 2, 2001 (with respect to Section 5(b) only), incorporated by reference to Exhibit 10.5 to the Company's Registration Statement on Form S-1 (Registration No. 333-67714).
  - (a) Amendment dated September 30, 2011 to Employment Agreement between Anthem Insurance Companies, Inc. and Samuel R. Nussbaum, M.D., dated as of January 2, 2001, incorporated by reference to Exhibit 10.12 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.
- 10.11 \* (a) Form of Employment Agreement between the Company and each of the following: Ken R. Goulet and Samuel R. Nussbaum, M.D., incorporated by reference to Exhibit 10.43 to the Company's Annual Report on Form 10-K for the year ended December 31, 2005, SEC File No. 001-16751.
  - (b) Form of Employment Agreement between the Company and Wayne S. DeVeydt, incorporated by reference to Exhibit A to Exhibit 10.7 to the Company's Current Report on Form 8-K filed on November 2, 2006, SEC File No. 001-16751.
  - (c) Form of Employment Agreement between the Company and each of the following: John Cannon, Jose D. Tomas and Gloria McCarthy incorporated by reference to Exhibit A to Exhibit 10.41 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, SEC File No. 001-16751.
  - (d) Form of Employment Agreement between the Company and Joseph R. Swedish, incorporated by reference to Exhibit A to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 12, 2013.
- 10.12 \* Employment Agreement between WellPoint, Inc. and Richard C. Zoretic dated as of July 9, 2012 and effective December 24, 2012, incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
  - (a) First Amendment to Employment Agreement between WellPoint, Inc. and Richard C. Zoretic dated as of October 26, 2012 and effective December 24, 2012, incorporated by reference to Exhibit 10.16(a) to the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
  - (b) Second Amendment to Employment Agreement between WellPoint, Inc. and Richard C. Zoretic dated as of April 23, 2013, incorporated by reference to Exhibit 10.16(b) to the Company's Current Report on Form 8-K filed on April 23, 2013.
- 10.13 Blue Cross License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by the Member Plans through June 21, 2012, incorporated by reference to Exhibit 10.17 to the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

Exhibit <u>Number</u>	<u>Exhibit</u>
10.14	Blue Shield License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by the Member Plans through June 21, 2012, incorporated by reference to Exhibit 10.18 to the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
10.15	Undertakings to California Department of Managed Health Care, dated October 15, 2012, delivered by Blue Cross of California, incorporated by reference to Exhibit 10.19 to the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
10.16	* Offer Letter, by and between WellPoint, Inc. and Joseph R. Swedish, dated as of February 6, 2013, incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 12, 2013.
21	Subsidiaries of the Company.
23	Consent of Independent Registered Public Accounting Firm.
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following materials from WellPoint, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Shareholders' Equity; (vi) the Notes to Consolidated Financial Statements and (vii) Financial Statement Schedule II.

<sup>\*</sup> Indicates management contracts or compensatory plans or arrangements.

#### Exhibit 21

#### Legal Name State American Imaging Management East, L.L.C. DE American Imaging Management, Inc. IL AMERIGROUP Arizona, Inc. ΑZ AMERIGROUP California, Inc. CA AMERIGROUP Colorado, Inc. CO AMERIGROUP Community Care of Arizona, Inc. AZAMERIGROUP Community Care of Mississippi, Inc. MS AMERIGROUP Community Care of New Mexico, Inc. NM AMERIGROUP Connecticut, Inc. CTAMERIGROUP Corporation DE AMERIGROUP Delaware, Inc. DE AMERIGROUP Florida, Inc. FL AMERIGROUP Hawaii, Inc. HI AMERIGROUP Health Solutions, Inc. DE AMERIGROUP Indiana, Inc. ΙN Amerigroup Insurance Company TXAmerigroup Kansas, Inc. KS AMERIGROUP Louisiana, Inc. LA AMERIGROUP Maine, Inc. ME AMERIGROUP Maryland, Inc. MD AMERIGROUP Massachusetts, Inc. MAAMERIGROUP Michigan, Inc. MI AMERIGROUP Nevada, Inc. NV AMERIGROUP New Jersey, Inc. NJ AMERIGROUP New York, LLC NY AMERIGROUP Ohio, Inc. ОН AMERIGROUP Pennsylvania, Inc. PA AMERIGROUP Puerto Rico, Inc. PR Amerigroup Services, Inc. VA AMERIGROUP Tennessee, Inc. TNAMERIGROUP Texas, Inc. TXAMERIGROUP Washington, Inc. WA AMERIGROUP Wisconsin, Inc. WI AMGP Georgia Managed Care Company, Inc. GA AMGP Georgia, Inc. GA Anthem Blue Cross Life and Health Insurance Company CAAnthem Financial, Inc. DE Anthem Health Insurance Company of Nevada NV Anthem Health Plans of Kentucky, Inc. KY Anthem Health Plans of Maine, Inc. ME Anthem Health Plans of New Hampshire, Inc. NH Anthem Health Plans of Virginia, Inc. VA Anthem Health Plans, Inc. CTAnthem Holding Corp. ΙN Anthem Insurance Companies, Inc. ΙN

-

Legal Name	State
Anthem Life & Disability Insurance Company	NY
Anthem Life Insurance Company	IN
Anthem Southeast, Inc.	IN
Anthem UM Services, Inc.	IN
Anthem Workers' Compensation, LLC	IN
Arcus Enterprises, Inc.	DE
ARCUS HealthyLiving Services, Inc.	IN
Associated Group, Inc.	IN
ATH Holding Company, LLC	IN
Blue Cross and Blue Shield of Georgia, Inc.	GA
Blue Cross Blue Shield Healthcare Plan of Georgia, Inc.	GA
Blue Cross Blue Shield of Wisconsin	WI
Blue Cross of California	CA
Blue Cross of California Partnership Plan, Inc.	CA
CareMore Health Group, Inc.	DE
CareMore Health Plan	CA
CareMore Health Plan of Arizona, Inc.	AZ
CareMore Health Plan of Colorado, Inc.	СО
CareMore Health Plan of Georgia, Inc.	GA
CareMore Health Plan of Nevada	NV
CareMore Health Plan of Texas, Inc.	TX
CareMore Health System	CA
CareMore Holdings, Inc.	DE
CareMore IPA of New York, LLC	NY
CareMore Medical Management Company, a California Limited Partnership	CA
CareMore Services Company, LLC	IN
CareMore, LLC	IN
CareNex Health Services, LLC	DE
Cerulean Companies, Inc.	GA
Claim Management Services, Inc.	WI
CMMC Holding Company, LLC	DE
Community Insurance Company	ОН
Compcare Health Services Insurance Corporation	WI
Crossroads Acquisition Corp.	DE
DeCare Analytics, LLC	MN
DeCare Dental Health International, LLC	MN
DeCare Dental Insurance Ireland, Ltd.	Ireland
DeCare Dental Networks, LLC	MN
DeCare Dental, LLC	MN
DeCare Operations Ireland, Limited	Ireland

.

Legal Name	State
DeCare Systems Ireland, Limited	Ireland
Designated Agent Company, Inc.	KY
EHC Benefits Agency, Inc.	NY
Empire HealthChoice Assurance, Inc.	NY
Empire HealthChoice HMO, Inc.	NY
Forty-Four Forest Park Redevelopment Corporation	MO
Golden West Health Plan, Inc.	CA
Government Health Services, L.L.C.	WI
Greater Georgia Life Insurance Company	GA
Health Core, Inc.	DE
Health Management Corporation	VA
Health Ventures Partner, L.L.C.	IL
HealthKeepers, Inc.	VA
HealthLink HMO, Inc.	MO
HealthLink, Inc.	IL
Healthy Alliance Life Insurance Company	MO
HMO Colorado, Inc.	CO
HMO Missouri, Inc.	MO
Imaging Management Holdings, L.L.C.	DE
Imaging Providers of Texas	TX
Matthew Thornton Health Plan, Inc.	NH
Meridian Resource Company, LLC	WI
National Government Services, Inc.	IN
National Telehealth Network, LLC	DE
OneNation Insurance Company	IN
Park Square Holdings, Inc.	CA
Park Square I, Inc.	CA
Park Square II, Inc.	CA
PHP Holdings, Inc.	FL
R&P Realty, Inc.	MO
Radiant Services, LLC	IN
Resolution Health, Inc.	DE
RightCHOICE Insurance Company	IL
RightCHOICE Managed Care, Inc.	DE
Rocky Mountain Hospital and Medical Service, Inc.	CO
SellCore, Inc.	DE
Southeast Services, Inc.	VA
State Sponsored Business UM Services, Inc.	IN
The WellPoint Companies of California, Inc.	CA
The WellPoint Companies, Inc.	IN
TrustSolutions, LLC	WI
UNICARE Health Insurance Company of the Midwest	IL
UNICARE Health Plan of Kansas, Inc.	KS
UNICARE Health Plan of West Virginia, Inc.	WV

Legal Name	State
UNICARE Health Plans of Texas, Inc.	TX
UNICARE Health Plans of the Midwest, Inc.	IL
UNICARE Illinois Services, Inc.	IL
UniCare Life & Health Insurance Company	IN
UNICARE National Services, Inc.	DE
UniCare Specialty Services, Inc.	DE
UtiliMed IPA, Inc.	NY
WellPoint Acquisition, LLC	IN
WellPoint Behavioral Health, Inc.	DE
WellPoint California Services, Inc.	DE
WellPoint Dental Services, Inc.	DE
WellPoint Holding Corp.	DE
WellPoint Information Technology Services, Inc.	CA
WellPoint Insurance Services, Inc.	HI
WellPoint Partnership Plan, LLC	IL
WellPoint, Inc.	IN
WPMI (Shanghai) Enterprise Service Co. Ltd.	China
WPMI, LLC	DE

#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

- Form S-8 No. 333-73516 and Form S-8 No. 333-110503 pertaining to the Anthem 2001 Stock Incentive Plan;
- Form S-8 No. 333-84906 and Form S-8 No. 333-129334 pertaining to the WellPoint 401(k) Retirement Savings Plan (formerly Anthem 401(k) Long-term Savings Investment Plan);
- Form S-8 No. 333-121596 pertaining to the 2005 Comprehensive Executive Non-Qualified Retirement Plan;
- Form S-8 No. 333-130743 pertaining to the WellChoice, Inc. 2003 Omnibus Incentive Plan;
- Form S-8 No. 333-134253 pertaining to the WellPoint 2006 Incentive Compensation Plan;
- Form S-8 No. 333-156099 pertaining to the WellPoint, Inc. Employee Stock Purchase Plan;
- Form S-3 No. 333-178394 pertaining to the WellPoint, Inc. automatic shelf registration;
- Form S-8 No. 333-159830 pertaining to the WellPoint Incentive Compensation Plan; and
- Form S-8 No. 333-185675 pertaining to the AMERIGROUP Corporation 2009 Equity Incentive Plan

of our report dated February 20, 2014, with respect to the consolidated financial statements and schedule of WellPoint, Inc. and the effectiveness of internal control over financial reporting of WellPoint, Inc. included in this Annual Report (Form 10-K) of WellPoint, Inc. for the year ended December 31, 2013.

February 20, 2014 Indianapolis, Indiana

# CERTIFICATION PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

#### I, Joseph R. Swedish, certify that:

- 1. I have reviewed this report on Form 10-K of WellPoint, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
    conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
    this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 20, 2014
/s/ JOSEPH R. SWEDISH

Chief Executive Officer

# CERTIFICATION PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

#### I, Wayne S. DeVeydt, certify that:

- 1. I have reviewed this report on Form 10-K of WellPoint, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
    under our supervision, to ensure that material information relating to the registrant, including its consolidated
    subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
    being prepared;
  - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
    conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
    this report based on such evaluation; and
  - disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
  - all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 20, 2014 /s/ WAYNE S. DEVEYDT

Executive Vice President and Chief Financial Officer

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of WellPoint, Inc. (the "Company") on Form 10-K for the period ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Joseph R. Swedish, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

#### /s/ JOSEPH R. SWEDISH

Joseph R. Swedish Chief Executive Officer February 20, 2014

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of WellPoint, Inc. (the "Company") on Form 10-K for the period ended December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Wayne S. DeVeydt, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

#### /s/ WAYNE S. DEVEYDT

Wayne S. DeVeydt Executive Vice President and Chief Financial Officer February 20, 2014

# Property And Equipment (Tables)

# 12 Months Ended Dec. 31, 2013

## **Property, Plant and Equipment [Abstract]**

Summary of Property and Equipment

A summary of property and equipment at December 31 is as follows:

	2013	2012
Land and improvements	\$ 35.4	\$ 45.9
Building and components	384.0	406.0
Data processing equipment, furniture and other		
equipment	861.5	783.3
Computer software, purchased and internally developed	1,879.0	1,656.5
Leasehold improvements	325.1	303.1
Property and equipment, gross	3,485.0	3,194.8
Accumulated depreciation and amortization	(1,683.5)	(1,477.5)
Property and equipment, net	\$1,801.5	\$1,717.3

## Reinsurance (Summary Of Direct, Assumed And Ceded Premiums Written And Earned) (Details) (USD \$) In Millions, unless otherwise specified

### 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

## **Reinsurance Disclosures [Abstract]**

Remourance Disclosures [Abstract]			
<u>Direct - Premium written</u>	\$ 65,939.1	\$ 56,443.6	\$ 56,190.3
Assumed - Premium written	174.3	197.0	179.9
Ceded - Premium written	(92.6)	(73.2)	(84.2)
Net premiums - written	66,020.8	56,567.4	56,286.0
Percentage - assumed to net premiums - writter	<u>1</u> 0.30%	0.30%	0.30%
<u>Direct - Premiums earned</u>	66,038.9	56,373.6	55,875.8
Assumed - Premium earned	174.0	196.4	178.5
Ceded - Premium earned	(93.8)	(73.3)	(84.7)
Premiums	\$ 66,119.1	\$ 56,496.7	\$ 55,969.6
Percentage - assumed to net premiums - earned	0.30%	0.30%	0.30%

# **Business Acquisitions and Divestitures (Assets**

## $\boldsymbol{Liabilities\ Acquired)\ (Details)}$

(USD \$)

Dec. 24, 2012

In Millions, unless otherwise specified

## **Business Combinations [Abstract]**

Current assets	\$ 2,716.5
Goodwill	3,062.0
Other intangible assets	975.0
Other non current assets	406.1
Total assets acquired	7,159.6
Current liabilities	1,416.6
Non current liabilities	967.5
Total liabilities assumed	2,384.1
Net assets acquired	\$ 4,775.5

## **Earnings Per Share (Tables)**

12 Months Ended Dec. 31, 2013

## **Earnings Per Share [Abstract]**

<u>Denominator For Basic And Diluted Earnings</u> <u>Per Share</u> The denominator for basic and diluted earnings per share at December 31 is as follows:

	2013	2012	2011
Denominator for basic earnings per share—weighted-average shares	298.5	321.5	360.2
Effect of dilutive securities—employee stock options, non-	5.3		
vested restricted stock awards and convertible debentures	5.3	3.3	4.9
Denominator for diluted earnings per share	303.8	324.8	365.1

Segment Information (Major Product Revenues From Enternal Customers) (Details)	12 Months Ended				
External Customers) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
<b>Revenue from External Customer [Line Items]</b>					
Reportable segments operating revenues	\$ 70,191.4	\$ 60,514.0	\$ 59,865.2		
Commercial and Specialty Business [Member]					
<b>Revenue from External Customer [Line Items]</b>					
Reportable segments operating revenues	38,790.1	38,852.9	39,961.2		
Commercial and Specialty Business [Member]   Managed Care Products [Member]					
<b>Revenue from External Customer [Line Items]</b>					
Reportable segments operating revenues	33,903.6	34,091.5	35,387.8		
Commercial and Specialty Business [Member]   Managed Care Services [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	3,472.1	3,444.8	3,374.5		
Commercial and Specialty Business [Member]   Dental/Vision Products And Services [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	952.5	903.9	826.8		
Commercial and Specialty Business [Member]   Other Products and Services [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	461.9	412.7	372.1		
Government Business [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	31,366.7	21,625.7	19,874.0		
Government Business [Member]   Managed Care Products [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	30,959.3	21,244.7	19,533.0		
Government Business [Member]   Managed Care Services [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	407.4	381.0	341.0		
Other [Member]					
Revenue from External Customer [Line Items]					
Reportable segments operating revenues	\$ 34.6	\$ 35.4	\$ 30.0		

Derivative Financial Instruments (Effect Of Non- Hedging Derivatives On Income Statement And Included In Net Realized		12 Months Ended				
Gains (Losses) On Investments) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011			
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized	\$ (52.7)	\$ (79.0)	\$ (57.2)			
Derivatives Embedded In Convertible Securities [Member]   Net Realized Gains (Losses) Investments [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized	31.5	(2.4)	(7.6)			
Interest Rate Swaps [Member]   Net Realized Gains (Losses) Investments [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized	2.2					
Credit Default And Interest Rate Swaps [Member]   Net Realized Gains (Losses) Investments [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized		(3.9)	(53.3)			
Options [Member]   Net Realized Gains (Losses) Investments [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized	(111.7)	(66.0)	9.6			
Futures [Member]   Net Realized Gains (Losses) Investments [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized	22.3	(6.7)	(5.9)			
Swaptions [Member]   Net Realized Gains (Losses) Investments [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Derivative Gain (Loss) Recognized	\$ 3.0					

Related Party Transactions (Details) (USD \$) In Millions, unless otherwise

12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

specified

Related Party Transactions [Abstract]

Amount received from related parties \$ 0.7 \$ 0.6 \$ 0.6

Contributions made to related parties \$ 10.0

Business Acquisitions and Divestitures Business	3 Months Ended				12 Months Ended						
Acquisitions and Divestitures (Summarized Financial Information) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	30,	30,	Mar. 31, 2013	31,	30,	30,	31,	31,	31,	Dec. 31, 2011
<b>Income Statement, Balance Sheet and</b>											
Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]											
Discontinued operations, net of tax	\$ (160.7)	\$ 2.4	\$ 0.8	\$ 12.9	\$ 0.8	\$ 3.7	\$0	\$ 0	\$ (144.6)	\$ 4.5	\$ 0
1-800 Contacts [Member]											
Income Statement, Balance Sheet and Additional Disclosures by Disposal											
Groups, Including Discontinued Operations [Line Items]											
Revenues									434.7	214.5	
Income from discontinued operations before tax									17.3	7.2	
Income tax (benefit) expense									(2.6)	2.7	
Income from discontinued operations									19.9	4.5	
Loss on disposal from discontinued operations, net of tax									(164.5)	0	
Discontinued operations, net of tax									\$ (144.6)	\$ 4.5	

Income Taxes (Change In The Carrying Amount Of	12 Months Ended			
Gross Unrecognized Tax Benefits From Uncertain Tax Positions) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012		
Change in carrying amount of gross unrecognized tax benefits from uncertain tax				
positions				
Balance at January 1	\$ 143.5	\$ 229.1		
Additions for tax positions related to current year	5.0	50.1		
Additions for tax positions related to prior years	0	13.0		
Reductions related to tax positions of prior years	(45.3)	0		
Reductions related to settlements with taxing authorities	0	(148.7)		
Balance at December 31	\$ 103.2	\$ 143.5		

Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock		12 Months Ended				
Units) (Details) (USD \$) In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011			
Restricted Stock Shares and Units						
Nonvested at beginning of period, Restricted Stock Shares and Units	2.6					
Granted, Restricted Stock Shares and Units	2.7					
Vested, Restricted Stock Shares and Units	(0.6)					
Forfeited, Restricted Stock Shares and Units	(0.5)					
Nonvested at end of period, Restricted Stock Shares and Units	4.2	2.6				
Weighted-Average Grant Date Fair Value per Share						
Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share	\$ 63.87					
Granted, Weighted-Average Grant Date Fair Value per Share	\$ 63.06	\$ 65.91	\$ 66.16			
Vested, Weighted-Average Grant Date Fair Value per Share	\$ 59.95					
Forfeited, Weighted-Average Grant Date Fair Value Per Share	\$ 64.84					
Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share	\$ 63.83	\$ 63.87				

### **Reinsurance (Tables)**

# 12 Months Ended Dec. 31, 2013

# **Reinsurance Disclosures** [Abstract]

<u>Summary Of Direct, Assumed And</u>
<u>Ceded Premiums Written And Earned</u>
A summary of direct, a December 31 is as follows:

A summary of direct, assumed and ceded premiums written and earned for the years ended December 31 is as follows:

	2013		20	)12	2011			
	Written	Earned	Written	Earned	Written	Earned		
Direct	\$65,939.1	\$66,038.9	\$56,443.6	\$56,373.6	\$56,190.3	\$55,875.8		
Assumed	174.3	174.0	197.0	196.4	179.9	178.5		
Ceded	(92.6)	(93.8)	(73.2)	(73.3)	(84.2)	(84.7)		
Net premiums	\$66,020.8	\$66,119.1	\$56,567.4	\$56,496.7	\$56,286.0	\$55,969.6		
Percentage— assumed to net	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%		
premiums	0.5%	0.5%	0.5%	0.3%	0.5%	0.5%		

## Summary Of Net Premiums Written And Earned By Segment

A summary of net premiums written and earned by segment (see Note 20, "Segment Information") for the years ended December 31 is as follows:

	20	13	20	12	2011		
	Written	Earned	Written	Earned	Written	Earned	
Reportable segments:							
Commercial and Specialty Business	\$ 35,126.0	\$ 35,159.8	\$ 35,352.1	\$ 35,251.9	\$ 36,476.3	\$ 36,436.7	
Government Business	30,894.8	30,959.3	21,215.3	21,244.8	19,809.7	19,532.9	
Other	_	_	_	_	_	_	
Net premiums	\$ 66,020.8	\$ 66,119.1	\$ 56,567.4	\$ 56,496.7	\$ 56,286.0	\$ 55,969.6	

# Effect Of Reinsurance On Benefit Expense

The effect of reinsurance on benefit expense for the years ended December 31 is as follows:

	2013	2012	2011
Direct	\$ 56,185.2	\$ 48,135.1	\$ 47,569.8
Assumed	155.6	173.0	165.0
Ceded	(103.7)	(94.5)	(87.3)
Net benefit expense	\$ 56,237.1	\$ 48,213.6	\$ 47,647.5

## Effect Of Reinsurance On Certain Assets And Liabilities

The effect of reinsurance on certain assets and liabilities at December 31 is as follows:

	2	2013	2012
Policy liabilities, assumed	\$	55.4	\$ 62.4
Unearned income, assumed		0.4	0.5
Premiums payable, ceded		17.1	18.1
Premiums receivable, assumed		14.1	16.6

### **Business Acquisitions and Divestitures (Tables)**

## 12 Months Ended Dec. 31, 2013

## **Business Combinations**[Abstract]

Business Acquisition Summary of Fair Value of Assets Acquired and Liabilities Assumed The following table summarizes the estimated fair values of Amerigroup assets acquired and liabilities assumed:

Current assets	\$ 2,716.5
Goodwill	3,062.0
Other intangible assets	975.0
Other noncurrent assets	406.1
Total assets acquired	7,159.6
Current liabilities	1,416.6
Noncurrent liabilities	967.5
Total liabilities assumed	2,384.1
Net assets acquired	\$ 4,775.5

### <u>Summarized Operational Results</u> for Discontinued Operations

Summarized financial information for the 1-800 CONTACTS discontinued operations for the years ended December 31, 2013 and 2012 is as follows:

	2013	2012
Revenues	\$ 434.7	214.5
Income from discontinued operations before tax	17.3	7.2
Income tax (benefit) expense	(2.6)	2.7
Income from discontinued operations	19.9	4.5
Loss on disposal from discontinued operations, net of tax	 (164.5)	
Discontinued operations, net of tax	\$ (144.6)	\$ 4.5

Summarized Assets and Liabilities for Discontinued Operations

The assets and liabilities of 1-800 CONTACTS are reported as held for sale in the accompanying consolidated balance sheets at December 31, 2013 and 2012 and consist of the following:

	2	2013	2012
Assets			
Cash and cash equivalents	\$	4.8	\$ 9.3
Property and equipment		27.6	21.0
Goodwill		409.9	620.7
Other intangibles		415.4	437.3
Other assets		49.2	9.7
Total assets	\$	906.9	\$ 1,098.0
Liabilities			
Accounts payable and other accrued expenses	\$	34.2	\$ 33.8
Deferred income taxes		142.5	158.1
Other liabilities		4.7	15.2
Total liabilities	\$	181.4	\$ 207.1

#### Property And Equipment (Narrative) (Details) (USD \$) In Millions, unless otherwise specified

#### 12 Months Ended

Dec. 31,	2013	Dec. 3	31, 2012	Dec.	31, 201	1

Property, Pla	ant and Equ	uipment [	Line Items]

Depreciation expense	\$ 107.9	\$ 107.1	\$ 95.7
Amortization expense on computer software and leasehold improvement	<u>ts</u> 351.8	260.6	204.6
Computer software amortization	313.6	239.5	183.9
Capitalized costs related to the internal development of software	1,561.0	1,316.8	
Computer software impairment	47.7	66.8	
Continuing Operations			
<b>Property, Plant and Equipment [Line Items]</b>			
Depreciation expense	\$ 105.3	\$ 102.9	\$ 95.7

Earnings Per Share (Denominator For Basic And		12 Months Ended			
Diluted Earnings Per Share) (Details) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
Earnings Per Share [Abstract]					
Denominator for basic earnings per share—weighted-average shares	298.5	321.5	360.2		
Effect of dilutive securities—employee stock options, non-vested restricted stock awards and convertible debentures	5.3	3.3	4.9		
Denominator for diluted earnings per share	303.8	324.8	365.1		

Schedule II-Condensed Financial Information Of Registrant (Balance Sheets) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Current assets:				
Cash and cash equivalents	\$ 1,582.1	\$ 2,475.3	\$ 2,201.6	
Fixed maturity securities (amortized cost of \$897.4 and \$1,415.5)	17,038.2	16,912.9		
Equity securities (cost of \$52.6 and \$26.7)	1,735.5	1,212.4		
Other invested assets, current	16.3	14.8		
Other receivables	1,063.3	927.6		
Income taxes receivable	235.7	228.5		
Securities lending collateral	969.8	564.6		
Deferred tax assets, net	383.0	236.4		
Other current assets	1,677.5	1,827.4		
<u>Total current assets</u>	29,745.8	29,347.5		
Equity securities (cost of \$6.7 and \$6.8)	31.3	30.1		
Other Long Term Investments	1,542.6	1,387.6		
Property and equipment, net	1,801.5	1,717.3		
Other noncurrent assets	645.2	486.1		
<u>Total assets</u>	59,574.5	58,955.4		
<b>Current liabilities:</b>				
Accounts payable and accrued expenses	3,426.3	3,098.7		
Security trades pending payable	95.2	69.3		
Securities lending payable	969.7	564.7		
Current portion of long-term debt	518.0	557.1		
Other current liabilities	1,674.7	1,769.8		
Total current liabilities	16,351.5	15,995.0		
Long-term debt, less current portion	13,573.6	14,170.8		
Other noncurrent liabilities	836.0	1,013.2		
Total liabilities	34,809.3	35,152.7		
Commitments and contingencies-Note 5				
Shareholders' equity				
<u>Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none</u>	0	0		
Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144	2.9	3.0		
Additional paid-in capital	10,765.2	10,853.5		
Retained earnings	13,813.9	12,647.1		
Accumulated other comprehensive income	183.2	299.1		
Total shareholders' equity	24,765.2	23,802.7	23,288.2	23,812.6
Total liabilities and shareholders' equity	59,574.5	58,955.4		
WellPoint, Inc. [Member]				
Current assets:				
Cash and cash equivalents	1,174.5	588.1		
· · · · · · · · · · · · · · · · · · ·	-			

Fixed maturity securities (amortized cost of \$897.4 and \$1,415.5)	900.4	1,425.9
Equity securities (cost of \$52.6 and \$26.7)	89.6	15.0
Other invested assets, current	1.9	1.6
Other receivables	35.6	37.7
Income taxes receivable	154.4	227.0
Net due from subsidiaries	893.4	0
Securities lending collateral	46.2	29.1
Deferred tax assets, net	11.8	7.9
Other current assets	183.1	145.7
Total current assets	3,490.9	2,478.0
Equity securities (cost of \$6.7 and \$6.8)	6.7	6.8
Other Long Term Investments	615.7	596.4
Property and equipment, net	148.3	110.2
Deferred tax assets, net	2.9	23.8
<u>Investment in subsidiaries</u>	35,516.2	35,462.2
Other noncurrent assets	152.3	218.9
Total assets	39,933.0	38,896.3
Current liabilities:		
Accounts payable and accrued expenses	592.1	402.1
Security trades pending payable	28.9	17.7
Securities lending payable	46.2	29.1
Net due to subsidiaries	0	89.7
Current portion of long-term debt	518.0	0
Other current liabilities	213.4	214.6
Total current liabilities	1,398.6	753.2
Long-term debt, less current portion	13,548.6	14,145.9
Other noncurrent liabilities	220.6	194.5
<u>Total liabilities</u>	15,167.8	15,093.6
Commitments and contingencies-Note 5		
Shareholders' equity		
Preferred stock, without par value, shares authorized—100,000,000; shares	0	0
issued and outstanding—none	O	O .
Common stock, par value \$0.01, shares authorized—900,000,000; shares	2.9	3.0
issued and outstanding: 293,273,830 and 304,715,144	10.765.0	10.052.5
Additional paid-in capital	10,765.2	10,853.5
Retained earnings	13,813.9	12,647.1
Accumulated other comprehensive income	183.2	299.1
Total shareholders' equity	24,765.2	23,802.7
Total liabilities and shareholders' equity	\$ 59,955.U	\$ 38,896.3

Fair Value (Carrying and Fair
Value By Level of Financial
<b>Instruments Not Recorded At</b>
Fair Value On Consolidated
<b>Balance Sheet) (Details)</b>
(USD \$)
In Millions, unless otherwise
specified

Dec. 31, Dec. 31, 2013

(USD \$)		
In Millions, unless otherwise		
specified		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Other invested assets, long-term	\$ 1,542.6	\$ 1,387.6
Short-term borrowings	400.0	250.0
Commercial paper	379.2	570.9
Convertible debentures	966.0	
Carrying Value [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line	2	
<u>Items</u> ]		
Other invested assets, long-term	1,542.6	1,387.7
Short-term borrowings	400.0	250.0
Commercial paper	379.2	570.9
Notes	12,746.4	13,198.9
Convertible debentures	966.0	958.1
Estimated Fair Value [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line	2	
<u>Items</u> ]		
Other invested assets, long-term	1,542.6	1,387.7
Short-term borrowings	400.0	250.0
Commercial paper	379.2	570.9
<u>Notes</u>	13,014.3	14,407.1
Convertible debentures	2,030.6	1,613.4
Estimated Fair Value [Member]   Level I [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line	2	
<u>Items</u> ]		
Other invested assets, long-term	0	0
Short-term borrowings	0	0
Commercial paper	0	0
Notes	0	0
Convertible debentures	0	0
Estimated Fair Value [Member]   Level II [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	2	
Other invested assets, long-term	0	0
Short-term borrowings	400.0	250.0
Commercial paper	379.2	570.9
	13,014.3	14,407.1
Notes Convertible debentures	2,030.6	1,613.4
Convertible debentures  Estimated Fair Value [Member]   Level III [Member]	4,030.0	1,013.4
Estimated Fair value [Member]   Level III [Member]		

## <u>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</u>

Other invested assets, long-term	1,542.6	1,387.7
Short-term borrowings	0	0
Commercial paper	0	0
<u>Notes</u>	0	0
Convertible debentures	\$ 0	\$0

Retirement Benefits (Weighted-Average

Assumptions Used In Calculating The Benefit

Obligations For All Plans) Dec. 31, 2013 Dec. 31, 2012

12 Months Ended

7.00%

7.00%

(Details)

Pension Benefits [Member]

Expected rate of return on plan assets

Discount rate	4.39%	3.60%				
Rate of compensation increase	3.00%	3.50%				
Kate of compensation increase	3.00%	3.30%				
Expected rate of return on plan assets	7.66%	7.66%				
Other Benefits [Member]						
Defined Benefit Plan Disclosure [Line Items]						
Discount rate	4.48%	3.71%				
Rate of compensation increase	3.00%	3.50%				

Restructuring Activities (Restructuring Activities)		12 Months Ended		
(Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012		
2012 Restructuring Activities [Member]				
Restructuring Cost and Reserve [Line Items]				
Liability for restructuring activities, ending balance	\$ 21.4			
2012 Restructuring Activities [Member]   Employee Termination Costs [Member]				
Restructuring Cost and Reserve [Line Items]				
Costs incurred		138.8		
<u>Payments</u>	(70.9)	(21.2)		
<u>Liability released</u>	(28.5)			
Liability for restructuring activities, ending balance	18.2	117.6		
2012 Restructuring Activities [Member]   Lease And Other Contract Exit Costs [Member]				
Restructuring Cost and Reserve [Line Items]				
Costs incurred		11.9		
<u>Payments</u>	(7.8)	(0.1)		
<u>Liability released</u>	(0.8)			
Liability for restructuring activities, ending balance	3.2	11.8		
2012 Restructuring Activities [Member]   Commercial and Specialty Business [Member]				
Restructuring Cost and Reserve [Line Items]				
Liability for restructuring activities, ending balance	15.8			
2012 Restructuring Activities [Member]   Commercial and Specialty Business [Member]   Employee Termination Costs [Member]				
Restructuring Cost and Reserve [Line Items]				
Costs incurred		70.8		
<u>Payments</u>	(34.6)	(10.8)		
<u>Liability released</u>	(12.0)			
Liability for restructuring activities, ending balance	13.4	60.0		
2012 Restructuring Activities [Member]   Commercial and Specialty Business [Member]   Lease And Other Contract Exit Costs [Member]				
Restructuring Cost and Reserve [Line Items]				
Costs incurred		8.8		
<u>Payments</u>	(5.7)	(0.1)		
<u>Liability released</u>	(0.6)			
Liability for restructuring activities, ending balance	2.4	8.7		
2012 Restructuring Activities [Member]   Government Business [Member]				
Restructuring Cost and Reserve [Line Items]				
Liability for restructuring activities, ending balance	5.0			
2012 Restructuring Activities [Member]   Government Business [Member]   Employee Termination Costs [Member]				
Restructuring Cost and Reserve [Line Items]				
Costs incurred		64.5		
<u>Payments</u>	(34.6)	(9.8)		
<u>Liability released</u>	(15.9)			

<u>Liability for restructuring activities, ending balance</u>	4.2	54.7
2012 Restructuring Activities [Member]   Government Business [Member]   Lease And Other Contrac Exit Costs [Member]	ct	
Restructuring Cost and Reserve [Line Items]		
Costs incurred		3.0
<u>Payments</u>	(2.0)	0
<u>Liability released</u>	(0.2)	
<u>Liability for restructuring activities, ending balance</u>	0.8	3.0
2012 Restructuring Activities [Member]   Other [Member]		
Restructuring Cost and Reserve [Line Items]		
<u>Liability for restructuring activities, ending balance</u>	0.6	
2012 Restructuring Activities [Member]   Other [Member]   Employee Termination Costs [Member]		
Restructuring Cost and Reserve [Line Items]		
Costs incurred		3.5
<u>Payments</u>	(1.7)	(0.6)
<u>Liability released</u>	(0.6)	
Liability for restructuring activities, ending balance	0.6	2.9
2012 Restructuring Activities [Member]   Other [Member]   Lease And Other Contract Exit Costs		
[Member]		
Restructuring Cost and Reserve [Line Items]		
Costs incurred		0.1
<u>Payments</u>	(0.1)	0
<u>Liability released</u>	0	
<u>Liability for restructuring activities</u> , ending balance	0	0.1
2011 Restructuring Activities [Member]		
Restructuring Cost and Reserve [Line Items]		
<u>Liability for restructuring activities</u> , ending balance	17.5	
2011 Restructuring Activities [Member]   Employee Termination Costs [Member]		
Restructuring Cost and Reserve [Line Items]		
<u>Liability for restructuring activities, ending balance</u>	1.9	
2011 Restructuring Activities [Member]   Lease And Other Contract Exit Costs [Member]		
Restructuring Cost and Reserve [Line Items]		
<u>Liability for restructuring activities, ending balance</u>	\$ 15.6	

## Accumulated Other Comprehensive Income

## (Loss) (Reconciliation Of The Components Of Accumulated

#### Other Comprehensive

Income) (Details) (USD \$)

In Millions, unless otherwise specified

#### 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012

#### **Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]**

Investments, Gross unrealized gains	\$ 1,054.2	\$ 1,282.1
Investments, Gross unrealized losses	(277.8)	(51.3)
Investments, Net pretax unrealized gains	776.4	1,230.8
Investments, Deferred tax liability	(267.4)	(427.1)
Net unrealized gains on investments	509.0	803.7
Non-credit components of OTTI on investments, Unrealized losses	(0.8)	(3.4)
Non-credit components of OTTI on investments, Deferred tax asset	0.3	1.2
Net unrealized non-credit component of OTTI on investments	(0.5)	(2.2)
Cash flow hedges, Gross unrealized losses	(49.7)	(54.3)
Cash flow hedges, Deferred tax asset	17.4	19.0
Net unrealized losses on cash flow hedges	(32.3)	(35.3)
Defined benefit pension plans, Deferred net actuarial loss	(427.2)	(686.8)
Defined benefit pension plans, Deferred prior service credits	3.0	3.9
Defined benefit pension plans, Deferred tax asset	169.9	269.1
Net unrecognized periodic benefit costs for defined benefit pension plans	(254.3)	(413.8)
Deferred Net Actuarial Loss Postretirement Benefits	(169.6)	(191.0)
Deferred Prior Service Credit Postretirement Benefit Plans	102.4	103.0
Postretirement benefit plans, Deferred tax asset	27.0	34.6
Net unrecognized periodic benefit costs for postretirement benefit plans	(40.2)	(53.4)
Foreign currency translation adjustments, Gross unrealized losses	2.2	0.2
Foreign currency translation adjustments, Deferred tax asset	(0.7)	(0.1)
Net unrealized losses on foreign currency translation adjustment	1.5	0.1
Accumulated other comprehensive income	\$ 183.2	\$ 299.1

**Income Taxes (Components** Of Provision For Income

12 Months Ended

Taxes) (Details) (USD \$)

specified

In Millions, unless otherwise Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

#### **Current tax expense (benefit):**

<u>Federal</u>	\$ 1,226.4	\$ 1,060.2	\$ 1,150.4
State and local	(42.6)	95.7	21.6
Total current tax expense	1,183.8	1,155.9	1,172.0
Deferred tax expense	22.1	51.4	139.2
Total income tax expense	\$ 1,205.9	\$ 1,207.3	\$ 1,311.2

<b>Retirement Benefits</b>					12 Months Ended			
(Changes In Fair Value Of Plan Assets) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013 Pension Benefits [Member]	Dec. 31, 2012 Pension Benefits [Member]	Dec. 31, 2013 Other Benefits [Member]	Dec. 31, 2012 Other Benefits [Member]
Change in fair value of plan								
<u>assets</u>								
Beginning balance	\$ 587.7	\$ 583.9	\$ 774.9	\$ 771.7	\$ 1,817.9	\$ 1,721.8	\$ 320.3	\$ 301.1
Actual return on plan assets					223.4	186.8	37.0	21.9
Employer contributions					38.6	34.5	31.3	38.4
Benefits paid					(135.9)	(125.2)	(38.8)	(41.1)
Ending balance	\$ 587.7	\$ 583.9	\$ 774.9	\$ 771.7	\$ 1,944.0	\$ 1,817.9	\$ 349.8	\$ 320.3

## Goodwill And Other Intangible Assets (Narrative) (Details) (USD \$) In Millions, unless otherwise

Dec. 31, 2013 Dec. 31, 2012

12 Months Ended

#### specified

#### **Goodwill and Intangible Assets Disclosure [Abstract]**

Goodwill adjustment for tax benefit on exercise of stock options, reduction	on \$ 1.5	\$ 0.4
Increase (decrease) related to other measurement period adjustments	28.9	(1.6)
Estimated amortization expense 2014	213.3	
Estimated amortization expense 2015	182.1	
Estimated amortization expense 2016	151.4	
Estimated amortization expense 2017	131.5	
Estimated amortization expense 2018	\$ 111.7	

# Retirement Benefits (Net Amount Included In Consolidated Balance Sheets) (Details) (USD \$) In Millions, unless otherwise specified

Dec. 31, 2013 Dec. 31, 2012

\$ (257.7)

\$ (302.7)

Pension Benefits [Member]

Net amount at December 31

	L					
Noncurrent assets	\$ 240.8	\$ 3.0				
Current liabilities	(3.5)	(11.5)				
Noncurrent liabilities	(58.0)	(122.1)				
Net amount at December 31	179.3	(130.6)				
Other Benefits [Member]						
<b>Defined Benefit Plan Disclosure [Line Items]</b>						
Noncurrent assets	0	0				
Current liabilities	0	0				
Noncurrent liabilities	(257.7)	(302.7)				

# Income Taxes (Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate) (Details) (USD \$) In Millions, unless otherwise

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

12 Months Ended

specified

#### **Income Tax Disclosure [Abstract]**

Amount at statutory rate, amount	\$ 1,344.1	\$ 1,350.4	\$ 1,385.3
Amount at statutory rate, percent	35.00%	35.00%	35.00%
State and local income taxes net of federal tax benefit, amount	24.4	25.5	42.3
State and local income taxes net of federal tax benefit, percent	0.60%	0.60%	1.10%
Tax exempt interest and dividends received deduction, amount	(64.9)	(59.3)	(58.6)
Tax exempt interest and dividends received deduction, percent	(1.70%)	(1.50%)	(1.50%)
Audit settlements, amount	0	(200.5)	(49.7)
Audit settlements, percent	0.00%	(5.20%)	(1.30%)
Other, net amount	(97.7)	91.2	(8.1)
Other, net percent	(2.50%)	2.40%	(0.20%)
Total income tax expense	\$ 1,205.9	\$ 1,207.3	\$ 1,311.2
Total income tax expense, percent	31.40%	31.30%	33.10%

Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) (USD \$) In Millions, unless otherwise specified Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	Dec. 31, 2013	Dec. 31, 2012
Cash equivalents	\$ 632.3	\$ 728.3
Fair value assets measured on recurring basis available-for-sale securities	19,254.9	18,586.9
Securities lending collateral	969.8	564.6
Total assets	20,931.7	19,953.2
Total liabilities	(20.7)	(0.1)
Fixed Maturity Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	17,488.1	17,344.4
Fixed Maturity Securities [Member]   United States Government Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items  Fair value assets measured on recurring basis available-for-sale securities	299.9	343.2
Fixed Maturity Securities [Member]   Government Sponsored Securities [Member]	277.7	545.2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items]		
Fair value assets measured on recurring basis available-for-sale securities	173.5	156.2
Fixed Maturity Securities [Member]   States, Municipalities And Political Subdivisions - Tax-Exemp [Member]	t	
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	6,002.7	5,882.2
Fixed Maturity Securities [Member]   Corporate Securities [Member]		

	,	,
Total liabilities	(20.7)	(0.1)
Fixed Maturity Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	17,488.1	17,344.4
Fixed Maturity Securities [Member]   United States Government Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	299.9	343.2
Fixed Maturity Securities [Member]   Government Sponsored Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	173.5	156.2
Fixed Maturity Securities [Member]   States, Municipalities And Political Subdivisions - Tax-Exempt [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	6,002.7	5,882.2
Fixed Maturity Securities [Member]   Corporate Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	7,708.6	8,004.0
Fixed Maturity Securities [Member]   Options Embedded In Convertible Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	89.2	67.2
Fixed Maturity Securities [Member]   Residential Mortgage-Backed Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	2,268.9	2,304.8
Fixed Maturity Securities [Member]   Commercial Mortgage-Backed Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	486.6	345.7

Fixed Maturity Securities [Member] | Other Debt Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	458.7	241.1
Equity Securities [Member]	100.7	2.1.1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	1,766.8	1,242.5
Other Invested Assets, Current [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Other invested assets, current	16.3	14.8
Derivatives Excluding Embedded Options [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items]	<b>5</b> 0.4	<b>7</b> 0.6
Derivatives excluding embedded options (reported with other assets)	58.4	58.6
Derivatives excluding embedded options (reported with other liabilities)	(20.7)	(0.1)
Level I [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Cash equivalents	632.3	728.3
Securities lending collateral	408.5	231.7
Total assets	2,868.3	2,454.9
Total liabilities	0	0
Level I [Member]   Fixed Maturity Securities [Member]	O	O
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items]		
Fair value assets measured on recurring basis available-for-sale securities	335.5	377.0
Level I [Member]   Fixed Maturity Securities [Member]   United States Government Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	299.9	343.2
Level I [Member]   Fixed Maturity Securities [Member]   Government Sponsored Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level I [Member]   Fixed Maturity Securities [Member]   States, Municipalities And Political Subdivisions - Tax-Exempt [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level I [Member]   Fixed Maturity Securities [Member]   Corporate Securities [Member]		
<u>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</u>		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level I [Member]   Fixed Maturity Securities [Member]   Options Embedded In Convertible Securities [Member]		

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level I [Member]   Fixed Maturity Securities [Member]   Residential Mortgage-Backed Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level I [Member]   Fixed Maturity Securities [Member]   Commercial Mortgage-Backed Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level I [Member]   Fixed Maturity Securities [Member]   Other Debt Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	35.6	33.8
Level I [Member]   Equity Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	1,475.7	1,103.1
Level I [Member]   Other Invested Assets, Current [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Other invested assets, current	16.3	14.8
Level I [Member]   Derivatives Excluding Embedded Options [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Derivatives excluding embedded options (reported with other assets)	0	0
Derivatives excluding embedded options (reported with other liabilities)	0	0
Level II [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
<u>Cash equivalents</u>	0	0
Securities lending collateral	561.3	332.9
<u>Total assets</u>	17,885.5	17,342.8
Total liabilities	(20.7)	(0.1)
Level II [Member]   Fixed Maturity Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	17,016.1	16,838.1
Level II [Member]   Fixed Maturity Securities [Member]   United States Government Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level II [Member]   Fixed Maturity Securities [Member]   Government Sponsored Securities [Member]		

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Items]	<u>Line</u>	
Fair value assets measured on recurring basis available-for-sale securities	173.5	156.2
Level II [Member]   Fixed Maturity Securities [Member]   States, Municipalities And Politica Subdivisions - Tax-Exempt [Member]		130.2
	Lino	
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Items]	Line	
Fair value assets measured on recurring basis available-for-sale securities	6,002.7	5,882.2
Level II [Member]   Fixed Maturity Securities [Member]   Corporate Securities [Member]	0,002.7	2,002.2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	Line	
Items]	<u>Line</u>	
Fair value assets measured on recurring basis available-for-sale securities	7,593.4	7,882.9
Level II [Member]   Fixed Maturity Securities [Member]   Options Embedded In Convertible Securities [Member]	e	ŕ
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	Line	
<u>Items</u> ]	<del></del>	
Fair value assets measured on recurring basis available-for-sale securities	89.2	67.2
Level II [Member]   Fixed Maturity Securities [Member]   Residential Mortgage-Backed Sec [Member]	eurities	
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	<u>Line</u>	
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	2,268.9	2,300.5
Level II [Member]   Fixed Maturity Securities [Member]   Commercial Mortgage-Backed Se [Member]	ecurities	
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	<u>Line</u>	
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	480.1	345.7
Level II [Member]   Fixed Maturity Securities [Member]   Other Debt Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis	<u>Line</u>	
Items]	400.2	202.4
Fair value assets measured on recurring basis available-for-sale securities	408.3	203.4
Level II [Member]   Equity Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	<u>Line</u>	
Items  Fair value assets measured on recurring basis available-for-sale securities	249.7	113.2
Level II [Member]   Other Invested Assets, Current [Member]	249.1	113.2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	Lino	
Items]	Line	
Other invested assets, current	0	0
Level II [Member]   Derivatives Excluding Embedded Options [Member]	Ü	V
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	Line	
Items]	<u> Line</u>	
Derivatives excluding embedded options (reported with other assets)	58.4	58.6
Derivatives excluding embedded options (reported with other liabilities)	(20.7)	(0.1)
Level III [Member]	( /	
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [	Line	
Items]	<u> </u>	
<u>Cash equivalents</u>	0	0

Securities lending collateral Total assets	0 177.9	0 155.5
Total liabilities	0	0
Level III [Member]   Fixed Maturity Securities [Member]	U	O
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items]		
Fair value assets measured on recurring basis available-for-sale securities	136.5	129.3
Level III [Member]   Fixed Maturity Securities [Member]   United States Government Securities	100.0	12,10
[Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level III [Member]   Fixed Maturity Securities [Member]   Government Sponsored Securities		
[Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	0	0
Level III [Member]   Fixed Maturity Securities [Member]   States, Municipalities And Political		
Subdivisions - Tax-Exempt [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items	0	0
Fair value assets measured on recurring basis available-for-sale securities	U	U
Level III [Member]   Fixed Maturity Securities [Member]   Corporate Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fair value assets measured on recurring basis available-for-sale securities	115.2	121.1
Level III [Member]   Fixed Maturity Securities [Member]   Options Embedded In Convertible	113.2	121.1
Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items	0	0
Fair value assets measured on recurring basis available-for-sale securities  Level III [Marshard   Fixed Maturity Securities [Marshard   Besidential Martages Backed Securities]		0
Level III [Member]   Fixed Maturity Securities [Member]   Residential Mortgage-Backed Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
Items]		
Fair value assets measured on recurring basis available-for-sale securities	0	4.3
Level III [Member]   Fixed Maturity Securities [Member]   Commercial Mortgage-Backed		
Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	6.5	0
Level III [Member]   Fixed Maturity Securities [Member]   Other Debt Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Fair value assets measured on recurring basis available-for-sale securities	14.8	3.9
Level III [Member]   Equity Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		

Fair value assets measured on recurring basis available-for-sale securities	41.4	26.2
Level III [Member]   Other Invested Assets, Current [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Other invested assets, current	0	0
Level III [Member]   Derivatives Excluding Embedded Options [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line		
<u>Items</u> ]		
Derivatives excluding embedded options (reported with other assets)	0	0
Derivatives excluding embedded options (reported with other liabilities)	\$ 0	\$0

## 12 Months Ended Dec. 31, 2013

#### **Leases, Operating [Abstract]**

Leases

#### Leases

We lease office space and certain computer and related equipment using noncancelable operating leases. At December 31, 2013, future lease payments for operating leases with initial or remaining noncancelable terms of one year or more consist of the following:

2014	\$ 133.0
2015	126.7
2016	99.6
2017	97.3
2018	91.1
Thereafter	221.6
Total minimum payments required	\$ 769.3

We have certain lease agreements that contain contingent payment provisions. Under these provisions, we pay contingent amounts in addition to base rent, primarily based upon annual changes in the consumer price index. The schedule above contains estimated amounts for potential future increases in lease payments based on the contingent payment provisions.

Lease expense for 2013, 2012 and 2011 was \$185.9, \$153.3 and \$148.6, respectively.

## Selected Quarterly Financial Data (Tables)

#### <u>Selected Quarterly Financial Information</u> [Abstract]

Schedule of Quarterly Financial Data

Dec. 31, 2013

12 Months Ended

Selected quarterly financial data is as follows:

	For the Quarter Ended					
	March 31	June 30	September 30	December 31		
2013						
Total revenues	\$17,576.0	\$17,690.3	\$ 17,855.5	\$ 17,901.7		
Income from continuing operations						
before income taxes	1,282.5	1,208.1	879.7	469.9		
Income from continuing operations	872.3	799.3	653.8	308.9		
Income (loss) from discontinued operations	12.9	0.8	2.4	(160.7)		
Net income	885.2	800.1	656.2	148.2		
	000.2	000.1	000.2	1.0,2		
Basic net income per share - continuing operations	\$ 2.88	\$ 2.67	\$ 2.20	\$ 1.05		
Basic net income (loss) per share -						
discontinued operations	0.04	_	0.01	(0.55)		
Basic net income per share	2.92	2.67	2.21	0.50		
Diluted net income per share - continuing operations	\$ 2.85	\$ 2.64	\$ 2.15	\$ 1.02		
Diluted net income (loss) per share - discontinued operations	0.04	_	0.01	(0.53)		
Diluted net income per share	2.89	2.64	2.16	0.49		
·						
2012						
Total revenues	\$15,415.2	\$15,396.3	\$ 15,247.4	\$ 15,438.3		
Income from continuing operations before income taxes	1,309.8	1,048.7	1,019.6	480.2		
Income from continuing operations	856.5	643.6	687.5	463.4		
Income from discontinued operations	_	_	3.7	0.8		
Net income	856.5	643.6	691.2	464.2		
1 tot moonie	0000	0.0.0	0,1.2	102		
Basic net income per share - continuing operations	\$ 2.56	\$ 1.96	\$ 2.16	\$ 1.52		
Basic net income per share - discontinued operations	_	_	0.01	_		
Basic net income per share	2.56	1.96	2.17	1.52		
Diluted net income per share - continuing operations	\$ 2.53	\$ 1.94	\$ 2.14	\$ 1.51		
Diluted net income per share - discontinued operations	_	_	0.01	_		
Diluted net income per share	2.53	1.94	2.15	1.51		
r						

## Medical Claims Payable (Tables)

## 12 Months Ended Dec. 31, 2013

## Medical Claims Payable [Abstract]

Reconciliation Of The Beginning And Ending Balances For Medical Claims
Payable

A reconciliation of the beginning And ended December 31 is as follows:

A reconciliation of the beginning and ending balances for medical claims payable for the years ended December 31 is as follows:

	Years Ended December 31				
		2013	2012		2011
Gross medical claims payable, beginning of year	\$	6,174.5	\$	5,489.0	\$ 4,852.4
Ceded medical claims payable, beginning of year		(27.2)		(16.4)	(32.9)
Net medical claims payable, beginning of year		6,147.3		5,472.6	4,819.5
Business combinations and purchase adjustments		_		804.4	100.9
Net incurred medical claims:					
Current year		55,894.3		48,080.1	47,281.6
Prior years redundancies		(599.1)		(513.6)	(209.7)
Total net incurred medical claims		55,295.2		47,566.5	47,071.9
Net payments attributable to:					
Current year medical claims		49,887.2		42,832.4	41,999.0
Prior years medical claims		5,451.5		4,863.8	4,520.7
Total net payments		55,338.7		47,696.2	46,519.7
Net medical claims payable, end of year		6,103.8		6,147.3	5,472.6
Ceded medical claims payable, end of year		23.4		27.2	16.4
Gross medical claims payable, end of year	\$	6,127.2	\$	6,174.5	\$ 5,489.0

(Favorable) Unfavorable
Developments By Changes In Key
Assumptions

The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December 31, 2013, 2012 and 2011, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.

	(1	(Favorable) Unfavorable Development by Changes in Key Assumptions				•
		2013		2012		2011
Assumed trend factors	\$	(428.4)	\$	(394.4)	\$	(264.8)
Assumed completion factors		(170.7)		(119.2)		55.1
Total	\$	(599.1)	\$	(513.6)	\$	(209.7)

#### Income Taxes (Components Of Deferred Income Taxes) (Details) (USD \$)

## In Millions, unless otherwise specified

Deletted tax abbets	D	ef	er	red	tax	assets
---------------------	---	----	----	-----	-----	--------

Deferred tax assets		
Retirement benefits	\$ 287.8	\$ 405.3
Accrued expenses	342.8	431.2
<u>Insurance reserves</u>	213.1	221.2
Net operating loss carryforwards	17.2	19.2
Bad debt reserves	124.8	108.2
State income tax	32.9	79.3
<u>Deferred compensation</u>	52.0	55.7
Investment basis difference	166.3	138.2
Other	84.0	47.0
<u>Total deferred tax assets</u>	1,320.9	1,505.3
<u>Valuation allowance</u>	(24.1)	(18.1)
Total deferred tax assets, net of valuation allowance	1,296.8	1,487.2
Deferred tax liabilities		
Unrealized gains on securities	266.5	431.0
Trademarks and other non-amortizable intangible assets	2,200.5	2,200.5
Subscriber base, provider and hospital networks	370.9	447.7
Internally developed software and other amortization differences	703.9	599.3
Retirement benefits	231.5	214.1
Debt discount	186.9	189.7
State deferred tax	55.3	165.9
Depreciation and amortization	33.1	73.9
Other	190.4	151.6
Total deferred tax liabilities	4,239.0	4,473.7
Deferred tax asset-current	383.0	236.4
Deferred tax liability-noncurrent	(3,325.2)	(3,222.9)
Net deferred tax liability	\$ (2,942.2)	\$ (2,986.5)

Dec. 31, 2013 Dec. 31, 2012

**Medical Claims Payable** 

((Favorable) Unfavorable 12 Months Ended

Developments By Changes In Key Assumptions) (Details)

(USD \$)

In Millions, unless otherwise Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

specified

#### **Medical Claims Payable [Abstract]**

Assumed trend factors	\$ (428.4)	\$ (394.4)	\$ (264.8)
Assumed completion factors	(170.7)	(119.2)	55.1
<u>Total</u>	\$ (599.1)	\$ (513.6)	\$ (209.7)

#### Fair Value (Tables)

## 12 Months Ended Dec. 31, 2013

#### **Fair Value Disclosures [Abstract]**

Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December 31, 2013 and 2012 is as follows:

	Level I		Level III	Total	
December 31, 2013					
Assets:					
Cash equivalents	\$ 632.3	\$ —	\$ —	\$ 632.3	
Investments available-for-sale:					
Fixed maturity securities:					
United States Government securities	299.9	_	_	299.9	
Government sponsored securities		173.5	_	173.5	
States, municipalities and political subdivisions, tax-exempt	_	6,002.7	_	6,002.7	
Corporate securities	_	7,593.4	115.2	7,708.6	
Options embedded in convertible securities	_	89.2	_	89.2	
Residential mortgage-backed securities	_	2,268.9	_	2,268.9	
Commercial mortgage-backed securities	_	480.1	6.5	486.6	
Other debt securities	35.6	408.3	14.8	458.7	
Total fixed maturity securities	335.5	17,016.1	136.5	17,488.1	
Equity securities	1,475.7	249.7	41.4	1,766.8	
Other invested assets, current	16.3	_	_	16.3	
Securities lending collateral	408.5	561.3	_	969.8	
Derivatives excluding embedded options (reported with other assets)	_	58.4	_	58.4	
<b>Total assets</b>	\$2,868.3	\$17,885.5	\$ 177.9	\$20,931.7	
Liabilities:					
Derivatives excluding embedded options (reported					
with other liabilities)	\$ —	\$ (20.7)	\$ —	\$ (20.7)	
Total liabilities	\$	\$ (20.7)	\$ —	\$ (20.7)	
December 31, 2012:					
Assets:					
Cash equivalents	\$ 728.3	\$ —	\$ —	\$ 728.3	
Investments available-for-sale:					
Fixed maturity securities:					
United States Government securities	343.2	_	_	343.2	
Government sponsored securities	_	156.2	_	156.2	
States, municipalities and political subdivisions, tax-exempt	_	5,882.2	_	5,882.2	
Corporate securities	_	7,882.9	121.1	8,004.0	
Options embedded in convertible securities	_	67.2	_	67.2	
Residential mortgage-backed securities	_	2,300.5	4.3	2,304.8	
Commercial mortgage-backed securities	_	345.7	_	345.7	
Other debt securities	33.8	203.4	3.9	241.1	
Total fixed maturity securities	377.0	16,838.1	129.3	17,344.4	
Equity securities	1,103.1	113.2	26.2	1,242.5	
Other invested assets, current	14.8	_	_	14.8	
Securities lending collateral	231.7	332.9	_	564.6	
Derivatives excluding embedded options (reported with other assets)	_	58.6	_	58.6	
Total assets	\$2,454.9	\$17,342.8	\$ 155.5	\$19,953.2	

#### Liabilities: Derivatives excluding embedded options (reported with other liabilities) (0.1)**Total liabilities** (0.1) \$ (0.1)

Reconciliation Of The Beginning And Fair Value On A Recurring Basis Using Level III Inputs

A reconciliation of the beginning and ending balances of assets measured at fair value on a Ending Balances Of Assets Measured At recurring basis using Level III inputs for the years ended December 31, 2013, 2012 and 2011 is as

	rporate curities	M	sidential ortgage- backed curities	N	ommercial Aortgage- backed Securities	Other Debt curities	Equity curities	Total
Year Ended December 31, 2013:	 					 -	 -	1000
Beginning balance at				_				
January 1, 2013	\$ 121.1	\$	4.3	\$	_	\$ 3.9	\$ 26.2	\$155.5
Total gains (losses):  Recognized in net								
income	(30.3)		_			(0.1)	(4.8)	(35.2)
Recognized in accumulated other comprehensive								
income	(3.5)		_		_	0.6	9.5	6.6
Purchases	51.9				_	1.6	17.6	71.1
Sales	(4.8)		_		_	_	(7.1)	(11.9)
Settlements	(15.5)		(1.9)		(6.1)	(0.7)	_	(24.2)
Transfers into Level III	3.0		13.1		12.6	9.8	_	38.5
Transfers out of Level III	 (6.7)		(15.5)			 (0.3)	 	(22.5)
Ending balance at December 31, 2013	\$ 115.2	\$	_	\$	6.5	\$ 14.8	\$ 41.4	\$177.9
Change in unrealized losses included in net income related to assets still held for the year ended								
December 31, 2013	\$ (30.8)	\$		\$		\$ (0.1)	\$ (6.5)	\$ (37.4)
Year Ended December 31, 2012:								
Beginning balance at January 1, 2012	\$ 195.1	\$	_	\$	6.3	\$ 59.0	\$ 24.4	\$284.8
Total gains (losses):								
Recognized in net income	15.2		_		_	0.1	(0.9)	14.4
Recognized in accumulated other comprehensive								
income	(19.7)		_		0.1	0.7	(14.2)	(33.1)
Purchases	77.8		3.0		3.4	_	4.9	89.1
Business combinations	2.6				_			2.6
Sales	(29.8)		(0.1)		(0.1)	(16.6)	(0.5)	(46.9)
Settlements Transfers into Level III	(67.8)		(0.1)		(0.1)	(1.3)	12.5	(69.3)
Transfers out of Level III	2.9 (55.2)		1.4		1.9 (11.6)	12.0 (50.0)	12.5	(116.8)
Ending balance at December 31, 2012	\$ 121.1	\$	4.3	\$	— (11.0) —	\$ 3.9	\$ 26.2	\$155.5
Change in unrealized losses included in net income related to assets still held for the year ended						3.5		
December 31, 2012	\$ 	\$		\$	<u> </u>	\$ 	\$ (0.7)	\$ (0.7)
Year Ended								

December 31, 2011:

Beginning balance at January 1, 2011	\$ 278.4	\$ 3.8	\$ 7.8	\$ 81.4	\$ 17.3	\$388.7
Total gains (losses):						
Recognized in net income	5.2	_	_	(1.7)	(7.0)	(3.5)
Recognized in accumulated other comprehensive						
income	(3.0)	0.1	0.1	_	4.1	1.3
Purchases	31.2	2.8	2.6	12.2	10.2	59.0
Sales	(27.6)	(9.1)	(8.2)	(22.9)	(0.4)	(68.2)
Settlements	(130.5)	(0.8)	(1.4)	(17.7)	_	(150.4)
Transfers into Level III	41.4	9.7	5.4	7.8	0.2	64.5
Transfers out of Level III	_	(6.5)	_	(0.1)	_	(6.6)
Ending balance at December 31, 2011	\$ 195.1	\$ 	\$ 6.3	\$ 59.0	\$ 24.4	\$284.8
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2011	(0.6)	\$ _	\$ _	\$ (1.2)	\$ (7.0)	\$ (8.8)

Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet A summary of the carrying value and fair value by level of financial instruments not recorded at fair value on our consolidated balance sheets at December 31, 2013 and 2012 are as follows:

	Carrying Fair Value					
	Value	Leve	el I	Level II	Level III	Total
December 31, 2013						
Assets:						
Other invested assets, long-term	\$ 1,542.6	\$	_	\$ —	\$1,542.6	\$ 1,542.6
Liabilities:						
Debt:						
Short-term borrowings	400.0		_	400.0	_	400.0
Commercial paper	379.2		_	379.2	_	379.2
Notes	12,746.4			13,014.3	_	13,014.3
Convertible debentures	966.0		_	2,030.6	_	2,030.6
December 31, 2012						
Assets:						
Other invested assets, long-term	\$ 1,387.7	\$	—	\$ —	\$1,387.7	\$ 1,387.7
Liabilities:						
Debt:						
Short-term borrowings	250.0		_	250.0		250.0
Commercial paper	570.9		_	570.9	_	570.9
Notes	13,198.9		_	14,407.1	_	14,407.1
Convertible debentures	958.1		_	1,613.4	_	1,613.4

Basis Of Presentation And Significant Accounting	12 Months Ended				
Policies (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
<b>Basis Of Presentation And Significant Accounting Policies [Line Items]</b>					
Reserves for future policy benefits, maximum payable period	1 year				
Initial cash collateral percentage value on securities loan	102.00%				
Minimum percentage of cash collateral on market value of security loan	100.00%				
Fair value of collateral received	\$ 969.7	\$ 564.7			
Percentage of collateral delivered on market value security loan	102.00%				
Employee stock purchase plan purchase price per share as a percent of closing price	95.00%				
Advertising and marketing expense	350.9	285.4	287.8		
2014 Federal Government fees to be allocated to health insurers	8,000.0				
Estimated portion of fees paid to the federal government by health insurers	900.0				
Buildings and Components [Member]   Minimum [Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					
Property and equipment, useful life	15 years				
Buildings and Components [Member]   Maximum [Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					
Property and equipment, useful life	39 years				
Data Processing Equipment, Furniture And Other Equipment [Member]   Minimum					
[Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					
Property and equipment, useful life	3 years				
Data Processing Equipment, Furniture And Other Equipment [Member]   Maximum [Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					
Property and equipment, useful life	7 years				
Computer Software [Member]   Minimum [Member]					
<b>Basis Of Presentation And Significant Accounting Policies [Line Items]</b>					
Property and equipment, useful life	3 years				
Computer Software [Member]   Maximum [Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					
Property and equipment, useful life	5 years				
Premium And Self-Funded Receivables [Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					
Allowance for doubtful accounts, premiums receivable	223.6	197.1			
Other Receivables [Member]					
Basis Of Presentation And Significant Accounting Policies [Line Items]					

Allowance for doubtful accounts, other receivables

\$ 79.0

\$ 115.0

Derivative Financial Instruments (Summary Of Outstanding Fair Value Hedges) (Details) (USD \$)	12 Months Ended	D 21	
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	
Derivative [Line Items]			
Outstanding Notional Amount	\$ 1,660.0	\$ 1,650.0	
Interest Rate Received 4.350% [Member]   Interest Rate Swaps [Member]   2013 [Member]   Expiration Date August 15, 2020 [Member]			
<b>Derivative [Line Items]</b>			
Outstanding Notional Amount	10.0	0	
Interest Rate Received	4.35%		
Expiration Date	Aug. 15, 2020		
Interest Rate Received 4.350% [Member]   Interest Rate Swaps [Member]   2012 [Member]   Expiration Date August 15, 2020 [Member]			
Derivative [Line Items]			
Outstanding Notional Amount	200.0	200.0	
Interest Rate Received	4.35%		
Expiration Date	Aug. 15, 2020		
Interest Rate Received 1.875% [Member]   Interest Rate Swaps [Member]   2012 [Member]   Expiration Date January 15, 2018 [Member]			
Derivative [Line Items]			
Outstanding Notional Amount	625.0	625.0	
Interest Rate Received	1.875%		
Expiration Date	Jan. 15, 2018		
Interest Rate Received 2.375% [Member]   Interest Rate Swaps [Member]   2012 [Member]   Expiration Date February 15, 2017 [Member]			
<b>Derivative [Line Items]</b>			
Outstanding Notional Amount	200.0	200.0	
Interest Rate Received	2.375%		
Expiration Date	Feb. 15, 2017		
Interest Rate Received 5.250% [Member]   Interest Rate Swaps [Member]   2011 [Member]   Expiration Date January 15, 2016 [Member]			
Derivative [Line Items]			
Outstanding Notional Amount	200.0	200.0	
Interest Rate Received	5.25%		
Expiration Date	Jan. 15, 2016		
Interest Rate Received 5.250% [Member]   Interest Rate Swaps [Member]   2010 [Member]   Expiration Date January 15, 2016 [Member]			
<b>Derivative [Line Items]</b>			
Outstanding Notional Amount	25.0	25.0	
Interest Rate Received	5.25%		
Expiration Date	Jan. 15, 2016		
Interest Rate Received 5.000% [Member]   Interest Rate Swaps [Member]   2006 [Member]   Expiration Date December 15, 2014 [Member]			

**Derivative [Line Items]** 

Outstanding Notional Amount200.0200.0Interest Rate Received5.00%Expiration DateDec. 15, 2014

Interest Rate Received 5.000% [Member] | Interest Rate Swaps [Member] | 2005 [Member] | Expiration Date December 15, 2014 [Member]

**Derivative [Line Items]** 

Outstanding Notional Amount \$ 200.0

Interest Rate Received 5.00%

Expiration Date Dec. 15, 2014

Accumulated Other Comprehensive Income (Loss) (Other Comprehensive	12 Months Ended				
Income (Loss) Reclassification Adjustments) (Parentheticals) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]					
Net holding loss investment securities arising during the period, tax benefit	\$ 223.6	\$ 5.4	\$ 38.2		
Reclassification adjustment for net realized gain on investment securities, tax	(60.6)	(104.0)	(49.6)		
Non-credit component of OTTI on investments, tax expense (benefit)	(0.9)	(2.4)	0.5		
Cash flow hedges, holding gain (loss), tax (expense) benefit	(1.6)	(0.1)	5.3		
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense (benefit)	(106.8)	(7.1)	81.7		
Foreign currency translation adjustment, tax (expense) benefit	(0.6)	(0.3)	(0.2)		
Net (loss) gain realized in other comprehensive income, tax benefit (expense)	\$ 53.1	\$ (108.5)	\$ 75.9		

**Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity**) (Details) (USD \$) In Millions, unless otherwise

Dec. 31, 2013 Dec. 31, 2012

specified

A	4.		•
Δm	Arti7	red (	Cost
	UI UI		COST

Amortized Cost		
Available For Sale Securities Amortized Cost	\$ 18,478.5	\$ 17,356.1
Fixed Maturity Securities [Member]		
Amortized Cost		
Due in one year or less, Amortized Cost	423.9	
Due after one year through five years, Amortized Cost	4,580.5	
Due after five years through ten years, Amortized Cost	5,105.4	
Due after ten years, Amortized Cost	4,424.4	
Mortgage-backed securities, Amortized Cost	2,748.4	
Available For Sale Securities Amortized Cost	17,282.6	16,459.1
Fair Value		
Due in one year or less, Estimated Fair Value	426.3	
Due after one year through five years, Estimated Fair Value	4,712.1	
Due after five years through ten years, Estimated Fair Value	<u>e</u> 5,196.6	
Due after ten years, Estimated Fair Value	4,397.6	
Mortgage-backed securities, Estimated Fair Value	2,755.5	
Available for sale securities Fair Value	\$ 17,488.1	

#### Leases (Tables)

#### **Leases, Operating [Abstract]**

Operating Leases, Future Minimum Payments Due

## 12 Months Ended Dec. 31, 2013

At December 31, 2013, future lease payments for operating leases with initial or remaining noncancelable terms of one year or more consist of the following:

2014	\$ 133.0
2015	126.7
2016	99.6
2017	97.3
2018	91.1
Thereafter	 221.6
Total minimum payments required	\$ 769.3

### Basis Of Presentation And Significant Accounting Policies

**Accounting Policies [Abstract]** 

Basis Of Presentation And Significant Accounting Policies 12 Months Ended
Dec. 31, 2013

#### **Basis of Presentation and Significant Accounting Policies**

**Basis of Presentation:** The accompanying consolidated financial statements include the accounts of WellPoint and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles, or GAAP. All significant intercompany accounts and transactions have been eliminated in consolidation.

Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in "Foreign currency translation adjustments" in our consolidated statements of shareholders' equity.

**Reclassifications:** Certain prior year amounts have been reclassified to conform to the current year presentation. The operating results for 1-800 CONTACTS are reported as discontinued operations as a result of the pending divestiture at December 31, 2013. These results were previously reported in the Commercial and Specialty Business segment. Additionally, the assets and liabilities of 1-800-CONTACTS are reported as held for sale in the consolidated balance sheets. Unless otherwise specified, all financial information presented in the accompanying consolidated financial statements and in the notes to consolidated financial statements relates only to our continuing operations, other than cash flows presented on the consolidated statements of cash flows. In accordance with Financial Accounting Standards Board, or FASB, guidance, we have elected to not separately disclose net cash provided by or used in operating, investing, and financing activities and the net effect of those cash flows on cash and cash equivalents for discontinued operations during the periods presented. Information related to discontinued operations is included in Note 3, "Business Acquisitions and Divestitures," and in some instances, where appropriate, is included as a separate disclosure within the individual footnotes.

*Use of Estimates:* The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

*Cash Equivalents:* All highly liquid investments with maturities of three months or less when purchased are classified as cash equivalents.

Investments: Certain FASB other-than-temporary impairment, or FASB OTTI, guidance applies to fixed maturity securities and provides guidance on the recognition and presentation of other-than-temporary impairments. In addition, this FASB OTTI guidance requires disclosures related to other-than-temporary impairments. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in our consolidated income statements. For impaired fixed maturity securities that we do not intend to sell or it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment is recognized in other-than-temporary impairment losses recognized in income in our consolidated income statements and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income, or AOCI.

The credit component of an other-than-temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other debt securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings, and estimates regarding timing and amount of recoveries associated with a default.

The unrealized gains or losses on our current and long-term equity securities classified as available-for-sale are included in accumulated other comprehensive income as a separate component of shareholders' equity, unless the decline in value is deemed to be other-than-temporary and we do not have the intent and ability to hold such equity securities until their full cost can be recovered, in which case such equity securities are written down to fair value and the loss is charged to other-than-temporary impairment losses recognized in income.

We maintain various rabbi trusts to account for the assets and liabilities under certain deferred compensation plans. Under these plans, the participants can defer certain types of compensation and elect to receive a return on the deferred amounts based on the changes in fair value of various investment options, primarily a variety of mutual funds. Rabbi trust assets are classified as trading, which are reported in other invested assets, current, in the consolidated balance sheets.

We use the equity method of accounting for investments in companies in which our ownership interest enables us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported with net investment income.

For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments are reported with net investment income.

Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for cash collateral initially equal to at least 102% of the value of the securities on loan and is thereafter maintained at a minimum of 100% of the market value of the securities loaned (calculated as the ratio of initial market value of cash collateral to current market value of the securities on loan). Accordingly, the market value of the securities on loan to each borrower is monitored daily and the borrower is required to deliver additional cash collateral if the market value of the securities on loan exceeds the initial market value of cash collateral delivered. The fair value of the collateral received at the time of the transaction amounted to \$969.7 and \$564.7 at December 31, 2013 and 2012, respectively. The value of the cash collateral delivered represented 102% of the market value of the securities on loan at December 31, 2013 and 2012. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the cash collateral as an asset, which is reported as "securities lending collateral" on our consolidated balance sheets and we record a corresponding liability for the obligation to return the cash collateral to the borrower, which is reported as "securities lending payable." The securities on loan are reported in the applicable investment category on the consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders' equity.

**Premium and Self-Funded Receivables:** Premium and self-funded receivables include the uncollected amounts from fully-insured and self-funded groups, and are reported net of an allowance for doubtful accounts of \$223.6 and \$197.1 at December 31, 2013 and 2012, respectively. The allowance for doubtful accounts is based on historical collection trends and our judgment regarding the ability to collect specific accounts.

*Other Receivables:* Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance, government programs, proceeds due from brokers on investment trades and other miscellaneous amounts due to us. These receivables are reported net of an allowance for uncollectible amounts of \$115.0 and \$79.0 at December 31, 2013 and 2012, respectively, which is based on historical collection trends and our judgment regarding the ability to collect specific amounts.

Income Taxes: We file a consolidated income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities based on enacted tax rates and laws. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact from amounts initially recorded for business combinations, if any. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.

We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.

**Property and Equipment:** Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from 15 to 39 years for buildings and improvements, three to seven years for data processing equipment, furniture and other equipment, and three to five years for computer software. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized.

Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the acquisition method of accounting and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to subscriber bases, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses, non-compete and other agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.

Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.

FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. We begin our annual tests with quantitative analyses. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used.

Fair value for purposes of the goodwill impairment test is calculated using a blend of a projected income and market valuation approach. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry's weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations are based on observed multiples of certain measures including membership, revenue, EBITDA (earnings before interest, taxes, depreciation and amortization) and net income as well as market capitalization analyses of WellPoint and other comparable companies. A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset's fair value. This determination is made at the reporting unit level and consists of two steps. First, the fair value of a reporting unit is determined and compared to its carrying amount. Second, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation on a business acquisition, at the impairment test date.

The fair value of indefinite-lived intangible assets is estimated and compared to the carrying value. We estimate the fair value of indefinite-lived intangible assets using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

**Derivative Financial Instruments:** We primarily invest in the following types of derivative financial instruments: interest rate swaps, forward contracts, put and call options, credit default swaps, embedded derivatives, warrants and swaptions. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is

limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.

We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.

All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, as well as the ineffective portion of the gain or loss, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.

From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in income immediately.

Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December 31, 2013, we believe there were no material concentrations of credit risk with any individual counterparty.

Certain of our derivative agreements contain credit support provisions that require us to post collateral if there are declines in the derivative fair value or our credit rating.

Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with current and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.

*Medical Claims Payable:* Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2) claims reported to us and processed through our systems but not yet paid.

Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in aggregate by employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities.

We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If our assumptions regarding cost trends and utilization are significantly different than actual results, our income statement and financial position could be impacted

in future periods.

Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December 31, 2013 or 2012.

**Reserves for Future Policy Benefits:** Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.

The current portion of reserves for future policy benefits relates to the portion of such reserves that we expect to pay within one year. We believe that our liabilities for future policy benefits, along with future premiums received are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.

Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves as well as liabilities for minimum medical loss ratio, or MLR, rebates. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with the customers and can vary from period to period based on the specific contractual requirements.

Effective beginning in 2011, we are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and related Health Care and Education Reconciliation Act of 2010, or collectively, Health Care Reform. If we do not meet or exceed the minimum MLR thresholds specified by Health Care Reform, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by applicable line of business (large group, small group and individual) and legal entity in accordance with regulations issued by the Department of Health and Human Services, or HHS. Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.

We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our GAAP basis consolidated financial statements may be reported as a reduction of premiums in accordance with HHS regulations. For example, certain federal and state income taxes and assessments recorded as income tax expense or general and administrative expense, as appropriate, in our consolidated GAAP financial statements are allowed to be included as a reduction of premium revenue in HHS' calculation of minimum MLR. In addition, profit amounts included in our payments to third party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.

Revenue Recognition: Premiums for fully-insured contracts are recognized as revenue over the period insurance coverage is provided, net of amounts recognized for minimum MLR rebates, if applicable. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue from retrospectively rated contracts where revenue is based on the estimated ultimate loss experience of the contract. Premium revenue includes an adjustment for retrospectively rated refunds based on an estimate of incurred claims. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state.

Administrative fees include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion of their claims experience. We charge these self-funded groups an administrative fee, which is based on the number of members in a group or the group's claim experience. In addition, administrative fees include amounts received for the administration of Medicare or certain other government programs. Under our self-funded arrangements, revenue is recognized as administrative services are performed. All benefit payments under these programs are excluded from benefit expense.

Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including stock options and restricted stock awards. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. Effective January 1, 2014, the employee stock purchase plan will allow for a purchase price per share which is 95% of the fair value of a share of common stock on the last trading day of the plan quarter. The employee stock purchase plan discount is not recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in the income statement based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as additional paid-in-capital and are reclassified from operating cash flows to financing cash flows in the consolidated statements of cash flows. Our share-based employee compensation plans and assumptions are described in Note 15, "Capital Stock."

Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for individual and Medicare customers, and for certain Local Group customers with a smaller employee base. Products for National Accounts and Local Group customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer and working with industry specialists from our in-house sales force. In the individual and small group markets we offer on-exchange products through state or federally facilitated marketplaces and off-exchange products. Federal premium subsidies are available only for certain on-exchange products. The cost of advertising and marketing for product promotion is expensed as incurred while advertising and marketing costs associated with corporate image is expensed when first aired. Total advertising and marketing expense was \$350.9, \$285.4 and \$287.8 for the years ended December 31, 2013, 2012 and 2011, respectively.

*Earnings per Share:* Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.

Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share includes the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.

New Accounting Pronouncements: In February 2013, the FASB issued Accounting Standards Update 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, or ASU 2013-02. ASU 2013-02 amends certain portions of Accounting Standards Codification Topic 220, Comprehensive Income, or ASC 220, to improve reporting by requiring the presentation, in one place, of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, cross-references to other disclosures that provide additional detail about those amounts is required. The adoption of ASU 2013-02 in the first quarter of 2013 did not have an impact on our consolidated financial position, results of operations or cash flows.

In July 2011, the FASB issued ASU No. 2011-06, Other Expenses (Topic 720): Fees Paid to the Federal Government by Health Insurers (a consensus of the FASB Emerging Issues Task Force), or ASU 2011-06. Health Care Reform imposes a mandatory annual fee on health insurers that write certain types of health insurance on U.S. risks for each calendar year beginning on or after January 1, 2014. The annual fee will be allocated to health insurers based on the ratio of the amount of an insurer's net premium revenues written during the preceding calendar year to the amount of health insurance for all U.S. health risk for those certain lines of business that is written during the preceding calendar year. ASU 2011-06 addresses how this fee should be recognized and classified in the income statements of health insurers and stipulates that the liability for the fee should be estimated and recorded in full once the insurer provides qualifying health insurance in the applicable calendar year in which the fee is payable, with a corresponding deferred cost that is amortized to expense using a straight-line method of allocation, unless another method better allocates the fee over the calendar year that it is payable. This ASU is effective for calendar years beginning after December 31, 2013, when the fee initially becomes effective. The total amount to be collected from allocations to health insurers in 2014 is \$8,000.0. Our portion of the 2014 fee is currently estimated to be at least \$900.0. This fee is non-deductible for income tax purposes. Accordingly, adoption of this guidance and the enactment of this fee could have a material impact on our financial

position, results of operations or cash flows in future periods.

There were no other new accounting pronouncements that were issued or became effective during the year ended December 31, 2013 that had, or are expected to have, a material impact on our financial position, results of operations or financial statement disclosures.

## Leases (Details) (USD \$) 12 Months Ended

In Millions, unless otherwise

specified Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

## **Leases, Operating [Abstract]**

 2014
 \$ 133.0

 2015
 126.7

 2016
 99.6

 2017
 97.3

 2018
 91.1

 Thereafter
 221.6

Total minimum payments required 769.3

<u>Lease expense</u> \$ 185.9 \$ 153.3 \$ 148.6

## **Investments (Major Categories Of Net**

## 12 Months Ended

**Investment Income) (Details)** 

(USD \$)

In Millions, unless otherwise Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011 specified

## **Investments [Abstract]**

Fixed maturity securities	\$ 638.9	\$ 671.2	\$ 692.4
Equity securities	45.9	38.4	34.0
Cash and cash equivalents	1.0	2.5	3.7
<u>Other</u>	19.8	16.2	2.4
<u>Investment income</u>	705.6	728.3	732.5
<u>Investment expense</u>	(46.5)	(42.2)	(28.8)
Net investment income	\$ 659.1	\$ 686.1	\$ 703.7

## Schedule II-Condensed Financial Information Of Registrant (Balance Sheets (Parenthetical)) (Details) (USD \$)

# In Millions, except Share data, unless otherwise specified

Fixed maturity securities investments, amortized cost	\$ 16,826.7	\$ 16,033.1
Equity securities investments, cost	1,168.5	869.9
Fixed maturity securities long-term investment, amortized cost	455.9	426.0
Equity securities long-term investments, cost	27.4	27.1
Preferred stock, par value	\$ 0	\$ 0
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	\$ 0.01	\$ 0.01
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	293,273,830	304,715,144
Common stock, shares outstanding	293,273,830	304,715,144
WellPoint, Inc. [Member]		
Fixed maturity securities investments, amortized cost	897.4	1,415.5
Equity securities investments, cost	52.6	26.7
Equity securities long-term investments, cost	\$ 6.7	\$ 6.8
Preferred stock, par value	\$ 0	\$ 0
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	\$ 0.01	\$ 0.01
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	293,273,830	304,715,144
Common stock, shares outstanding	293,273,830	304,715,144

Dec. 31, 2013 Dec. 31, 2012

## Debt (Tables)

## 12 Months Ended Dec. 31, 2013

## **Debt Disclosure [Abstract]**

The Carrying Value Of Long-Term Debt

The carrying value of long-term debt at December 31 consists of the following:

	2013	2012
Senior unsecured notes:		
6.000%, due 2014	\$ —	\$ 399.8
5.000%, due 2014	518.0	535.9
1.250%, due 2015	624.9	624.8
5.250%, due 2016	1,109.6	1,114.0
2.375%, due 2017	399.6	401.5
5.875%, due 2017	545.1	697.4
1.875%, due 2018	614.5	625.2
2.300%, due 2018	647.5	_
7.500%, due 2019		556.9
7.000%, due 2019	452.9	599.3
4.350%, due 2020	688.9	701.0
3.700%, due 2021	699.4	699.3
3.125%, due 2022	846.3	845.9
3.300%, due 2023	996.9	996.7
5.950%, due 2034	447.3	498.8
5.850%, due 2036	775.6	895.7
6.375%, due 2037	651.4	796.7
5.800%, due 2040	216.2	296.8
4.625%, due 2042	893.9	893.7
4.650%, due 2043	994.4	994.2
5.100%, due 2044	599.1	_
Senior convertible debentures:		
2.750%, due 2042	966.0	958.1
Surplus notes:		
9.000%, due 2027	24.9	25.0
Variable rate debt:		
Commercial paper program	379.2	570.9
Capital leases		0.3
Total long-term debt	14,091.6	14,727.9
Current portion of long-term debt	(518.0)	(557.1)
Long-term debt, less current portion	\$13,573.6	\$14,170.8

## Convertible Debenture Terms

The following table summarizes at December 31, 2013 the related balances, conversion rate and conversion price of the Debentures:

Outstanding principal amount	\$ 1,500.0
Unamortized debt discount	534.0
Net debt carrying amount	966.0
Equity component carrying amount	543.6
Conversion rate (shares of common stock per \$1,000 of principal amount)	13.2917
Effective conversion price (per \$1,000 of principal amount)	75 2345

#### **Statutory Information**

12 Months Ended Dec. 31, 2013

Statutory Information [Abstract]

**Statutory Information** 

#### **Statutory Information**

The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance regulatory authorities, or statutory, which vary in certain respects from GAAP. However, certain of our insurance and HMO subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care, or DMHC, and report their accounts in conformity with GAAP (these entities are collectively referred to as the "DMHC regulated entities"). Typical differences of GAAP reporting as compared to statutory reporting are the inclusion of unrealized gains or losses relating to fixed maturity securities in shareholders' equity, recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits. The National Association of Insurance Commissioners, or NAIC, developed a codified version of the statutory accounting principles, designed to foster more consistency among the states for accounting guidelines and reporting.

Our insurance and HMO subsidiaries that are subject to statutory reporting are domiciled in various jurisdictions. These subsidiaries prepare statutory financial statements in accordance with accounting practices prescribed or permitted by the respective jurisdictions' insurance regulators. Prescribed statutory accounting practices are set forth in a variety of publications of the NAIC as well as state laws, regulations and general administrative rules.

Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary's domiciliary jurisdiction is limited by formula. Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC.

Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital requirements. Risk-based capital is a method developed by the NAIC to determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its size and risk profile. The formula for determining the amount of risk-based capital specifies various factors, weighted based on the perceived degree of risk, which are applied to certain financial balances and financial activity. Below minimum risk-based capital requirements are classified within certain levels, each of which requires specified corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December 31, 2013 and 2012, all of our regulated subsidiaries exceeded the minimum risk-based capital requirements and/or capital and solvency requirements of their applicable governmental regulator. The statutory risk-based capital necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately \$3,500.0 and \$3,400.0 as of December 31, 2013 and 2012, respectively. The tangible net equity required for the DMHC regulated entities was approximately \$450.0 as of December 31, 2013 and 2012.

Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC regulated entities, was \$10,003.0 and \$9,967.7 at December 31, 2013 and 2012, respectively. Statutory-basis net income of our insurance and HMO subsidiaries and net income of our other regulated subsidiaries, excluding the DMHC regulated entities, was \$2,594.8, \$2,800.0 and \$2,402.5 for 2013, 2012 and 2011, respectively. GAAP equity of the DMHC regulated entities was \$1,449.2 and \$1,312.5 at December 31, 2013 and 2012, respectively. GAAP net income of the DMHC regulated entities was \$487.7, \$469.7 and \$524.3 for the years ended December 31, 2013, 2012 and 2011, respectively.

#### **Related Party Transactions**

12 Months Ended Dec. 31, 2013

Related Party Transactions
[Abstract]

**Related Party Transactions** 

#### **Related Party Transactions**

WellPoint Foundation, Inc., or the Foundation, is an Indiana non-profit organization exempt from federal taxation under Section 501(c)(3) of the Internal Revenue Code. The Foundation was formed to conduct, support and assist charitable, health-related, educational, and other community-based programs and projects. The officers and directors of the Foundation are also our officers. These officers and directors receive no compensation from the Foundation for the management services performed for the Foundation but may be reimbursed by the Foundation for any cash expenditures incurred on behalf of the Foundation. During the years ended December 31, 2013, 2012 and 2011, we received \$0.7, \$0.6 and \$0.6, respectively, from the Foundation for administrative services provided by our associates. We contributed \$10.0 to the Foundation during the year ended December 31, 2013. We made no contributions to the Foundation during the years ended December 31, 2012 and 2011. The Foundation is not a subsidiary of ours and the financial results of the Foundation are not consolidated with our financial statements. We have no current legal obligations for future commitments to the Foundation.

Debt (Convertible Debenture
Terms) (Details) (USD \$)

In Millions, except Per Share
data, unless otherwise
specified

Dec. 31, 2013

## **Debt Disclosure [Abstract]**

Outstanding principal amount	\$ 1,500.0
<u>Unamortized debt discount</u>	534.0
Net debt carrying amount	966.0
Equity Component carrying amount	\$ 543.6
Conversion rate (shares of common stock per \$1,000 principal)	13.2917
Effective conversion price (per \$1,000 of principal)	\$ 75.2345

## Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Assets and Liabilities Held for Sale) (Details) (USD \$) In Millions, unless otherwise specified

## Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

Assets			
Cash and cash equivalents	\$ 4.8	\$ 9.3	\$0
1-800 Contacts [Member]			
Assets			
Cash and cash equivalents	4.8	9.3	
Property and equipment	27.6	21.0	
Goodwill	409.9	620.7	
Other intangibles	415.4	437.3	
Other assets	49.2	9.7	
<u>Total assets</u>	906.9	1,098.0	
<u>Liabilities</u>			
Accounts payable and other accrued expenses	34.2	33.8	
Deferred income taxes	142.5	158.1	
Other liabilities	4.7	15.2	
Total liabilities	\$ 181.4	\$ 207.1	

### **Capital Stock (Tables)**

## 12 Months Ended Dec. 31, 2013

### **Capital [Abstract]**

**Summary Of Stock Option Activity** 

A summary of stock option activity for the year ended December 31, 2013 is as follows:

	Number of Shares	1	Veighted- Average tion Price per Share	Weighted- Average Remaining Contractual Life (Years)	I	ggregate ntrinsic Value
Outstanding at January 1, 2013	17.8	\$	64.67			
Granted	2.0		62.55			
Exercised	(8.4)		62.34			
Forfeited or expired	(1.4)		70.77			
Outstanding at December 31, 2013	10.0		65.38	3.3	\$	270.9
Exercisable at December 31, 2013	7.6		66.04	2.6	\$	199.9

Nonvested Restricted Stock Activity Including Restricted Stock Units A summary of the status of nonvested restricted stock activity, including restricted stock units, for the year ended December 31, 2013 is as follows:

	Restricted Stock Shares and Units	Ave Gran Fair	ghted- erage it Date Value Share
Nonvested at January 1, 2013	2.6	\$	63.87
Granted	2.7		63.06
Vested	(0.6)		59.95
Forfeited	(0.5)		64.84
Nonvested at December 31, 2013	4.2		63.83

Fair Values Of Options Granted During
The Period Estimated Using WeightedAverage Assumptions

The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December 31:

	2013	2012	2011
Risk-free interest rate	1.25%	1.41%	2.84%
Volatility factor	35.00%	34.00%	34.00%
Dividend yield (annual)	2.40%	1.60%	1.50%
Weighted-average expected life (years)	4.0	4.1	4.0

Schedule Of Weighted-Average Fair Values Determined For The Periods

The following weighted-average fair values were determined for the years ending December 31:

	2013	2012	2011
Options granted during the year	\$ 14.64	\$ 16.50	\$ 17.84
Restricted stock and stock awards granted during the year	63.06	65.91	66.16

#### Cash Dividend Activity

A summary of the cash dividend activity for the years ended December 31, 2013 and 2012 is as follows:

	otal
11 11 17 17 17 17 17 17 17 17 17 17 17 1	
May 15 2013 June 10 2013 June 25 2013 0 2750 1	113.4
Whay 13, 2013 Julie 10, 2013 Julie 23, 2013 0.3730	112.7
July 23, 2013 September 10, September 25, 2013 2013 0.3750	111.4
October 22, 2013 December 23,	

#### 2013 0.3750 110.5 December 9, 2013 Year Ended December 31, 2012 January 24, 2012 March 9, 2012 March 23, 2012 \$ \$ 95.8 0.2875 May 16, 2012 June 8, 2012 June 25, 2012 0.2875 93.5 July 24, 2012 September 10, September 25, 2012 90.7 2012 0.2875November 6, 2012 December 21, December 7, 2012 2012 87.1 0.2875

### **Share Repurchases**

A summary of common stock repurchases for the period January 1, 2014 through February 7, 2014 (subsequent to December 31, 2013) and for the years ended December 31, 2013 and 2012 is as follows:

	t!	January 1, 2014 Years End through February 7,				
		2014		2013		2012
Shares repurchased		5.4		20.7		39.7
Average price per share	\$	84.96	\$	78.08	\$	62.96
Aggregate cost	\$	457.6	\$	1,620.1	\$	2,496.8
Authorization remaining at the end of each period	\$	2,633.4	\$	3,691.0	\$	1,836.9

## Selected Quarterly Financial Data

12 Months Ended Dec. 31, 2013

## **Selected Quarterly Financial Information** [Abstract]

Selected Quarterly Financial Data

### **Selected Quarterly Financial Data (Unaudited)**

Selected quarterly financial data is as follows:

	For the Quarter Ended										
	Marc	h 31		ne 30		ptember 30		cember 31			
2013						-					
Total revenues	\$17,5	76.0	\$1 <sup>′</sup>	7,690.3	\$	17,855.5	\$	17,901.7			
Income from continuing operations											
before income taxes	1,2	82.5		1,208.1		879.7		469.9			
Income from continuing operations	8	72.3		799.3		653.8		308.9			
Income (loss) from discontinued operations		12.9		0.8		2.4		(160.7)			
Net income	8	85.2		800.1		656.2		148.2			
Basic net income per share - continuing operations		2.88	\$	2.67	\$	2.20	\$	1.05			
Basic net income (loss) per share - discontinued operations		0.04				0.01		(0.55)			
Basic net income per share		2.92		2.67		2.21		0.50			
busic net meome per snare		2.72		2.07		2.21		0.50			
Dileta I and in a constant											
Diluted net income per share - continuing operations	\$	2.85	\$	2.64	\$	2.15	\$	1.02			
Diluted net income (loss) per share -	Ψ	2.03	Ψ	2.01	Ψ	2.13	Ψ	1.02			
discontinued operations		0.04		_		0.01		(0.53)			
Diluted net income per share		2.89		2.64		2.16		0.49			
2012											
Total revenues	\$15,4	15.2	\$1:	5,396.3	\$	15,247.4	\$	15,438.3			
Income from continuing operations before income taxes	1,3	09.8		1,048.7		1,019.6		480.2			
Income from continuing operations	8.	56.5		643.6		687.5		463.4			
Income from discontinued operations		_		_		3.7		0.8			
Net income	8	56.5		643.6		691.2		464.2			
Basic net income per share - continuing operations		2.56	\$	1.96	\$	2.16	\$	1.52			
Basic net income per share - discontinued operations		_		_		0.01					
Basic net income per share		2.56		1.96		2.17		1.52			
Diluted net income per share - continuing operations	\$	2.53	\$	1.94	\$	2.14	\$	1.51			
Diluted net income per share -	Ψ .		Ψ'	2.07	Ψ		Ψ	1.01			
discontinued operations		_		_		0.01		_			
Diluted net income per share		2.53		1.94		2.15		1.51			

## Schedule II-Condensed Financial Information Of Registrant

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

<u>Schedule II-Condensed Financial</u> <u>Information Of Registrant</u>

## 12 Months Ended

Dec. 31, 2013

## WellPoint, Inc. (Parent Company Only) Balance Sheets

(In millions, except share data)	Dec	cember 31, 2013	December 31, 2012		
Assets					
Current assets:					
Cash and cash equivalents	\$	1,174.5	\$	588.1	
Investments available-for-sale, at fair value:					
Fixed maturity securities (amortized cost of \$897.4 and \$1,415.5)		900.4		1,425.9	
Equity securities (cost of \$52.6 and \$26.7)		89.6		15.0	
Other invested assets, current		1.9		1.6	
Other receivables		35.6		37.7	
Income taxes receivable		154.4		227.0	
Net due from subsidiaries		893.4		_	
Securities lending collateral		46.2		29.1	
Deferred tax assets, net		11.8		7.9	
Other current assets		183.1		145.7	
Total current assets		3,490.9		2,478.0	
Long-term investments available-for-sale, at fair value:					
Equity securities (cost of \$6.7 and \$6.8)		6.7		6.8	
Other invested assets, long-term		615.7		596.4	
Property and equipment, net		148.3		110.2	
Deferred tax assets, net		2.9		23.8	
Investments in subsidiaries		35,516.2		35,462.2	
Other noncurrent assets		152.3		218.9	
Total assets	\$	39,933.0	\$	38,896.3	
Liabilities and shareholders' equity					
Liabilities					
Current liabilities:					
Accounts payable and accrued expenses	\$	592.1	\$	402.1	
Security trades pending payable		28.9		17.7	
Securities lending payable		46.2		29.1	
Net due to subsidiaries		_		89.7	
Current portion of long-term debt		518.0		_	
Other current liabilities		213.4		214.6	
Total current liabilities		1,398.6	-	753.2	
Long-term debt, less current portion		13,548.6		14,145.9	
Other noncurrent liabilities		220.6		194.5	
Total liabilities		15,167.8		15,093.6	
Commitments and contingencies—Note 5	_	10,107.0	_	10,070.0	
Shareholders' equity					
Preferred stock, without par value, shares authorized—100,000,000;					
shares issued and outstanding—none		_		_	
Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144		2.9		3.0	
Additional paid-in capital		10,765.2		10,853.5	
Retained earnings		13,813.9		12,647.1	
Accumulated other comprehensive income		183.2		299.1	

Total shareholders' equity	24,765.2	23,802.7
Total liabilities and shareholders' equity	\$ 39,933.0	\$ 38,896.3

## WellPoint, Inc. (Parent Company Only) Statements of Income

	Years ended December 31						
(In millions)		2013		2012		2011	
Revenues							
Net investment income	\$	61.2	\$	95.3	\$	116.6	
Net realized losses on investments		(83.2)		(28.5)		(17.9)	
Other-than-temporary impairment losses on investments:							
Total other-than-temporary impairment losses on investments		(51.6)		(15.3)		(18.3)	
Portion of other-than-temporary impairment losses recognized in other comprehensive income		0.2		1.3		0.3	
Other-than-temporary impairment losses recognized in income		(51.4)		(14.0)		(18.0)	
Other revenue		4.4		3.5		3.1	
Total revenues		(69.0)		56.3		83.8	
Expenses							
General and administrative expense		196.6		211.9		53.4	
Interest expense		598.4		507.0		407.3	
Loss on extinguishment of debt		145.3				_	
Total expenses		940.3		718.9		460.7	
Loss before income tax credits and equity in net income of subsidiaries		(1,009.3)		(662.6)		(376.9)	
Income tax credits		(369.7)		(172.1)		(207.0)	
Equity in net income of subsidiaries		3,129.3		3,146.0		2,816.6	
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7	

## WellPoint, Inc. (Parent Company Only) Statements of Comprehensive Income

(in millions)	Years ended December 31								
		2013		2012		2011			
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7			
Other comprehensive (loss) income, net of tax:									
Change in net unrealized gains/losses on investments		(294.7)		189.9		20.6			
Change in non-credit component of other-than-temporary impairment losses on investments		1.7		4.5		(0.7)			
Change in net unrealized gains/losses on cash flow hedges		3.0		0.1		(10.0)			
Change in net periodic pension and postretirement costs		172.7		(10.9)		(119.8)			
Foreign currency translation adjustments		1.4		0.6		0.2			
Other comprehensive (loss) income		(115.9)		184.2		(109.7)			
Total comprehensive income	\$	2,373.8	\$	2,839.7	\$	2,537.0			

## WellPoint, Inc. (Parent Company Only) Statements of Cash Flows

(In millions)	Years ended December 31								
		2013		2012		2011			
Operating activities									
Net income	\$	2,489.7	\$	2,655.5	\$	2,646.7			
Adjustments to reconcile net income to net cash provided by operating activities:									
(Undistributed) distributed earnings of subsidiaries		(78.5)		(432.0)		399.3			

Net realized losses on investments	83.2	28.5	17.9
Other-than-temporary impairment losses recognized in income	51.4	14.0	18.0
Loss on extinguishment of debt	145.3	_	_
Loss on disposal of assets	3.6	_	_
Deferred income taxes	(4.5)	49.2	95.3
Amortization, net of accretion	25.2	23.2	3.1
Depreciation	45.7	13.1	0.3
Share-based compensation	146.0	146.5	134.8
Excess tax benefits from share-based compensation	(30.1)	(28.8)	(42.2)
Changes in operating assets and liabilities, net of effect of business combinations:			
Receivables, net	3.5	9.6	13.5
Other invested assets, current	(0.3)	0.2	4.6
Other assets	42.3	(31.7)	(52.0)
Amounts due (from) to subsidiaries	(983.1)	754.7	(497.2)
Accounts payable and accrued expenses	111.8	(34.5)	1.5
Other liabilities	(18.6)	8.9	(0.9)
Income taxes	83.9	(204.0)	35.3
Net cash provided by operating activities	2,116.5	2,972.4	2,778.0
nvesting activities			
Purchases of investments	(1,964.3)	(5,383.2)	(2,681.7)
Proceeds from sales, maturities, calls and redemptions of nvestments	2,443.3	5,554.5	3,689.6
Settlement of non-hedging derivatives	(109.8)	(59.8)	(96.6)
Capitalization of subsidiaries	(121.2)	(6,085.1)	(832.1)
Changes in securities lending collateral	(17.0)	73.8	17.3
(Purchases) sales of property and equipment, net	(87.4)	(117.1)	2.3
Other, net	(18.9)	(114.4)	(49.6)
Net cash provided by (used in) investing activities	124.7	(6,131.3)	49.2
Financing activities			
Net (repayments of) proceeds from commercial paper borrowings	(191.7)	(229.0)	463.7
Proceeds from long-term borrowings	1,250.0	6,468.9	1,097.4
Repayments of long-term borrowings	(1,245.0)	(800.0)	(700.0)
Changes in securities lending payable	17.1	(72.7)	(17.3)
Changes in bank overdrafts	71.8	30.5	(66.9)
Premiums paid on equity options	(25.8)	_	
Repurchase and retirement of common stock	(1,620.1)	(2,496.8)	(3,039.8)
Cash dividends	(465.9)	(380.9)	(369.8)
Proceeds from issuance of common stock under employee stock plans	524.7	110.8	245.0
Excess tax benefits from share-based compensation	30.1	28.8	42.2
Net cash (used in) provided by financing activities	(1,654.8)	2,659.6	(2,345.5)
Change in cash and cash equivalents	586.4	(499.3)	481.7
Cash and cash equivalents at beginning of year	588.1	1,087.4	605.7
Cash and cash equivalents at end of year	\$ 1,174.5	\$ 588.1	\$ 1,087.4

#### 1. Basis of Presentation and Significant Accounting Policies

In the parent company only financial statements of WellPoint, Inc., or WellPoint, WellPoint's investment in subsidiaries is stated at cost plus equity in undistributed earnings of the subsidiaries. WellPoint's share of net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.

Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of WellPoint.

Certain prior year amounts have been reclassified to conform to the current year presentation.

WellPoint's parent company only financial statements should be read in conjunction with WellPoint's audited consolidated financial statements and the accompanying notes included in this Form 10-K.

#### 2. Subsidiary Transactions

#### Dividends from Subsidiaries

WellPoint received cash dividends from subsidiaries of \$3,046.5, \$2,935.1 and \$2,915.9 during 2013, 2012 and 2011, respectively.

#### Dividends to Subsidiaries

Certain subsidiaries of WellPoint own shares of WellPoint common stock. WellPoint paid cash dividends to subsidiaries related to these shares of common stock in the amount of \$17.9, \$13.8 and \$12.0 during 2013, 2012 and 2011, respectively.

#### Investments in Subsidiaries

Capital contributions to subsidiaries were \$121.2, \$6,085.1 and \$832.1 during 2013, 2012 and 2011, respectively.

#### Amounts Due to and From Subsidiaries

At December 31, 2013 and 2012, WellPoint reported \$893.4 due from subsidiaries and \$89.7 payable to subsidiaries, respectively. The amounts due to or from subsidiaries primarily include amounts for allocated administrative expenses or cash held overnight at the parent level resulting from daily cash management activities. These items are routinely settled, and as such, are classified as current assets or liabilities.

#### 3. Derivative Financial Instruments

The information regarding derivative financial instruments contained in Note 6, "Derivative Financial Instruments," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### 4. Long-Term Debt

The information regarding long-term debt contained in Note 13, "Debt," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### 5. Commitments and Contingencies

The information regarding commitments and contingencies contained in Note 14, "Commitments and Contingencies," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### 6. Capital Stock

The information regarding capital stock contained in Note 15, "Capital Stock," of the Notes to Consolidated Financial Statements of WellPoint and its subsidiaries is incorporated herein by reference.

#### **Organization**

12 Months Ended Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

#### Organization

References to the terms "we", "our", "us", "WellPoint" or the "Company" used throughout these Notes to Consolidated Financial Statements refer to WellPoint, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.

We are one of the largest health benefits companies in terms of medical membership in the United States, serving 35.7 medical members through our affiliated health plans and approximately 67.8 individuals through our subsidiaries as of December 31, 2013. We offer a broad spectrum of networkbased managed care health benefit plans to large and small employer, individual, Medicaid and senior markets. Our managed care plans include: preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; point-of-service, or POS, plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance. We also provide services to the Federal Government in connection with the Federal Employee Program, or FEP, and various Medicare programs. We also sold contact lenses, eyeglasses and other ocular products through our 1-800 CONTACTS, Inc., or 1-800 CONTACTS, business, which was divested on January 31, 2014.

We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for: Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as BCBS in 10 New York City metropolitan and surrounding counties, and as Blue Cross or BCBS in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Georgia, and Empire Blue Cross Blue Shield, or Empire Blue Cross (in our New York service areas). We also conduct business through our AMERIGROUP Corporation, or Amerigroup, subsidiary, in Florida, Georgia, Kansas, Louisiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas and Washington. Amerigroup also provided services in the state of Ohio through June 30, 2013 and in the state of New Mexico through December 31, 2013. We also serve customers throughout the country as HealthLink, UniCare, and in certain Arizona, California, Nevada, New York and Virginia markets through our CareMore Health Group, Inc., or CareMore, subsidiary. We are licensed to conduct insurance operations in all 50 states through our subsidiaries.

### Basis Of Presentation And Significant Accounting Policies (Policy)

## 12 Months Ended

Dec. 31, 2013

#### **Accounting Policies [Abstract]**

**Basis Of Presentation** 

**Basis of Presentation:** The accompanying consolidated financial statements include the accounts of WellPoint and its subsidiaries and have been prepared in conformity with U.S. generally accepted accounting principles, or GAAP. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency

Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in "Foreign currency translation adjustments" in our consolidated statements of shareholders' equity.

Reclassifications

Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation. The operating results for 1-800 CONTACTS are reported as discontinued operations as a result of the pending divestiture at December 31, 2013. These results were previously reported in the Commercial and Specialty Business segment. Additionally, the assets and liabilities of 1-800-CONTACTS are reported as held for sale in the consolidated balance sheets. Unless otherwise specified, all financial information presented in the accompanying consolidated financial statements and in the notes to consolidated financial statements relates only to our continuing operations, other than cash flows presented on the consolidated statements of cash flows. In accordance with Financial Accounting Standards Board, or FASB, guidance, we have elected to not separately disclose net cash provided by or used in operating, investing, and financing activities and the net effect of those cash flows on cash and cash equivalents for discontinued operations during the periods presented. Information related to discontinued operations is included in Note 3, "Business Acquisitions and Divestitures," and in some instances, where appropriate, is included as a separate disclosure within the individual footnotes.

**Use Of Estimates** 

*Use of Estimates:* The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash Equivalents

*Cash Equivalents:* All highly liquid investments with maturities of three months or less when purchased are classified as cash equivalents.

Investments

Investments: Certain FASB other-than-temporary impairment, or FASB OTTI, guidance applies to fixed maturity securities and provides guidance on the recognition and presentation of other-than-temporary impairments. In addition, this FASB OTTI guidance requires disclosures related to other-than-temporary impairments. If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in our consolidated income statements. For impaired fixed maturity securities that we do not intend to sell or it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment is recognized in other-than-temporary impairment losses recognized in income in our consolidated income statements and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income, or AOCI.

The credit component of an other-than-temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of acquisition. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other debt securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings, and estimates regarding timing and amount of recoveries associated with a default.

The unrealized gains or losses on our current and long-term equity securities classified as available-

for-sale are included in accumulated other comprehensive income as a separate component of shareholders' equity, unless the decline in value is deemed to be other-than-temporary and we do not have the intent and ability to hold such equity securities until their full cost can be recovered, in which case such equity securities are written down to fair value and the loss is charged to other-than-temporary impairment losses recognized in income.

We maintain various rabbi trusts to account for the assets and liabilities under certain deferred compensation plans. Under these plans, the participants can defer certain types of compensation and elect to receive a return on the deferred amounts based on the changes in fair value of various investment options, primarily a variety of mutual funds. Rabbi trust assets are classified as trading, which are reported in other invested assets, current, in the consolidated balance sheets.

We use the equity method of accounting for investments in companies in which our ownership interest enables us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported with net investment income.

For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments are reported with net investment income.

Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for cash collateral initially equal to at least 102% of the value of the securities on loan and is thereafter maintained at a minimum of 100% of the market value of the securities loaned (calculated as the ratio of initial market value of cash collateral to current market value of the securities on loan). Accordingly, the market value of the securities on loan to each borrower is monitored daily and the borrower is required to deliver additional cash collateral if the market value of the securities on loan exceeds the initial market value of cash collateral delivered. The fair value of the collateral received at the time of the transaction amounted to \$969.7 and \$564.7 at December 31, 2013 and 2012, respectively. The value of the cash collateral delivered represented 102% of the market value of the securities on loan at December 31, 2013 and 2012. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of liabilities, we recognize the cash collateral as an asset, which is reported as "securities lending collateral" on our consolidated balance sheets and we record a corresponding liability for the obligation to return the cash collateral to the borrower, which is reported as "securities lending payable." The securities on loan are reported in the applicable investment category on the consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive income as a separate component of shareholders' equity.

<u>Premium And Self-Funded</u> <u>Receivables</u> **Premium and Self-Funded Receivables:** Premium and self-funded receivables include the uncollected amounts from fully-insured and self-funded groups, and are reported net of an allowance for doubtful accounts of \$223.6 and \$197.1 at December 31, 2013 and 2012, respectively. The allowance for doubtful accounts is based on historical collection trends and our judgment regarding the ability to collect specific accounts.

Other Receivables

Other Receivables: Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance, government programs, proceeds due from brokers on investment trades and other miscellaneous amounts due to us. These receivables are reported net of an allowance for uncollectible amounts of \$115.0 and \$79.0 at December 31, 2013 and 2012, respectively, which is based on historical collection trends and our judgment regarding the ability to collect specific amounts.

**Income Taxes** 

Income Taxes: We file a consolidated income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities based on enacted tax rates and laws. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact from amounts initially recorded for business combinations, if any. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.

We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial statements.

#### **Property And Equipment**

**Property and Equipment:** Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-line method over estimated useful lives ranging from 15 to 39 years for buildings and improvements, three to seven years for data processing equipment, furniture and other equipment, and three to five years for computer software. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized.

## Goodwill And Other Intangible Assets

Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the acquisition method of accounting and it also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to subscriber bases, provider and hospital networks, Blue Cross and Blue Shield and other trademarks, licenses, non-compete and other agreements. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.

Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our business or other triggering events occur. Goodwill and other intangible assets are allocated to reporting units for purposes of the annual goodwill impairment test. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.

FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-lived intangible asset impairment analysis. Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors and proceed directly to performing quantitative analyses. We begin our annual tests with quantitative analyses. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and other intangible assets with indefinite lives. Estimated fair values developed based on our assumptions and judgments might be significantly different if other reasonable assumptions and estimates were to be used.

Fair value for purposes of the goodwill impairment test is calculated using a blend of a projected income and market valuation approach. The projected income approach is developed using assumptions about future revenue, expenses and net income derived from our internal planning process. Our assumed discount rate is based on our industry's weighted-average cost of capital and reflects volatility associated with the cost of equity capital. Market valuations are based on observed multiples of certain measures including membership, revenue, EBITDA (earnings before interest, taxes, depreciation and amortization) and net income as well as market capitalization analyses of WellPoint and other comparable companies. A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset's fair value. This determination is made at the reporting unit level and consists of two steps. First, the fair value of a reporting unit is determined and compared to its carrying amount. Second, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized for any excess of the carrying amount of the reporting unit's goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation on a business acquisition, at the impairment test date.

The fair value of indefinite-lived intangible assets is estimated and compared to the carrying value. We estimate the fair value of indefinite-lived intangible assets using a projected income approach. We recognize an impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.

#### **Derivative Financial Instruments**

**Derivative Financial Instruments:** We primarily invest in the following types of derivative financial instruments: interest rate swaps, forward contracts, put and call options, credit default swaps, embedded derivatives, warrants and swaptions. Derivatives embedded within non-derivative instruments, such as options embedded in convertible fixed maturity securities, are bifurcated from the host instrument when

the embedded derivative is not clearly and closely related to the host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for speculative purposes.

We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific liabilities.

All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if any, as well as the ineffective portion of the gain or loss, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a net basis in investing activity in our consolidated statements of cash flow.

From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as hedges and, accordingly, the changes in fair value of these derivatives are recognized in income immediately.

Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December 31, 2013, we believe there were no material concentrations of credit risk with any individual counterparty.

Certain of our derivative agreements contain credit support provisions that require us to post collateral if there are declines in the derivative fair value or our credit rating.

#### **Retirement Benefits**

Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-end measurements of plan assets and benefit obligations. Prepaid pension benefits represent prepaid costs related to defined benefit pension plans and are reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension and other postretirement benefits are reported with current and noncurrent liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.

#### Medical Claims Payable

*Medical Claims Payable:* Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not reported, as well as claims reported to us but not yet processed through our systems; and (2) claims reported to us and processed through our systems but not yet paid.

Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in aggregate by employing actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a detailed actuarial process that entails using both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities.

We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust the claims liability and benefit expense based on subsequent paid claims activity. If our assumptions regarding cost trends and utilization are significantly different than actual results, our income statement and financial position could be impacted in

future periods.

Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December 31, 2013 or 2012.

## Reserves For Future Policy Benefits

**Reserves for Future Policy Benefits:** Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years. Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.

The current portion of reserves for future policy benefits relates to the portion of such reserves that we expect to pay within one year. We believe that our liabilities for future policy benefits, along with future premiums received are adequate to satisfy our ultimate benefit liability; however, these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated financial statements.

#### Other Policyholder Liabilities

Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and certain case-specific reserves as well as liabilities for minimum medical loss ratio, or MLR, rebates. Rate stabilization reserves represent accumulated premiums that exceed what customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with the customers and can vary from period to period based on the specific contractual requirements.

Effective beginning in 2011, we are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and related Health Care and Education Reconciliation Act of 2010, or collectively, Health Care Reform. If we do not meet or exceed the minimum MLR thresholds specified by Health Care Reform, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by applicable line of business (large group, small group and individual) and legal entity in accordance with regulations issued by the Department of Health and Human Services, or HHS. Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.

We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our GAAP basis consolidated financial statements may be reported as a reduction of premiums in accordance with HHS regulations. For example, certain federal and state income taxes and assessments recorded as income tax expense or general and administrative expense, as appropriate, in our consolidated GAAP financial statements are allowed to be included as a reduction of premium revenue in HHS' calculation of minimum MLR. In addition, profit amounts included in our payments to third party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements while HHS does not allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.

#### Revenue Recognition

Revenue Recognition: Premiums for fully-insured contracts are recognized as revenue over the period insurance coverage is provided, net of amounts recognized for minimum MLR rebates, if applicable. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include revenue from retrospectively rated contracts where revenue is based on the estimated ultimate loss experience of the contract. Premium revenue includes an adjustment for retrospectively rated refunds based on an estimate of incurred claims. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state.

Administrative fees include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a portion of their claims experience. We charge these self-funded groups an administrative fee, which is based on the number of members in a group or the group's claim experience. In addition, administrative fees include amounts received for the administration of Medicare or certain other government programs. Under our self-funded arrangements, revenue is recognized as administrative services are performed. All benefit payments under these programs are

excluded from benefit expense.

#### **Share-Based Compensation**

Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including stock options and restricted stock awards. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. Effective January 1, 2014, the employee stock purchase plan will allow for a purchase price per share which is 95% of the fair value of a share of common stock on the last trading day of the plan quarter. The employee stock purchase plan discount is not recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in the income statement based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as additional paid-incapital and are reclassified from operating cash flows to financing cash flows in the consolidated statements of cash flows. Our share-based employee compensation plans and assumptions are described in Note 15, "Capital Stock."

#### **Advertising Costs**

Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for individual and Medicare customers, and for certain Local Group customers with a smaller employee base. Products for National Accounts and Local Group customers with a larger employee base are generally sold through independent brokers or consultants retained by the customer and working with industry specialists from our in-house sales force. In the individual and small group markets we offer on-exchange products through state or federally facilitated marketplaces and off-exchange products. Federal premium subsidies are available only for certain on-exchange products. The cost of advertising and marketing for product promotion is expensed as incurred while advertising and marketing costs associated with corporate image is expensed when first aired. Total advertising and marketing expense was \$350.9, \$285.4 and \$287.8 for the years ended December 31, 2013, 2012 and 2011, respectively.

#### **Earnings Per Share**

*Earnings per Share:* Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares outstanding for the period.

Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share includes the dilutive effect of stock options, restricted stock and convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.

New Accounting Pronouncements

New Accounting Pronouncements: In February 2013, the FASB issued Accounting Standards Update 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, or ASU 2013-02. ASU 2013-02 amends certain portions of Accounting Standards Codification Topic 220, Comprehensive Income, or ASC 220, to improve reporting by requiring the presentation, in one place, of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, cross-references to other disclosures that provide additional detail about those amounts is required. The adoption of ASU 2013-02 in the first quarter of 2013 did not have an impact on our consolidated financial position, results of operations or cash flows.

In July 2011, the FASB issued ASU No. 2011-06, Other Expenses (Topic 720): Fees Paid to the Federal Government by Health Insurers (a consensus of the FASB Emerging Issues Task Force), or ASU 2011-06. Health Care Reform imposes a mandatory annual fee on health insurers that write certain types of health insurance on U.S. risks for each calendar year beginning on or after January 1, 2014. The annual fee will be allocated to health insurers based on the ratio of the amount of an insurer's net premium revenues written during the preceding calendar year to the amount of health insurance for all U.S. health risk for those certain lines of business that is written during the preceding calendar year. ASU 2011-06 addresses how this fee should be recognized and classified in the income statements of health insurers and stipulates that the liability for the fee should be estimated and recorded in full once the insurer provides qualifying health insurance in the applicable calendar year in which the fee is payable, with a corresponding deferred cost that is amortized to expense using a straight-line method of allocation, unless another method better allocates the fee over the calendar year that it is payable. This ASU is effective for calendar years beginning after December 31, 2013, when the fee initially becomes effective. The total amount to be collected from allocations to health insurers in 2014 is \$8,000.0. Our portion of the 2014 fee is currently

estimated to be at least \$900.0. This fee is non-deductible for income tax purposes. Accordingly, adoption of this guidance and the enactment of this fee could have a material impact on our financial position, results of operations or cash flows in future periods.

There were no other new accounting pronouncements that were issued or became effective during the year ended December 31, 2013 that had, or are expected to have, a material impact on our financial position, results of operations or financial statement disclosures.

Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) (USD \$)	12 Months Ended					
In Millions, unless otherwise	Dec. 31, 201	3 Dec. 31, 2012				
specified  Intangible Assets [Line Items]						
Gross Carrying Amount, Finite Lived Intangibles	\$ 3,511.1	\$ 3,541.4				
Accumulated Amortization, Finite Lived Intangibles	(2,337.2)	(2,123.0)				
Net Carrying Amount, Finite Lived Intangibles	1,173.9	1,418.4				
Gross Carrying Amount, Indefinite Lived Intangibles	7,267.1	7,247.1				
Net Carrying Amount, Indefinite Lived Intangibles	7,267.1	7,247.1				
Gross Carry Amount, Total Intangble Assets	10,778.2	10,788.5				
Accumulated Amortization, Total Intangible Assets	(2,337.2)	(2,123.0)				
Net Carrying Amount, Total Intangible Assets	8,441.0	8,665.5				
Blue Cross And Blue Shield And Other Trademarks [Member	•	3,332.12				
Intangible Assets [Line Items]	J					
Gross Carrying Amount, Indefinite Lived Intangibles	6,298.7	6,298.7				
Net Carrying Amount, Indefinite Lived Intangibles	6,298.7	6,298.7				
Provider Network [Member]	,	,				
Intangible Assets [Line Items]						
Gross Carrying Amount, Indefinite Lived Intangibles	271.8	271.8				
Net Carrying Amount, Indefinite Lived Intangibles	271.8	271.8				
State Medicaid Contracts [Member]						
Intangible Assets [Line Items]						
Gross Carrying Amount, Indefinite Lived Intangibles	696.6	676.6				
Net Carrying Amount, Indefinite Lived Intangibles	696.6	676.6				
Customer Relationships [Member]						
Intangible Assets [Line Items]						
Gross Carrying Amount, Finite Lived Intangibles	3,308.9	3,334.8				
Accumulated Amortization, Finite Lived Intangibles	(2,264.2)	(2,058.0)				
Net Carrying Amount, Finite Lived Intangibles	1,044.7	1,276.8				
Provider And Hospital Relationships [Member]						
Intangible Assets [Line Items]						
Gross Carrying Amount, Finite Lived Intangibles	140.5	140.5				
Accumulated Amortization, Finite Lived Intangibles	(44.7)	(38.1)				
Net Carrying Amount, Finite Lived Intangibles	95.8	102.4				
Other [Member]						
<b>Intangible Assets [Line Items]</b>						
Gross Carrying Amount, Finite Lived Intangibles	61.7	66.1				
Accumulated Amortization, Finite Lived Intangibles	(28.3)	(26.9)				
Net Carrying Amount, Finite Lived Intangibles	\$ 33.4	\$ 39.2				

Reinsurance (Effect Of Reinsurance On Benefit

## 12 Months Ended

Expense) (Details) (USD \$) In Millions, unless otherwise

In Millions, unless otherwise specified

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

## **Reinsurance Disclosures [Abstract]**

Direct	\$ 56,185.2	\$ 48,135.1	\$ 47,569.8
Assumed	155.6	173.0	165.0
Ceded	(103.7)	(94.5)	(87.3)
Net benefit expense	\$ 56,237.1	\$ 48,213.6	\$ 47,647.5

### Goodwill And Other Intangible Assets (Tables)

## Goodwill and Intangible Assets Disclosure [Abstract]

Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment

## 12 Months Ended Dec. 31, 2013

A summary of the change in the carrying amount of goodwill by reportable segment (see Note 20, "Segment Information") for 2013 and 2012 is as follows:

	and	ommercial d Specialty Business	 overnment Business	Ot	her	Total
Balance as of January 1, 2012	\$	11,555.6	\$ 2,303.1	\$	_	\$13,858.7
Amerigroup acquisition		_	3,033.1		_	3,033.1
Measurement period adjustments		(0.3)	 (1.7)			(2.0)
Balance as of December 31, 2012	\$	11,555.3	\$ 5,334.5		_	\$16,889.8
Measurement period adjustments		(1.3)	28.7		_	27.4
Balance as of December 31, 2013	\$	11,554.0	\$ 5,363.2			\$16,917.2
Accumulated impairment as of December 31, 2013	\$	(41.0)	\$			\$ (41.0)

<u>Components Of Other Intangible</u> <u>Assets</u> The components of other intangible assets as of December 31 are as follows:

		2013		2012						
	Gross Carrying Amount	cumulated nortization	Net Carrying Amount	Gross Carrying Amount		cumulated nortization	Net Carrying Amount			
Intangible assets with finite lives:										
Customer relationships	\$ 3,308.9	\$ (2,264.2)	\$ 1,044.7	\$ 3,334.8	\$	(2,058.0)	\$ 1,276.8			
Provider and hospital relationships	140.5	(44.7)	95.8	140.5		(38.1)	102.4			
Other	61.7	(28.3)	33.4	66.1		(26.9)	39.2			
Total	3,511.1	(2,337.2)	1,173.9	3,541.4		(2,123.0)	1,418.4			
Intangible assets with indefinite lives:										
Blue Cross and Blue Shield and other trademarks	6,298.7		6,298.7	6,298.7			6,298.7			
Provider network	271.8	_	271.8	271.8		_	271.8			
State Medicaid										
contracts	696.6		696.6	676.6			676.6			
Total	7,267.1	 	7,267.1	7,247.1			7,247.1			
Other intangible assets	\$10,778.2	\$ (2,337.2)	\$ 8,441.0	\$10,788.5	\$	(2,123.0)	\$ 8,665.5			

<b>Business Acquisitions and</b>															
Divestitures (Narrative)													D 21	D 21	D 21
(Details) (USD \$)													Dec. 31,	Dec. 31,	Dec. 31,
In Millions, except Per Share	Dec.	Sep.	Jun.	Mar.	Dec.	Sep.	Jun.	Mar.	Dog 31	Doc. 31	Dec. 31,	Dec.	2013	2012	2011
data, unless otherwise	31,	30,	30,	31,	31,	30,	30,	31,	2013	2012	2011	24,	Government	Government	Government
specified	2013	2013	2013	2013	2012	2012	2012	2012	2013	2012	2011	2012	Business	Business	Business
specified													[Member]	[Member]	[Member]

<b>Business Acq</b>	uisition and
Divestitures	Line Items

\$ 975.0 Other intangible assets

Cash consideration per share

<u>amount</u>

Cash consideration

Number of Amerigroup awards

converted

Number of WellPoint awards

received

Fair value of converted

Amerigroup stock awards

Transaction costs Measurement period 27.4 (2.0)

adjustments, goodwill

Measurement period

adjustments, other intangible

assets

Measurement period

adjustments, current liabilities

Measurement period

adjustments, noncurrent liabilities

3,062.0 Goodwill

Other finite-lived intangible

assets

Intangible assets amortization

period, years

Indefinite-lived intangible assets,

Medicaid contracts and trade

names

Operating revenue 70,191.4 60,514.0 59,865.2 31,366.7 19,874.0 21,625.7

148.2 656.2 800.1 885.2 464.2 691.2 643.6 856.5 2,489.7 2,655.5 2,646.7 Net loss

Loss on disposal from 221.8 0 0

discontinued operations

Tax benefit from loss on disposal \$ 57.3 from discontinued operations

Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On	12 Months Ended		
A Recurring Basis Using Level III Inputs) (Details) (USD \$) In Millians, unless otherwise	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Millions, unless otherwise specified			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input			
Reconciliation, Calculation [Roll Forward]			
Beginning balance	\$ 155.5	\$ 284.8	\$ 388.7
Gains (losses) recognized in net income	(35.2)	14.4	(3.5)
Gains (losses) recognized in accumulated other comprehensive income	6.6	(33.1)	1.3
<u>Purchases</u>	71.1	89.1	59.0
Business combinations		2.6	
Sales	(11.9)	(46.9)	(68.2)
<u>Settlements</u>	(24.2)	(69.3)	(150.4)
Transfers into Level III	38.5	30.7	64.5
Transfers out of Level III	(22.5)	(116.8)	(6.6)
Ending balance	177.9	155.5	284.8
Change in unrealized losses included in net income related to assets still held	(37.4)	(0.7)	(8.8)
Corporate Securities [Member]			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]			
Beginning balance	121.1	195.1	278.4
Gains (losses) recognized in net income	(30.3)	15.2	5.2
Gains (losses) recognized in accumulated other comprehensive income	(3.5)	(19.7)	(3.0)
<u>Purchases</u>	51.9	77.8	31.2
Business combinations		2.6	
Sales	(4.8)	(29.8)	(27.6)
Settlements	(15.5)	(67.8)	(130.5)
Transfers into Level III	3.0	2.9	41.4
Transfers out of Level III	(6.7)	(55.2)	0
Ending balance	115.2	121.1	195.1
Change in unrealized losses included in net income related to assets still held	(30.8)	0	(0.6)
Residential Mortgage-Backed Securities [Member]			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]			
Beginning balance	4.3	0	3.8
Gains (losses) recognized in net income	0	0	0
Gains (losses) recognized in accumulated other comprehensive income	0	0	0.1
Purchases	0	3.0	2.8
Business combinations		0	
Sales	0	0	(9.1)
Settlements	(1.9)	(0.1)	(0.8)
Transfers into Level III	13.1	1.4	9.7

Transfers out of Level III	(15.5)	0	(6.5)
Ending balance	0	4.3	0
Change in unrealized losses included in net income related to assets still held	0	0	0
Commercial Mortgage-Backed Securities [Member]	O	O	O
Fair Value, Assets Measured on Recurring Basis, Unobservable Input			
Reconciliation, Calculation [Roll Forward]			
Beginning balance	0	6.3	7.8
Gains (losses) recognized in net income	0	0	0
Gains (losses) recognized in accumulated other comprehensive income	0	0.1	0.1
Purchases	0	3.4	2.6
Business combinations		0	
Sales	0	0	(8.2)
Settlements	(6.1)	(0.1)	(1.4)
Transfers into Level III	12.6	1.9	5.4
Transfers out of Level III	0	(11.6)	0
Ending balance	6.5	0	6.3
Change in unrealized losses included in net income related to assets still held	0	0	0
Other Debt Securities [Member]			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input			
Reconciliation, Calculation [Roll Forward]			
Beginning balance	3.9	59.0	81.4
Gains (losses) recognized in net income	(0.1)	0.1	(1.7)
Gains (losses) recognized in accumulated other comprehensive income	0.6	0.7	0
Purchases	1.6	0	12.2
Business combinations		0	
Sales	0	(16.6)	(22.9)
Settlements	(0.7)	(1.3)	(17.7)
Transfers into Level III	9.8	12.0	7.8
Transfers out of Level III	(0.3)	(50.0)	(0.1)
Ending balance	14.8	3.9	59.0
Change in unrealized losses included in net income related to assets still held	(0.1)	0	(1.2)
Equity Securities [Member]			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input			
Reconciliation, Calculation [Roll Forward]			
Beginning balance	26.2	24.4	17.3
Gains (losses) recognized in net income	(4.8)	(0.9)	(7.0)
Gains (losses) recognized in accumulated other comprehensive income	9.5	(14.2)	4.1
<u>Purchases</u>	17.6	4.9	10.2
Business combinations		0	
Sales	(7.1)	(0.5)	(0.4)
<u>Settlements</u>	0	0	0
Transfers into Level III	0	12.5	0.2
Transfers out of Level III	0	0	0
Ending balance	41.4	26.2	24.4
Change in unrealized losses included in net income related to assets still held	\$ (6.5)	\$ (0.7)	\$ (7.0)

Consolidated Balance Sheets (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:		
Cash and cash equivalents	\$ 1,582.1	\$ 2,475.3
Investments available-for-sale, at fair value:		
Fixed maturity securities (amortized cost of \$16,826.7 and \$16,033.1)	17,038.2	16,912.9
Equity securities (cost of \$1,168.5 and \$869.9)	1,735.5	1,212.4
Other invested assets, current	16.3	14.8
Accrued investment income	168.8	162.2
<u>Premium and self-funded receivables</u>	3,968.7	3,687.4
Other receivables	1,063.3	927.6
<u>Income taxes receivable</u>	235.7	228.5
Securities lending collateral	969.8	564.6
<u>Deferred tax assets, net</u>	383.0	236.4
Other current assets	1,677.5	1,827.4
Assets held for sale	906.9	1,098.0
<u>Total current assets</u>	29,745.8	29,347.5
Long-term investments available-for-sale, at fair value:		
Fixed maturity securities (amortized cost of \$455.9 and \$426.0)	449.9	431.5
Equity securities (cost of \$27.4 and \$27.1)	31.3	30.1
Other invested assets, long-term	1,542.6	1,387.6
Property and equipment, net	1,801.5	1,717.3
Goodwill	16,917.2	16,889.8
Other intangible assets	8,441.0	8,665.5
Other noncurrent assets	645.2	486.1
<u>Total assets</u>	59,574.5	58,955.4
Liabilities and shareholders' equity		
Medical claims payable	6,127.2	6,174.5
Reserves for future policy benefits	63.1	61.3
Other policyholder liabilities	2,073.2	2,345.7
Total policy liabilities	8,263.5	8,581.5
<u>Unearned income</u>	822.7	896.8
Accounts payable and accrued expenses	3,426.3	3,098.7
Security trades pending payable	95.2	69.3
Securities lending payable	969.7	564.7
Short-term borrowings	400.0	250.0
Current portion of long-term debt	518.0	557.1
Other current liabilities	1,674.7	1,769.8
<u>Liabilities held for sale</u>	181.4	207.1
Total current liabilities	16,351.5	15,995.0
Long-term debt, less current portion	13,573.6	14,170.8
Reserves for future policy benefits, noncurrent	723.0	750.8
Deferred tax liabilities, net	3,325.2	3,222.9

Other noncurrent liabilities	836.0	1,013.2
<u>Total liabilities</u>	34,809.3	35,152.7
Commitments and contingencies-Note 14		
Shareholders' equity		
Preferred stock, without par value, shares authorized—100,000,000; shares issued and outstanding—none	0	0
Common stock, par value \$0.01, shares authorized—900,000,000; shares issued and outstanding: 293,273,830 and 304,715,144	2.9	3.0
Additional paid-in capital	10,765.2	10,853.5
Retained earnings	13,813.9	12,647.1
Accumulated other comprehensive income	183.2	299.1
Total shareholders' equity	24,765.2	23,802.7
Total liabilities and shareholders' equity	\$ 59,574.5	\$ 58,955.4

## Accumulated Other Comprehensive Income (Loss) (Tables)

<u>Comprehensive Income (Loss), Net of</u> Tax, Attributable to Parent [Abstract]

<u>Components of Accumulated Other</u> <u>Comprehensive Income (Loss)</u>

# 12 Months Ended

Dec. 31, 2013

A reconciliation of the components of accumulated other comprehensive income at December 31 is as follows:

	2013		2012
Investments:			
Gross unrealized gains	\$ 1,054.2	\$	1,282.1
Gross unrealized losses	(277.8)		(51.3)
Net pretax unrealized gains	776.4		1,230.8
Deferred tax liability	(267.4)		(427.1)
Net unrealized gains on investments	509.0		803.7
Non-credit components of OTTI on investments:			
Unrealized losses	(0.8)		(3.4)
Deferred tax asset	0.3		1.2
Net unrealized non-credit component of OTTI on investments	(0.5)		(2.2)
Cash flow hedges:			
Gross unrealized losses	(49.7)		(54.3)
Deferred tax asset	17.4		19.0
Net unrealized losses on cash flow hedges	(32.3)		(35.3)
Defined benefit pension plans:			
Deferred net actuarial loss	(427.2)		(686.8)
Deferred prior service credits	3.0		3.9
Deferred tax asset	169.9		269.1
Net unrecognized periodic benefit costs for defined benefit pension plans	(254.3)		(413.8)
Postretirement benefit plans:			
Deferred net actuarial loss	(169.6)		(191.0)
Deferred prior service credits	102.4		103.0
Deferred tax asset	27.0		34.6
Net unrecognized periodic benefit costs for postretirement benefit plans	(40.2)		(53.4)
Foreign currency translation adjustments:			
Gross unrealized gains	2.2		0.2
Deferred tax liability	(0.7)		(0.1)
Net unrealized gains on foreign currency translation adjustments	1.5	_	0.1
Accumulated other comprehensive income	\$ 183.2	\$	299.1

Other Comprehensive Income (Loss) Reclassification Adjustments Other comprehensive income (loss) reclassification adjustments for the years ended December 31 are as follows:

	2013	2012	2011
Investments:			
Net holding loss on investment securities arising during the period, net of tax benefit of \$223.6, \$5.4 and \$38.2, respectively	\$ (407.2)	\$ (3.2)	\$ (71.6)
Reclassification adjustment for net realized gain on investment securities, net of tax expense of (\$60.6), (\$104.0) and (\$49.6), respectively	112.5	193.1	92.2
Total reclassification adjustment on investments	(294.7)	189.9	20.6
Non-credit component of OTTI on investments:			

Non-credit component of OTTI on investments, net of tax (expense) benefit of (\$0.9), (\$2.4) and \$0.5,

respectively	1.7	4.5	(0.7)
Cash flow hedges:			
Holding gain (loss), net of tax (expense) benefit of (\$1.6), (\$0.1) and \$5.3, respectively	3.0	0.1	(10.0)
Other:			
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax (expense) benefit of (\$106.8), (\$7.1) and \$81.7, respectively	172.7	(10.9)	(119.8)
Foreign currency translation adjustment, net of tax expense of (\$0.6), (\$0.3) and (\$0.2), respectively	1.4	0.6	0.2
Net (loss) gain recognized in other comprehensive income, net of tax benefit (expense) of \$53.1, (\$108.5) and \$75.9, respectively	\$ (115.9)	\$ 184.2	\$ (109.7)

Medical Claims Payable (Reconciliation Of The Beginning And Ending	12 Months Ended		12 Months Ended	
Balances For Medical Claims Payable) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	
Reconciliation of beginning and ending balances for medical claims				
<u>payable</u>				
Gross medical claims payable, beginning of year	\$ 6,174.5	\$ 5,489.0	\$ 4,852.4	
Ceded medical claims payable, beginning of year	(27.2)	(16.4)	(32.9)	
Net medical claims payable, beginning of year	6,147.3	5,472.6	4,819.5	
Business combinations and purchase adjustments	0	804.4	100.9	
Net incurred medical claims in current year	55,894.3	48,080.1	47,281.6	
Net incurred medical claims in prior years redundancies	(599.1)	(513.6)	(209.7)	
Total net incurred medical claims	55,295.2	47,566.5	47,071.9	
Net payments attributable to current year medical claims	49,887.2	42,832.4	41,999.0	
Net payments attributable to prior years medical claims	5,451.5	4,863.8	4,520.7	
Total net payments	55,338.7	47,696.2	46,519.7	
Net medical claims payable, end of year	6,103.8	6,147.3	5,472.6	
Ceded medical claims payable, end of year	23.4	27.2	16.4	
Gross medical claims payable, end of year	\$ 6,127.2	\$ 6,174.5	\$ 5,489.0	

## Reinsurance (Summary Of **Net Premiums Written And Earned By Segment) (Details)**

(USD \$)

Premiums Written Net

Premiums Earned Net

In Millions, unless otherwise specified

## 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

0

\$0

0

\$0

specified			
Net Premiums Written And Earned By Segment [Line Items	<u>s]</u>		
Premiums Written Net	\$ 66,020.8	\$ 56,567.4	\$ 56,286.0
Premiums Earned Net	66,119.1	56,496.7	55,969.6
Commercial and Specialty Business [Member]			
Net Premiums Written And Earned By Segment [Line Items	<u>s]</u>		
Premiums Written Net	35,126.0	35,352.1	36,476.3
Premiums Earned Net	35,159.8	35,251.9	36,436.7
Government Business [Member]			
Net Premiums Written And Earned By Segment [Line Items	<u>s]</u>		
Premiums Written Net	30,894.8	21,215.3	19,809.7
Premiums Earned Net	30,959.3	21,244.8	19,532.9
Other [Member]			
Net Premiums Written And Earned By Segment [Line Items	<u>s]</u>		

0

\$0

Consolidated Statements of	12 Months Ended		
Cash Flows (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities			
Net income	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7
Adjustments to reconcile net income to net cash provided by operating			
activities:			
Net realized gains on investments	(271.9)	(334.9)	(235.1)
Other-than-temporary impairment losses recognized in income	98.9	37.8	93.3
Loss on extinguishment of debt	145.3	0	0
Loss on disposal from discontinued operations	221.8	0	0
Loss on disposal of assets	3.9	4.7	3.3
<u>Deferred income taxes</u>	59.1	127.5	74.3
Amortization, net of accretion	800.9	633.6	541.5
<u>Depreciation expense</u>	107.9	107.1	95.7
Impairment of property and equipment	47.7	66.8	0
Share-based compensation	146.0	146.5	134.8
Excess tax benefits from share-based compensation	(30.1)	(28.8)	(42.2)
Changes in operating assets and liabilities, net of effect of business combinations:			
Receivables, net	(418.3)	189.9	(401.8)
Other invested assets	(15.1)	(38.9)	(8.9)
Other assets	(33.6)	79.2	(259.2)
Policy liabilities	(345.8)	(53.7)	978.0
Unearned income	(73.8)	(193.7)	35.1
Accounts payable and accrued expenses	303.6	(406.5)	(208.7)
Other liabilities	(154.6)	(132.8)	(13.6)
Income taxes	9.3	(73.9)	(44.6)
Other, net	(38.6)	(40.8)	(14.2)
Net cash provided by operating activities	3,052.3	2,744.6	3,374.4
Investing activities			
Purchases of fixed maturity securities	(13,704.5)	(15,040.4)	(11,914.8)
Proceeds from fixed maturity securities:			
Sales	10,977.9	13,675.9	10,446.2
Maturities, calls and redemptions	1,836.8	1,781.5	1,891.3
Purchases of equity securities	(820.3)	(232.8)	(259.0)
Proceeds from sales of equity securities	721.0	422.7	287.4
Purchases of other invested assets	(251.5)	(303.7)	(207.9)
Proceeds from sales of other invested assets	127.1	35.5	29.4
Settlement of non-hedging derivatives	(109.8)	(59.8)	(96.6)
Changes in securities lending collateral	(405.1)	307.9	28.9
Purchases of subsidiaries, net of cash acquired	0	(4,597.0)	(600.0)
Purchases of property and equipment	(646.5)	(544.9)	(519.5)
Proceeds from sales of property and equipment	39.2	0.4	3.7
Other, net	1.3	3.1	(31.1)
Other, not	1.5	J.1	(31.1)

Net cash used in investing activities	(2,234.4)	(4,551.6)	(942.0)
Financing activities			
Net proceeds from (repayments of) commercial paper borrowings	(191.7)	(229.0)	463.6
Proceeds from long-term borrowings	1,250.0	6,468.9	1,097.4
Repayments of long-term borrowings	(1,801.9)	(1,251.3)	(705.1)
Proceeds from short-term borrowings	1,100.0	642.0	100.0
Repayments of short-term borrowings	(950.0)	(492.0)	(100.0)
Changes in securities lending payable	405.0	(307.8)	(29.0)
Changes in bank overdrafts	9.9	(17.6)	264.3
Premiums paid on equity options	(25.8)	0	0
Repurchase and retirement of common stock	(1,620.1)	(2,496.8)	(3,039.8)
<u>Cash dividends</u>	(448.0)	(367.1)	(357.8)
Proceeds from issuance of common stock under employee stock plans	524.7	110.8	245.0
Excess tax benefits from share-based compensation	30.1	28.8	42.2
Net cash (used in) provided by financing activities	(1,717.8)	2,088.9	(2,019.2)
Effect of foreign exchange rates on cash and cash equivalents	2.2	1.1	(0.4)
Change in cash and cash equivalents	(897.7)	283.0	412.8
Cash and cash equivalents at beginning of year	2,484.6	2,201.6	1,788.8
Cash and cash equivalents at end of year	1,586.9	2,484.6	2,201.6
Less cash and cash equivalents of discontinued operations at end of year	(4.8)	(9.3)	0
Cash and cash equivalents of continuing operations at end of year	\$ 1,582.1	\$ 2,475.3	\$ 2,201.6

## Retirement Benefits (Estimated Future Payments For Pension Benefits And Postretirement Benefits)

(Details) (USD \$)

Dec. 31, 2013

# In Millions, unless otherwise specified

Pension Benefits [Member]

## **Defined Benefit Plan Disclosure [Line Items]**

2014	\$ 138.2
<u>2015</u>	147.9
<u>2016</u>	141.0
<u>2017</u>	145.6
<u>2018</u>	148.3
2019 - 2023	656.5

Other Benefits [Member]

## **Defined Benefit Plan Disclosure [Line Items]**

<u>2014</u>	43.4
<u>2015</u>	43.5
<u>2016</u>	43.9
<u>2017</u>	44.7
<u>2018</u>	45.4
<u>2019 - 2023</u>	\$ 225.8

Investments (Current And Long-Term Investments, Available-For-Sale) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Investment [Line Items]		
Cost or Amortized Cost	\$ 18,478.5	\$ 17,356.1
Gross Unrealized Gains	1,054.2	1,282.1
Gross Unrealized Losses, Less than 12 Months	(244.5)	(36.7)
Gross Unrealized Losses, 12 Months or Greater	(33.3)	(14.6)
Estimated Fair Value	19,254.9	18,586.9
Fixed Maturity Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	17,282.6	16,459.1
Gross Unrealized Gains	475.3	924.1
Gross Unrealized Losses, Less than 12 Months	(236.5)	(24.2)
Gross Unrealized Losses, 12 Months or Greater	(33.3)	(14.6)
Estimated Fair Value	17,488.1	17,344.4
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	(0.8)	(3.4)
Fixed Maturity Securities [Member]   United States Government Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	300.8	330.3
Gross Unrealized Gains	2.5	13.1
Gross Unrealized Losses, Less than 12 Months	(3.4)	(0.2)
Gross Unrealized Losses, 12 Months or Greater	0	0
Estimated Fair Value	299.9	343.2
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	0	0
Fixed Maturity Securities [Member]   Government Sponsored Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	174.4	153.6
Gross Unrealized Gains	0.4	2.6
Gross Unrealized Losses, Less than 12 Months	(1.3)	0
Gross Unrealized Losses, 12 Months or Greater	0	0
Estimated Fair Value	173.5	156.2
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	0	0
Fixed Maturity Securities [Member]   States, Municipalities And Political Subdivisions - Tax-		
Exempt [Member]		
Investment [Line Items]		
Cost or Amortized Cost	5,899.5	5,501.3
Gross Unrealized Gains	202.9	388.2
Gross Unrealized Losses, Less than 12 Months	(90.1)	(5.7)
Gross Unrealized Losses, 12 Months or Greater	(9.6)	(1.6)
Estimated Fair Value	6,002.7	5,882.2
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	(0.6)	0
Fixed Maturity Securities [Member]   Corporate Securities [Member]		

Investment [Line Items]		
Cost or Amortized Cost	7,614.1	7,642.0
Gross Unrealized Gains	205.2	387.0
Gross Unrealized Losses, Less than 12 Months	(95.2)	(17.0)
Gross Unrealized Losses, 12 Months or Greater	(15.5)	(8.0)
Estimated Fair Value	7,708.6	8,004.0
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	(0.1)	(1.7)
Fixed Maturity Securities [Member]   Options Embedded in Convertible Securities [Member]	(3.7)	()
Investment [Line Items]		
Cost or Amortized Cost	89.2	67.2
Gross Unrealized Gains	0	0
Gross Unrealized Losses, Less than 12 Months	0	0
Gross Unrealized Losses, 12 Months or Greater	0	0
Estimated Fair Value	89.2	67.2
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	0	0
Fixed Maturity Securities [Member]   Residential Mortgage-Backed Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	2,269.4	2,204.7
Gross Unrealized Gains	48.0	103.1
Gross Unrealized Losses, Less than 12 Months	(41.4)	(1.1)
Gross Unrealized Losses, 12 Months or Greater	(7.1)	(1.9)
Estimated Fair Value	2,268.9	2,304.8
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	0	(0.4)
Fixed Maturity Securities [Member]   Commercial Mortgage-Backed Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	479.0	323.2
Gross Unrealized Gains	10.5	22.5
Gross Unrealized Losses, Less than 12 Months	(2.6)	0
Gross Unrealized Losses, 12 Months or Greater	(0.3)	0
Estimated Fair Value	486.6	345.7
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	0	0
Fixed Maturity Securities [Member]   Other Debt Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	456.2	236.8
Gross Unrealized Gains	5.8	7.6
Gross Unrealized Losses, Less than 12 Months	(2.5)	(0.2)
Gross Unrealized Losses, 12 Months or Greater	(0.8)	(3.1)
Estimated Fair Value	458.7	241.1
Non-Credit Component of Other-Than-Temporary Impairments Recognized in AOCI	(0.1)	(1.3)
Equity Securities [Member]		
Investment [Line Items]		
Cost or Amortized Cost	1,195.9	897.0
Gross Unrealized Gains	578.9	358.0
Gross Unrealized Losses, Less than 12 Months	(8.0)	(12.5)
Gross Unrealized Losses, 12 Months or Greater	0	0
Estimated Fair Value	\$ 1,766.8	\$ 1,242.5

# Debt (The Carrying Value Of Long-Term Debt) (Details) (USD \$)

Dec. 31, 2013 Dec. 31, 2012

# In Millions, unless otherwise specified

Debt Instrument [Line Items]		
Long-term debt	\$ 14,091.6	\$ 14,727.9
Commercial paper program	379.2	570.9
Capital Lease Obligations	0	0.3
<u>Current portion of long-term debt</u>	(518.0)	(557.1)
Long-term debt, less current portion	13,573.6	14,170.8
Senior Unsecured Notes [Member]   6.000%, due 2014 [Member]		
<b>Debt Instrument [Line Items]</b>		
Long-term debt	0	399.8
Interest rate on long-term debt	6.00%	6.00%
Senior Unsecured Notes [Member]   5.000%, due 2014 [Member]		
<b>Debt Instrument [Line Items]</b>		
Long-term debt	518.0	535.9
Interest rate on long-term debt	5.00%	5.00%
Senior Unsecured Notes [Member]   1.250%, due 2015 [Member]		
<b>Debt Instrument [Line Items]</b>		
Long-term debt	624.9	624.8
Interest rate on long-term debt	1.25%	1.25%
Senior Unsecured Notes [Member]   5.250%, due 2016 [Member]		
<b>Debt Instrument [Line Items]</b>		
Long-term debt	1,109.6	1,114.0
Interest rate on long-term debt	5.25%	5.25%
Senior Unsecured Notes [Member]   2.375%, due 2017 [Member]		
<b>Debt Instrument [Line Items]</b>		
<u>Long-term debt</u>	399.6	401.5
Interest rate on long-term debt	2.375%	2.375%
Senior Unsecured Notes [Member]   5.875%, due 2017 [Member]		
<b>Debt Instrument [Line Items]</b>		
<u>Long-term debt</u>	545.1	697.4
Interest rate on long-term debt	5.875%	5.875%
Senior Unsecured Notes [Member]   1.875%, due 2018 [Member]		
<b>Debt Instrument [Line Items]</b>		
<u>Long-term debt</u>	614.5	625.2
Interest rate on long-term debt	1.875%	1.875%
Senior Unsecured Notes [Member]   2.300%, due 2018 [Member]		
<b>Debt Instrument [Line Items]</b>		
<u>Long-term debt</u>	647.5	0
Interest rate on long-term debt	2.30%	2.30%
Senior Unsecured Notes [Member]   7.500%, due 2019 [Member]		
<b>Debt Instrument [Line Items]</b>		

Long-term debt	0	556.9
Interest rate on long-term debt	7.50%	7.50%
Senior Unsecured Notes [Member]   7.000%, due 2019 [Member]	7.5070	7.5070
Debt Instrument [Line Items]		
Long-term debt	452.9	599.3
Interest rate on long-term debt	7.00%	7.00%
Senior Unsecured Notes [Member]   4.350%, due 2020 [Member]	7.0070	7.0070
Debt Instrument [Line Items]		
Long-term debt	688.9	701.0
Interest rate on long-term debt	4.35%	4.35%
Senior Unsecured Notes [Member]   3.700%, due 2021 [Member]	4.55/0	4.33/0
Debt Instrument [Line Items] Long town debt	699.4	699.3
Long-term debt	3.70%	3.70%
Interest rate on long-term debt  Series Unseemed Notes [Member]   2 1250/ due 2022 [Member]	3.70%	3.70%
Senior Unsecured Notes [Member]   3.125%, due 2022 [Member]		
Debt Instrument [Line Items]	046.2	945.0
Long-term debt	846.3	845.9
Interest rate on long-term debt	3.125%	3.125%
Senior Unsecured Notes [Member]   3.300%, due 2023 [Member]		
Debt Instrument [Line Items]	0060	0067
Long-term debt	996.9	996.7
Interest rate on long-term debt	3.30%	3.30%
Senior Unsecured Notes [Member]   5.950%, due 2034 [Member]		
Debt Instrument [Line Items]	4.45.0	400.0
Long-term debt	447.3	498.8
Interest rate on long-term debt	5.95%	5.95%
Senior Unsecured Notes [Member]   5.850%, due 2036 [Member]		
Debt Instrument [Line Items]		007.
Long-term debt	775.6	895.7
Interest rate on long-term debt	5.85%	5.85%
Senior Unsecured Notes [Member]   6.375%, due 2037 [Member]		
Debt Instrument [Line Items]		
Long-term debt	651.4	796.7
Interest rate on long-term debt	6.375%	6.375%
Senior Unsecured Notes [Member]   5.800%, due 2040 [Member]		
Debt Instrument [Line Items]		
<u>Long-term debt</u>	216.2	296.8
Interest rate on long-term debt	5.80%	5.80%
Senior Unsecured Notes [Member]   4.625%, due 2042 [Member]		
Debt Instrument [Line Items]		
Long-term debt	893.9	893.7
Interest rate on long-term debt	4.625%	4.625%
Senior Unsecured Notes [Member]   4.650%, due 2043 [Member]		
Debt Instrument [Line Items]		
<u>Long-term debt</u>	994.4	994.2
Interest rate on long-term debt	4.65%	4.65%

Senior Unsecured Notes [Member]   5.100%, due 2044 [Mem	ber]	
<b>Debt Instrument [Line Items]</b>		
Long-term debt	599.1	0
Interest rate on long-term debt	5.10%	5.10
Senior Convertible Debentures [Member]   2.750%, due 2042	[Member]	
Debt Instrument [Line Items]		

<b>Debt Instrument</b>	[Line Items	1
------------------------	-------------	---

Interest rate on long-term debt

<u>Long-term debt</u>	966.0	958.1
Interest rate on long-term debt	2.75%	2.75%
Surplus Notes [Member]   9.000%, due 2027 [Member]		
<b>Debt Instrument [Line Items]</b>		
Long-term debt	\$ 24.9	\$ 25.0

5.10%

9.00%

9.00%

### **Investments (Tables)**

# 12 Months Ended Dec. 31, 2013

Non-Credit

### **Investments** [Abstract]

<u>Current And Long-Term</u> Investments, Available-For-Sale A summary of current and long-term investments, available-for-sale, at December 31, 2013 and 2012 is as follows:

				C	ross Unrea	lizad	Lossos			Co O	mponent of ther-Than-
	Cost or nortized Cost	Uı	Gross realized Gains	Less than 12 Months		12 Months or Greater		- Estimated Fair Value		In	emporary pairments cognized in AOCI
December 31, 2013:											
Fixed maturity securities:											
United States Government securities	\$ 300.8	\$	2.5	\$	(3.4)	\$	_	\$	299.9	\$	_
Government sponsored securities	174.4		0.4		(1.3)		_		173.5		_
States, municipalities and political subdivisions, tax-exempt	5,899.5		202.9		(90.1)		(9.6)		6,002.7		(0.6)
Corporate securities	7,614.1		205.2		(95.2)		(15.5)		7,708.6		(0.1)
Options embedded in convertible securities	89.2		_		_		_		89.2		_
Residential mortgage-backed securities	2,269.4		48.0		(41.4)		(7.1)		2,268.9		_
Commercial mortgage-backed securities	479.0		10.5		(2.6)		(0.3)		486.6		_
Other debt securities	456.2		5.8		(2.5)		(0.8)		458.7		(0.1)
Total fixed maturity securities	17,282.6		475.3		(236.5)		(33.3)		17,488.1	\$	(0.8)
Equity securities	1,195.9		578.9		(8.0)		_		1,766.8		
Total investments, available-for-sale	\$ 18,478.5	\$	1,054.2	\$	(244.5)	\$	(33.3)	\$	19,254.9		
December 31, 2012	 						-	_			
Fixed maturity securities:											
United States Government securities	\$ 330.3	\$	13.1	\$	(0.2)	\$	_	\$	343.2	\$	_
Government sponsored securities	153.6		2.6		_		_		156.2		_
States, municipalities and political subdivisions, tax-exempt	5,501.3		388.2		(5.7)		(1.6)		5,882.2		_
Corporate securities	7,642.0		387.0		(17.0)		(8.0)		8,004.0		(1.7)
Options embedded in convertible securities	67.2		_		_		_		67.2		_
Residential mortgage-backed securities	2,204.7		103.1		(1.1)		(1.9)		2,304.8		(0.4)
Commercial mortgage-backed securities	323.2		22.5		_		_		345.7		_
Other debt securities	236.8		7.6		(0.2)		(3.1)		241.1		(1.3)
Total fixed maturity securities	16,459.1		924.1		(24.2)		(14.6)		17,344.4	\$	(3.4)
Equity securities	897.0		358.0		(12.5)		_		1,242.5	_	
Total investments, available-for-sale	\$ 17,356.1	\$	1,282.1	\$	(36.7)	\$	(14.6)	\$	18,586.9		

Aggregate Fair Value And Gross
Unrealized Loss Of Fixed
Maturity Securities And Equity
Securities In An Unrealized Loss
Position

The following tables summarize for fixed maturity securities and equity securities in an unrealized loss position at December 31, 2013 and 2012, the aggregate fair value and gross unrealized loss by length of time those securities have been continuously in an unrealized loss position.

	Le	ss tha	n 12 Moi	nths		12 Months or Greater				
	Number of Securities		timated r Value	Uı	Gross nrealized Loss	Number of Securities	Estimated Fair Valu		Gross Unrealized Loss	
(Securities are whole amounts)										
December 31, 2013:										
Fixed maturity securities:										
United States Government securities	27	\$	179.2	\$	(3.4)	_	\$	-	\$ —	
Government sponsored securities	22		73.4		(1.3)	_	_	-	_	
States, municipalities and political subdivisions, tax-exempt	806		2,070.9		(90.1)	42	82.4	ļ	(9.6)	
Corporate securities	1,448		2,586.6		(95.2)	107	81.3	3	(15.5)	

Residential mortgage-backed securities	605	1,243.0	(41.4)	80	116.2	(7.1)
Commercial mortgage-backed securities	52	177.7	(2.6)	4	5.6	(0.3)
Other debt securities	65	185.3	(2.5)	17	16.2	(0.8)
Total fixed maturity securities	3,025	6,516.1	(236.5)	250	301.7	(33.3)
Equity securities	426	120.8	(8.0)	_	_	_
Total fixed maturity and equity securities	3,451	\$ 6,636.9	\$ (244.5)	250	\$ 301.7	\$ (33.3)
December 31, 2012				-		 
Fixed maturity securities:						
United States Government securities	17	\$ 48.5	\$ (0.2)	_	\$ _	\$ _
States, municipalities and political subdivisions, tax-exempt	184	420.1	(5.7)	1	46.9	(1.6)
Corporate securities	457	1,066.5	(17.0)	74	52.6	(8.0)
Residential mortgage-backed securities	79	211.0	(1.1)	44	25.5	(1.9)
Commercial mortgage-backed securities	4	10.1	_	3	4.1	_
Other debt securities	7	5.4	(0.2)	21	28.9	(3.1)
Total fixed maturity securities	748	1,761.6	(24.2)	143	158.0	(14.6)
Equity securities	961	149.6	(12.5)	_	_	_
Total fixed maturity and equity securities	1,709	\$ 1,911.2	\$ (36.7)	143	\$ 158.0	\$ (14.6)

Amortized Cost And Fair Value **Contractual Maturity** 

The amortized cost and fair value of fixed maturity securities at December 31, 2013, by contractual maturity, are shown Of Fixed Maturity Securities, By below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.

	A	mortized Cost	Estimated air Value
Due in one year or less	\$	423.9	\$ 426.3
Due after one year through five years		4,580.5	4,712.1
Due after five years through ten years		5,105.4	5,196.6
Due after ten years		4,424.4	4,397.6
Mortgage-backed securities		2,748.4	 2,755.5
Total available-for-sale fixed maturity securities	\$	17,282.6	\$ 17,488.1

Major Categories Of Net **Investment Income** 

The major categories of net investment income for the years ended December 31 are as follows:

	2013	2012	2011
Fixed maturity securities	\$ 638.9	\$ 671.2	\$ 692.4
Equity securities	45.9	38.4	34.0
Cash and cash equivalents	1.0	2.5	3.7
Other	19.8	16.2	2.4
Investment income	705.6	728.3	732.5
Investment expense	(46.5)	(42.2)	(28.8)
Net investment income	\$ 659.1	\$ 686.1	\$ 703.7

Net Realized Investment Gains/Losses And Net Change In Unrealized Appreciation/Depreciation In **Investments** 

Net realized investment gains/losses and net change in unrealized appreciation/depreciation in investments for the years ended December 31 are as follows:

	2013	_	2012	2011
Net realized gains (losses) on investments:				
Fixed maturity securities:				
Gross realized gains from sales	\$ 225.9	\$	401.0	\$ 289.2
Gross realized losses from sales	(125.7	)	(54.8)	(65.1)
Net realized gains from sales of fixed maturity securities	100.2		346.2	224.1
Equity securities:				
Gross realized gains from sales	224.1		82.0	75.4
Gross realized losses from sales	(100.5	)	(93.8)	 (68.0)
Net realized gains (losses) from sales of equity securities	123.6		(11.8)	7.4
Other realized gains on investments	48.1	_	0.5	 3.6
Net realized gains on investments	271.9		334.9	235.1

Other-than-temporary impairment losses recognized in income:			
Fixed maturity securities	(42.5)	(11.8)	(24.2)
Equity securities	(13.9)	(17.5)	(27.9)
Other invested assets, long-term	(42.5)	(8.5)	(41.2)
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)
Change in net unrealized (losses) gains on investments:			
Fixed maturity securities	(679.8)	199.8	155.9
Equity securities	225.4	94.7	(124.6)
Total change in net unrealized (losses) gains on investments	(454.4)	294.5	31.3
Deferred income tax benefit (expense)	159.7	(104.6)	(10.7)
Net change in net unrealized (losses) gains on investments	(294.7)	189.9	20.6
Net realized gains on investments, other-than-temporary impairment losses recognized in income and net change in net unrealized (losses) gains on investments	\$ (121.7)	\$ 487.0	\$ 162.4

# <u>Proceeds and Realized Gains and Losses from Investments</u>

Proceeds from fixed maturity securities, equity securities and other invested assets and the related gross realized gains and gross realized losses for the years ended December 31 are as follows:

	2013		2012	2011
Proceeds	\$ 13,662	.8 \$	15,915.6	\$ 12,654.3
Gross realized gains	498	.1	483.5	368.2
Gross realized losses	(226	.2)	(148.6)	(133.1)

Schedule II-Condensed	4037 1 7 1 3
Financial Information Of	12 Months Ended

Schedule II-Condensed Financial Information Of Registrant (Statement Of	12 Months Ended				
Cash Flows) (Details) (USD  \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
Operating activities					
Net income	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7		
Adjustments to reconcile net income to net cash provided by operating activities:					
Net realized losses on investments	(271.9)	(334.9)	(235.1)		
Other-than-temporary impairment losses recognized in income	98.9	37.8	93.3		
Loss on extinguishment of debt	145.3	0	0		
Loss on disposal of assets	3.9	4.7	3.3		
<u>Deferred income taxes</u>	59.1	127.5	74.3		
Amortization, net of accretion	800.9	633.6	541.5		
<u>Depreciation</u>	107.9	107.1	95.7		
Share-based compensation cost	146.0	146.5	134.8		
Excess tax benefits from share-based compensation	(30.1)	(28.8)	(42.2)		
Changes in operating assets and liabilities, net of effect of business combinations:					
Receivables, net	(418.3)	189.9	(401.8)		
Other invested assets, current	(15.1)	(38.9)	(8.9)		
Other assets	(33.6)	79.2	(259.2)		
Accounts payable and accrued expenses	303.6	(406.5)	(208.7)		
Other liabilities	(154.6)	(132.8)	(13.6)		
<u>Income taxes</u>	9.3	(73.9)	(44.6)		
Net cash provided by operating activities	3,052.3	2,744.6	3,374.4		
<u>Investing activities</u>					
Settlement of non-hedging derivatives	(109.8)	(59.8)	(96.6)		
Changes in securities lending collateral	(405.1)	307.9	28.9		
Other, net	1.3	3.1	(31.1)		
Net cash used in investing activities	(2,234.4)	(4,551.6)	(942.0)		
Financing activities					
Net (repayments of) proceeds from commercial paper borrowings	(191.7)	(229.0)	463.6		
Proceeds from long-term borrowings	1,250.0	6,468.9	1,097.4		
Repayments of long term borrowings	(1,801.9)	(1,251.3)	(705.1)		
Changes in securities lending payable	405.0	(307.8)	(29.0)		
Changes in bank overdrafts	9.9	(17.6)	264.3		
Premiums paid on equity options	(25.8)	0	0		
Repurchase and retirement of common stock	(1,620.1)	(2,496.8)	(3,039.8)		
Cash dividends	(448.0)	(367.1)	(357.8)		
Proceeds from issuance of common stock under employee stock plans	524.7	110.8	245.0		
Excess tax benefits from share-based compensation	30.1	28.8	42.2		
Net cash (used in) provided by financing activities	(1,717.8)	2,088.9	(2,019.2)		

Change in cash and cash equivalents	(897.7)	283.0	412.8
Cash and cash equivalents at beginning of year	2,475.3	2,201.6	412.0
Cash and cash equivalents at beginning of year  Cash and cash equivalents of continuing operations at end of year	1,582.1	2,475.3	2,201.6
WellPoint, Inc. [Member]	1,502.1	2,473.3	2,201.0
Operating activities			
Net income	2,489.7	2,655.5	2,646.7
Adjustments to reconcile net income to net cash provided by operating	2,409.1	2,033.3	2,040.7
activities:			
(Undistributed) distributed earnings of subsidiaries	(78.5)	(432.0)	399.3
Net realized losses on investments	83.2	28.5	17.9
Other-than-temporary impairment losses recognized in income	51.4	14.0	18.0
Loss on extinguishment of debt	145.3	0	0
Loss on disposal of assets	3.6	0	0
Deferred income taxes	(4.5)	49.2	95.3
Amortization, net of accretion	25.2	23.2	3.1
Depreciation	45.7	13.1	0.3
Share-based compensation cost	146.0	146.5	134.8
Excess tax benefits from share-based compensation	(30.1)	(28.8)	(42.2)
Changes in operating assets and liabilities, net of effect of business	(30.1)	(20.0)	(12.2)
combinations:			
Receivables, net	3.5	9.6	13.5
Other invested assets, current	(0.3)	0.2	4.6
Other assets	42.3	(31.7)	(52.0)
Amounts due (from) to subsidiaries	(983.1)	754.7	(497.2)
Accounts payable and accrued expenses	111.8	(34.5)	1.5
Other liabilities	(18.6)	8.9	(0.9)
Income taxes	83.9	(204.0)	35.3
Net cash provided by operating activities	2,116.5	2,972.4	2,778.0
Investing activities	,	,	,
Purchases of investments	(1,964.3)	(5,383.2)	(2,681.7)
Proceeds from sales, maturities, calls and redemptions of investments	2,443.3	5,554.5	3,689.6
Settlement of non-hedging derivatives	(109.8)	(59.8)	(96.6)
Capitalization of subsidiaries	(121.2)	(6,085.1)	(832.1)
Changes in securities lending collateral	(17.0)	73.8	17.3
(Purchases of) proceeds from sale of property and equipment, net	(87.4)	(117.1)	2.3
Other, net	(18.9)	(114.4)	(49.6)
Net cash used in investing activities	124.7	(6,131.3)	49.2
Financing activities		( ) /	
Net (repayments of) proceeds from commercial paper borrowings	(191.7)	(229.0)	463.7
Proceeds from long-term borrowings	1,250.0	6,468.9	1,097.4
Repayments of long term borrowings	(1,245.0)	(800.0)	(700.0)
Changes in securities lending payable	17.1	(72.7)	(17.3)
Changes in bank overdrafts	71.8	30.5	(66.9)
Premiums paid on equity options	(25.8)	0	(- 3.2)
Repurchase and retirement of common stock	(1,620.1)	(2,496.8)	(3,039.8)
Cash dividends	(465.9)	(380.9)	(369.8)
Cuon dividendo	(403.7)	(300.7)	(307.0)

Proceeds from issuance of common stock under employee stock plans	524.7	110.8	245.0
Excess tax benefits from share-based compensation	30.1	28.8	42.2
Net cash (used in) provided by financing activities	(1,654.8)	2,659.6	(2,345.5)
Change in cash and cash equivalents	586.4	(499.3)	481.7
Cash and cash equivalents at beginning of year	588.1	1,087.4	605.7
Cash and cash equivalents of continuing operations at end of year	\$ 1,174.5	\$ 588.1	\$ 1,087.4

Derivative Financial Instruments (Narrative) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
<b>Derivative Instruments and Hedging Activities Disclosure [Abstract]</b>		
<u>Unrecognized losses for all cash flow hedges included in accumulated other comprehensive income</u>	\$ 32.3	\$ 35.3
Total amount of amortization over the next twelve months for all cash flow hedges	\$ 5.0	

# 12 Months Ended Dec. 31, 2013

### **Capital [Abstract]**

## Capital Stock

#### **Capital Stock**

#### Stock Incentive Plans

On March 15, 2006, our Board of Directors adopted the WellPoint 2006 Incentive Compensation Plan, or the 2006 Plan, which was approved by our shareholders on May 16, 2006. On March 4, 2009, our Board of Directors approved an amendment and restatement of the 2006 Plan to increase the number of shares available by 33.0 shares, to rename the plan as the WellPoint Incentive Compensation Plan, or Incentive Plan, and to extend the term of the Incentive Plan such that no awards may be granted on or after May 20, 2019, which was approved by our shareholders on May 20, 2009.

The Incentive Plan gives authority to the Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The Incentive Plan, as amended and restated, increases the number of available shares for issuance to 60.1 shares, subject to adjustment as set forth in the Incentive Plan.

Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest over three years in equal semi-annual installments and generally have a term of seven years from the grant date.

Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which the fair value of the awards will be recognized.

Restricted stock awards are issued at the fair value of the stock on the grant date and may also include one or more performance measures that must be met for the restricted stock award to vest. The restrictions lapse in three equal annual installments.

For the years ended December 31, 2013, 2012 and 2011, we recognized share-based compensation cost of \$146.0, \$146.5 and \$134.8, respectively, as well as related tax benefits of \$52.6, \$52.0 and \$48.6, respectively.

A summary of stock option activity for the year ended December 31, 2013 is as follows:

	Number of Shares	Weighted- Average Option Price per Share	Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2013	17.8	\$ 64.67		
Granted	2.0	62.55		
Exercised	(8.4)	62.34		
Forfeited or expired	(1.4)	70.77		
Outstanding at December 31, 2013	10.0	65.38	3.3	\$ 270.9
Exercisable at December 31, 2013	7.6	66.04	2.6	\$ 199.9

The intrinsic value of options exercised during the years ended December 31, 2013, 2012 and 2011 amounted to \$176.0, \$65.4 and \$115.8, respectively. We recognized tax benefits of \$56.8, \$22.9 and \$42.9 in 2013, 2012 and 2011, respectively, from option exercises and disqualifying dispositions. During the years ended December 31, 2013, 2012 and 2011 we received cash of \$524.7, \$110.8 and \$245.0, respectively, from exercises of stock options.

The total fair value of restricted stock awards that vested during the years ended December 31, 2013, 2012 and 2011 was \$46.7, \$222.3 and \$120.2, respectively.

A summary of the status of nonvested restricted stock activity, including restricted stock units, for the year ended December 31, 2013 is as follows:

	Restricted Stock Shares and Units	Weig Aver Grant Fair V	rage t Date Value
Nonvested at January 1, 2013	2.6	\$	63.87
Granted	2.7		63.06
Vested	(0.6)		59.95
Forfeited	(0.5)		64.84
Nonvested at December 31, 2013	4.2		63.83

During the year ended December 31, 2013, we granted approximately 0.9 restricted stock units under the Incentive Plan that were contingent upon us achieving specified operating gain targets for 2013. We expect to issue approximately 1.2 restricted stock units under this performance plan as certain performance targets were exceeded. These restricted stock units have been included in the activity shown above.

As of December 31, 2013, the total remaining unrecognized compensation cost related to nonvested stock options and restricted stock amounted to \$10.5 and \$88.1, respectively, which will be amortized over the weighted-average remaining requisite service periods of 11 months and 12 months, respectively.

As of December 31, 2013, there were approximately 24.9 shares of common stock available for future grants under the Incentive Plan.

#### Fair Value

We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice model are based on an analysis of implied volatilities of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model, which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the "multiple-grant" approach for recognizing compensation expense associated with each separately vesting portion of the share-based award.

The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December 31:

	2013	2012	2011
Risk-free interest rate	1.25%	1.41%	2.84%
Volatility factor	35.00%	34.00%	34.00%
Dividend yield (annual)	2.40%	1.60%	1.50%
Weighted-average expected life (years)	4.0	4.1	4.0

The following weighted-average fair values were determined for the years ending December 31:

	2013		2012		2011
Options granted during the year	\$ 14.64	\$	16.50	\$	17.84
Restricted stock and stock awards granted during the year	63.06		65.91		66.16

The binomial lattice option-pricing model requires the input of highly subjective assumptions including the expected stock price volatility. Because our stock option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.

#### Employee Stock Purchase Plan

We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan, or the Stock Purchase Plan, which is intended to provide a means to encourage and assist employees in acquiring a stock ownership interest in WellPoint. The Stock Purchase Plan was suspended effective January 1, 2011, and no shares were issued during 2013, 2012 or 2011. Effective January 1, 2014, the Stock Purchase Plan is being reinstated. Pursuant to terms of the Stock Purchase Plan, an employee is permitted to purchase no

more than \$23,750 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter. Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the employee's investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a price per share of 95% of the fair value of a share of common stock on the last trading day of the plan quarter. As of December 31, 2013, 6.1 shares were available for issuance under the Stock Purchase Plan.

#### Use of Capital and Stock Repurchase Program

We regularly review the appropriate use of capital, including common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt are at the discretion of our Board of Directors and depend upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. Historically our common stock repurchase program, discussed below, has been our primary use of capital. Beginning in 2011, our Board of Directors established a quarterly dividend to shareholders.

A summary of the cash dividend activity for the years ended December 31, 2013 and 2012 is as follows:

Declaration Date	Record Date	Payment Date	Cash Dividend per Share	Total
Year Ended December 31, 2013				
February 20, 2013	March 8, 2013	March 25, 2013	\$ 0.3750	\$ 113.4
May 15, 2013	June 10, 2013	June 25, 2013	0.3750	112.7
July 23, 2013	September 10, 2013	September 25, 2013	0.3750	111.4
October 22, 2013	December 9, 2013	December 23, 2013	0.3750	110.5
Year Ended December 31, 2012				
January 24, 2012	March 9, 2012	March 23, 2012	\$ 0.2875	\$ 95.8
May 16, 2012	June 8, 2012	June 25, 2012	0.2875	93.5
July 24, 2012	September 10, 2012	September 25, 2012	0.2875	90.7
November 6, 2012	December 7, 2012	December 21, 2012	0.2875	87.1

On January 28, 2014, the Board of Directors declared a quarterly cash dividend to shareholders of \$0.4375 per share on the outstanding shares of our common stock. This quarterly dividend will be paid on March 25, 2014 to the shareholders of record as of March 10, 2014.

Under our Board of Directors' authorization, we maintain a common stock repurchase program. On September 25, 2013, the Board of Directors authorized a \$3,500.0 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.

A summary of common stock repurchases for the period January 1, 2014 through February 7, 2014 (subsequent to December 31, 2013) and for the years ended December 31, 2013 and 2012 is as follows:

	January 1, 2014 through February 7, 2014	Y	ears Ended	Dec	ember 31 2012
Shares repurchased	5.4		20.7		39.7
Average price per share	\$ 84.96	\$	78.08	\$	62.96

Aggregate cost	\$ 457.6	\$ 1,620.1	\$ 2,496.8
Authorization remaining at the end of each period	\$ 2,633.4	\$ 3,691.0	\$ 1,836.9

During 2013, we purchased call options on 3.0 shares of our common stock. The call options allow us to repurchase shares at a predetermined strike price up through the expiration dates. The purpose of the call options is to reduce share price volatility on potential future common stock repurchases. The aggregate premium paid was \$25.8, of which \$7.9 was recorded as a reduction of shareholders' equity and the remaining \$17.9 was recorded as a derivative asset based on FASB guidance. The aggregate premium is reported in financing activities in our consolidated statements of cash flow. The call options had strike prices ranging from \$77.50 to \$83.10 per share. The aggregate fair value of the call options reported as a derivative asset was \$27.5 at December 31, 2013. The call options were exercised on various dates throughout January and February 2014.

On February 4, 2014, we entered into an accelerated share repurchase, or ASR, program with a counterparty. The agreement provides for a repurchase of a number of shares, equal to \$600.0, as determined by the dollar volume weighted-average share price during a period up through at least March 14, 2014, but not to exceed March 31, 2014. At the end of the term of the ASR, the initial amount of shares will be adjusted up or down based on the dollar volume weighted-average price during the same period. On February 4, 2014, we repurchased 6.0 shares under this program. These ASR shares are not included in the shares repurchased subsequent to December 31, 2013 shown in the table above as the final shares to be repurchased will not be determined until the completion of the program in March 2014. However the \$600.0 has been removed from the authorization remaining as of February 7, 2014 in the table above.

## **Derivative Financial Instruments (Tables)**

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary Of Aggregate Contractual
Or Notional Amounts And
Estimated Fair Values

12 Months Ended Dec. 31, 2013

A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December 31, 2013 and 2012 is as follows:

		Contractual/ Notional				nted Fair alue	
		Amount	<b>Balance Sheet Location</b>	Asset	(L	iability)	
December 31, 2013							
<b>Hedging instruments</b>							
			Other assets/other			( <b>-</b> 0 <b>-</b> )	
Interest rate swaps	\$	1,660.0	liabilities	\$ 30.9	\$	(20.7)	
Non-hedging instruments							
Derivatives embedded in convertible securities		295.0	Fixed maturity securities	89.2			
Interest rate swaps		72.6	Equity securities	1.8		(2.5)	
			Equity securities/other			( 12 )	
Options		7,891.6	assets	776.5		(787.7)	
Futures			Equity securities	3.5		(1.6)	
Subtotal non-hedging		8,259.2	Subtotal non-hedging	871.0		(791.8)	
Total derivatives	\$	9,919.2	Total derivatives	901.9		(812.5)	
			Amounts netted	(791.8)		791.8	
			Net derivatives \$ 110.1		\$	(20.7)	
December 31, 2012							
<b>Hedging instruments</b>							
Total and order areas	Ф	1.650.0	Other assets/other	¢ 50.6	¢	(0.1)	
Interest rate swaps	\$	1,650.0	liabilities	\$ 58.6	\$	(0.1)	
Non-hedging instruments Derivatives embedded in							
convertible securities		278.8	Fixed maturity securities	67.2			
Credit default and interest rate							
swaps		95.9	Equity securities	_		(7.3)	
Options		6,271.8	Equity securities 385.			(411.2)	
Futures			Equity securities 2.1		_	(0.4)	
Subtotal non-hedging		6,646.5	Subtotal non-hedging 454.9		_	(418.9)	
Total derivatives	\$	8,296.5	Total derivatives	513.5		(419.0)	
			Amounts netted	(418.9)	_	418.9	
			Net derivatives	\$ 94.6	\$	(0.1)	

<u>Summary Of Outstanding Fair Value</u> <u>Hedges</u> A summary of our outstanding fair value hedges at December 31, 2013 and 2012 is as follows:

	Year Entered	ered Outstanding Notional Amount		nt Interest	
Type of Fair Value Hedges	Into			Received	<b>Expiration Date</b>
Interest rate swap	2013	\$ 10.0	\$ —	4.350 %	August 15, 2020
Interest rate swap	2012	200.0	200.0	4.350	August 15, 2020
Interest rate swap	2012	625.0	625.0	1.875	January 15, 2018
					February 15,
Interest rate swap	2012	200.0	200.0	2.375	2017
Interest rate swap	2011	200.0	200.0	5.250	January 15, 2016
Interest rate swap	2010	25.0	25.0	5.250	January 15, 2016
					December 15,

Interest rate swap	2006	200.0	200.0	5.000	2014
Interest rate swap	2005	200.0	200.0	5.000	December 15, 2014
Total notional amount outstanding		\$ 1,660.0	\$ 1,650.0		

## Effect Of Fair Value Hedges On **Income Statement**

A summary of the effect of fair value hedges on our income statement for the years ended December 31, 2013, 2012 and 2011 is as follows:

Type of Fair Value Hedges	Income Statement Location of Hedge Gain	Hedge Gain Recognized	Hedged Item	Income Statement Location of Hedged Item Loss	Hedged Item Loss Recognized
Year ended December 31, 2013					
Interest rate swaps	Interest expense	\$ 31.5	Fixed rate debt	Interest expense	\$ (31.5)
Year ended December 31, 2012					
Interest rate swaps	Interest expense	\$ 38.2	Fixed rate debt	Interest expense	\$ (38.2)
Year ended December 31, 2011					
Interest rate swaps	Interest expense	\$ 45.1	Fixed rate debt	Interest expense	\$ (45.1)

## Effect Of Cash Flow Hedges On **Financial Statements**

A summary of the effect of cash flow hedges on our financial statements for the years ended December 31, 2013, 2012 and 2011 is as follows:

		<b>Effective Portion</b>			
		Income Statement Location of Loss	Hedge Loss	Ineffectiv	ve Portion
Type of Cash Flow Hedge	Pretax Hedge Loss Recognized in Other Comprehensive (Loss) Income	Reclassification from Accumulated Other Comprehensive Income	Reclassified from Accumulated Other Comprehensive Income	Income Statement Location of Loss Recognized	Hedge Loss Recognized
Year ended December 31, 2013					
Forward starting pay fixed swaps	\$ —	Interest expense	\$ (4.6)	None	\$
Year ended December 31, 2012					
Forward starting pay fixed swaps	\$ (4.0)	Interest expense	\$ (4.2)	Interest expense	\$ (0.1)
Year ended December 31, 2011					
Forward starting pay fixed swaps	\$ (18.2)	Interest expense	\$ (1.8)	None	<u>\$</u>

Effect Of Non-Hedging Derivatives Non-Hedging Derivatives On Income Statement And Included In Net Realized Gains (Losses) On Investments

A summary of the effect of non-hedging derivatives on our income statement for the years ended December 31, 2013, 2012 and 2011 is as follows:

Type of Non-hedging Derivatives	Gain (Loss) Recognized	Recognized		
Year ended December 31, 2013				
Derivatives embedded in convertible securities	Net realized gains on investments	\$	31.5	
Interest rate swaps	Net realized gains on investments		2.2	
Options	Net realized gains on investments		(111.7)	
Futures	Net realized gains on investments		22.3	
Swaptions	Net realized gains on investments	\$	3.0	
Total		\$	(52.7)	
Year ended December 31, 2012				
Derivatives embedded in convertible securities	Net realized gains on investments	\$	(2.4)	
Credit default and interest rate swaps	Net realized gains on investments		(3.9)	
Options	Net realized gains on investments		(66.0)	
Futures	Net realized gains on investments		(6.7)	
Total		\$	(79.0)	
Year ended December 31, 2011				
Derivatives embedded in convertible securities	Net realized gains on investments	\$	(7.6)	
Credit default and interest rate swaps	Net realized gains on investments		(53.3)	
Options	Net realized gains on investments		9.6	
Futures	Net realized gains on investments		(5.9)	
Total		\$	(57.2)	

## 12 Months Ended

Earliest Date for Conversion

Apr. 15, 2042

### 9 Months Ended

Debt (Narrative) (Details) (USD \$)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 25, 2013 7.500%, due 2019 [Member]	Aug. 01, 2012 Senior Unsecured Notes [Member]	Sep. 30, 2013 Senior Unsecured Notes [Member] 2.300%, due 2018 [Member]	Senior Unsecured Notes [Member]	Jul. 30, 2013 Senior Unsecured Notes [Member] 5.100%, due 2044 [Member]	Senior Unsecured Notes [Member]	T []
Debt Instrument [Line Items] Short-term FHLB borrowings outstanding Debt instrument interest rate Debt redemption date	\$ 400,000,000	\$ 250,000,000			6.80%		2.30%	5.10%	1.25%	1.8
Repurchased face amount Early repayment of senior debt Loss on extinguishment of debt Tender offer initiation date Repurchase tender offer, maximum amount Repurchase tender offer, additional amount of increase Date of increase to tender offer	145,300,000	0 0	)							
Repurchase tender offer, maximum amount after increase Issue date  Long-term debt face amount Maturity date on long-term debt	1,500,000,000					Jul. 30, 2013	650,000,000.0	600,000,000.0	625,000,000.0	1625
Repayments of Senior Debt Estimated fair value Debt Redemption Redemption Percent Line of credit facility, maximum	2,000,000,000.0			555,600,000 117.00%						
borrowing capacity		1								
Line of Credit Maturity Date Line of credit facility, amount	Sep. 29, 2016 0	0								
ouststanding Commercial paper authorized	2,500,000,000.0									
Weighted average interest rate on commercial paper borrowings	0.420/	0.396%								
Convertible Debt [Abstract]	•									
Number of trading days in 30 day period greater than 130%	20 years									
Number of trading days exceeding 130%	30 days									
Product of Conversion to Stock Price	130.00%									
Required days trading price less than 98%	5 days									
Measurement Period for testing	10 days									
Percent of Conversion Price to Closing Price	98.00%									
Fouliant Data for Conversion	Amm 15 2042									

Date debentures redeemable at

our option

Initial conversion rate (per

13.2917 \$1000 of principal)

Conversion premium (%)

Closing Price Company Stock

If-converted value per dollar

above the conversion price

Initial conversion price (per share \$ 75.2345

of stock)

Amount of debenture proceeds

to repurchase stock

Amortization period debt

discount

29 years

Effective interest rate

<u>Debentures Interest Expense</u>

Stated Interest Expense

<u>Debenture Amortization Expense</u>

Interest paid 597,200,000 479,100,000 432,900,000

Future maturities of debt in 2014 897,200,000

Future maturities of debt in 2015 624,900,000

Future maturities of debt in 2016 1,109,600,000

Future maturities of debt in 2017 944,700,000

Future maturities of debt in 2018 1,262,000,000

Future maturities of debt Thereafter

\$ 9,253,200,000

Segment Information (Reconciliation Of Operating Gain To Income From Reportable Segments To The Consolidated Statements Of Income) (Details) (USD \$) In Millions, unless otherwise

## 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

specified

# **Segment Reporting [Abstract]**

Reportable segments operating gain	\$ 4,001.4	\$ 3,619.9	\$ 3,782.1
Net investment income	659.1	686.1	703.7
Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)
<u>Interest expense</u>	(602.7)	(511.8)	(430.3)
Amortization of other intangible assets	(245.3)	(233.0)	(239.4)
Loss on extinguishment of debt	(145.3)	0	0
Loss before income tax credits and equity in net income of subsidiaries	\$ 3,840.2	\$ 3,858.3	\$ 3,957.9

### Reinsurance

# 12 Months Ended Dec. 31, 2013

# Reinsurance Disclosures [Abstract]

Reinsurance

#### Reinsurance

We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations.

We evaluate the financial condition of our reinsurers and monitor concentrations of credit risk arising from similar geographic regions, activities, or economic characteristics of the reinsurers to minimize our exposure to significant losses from reinsurer insolvencies.

A summary of direct, assumed and ceded premiums written and earned for the years ended December 31 is as follows:

	2013		20	)12	2011		
	Written	Earned	Written	Earned	Written	Earned	
Direct	\$65,939.1	\$66,038.9	\$56,443.6	\$56,373.6	\$56,190.3	\$55,875.8	
Assumed	174.3	174.0	197.0	196.4	179.9	178.5	
Ceded	(92.6)	(93.8)	(73.2)	(73.3)	(84.2)	(84.7)	
Net premiums	\$66,020.8	\$66,119.1	\$56,567.4	\$56,496.7	\$56,286.0	\$55,969.6	
Percentage—assumed to net premiums	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	

A summary of net premiums written and earned by segment (see Note 20, "Segment Information") for the years ended December 31 is as follows:

	2013		20	012	2011		
	Written	Earned	Written	Earned	Written	Earned	
Reportable segments:							
Commercial and Specialty Business	\$ 35,126.0	\$ 35,159.8	\$ 35,352.1	\$ 35,251.9	\$ 36,476.3	\$ 36,436.7	
Government Business	30,894.8	30,959.3	21,215.3	21,244.8	19,809.7	19,532.9	
Other	_	_	_	_	_	_	
Net premiums	\$ 66,020.8	\$ 66,119.1	\$ 56,567.4	\$ 56,496.7	\$ 56,286.0	\$ 55,969.6	

The effect of reinsurance on benefit expense for the years ended December 31 is as follows:

	2013	2012	2011
Direct	\$ 56,185.2	\$ 48,135.1	\$ 47,569.8
Assumed	155.6	173.0	165.0
Ceded	(103.7)	 (94.5)	 (87.3)
Net benefit expense	\$ 56,237.1	\$ 48,213.6	\$ 47,647.5

The effect of reinsurance on certain assets and liabilities at December 31 is as follows:

	2013		2012	
Policy liabilities, assumed	\$	55.4	\$	62.4
Unearned income, assumed		0.4		0.5
Premiums payable, ceded		17.1		18.1
Premiums receivable, assumed		14.1		16.6

Derivative Financial Instruments (Effect Of Fair Value Hedges On Income	12 Months Ended				
Statement) (Details) (Interest Expense [Member], Fixed Rate Debt [Member], Interest Rate Swaps [Member], USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
Interest Expense [Member]   Fixed Rate Debt [Member]   Interest Rate Swaps [Member]					
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>					
Hedge Gain (Loss) Recognized	\$ 31.5	\$ 38.2	\$ 45.1		
Hedged Item Gain (Loss) Recognized	\$ (31.5)	\$ (38.2)	\$ (45.1)		

Capital Stock (Share Repurchases) (Details) (USD	12 Months Ended			0 Months Ended	1 Months Ended	
\$) In Millions, except Per Share data, unless otherwise specified	Dec. 31, Dec. 31, Dec. 31, 2013 2012 2011		Feb. 04, 2014 Subsequent Event [Member]	Feb. 07, 2014 Subsequent Event [Member]		
Equity, Class of Treasury Stock [Line Items]						
Shares repurchased	20.7	39.7		6.0	5.4	
Average price per share	\$ 78.08	\$ 62.96			\$ 84.96	
Aggregate cost	\$ 1,620.1	\$ 2,496.8	\$ 3,039.8		\$ 457.6	
Authorization remaining at the end of each period	\$ 3,691.0	\$ 1,836.9			\$ 2,633.4	

Consolidated Statements of Shareholders' Equity (USD \$) In Millions, unless otherwise specified	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]
Balance at Dec. 31, 2010	\$ 23,812.6	\$ 3.8	\$ 12,862.6	\$ 10,721.6	\$ 224.6
Balance (in shares) at Dec. 31, 2010	23,812.0	377.7			
Increase (Decrease) in Stockholders'		311.1			
Equity [Roll Forward]					
Net income	2,646.7			2,646.7	
Other comprehensive income (loss)	(109.7)				(109.7)
Repurchase and retirement of common stock	(3,039.8)	(0.4)	(1,523.2)	(1,516.2)	
Repurchase and retirement of common stock, shares		(44.5)			
Dividends and dividend equivalents	(361.4)			(361.4)	
<u>Issuance of common stock under employee</u> stock plans, net of related tax benefits	339.8		339.8		
Issuance of common stock under employee		<i>-</i> 2			
stock plans, net of related tax benefits (in shares)		6.2			
Balance at Dec. 31, 2011	23,288.2	3.4	11,679.2	11,490.7	114.9
Balance (in shares) at Dec. 31, 2011	,	339.4	,	,	
Increase (Decrease) in Stockholders'					
<b>Equity [Roll Forward]</b>					
Net income	2,655.5			2,655.5	
Other comprehensive income (loss)	184.2				184.2
Repurchase and retirement of common stock	(2,496.8)	(0.4)	(1,368.5)	(1,127.9)	
Repurchase and retirement of common	(20.7)	(20.7)			
stock, shares	(39.7)	(39.7)			
<u>Dividends and dividend equivalents</u>	(371.2)			(371.2)	
Issuance of convertible debentures	331.5		331.5		
Conversion of stock awards in connection with AMERIGROUP Corporation acquisition	19.7		19.7		
Issuance of common stock under employee stock plans, net of related tax benefits	191.6		191.6		
Issuance of common stock under employee stock plans, net of related tax benefits (in		5.0			
shares)	22 002 7	2.0	10.050.5	10 < 15 1	200.1
Balance at Dec. 31, 2012	23,802.7		10,853.5	12,647.1	299.1
Balance (in shares) at Dec. 31, 2012  Increase (Decrease) in Stockholders'		304.7			
Equity [Roll Forward]					
Net income	2,489.7			2,489.7	
Other comprehensive income (loss)	(115.9)				(115.9)
Premiums paid on equity options	(7.9)		(7.9)		

Repurchase and retirement of common stock	(1,620.1)	(0.1)	(749.5)	(870.5)	
Repurchase and retirement of common stock, shares	(20.7)	(20.7)			
Convertible debentures tax adjustment	(3.3)		(3.3)		
Dividends and dividend equivalents	(452.4)			(452.4)	
<u>Issuance of common stock under employee</u> <u>stock plans, net of related tax benefits</u>	672.4		672.4		
Issuance of common stock under employee stock plans, net of related tax benefits (in shares)		9.3			
Balance at Dec. 31, 2013	\$ 24,765.2	\$ 2.9	\$ 10,765.2	\$ 13,813.9	\$ 183.2
Balance (in shares) at Dec. 31, 2013		293.3			

## Consolidated Balance Sheets (Parenthetical) (USD \$) In Millions, except Share data, unless otherwise specified

Dec. 31, 2013 Dec. 31, 2012

## **Statement of Financial Position [Abstract]**

Fixed maturity securities investments, amortized cost	\$ 16,826.7	\$ 16,033.1
Equity securities investments, cost	1,168.5	869.9
Fixed maturity securities long-term investment, amortized cost	455.9	426.0
Equity securities long-term investments, cost	\$ 27.4	\$ 27.1
Preferred stock, par value	\$ 0	\$ 0
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	\$ 0.01	\$ 0.01
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	293,273,830	304,715,144
Common stock, shares outstanding	293,273,830	304,715,144

## Goodwill And Other Intangible Assets

## **Goodwill and Intangible Assets Disclosure [Abstract]**

Goodwill And Other Intangible Assets

# 12 Months Ended Dec. 31, 2013

#### **Goodwill and Other Intangible Assets**

A summary of the change in the carrying amount of goodwill by reportable segment (see Note 20, "Segment Information") for 2013 and 2012 is as follows:

	an	ommercial d Specialty Business	 vernment Susiness	0	ther	Total
Balance as of January 1, 2012	\$	11,555.6	\$ 2,303.1	\$		\$13,858.7
Amerigroup acquisition		_	3,033.1		_	3,033.1
Measurement period adjustments		(0.3)	(1.7)		_	(2.0)
Balance as of December 31, 2012	\$	11,555.3	\$ 5,334.5			\$16,889.8
Measurement period adjustments		(1.3)	28.7			27.4
Balance as of December 31, 2013	\$	11,554.0	\$ 5,363.2			\$16,917.2
Accumulated impairment as of December 31, 2013	\$	(41.0)	\$ 			\$ (41.0)

Goodwill adjustments incurred during 2013 and 2012 included a reduction of \$1.5 and \$0.4, respectively, related to the tax benefit on the exercise of stock options issued as part of various acquisitions and an increase of \$28.9 and a decrease of \$1.6, respectively, related to other measurement period adjustments.

As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2013, 2012 and 2011. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and require a significant degree of management judgment and the use of subjective assumptions. The fair values were estimated using the income and market value valuation methods, incorporating Level III internal estimates for inputs, including, but not limited to, revenue projections, income projections, cash flows and discount rates. We did not incur any impairment losses in 2013, 2012 or 2011 as the estimated fair values of our reporting units were substantially in excess of their carrying values.

The components of other intangible assets as of December 31 are as follows:

			2013			2012			
	Gross Carrying Accumulated Amount Amortization		Net Carrying Amount	Gross Carrying Amount	Carrying Accum		Net Carrying Amount		
Intangible assets with finite lives:									
Customer relationships	\$ 3,308.9	\$	(2,264.2)	\$ 1,044.7	\$ 3,334.8	\$	(2,058.0)	\$ 1,276.8	
Provider and hospital relationships	140.5		(44.7)	95.8	140.5		(38.1)	102.4	
Other	61.7		(28.3)	33.4	66.1		(26.9)	39.2	
Total	3,511.1		(2,337.2)	1,173.9	3,541.4		(2,123.0)	1,418.4	
Intangible assets with indefinite lives:									
Blue Cross and Blue Shield and other trademarks	6,298.7		_	6,298.7	6,298.7		_	6,298.7	
Provider network	271.8		_	271.8	271.8		_	271.8	
State Medicaid contracts	696.6		_	696.6	676.6		_	676.6	
Total	7,267.1			7,267.1	7,247.1			7,247.1	
Other intangible assets	\$10,778.2	\$	(2,337.2)	\$ 8,441.0	\$10,788.5	\$	(2,123.0)	\$ 8,665.5	

As of December 31, 2013, the estimated amortization expense for each of the five succeeding years is as follows: 2014, \$213.3; 2015, \$182.1; 2016, \$151.4; 2017, \$131.5; and 2018, \$111.7.

Capital Stock (Summary Of Stock Option Activity) (Details) (USD \$)	12 Months Ended		
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013		
Number of Shares			
Outstanding at beginning of period, Number of Shares	17.8		
Granted, Number of Shares	2.0		
Exercised, Number of Shares	(8.4)		
Forfeited or expired, Number of Shares	(1.4)		
Outstanding at end of period, Number of Shares	10.0		
Exercisable at end of period, Number of Shares	7.6		
Weighted-Average Option Price per Share			
Outstanding at beginning of period, Weighted-Average Option Price per Share	<u>e</u> \$ 64.67		
Granted, Weighted-Average Option Price per Share	\$ 62.55		
Exercised, Weighted-Average Option Price per Share	\$ 62.34		
Forfeited or expired, Weighted-Average Option Price per Share	\$ 70.77		
Outstanding at end of period, Weighted-Average Option Price per Share	\$ 65.38		
Exercisable at end of period, Weighted-Average Option Price per Share	\$ 66.04		
Outstanding at end of period, Weighted-Average Remaining Contractual Life	3 years 4 months		
Exercisable at end of period, Weighted-Average Remaining Contractual Life	2 years 7 months		
Outstanding at end of period, Aggregate Intrinsic Value	\$ 270.9		
Exercisable at end of period, Aggregate Intrinsic Value	\$ 199.9		

Retirement Benefits (Reconciliation Of The Beginning And Ending Balances Of Plan Assets	12 Months Ended					
Measured At Fair Value Using Level III Inputs) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input						
Reconciliation, Calculation [Roll Forward]						
Beginning balance	\$ 583.9	\$ 774.9	\$ 771.7			
Actual return on plan assets, relating to assets still held at the reporting date	22.9	23.2	14.3			
<u>Purchases</u>	25.1	117.7	113.9			
Sales	(44.2)	(331.9)	(125.0)			
Ending balance	587.7	583.9	774.9			
U.S. Equity Securities [Member]						
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]						
Beginning balance	0	317.6	429.8			
Actual return on plan assets, relating to assets still held at the reporting date	0	0	4.8			
Purchases	0	0	0			
Sales	0	(317.6)	(117.0)			
Ending balance	0	0	317.6			
Partnership Interests [Member]	U	U	317.0			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input						
Reconciliation, Calculation [Roll Forward]						
Beginning balance	177.7	166.1	153.1			
Actual return on plan assets, relating to assets still held at the reporting date	2.2	4.5	5.8			
Purchases	15.6	14.1	7.6			
Sales	(35.2)	(7.0)	(0.4)			
Ending balance	160.3	177.7	166.1			
Insurance Company Contracts [Member]						
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]						
Beginning balance	202.5	195.5	188.8			
Actual return on plan assets, relating to assets still held at the reporting date	(5.6)	5.5	2.7			
Purchases	9.5	8.8	11.6			
Sales	(9.0)	(7.3)	(7.6)			
Ending balance	197.4	202.5	195.5			
Life Insurance Contracts [Member]						
Fair Value, Assets Measured on Recurring Basis, Unobservable Input						
Reconciliation, Calculation [Roll Forward]						
Beginning balance	203.7	95.7	0			
Actual return on plan assets, relating to assets still held at the reporting date	26.3	13.2	1.0			
<u>Purchases</u>	0	94.8	94.7			
Sales	0	0	0			

Ending balance \$ 230.0 \$ 203.7 \$ 95.7

## Retirement Benefits (Weighted-Average Assumptions Used In

Assumptions Used In Calculating Net Periodic

Benefit Cost For All Plans)

(Details)

## 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

Pension	Benefits	[Member]	J
---------	----------	----------	---

Discount rate	3.60%	4.29%	5.15%				
Rate of compensation increase	3.50%	3.50%	3.75%				
Expected rate of return on plan assets	7.91%	8.00%	8.00%				
Other Benefits [Member]							
Defined Benefit Plan Disclosure [Line Items]							
Discount rate	3.71%	4.36%	5.24%				
Rate of compensation increase	3.50%	3.50%	3.75%				
Expected rate of return on plan assets	7.00%	7.00%	6.75%				

Segment Information (Reconciliation Of Revenue From Reportable Segments				3 Month	ıs Ended				12 N	Months E	nded
To The Consolidated Statements Of Income) (Details) (USD \$) In Millions, unless otherwise specified	2013	, Sep. 30, 2013		Mar. 31, 2013		Sep. 30, 2012	-	Mar. 31, 2012		Dec. 31, 2012	, Dec. 31, 2011
Segment Reporting [Abstract]	l										
Reportable segments operating									\$	\$	\$
revenues									70,191.4	60,514.0	59,865.2
Net investment income									659.1	686.1	703.7
Net realized gains on investments									271.9	334.9	235.1
Other-than-temporary											
impairment losses recognized in									(98.9)	(37.8)	(93.3)
income											
<u>Total revenues</u>	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
	17,901.7	7 17,855.5	17,690.3	17,576.0	15,438.3	15,247.4	15,396.3	15,415.2	71,023.5	61,497.2	2 60,710.7

Schedule II-Condensed Financial Information Of Registrant (Narrative) (Details) (WellPoint, Inc. [Member], USD \$)

## 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

In Millions, unless otherwise specified

WellPoint, Inc. [Member]

Cash dividends from subsidiaries	\$ 3,046.5	\$ 2,935.1	\$ 2,915.9
Common stock, cash dividends paid to subsidiaries	17.9	13.8	12.0
Capital contribution to subsidiaries	121.2	6,085.1	832.1
Net due from subsidiaries	893.4		
Net due to subsidiaries		\$ 89.7	

## 12 Months Ended

Segment Information (Narrative) (Details)	Dec. 31, 2013 segment	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting [Abstract]			
Number of Reportable Segments	3		
Percentage of revenue generated from participation in various federal government programs	20.30%	23.70%	23.50%

Document And Entity 12 Months Ended

Information (USD \$) Dec. 31, 2013 Feb. 07, 2014 Jun. 28, 2013

**Document and Entity Information** 

Document Type 10-K
Amendment Flag false

<u>Document Period End Date</u> Dec. 31, 2013

Document Fiscal Year Focus2013Document Fiscal Period FocusFYTrading SymbolWLP

Entity Registrant Name WellPoint, Inc.
Entity Central Index Key 0001156039
Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Entity Current Reporting StatusYesEntity Voluntary FilersNoEntity Well-known Seasoned IssuerYes

Entity Public Float \$24,439,366,963

Entity Common Stock, Shares Outstanding 282,459,121

Statutory Information		3 Months Ended						12 Months Ended					
(Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	50,	50,	Mar. 31, 2013	Dec. 31, 2012	50,	Jun. 30, 2012	,	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	
Statutory Accounting Practices [Line Items]													
Statutory risk-based capital necessary to satisfy regulatory requirements	\$ 3,500.0				\$ 3,400.0				\$ 3,500.0	\$ 3,400.0			
GAAP equity	24,765.2				23,802.7				24,765.2	23,802.7	23,288.2	23,812.6	
Net income	148.2	656.2	800.1	885.2	464.2	691.2	643.6	856.5	2,489.7	2,655.5	2,646.7		
California Department of Managed Health Care [Member]	]												
Statutory Accounting Practices [Line Items]													
Statutory risk-based capital necessary to satisfy regulatory requirements	450.0				450.0				450.0	450.0			
Insurance And HMO Subsidiaries [Member]													
Statutory Accounting Practices [Line Items]													
Statutory-basis capital and surplus	10,003.0				9,967.7				10,003.0	9,967.7			
Statutory-basis net income									2,594.8	2,800.0	2,402.5		
DHMC Regulated Entities [Member]													
Statutory Accounting Practices [Line Items]													
GAAP equity	1,449.2				1,312.5				1,449.2	1,312.5			

Net income

\$ 487.7 \$ 469.7 \$ 524.3

#### **Retirement Benefits**

12 Months Ended Dec. 31, 2013

Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]

**Retirement Benefits** 

#### **Retirement Benefits**

We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.

The WellPoint Cash Balance Pension Plan, or the WellPoint Plan, is a cash balance pension plan covering certain eligible employees of the affiliated companies that participate in the WellPoint Plan. Effective January 1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met grandfathering rules continue to accrue benefits. Several pension plans acquired through various corporate mergers and acquisitions have been merged into the WellPoint Plan. Effective January 1, 2011, we split the WellPoint Plan, with no change in benefits for any participant. Current employees who are still receiving credits and/or benefit accruals were placed into a new plan, the WellPoint Cash Balance Pension Plan B. All other participants remain in the WellPoint Plan. Effective January 1, 2012, the WellPoint Plan was renamed the WellPoint Cash Balance Pension Plan A.

The UGS Pension Plan is a defined benefit pension plan with a cash balance component. The UGS Pension Plan covers eligible employees of the affiliated companies that participate in the UGS Pension Plan. Effective January 1, 2004, benefits were curtailed, with the result that most participants stopped accruing benefits but continue to earn interest on benefits previously accrued. Certain employees subject to collective bargaining and certain other employees who met grandfathering rules continue to accrue benefits.

The Employees' Retirement Plan of Blue Cross of California, or the BCC Plan, is a defined benefit pension plan that covers eligible employees of Blue Cross of California who are covered by a collective bargaining agreement. Effective January 1, 2007, benefits were curtailed under the BCC Plan with the result that no Blue Cross of California employees hired or rehired after December 31, 2006 are eligible to participate in the BCC Plan.

All of the plans' assets consist primarily of common stocks, fixed maturity securities, investment funds and short-term investments. The funding policies for all plans are to contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended, or ERISA, including amendment by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are necessary to provide assets sufficient to meet the benefits to be paid to plan participants.

We use a December 31 measurement date for determining benefit obligations and fair value of plan assets.

The following tables disclose consolidated "pension benefits," which include the defined benefit pension plans described above, and consolidated "other benefits," which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were computed using assumptions at the December 31 measurement dates.

The reconciliation of the benefit obligation is as follows:

	Pension	Benefits	Other l	Benefits
	2013	2012 2013		2012
Benefit obligation at beginning of year	\$1,948.5	\$1,851.3	\$ 623.0	\$ 651.3
Service cost	14.2	16.4	6.7	6.8
Interest cost	67.8	76.4	22.4	27.5
Actuarial (gain) loss	(129.9)	129.6	4.8	(28.4)
Benefits paid	(135.9)	(125.2)	(49.4)	(34.2)
Benefit obligation at end of year	\$1,764.7	\$1,948.5	\$ 607.5	\$ 623.0

The changes in the fair value of plan assets are as follows:

	Pension	Benefits	Other I	Benefits		
	2013			2012		
Fair value of plan assets at beginning of year	\$1,817.9	\$1,721.8	\$ 320.3	\$ 301.1		
Actual return on plan assets	223.4	186.8	37.0	21.9		
Employer contributions	38.6	34.5	31.3	38.4		
Benefits paid	(135.9)	(125.2)	(38.8)	(41.1)		
Fair value of plan assets at end of year	\$1,944.0	\$1,817.9	\$ 349.8	\$ 320.3		

The net amount included in the consolidated balance sheets is as follows:

	Pension	Benefits	Other	Benefits
	2013	2013 2012 2013		2012
Noncurrent assets	\$ 240.8	\$ 3.0	\$ —	\$ —
Current liabilities	(3.5)	(11.5)	_	_
Noncurrent liabilities	(58.0)	(122.1)	(257.7)	(302.7)
Net amount at December 31	\$ 179.3	\$ (130.6)	\$ (257.7)	\$ (302.7)

The net amounts included in accumulated other comprehensive loss (income) that have not been recognized as components of net periodic benefit costs are as follows:

	Pension	Benefits	Other 1	Benefits
	2013	2013 2012 20		
Net actuarial loss	\$ 427.2	\$ 686.8	\$ 169.6	\$ 191.0
Prior service credit	(3.0)	(3.9)	(102.4)	(103.0)
Net amount before tax at December 31	\$ 424.2	\$ 682.9	\$ 67.2	\$ 88.0

The estimated net actuarial loss and prior service credit for the defined benefit pension plans that will be reclassified from accumulated other comprehensive loss into net periodic benefit costs over the next year are \$18.8 and \$0.8, respectively. The estimated net actuarial loss and prior service credit for postretirement benefit plans that will be reclassified from accumulated other comprehensive loss into net periodic benefit costs over the next year are \$9.4 and \$14.5, respectively.

The accumulated benefit obligation for the defined benefit pension plans was \$1,758.2 and \$1,941.8 at December 31, 2013 and 2012, respectively.

As of December 31, 2013, certain pension plans had accumulated benefit obligations in excess of plan assets. For those same plans, the projected benefit obligation was also in excess of plan assets. Such plans had a combined projected benefit obligation, accumulated benefit obligation and fair value of plan assets of \$60.7, \$60.7 and \$0.0, respectively.

The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:

	Pension 1	Benefits	Other B	enefits
	2013	2012	2013	2012
Discount rate	4.39%	3.60%	4.48%	3.71%
Rate of compensation increase	3.00%	3.50%	3.00%	3.50%
Expected rate of return on plan assets	7.66%	7.66%	7.00%	7.00%

The components of net periodic benefit cost included in the consolidated statements of income are as follows:

	2	2013	2012	2	2011
Pension Benefits					
Service cost	\$	14.2	\$ 16.4	\$	17.3

Interest cost	67.8	76.4	84.7
Expected return on assets	(133.1)	(134.7)	(128.2)
Recognized actuarial loss	28.3	30.5	26.4
Amortization of prior service credit	(0.8)	(0.8)	(0.8)
Settlement loss	11.0	13.8	21.3
Net periodic benefit cost	\$ (12.6)	\$ 1.6	\$ 20.7
Other Benefits			
Service cost	\$ 6.7	\$ 6.8	\$ 6.3
Interest cost	22.4	27.5	31.4
Expected return on assets	(22.1)	(21.0)	(17.3)
Recognized actuarial loss	11.2	14.1	10.2
Amortization of prior service credit	(13.3)	(13.3)	(12.0)
Net periodic benefit cost	\$ 4.9	\$ 14.1	\$ 18.6

During the years ended December 31, 2013, 2012 and 2011 we incurred total settlement losses of \$11.0, \$13.8 and \$21.3, respectively, as lump-sum payments exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.

The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:

2013	2012	2011
3.60%	4.29%	5.15%
3.50%	3.50%	3.75%
7.91%	8.00%	8.00%
3.71%	4.36%	5.24%
3.50%	3.50%	3.75%
7.00%	7.00%	6.75%
	3.60% 3.50% 7.91% 3.71% 3.50%	3.60% 4.29% 3.50% 3.50% 7.91% 8.00% 3.71% 4.36% 3.50% 3.50%

The assumed health care cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other benefits at our December 31, 2013 measurement date was 8.00% for 2014 with a gradual decline to 4.50% by the year 2025. The assumed health care cost trend rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2013 measurement date was 6.00% for 2014 with a gradual decline to 4.50% by the year 2021. These estimated trend rates are subject to change in the future. The health care cost trend rate assumption has a significant effect on the amounts reported. For example, an increase in the assumed health care cost trend rate of one percentage point would increase the postretirement benefit obligation as of December 31, 2013 by \$44.2 and would increase service and interest costs by \$1.8. Conversely, a decrease in the assumed health care cost trend rate of one percentage point would decrease the postretirement benefit obligation by \$38.1 as of December 31, 2013 and would decrease service and interest costs by \$1.5.

Plan assets include a diversified mix of investment grade fixed maturity securities, equity securities and alternative investments across a range of sectors and levels of capitalization to maximize the long-term return for a prudent level of risk. The weighted-average target allocation for pension benefit plan assets is 45% equity securities, 46% fixed maturity securities, and 9% to all other types of investments. Equity securities primarily include a mix of domestic securities, foreign securities and mutual funds invested in equities. Fixed maturity securities primarily include treasury securities, corporate bonds, and asset-backed investments issued by corporations and the U.S. government. Other types of investments include partnership interests, collective trusts that replicate money market funds and insurance contracts designed specifically for employee benefit plans. As of December 31, 2013, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were invested in WellPoint common stock.

Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value.

The fair values of our pension benefit assets and other benefit assets at December 31, 2013, excluding \$3.9 of cash, investment income receivable and amounts due to/from brokers, by asset category and level inputs, as defined by FASB guidance regarding fair value measurements and disclosures (see Note 7, "Fair Value," for additional information regarding the definition of level inputs), are as follows:

	Level I		Level II		Le	evel III		Total	
December 31, 2013:									
Pension Benefit Assets:									
Equity securities:									
U.S. securities	\$	613.8	\$	_	\$	_	\$	613.8	
Foreign securities		296.8		_		_		296.8	
Mutual funds		37.4		_		_		37.4	
Fixed maturity securities:									
Government securities		177.9		11.5		_		189.4	
Corporate securities		_		272.1		_		272.1	
Asset-backed securities		_		127.0		_		127.0	
Other types of investments:									
Common and collective trusts				46.6		_		46.6	
Partnership interests		_		_		159.1		159.1	
Insurance company contracts				_		197.4		197.4	
Treasury futures contracts		0.7						0.7	
Total pension benefit assets	\$	1,126.6	\$	457.2	\$	356.5	\$	1,940.3	
Other Benefit Assets:									
Equity securities:									
U.S. securities	\$	39.0	\$	_	\$	_	\$	39.0	
Foreign securities		18.6		_		_		18.6	
Mutual funds		4.7		_		_		4.7	
Fixed maturity securities:									
Government securities		14.3		_		_		14.3	
Corporate securities		4.3		9.9		_		14.2	
Asset-backed securities				11.2		_		11.2	
Other types of investments:									
Common and collective trusts				2.2		_		2.2	
Partnership interests		_		_		1.2		1.2	
Life insurance contracts		_		_		230.0		230.0	
Investment in DOL 103-12 trust				14.2				14.2	
Total other benefit assets	\$	80.9	\$	37.5	\$	231.2	\$	349.6	

The fair values of our pension benefit assets and other benefit assets at December 31, 2012, excluding \$3.2 of cash, investment income receivable and amounts due to/from brokers, by asset category and level inputs, as defined by FASB guidance regarding fair value measurements and disclosures (see Note 7, "Fair Value," for additional information regarding the definition of level inputs) are as follows:

	Level I	Level II	Level III	Total
December 31, 2012:				
Pension Benefit Assets:				
Equity securities:				
U.S. securities	\$ 514.3	\$ —	\$	\$ 514.3
Foreign securities	272.5	_	_	272.5
Mutual funds	30.9	_	_	30.9
Fixed maturity securities:				
Government securities	192.1	18.0	_	210.1
Corporate securities	_	240.5	_	240.5

Common and collective trusts		_		28.9	_		28.9
Partnership interests	_		_		176.5		176.5
Insurance company contracts		_		_	202.5		202.5
Treasury futures contracts		(0.2)					(0.2)
Total pension benefit assets	\$1,	009.6	\$	426.1	\$ 379.0	\$1,	814.7
Other Benefit Assets:							
Equity securities:							
U.S. securities	\$	23.2	\$	_	\$ _	\$	23.2
Foreign securities		11.6		_	_		11.6
Mutual funds		36.1		_	_		36.1
Fixed maturity securities:							
Government securities		4.3		_	_		4.3
Corporate securities		_		9.2	_		9.2
Asset-backed securities		_		13.8	_		13.8
Other types of investments:							
Common and collective trusts		_		2.1	_		2.1
Partnership interests		_		_	1.2		1.2
Life insurance contracts		_		_	203.7		203.7
Investment in DOL 103-12 trust				15.1			15.1
Total other benefit assets	\$	75.2	\$	40.2	\$ 204.9	\$	320.3

138.7

138.7

Asset-backed securities

Other types of investments:

A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December 31, 2013, 2012 and 2011 is as follows:

	U.S. Equity curities	rtnership nterests	Co	surance ompany ontracts	Life surance ontracts	Total
Year Ended December 31, 2013:						
Beginning balance at January 1, 2013	\$ 	\$ 177.7	\$	202.5	\$ 203.7	\$583.9
Actual return on plan assets:						
Relating to assets still held at the reporting date	_	2.2		(5.6)	26.3	22.9
Purchases	_	15.6		9.5	_	25.1
Sales	_	(35.2)		(9.0)	_	(44.2)
Ending balance at December 31, 2013	\$ 	\$ 160.3	\$	197.4	\$ 230.0	\$587.7
Year Ended December 31, 2012:						
Beginning balance at January 1, 2012	\$ 317.6	\$ 166.1	\$	195.5	\$ 95.7	\$774.9
Actual return on plan assets:						
Relating to assets still held at the reporting date	_	4.5		5.5	13.2	23.2
Purchases	_	14.1		8.8	94.8	117.7
Sales	(317.6)	(7.0)		(7.3)	_	(331.9)
Ending balance at December 31, 2012	\$ 	\$ 177.7	\$	202.5	\$ 203.7	\$583.9
	,				,	
Year Ended December 31, 2011:						
Beginning balance at January 1, 2011	\$ 429.8	\$ 153.1	\$	188.8	\$ _	\$771.7
Actual return on plan assets:						
Relating to assets still held at the reporting date	4.8	5.8		2.7	1.0	14.3
Purchases	_	7.6		11.6	94.7	113.9
Sales	(117.0)	(0.4)		(7.6)		(125.0)

There were no transfers between Levels I, II and III during the years ended December 31, 2013, 2012 and 2011. The significant decline in plan assets measured using Level III inputs as of December 31, 2012 was primarily due to the sale of an equity partnership.

Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended December 31, 2013, 2012 and 2011, no material contributions were necessary to meet ERISA required funding levels. However, during the years ended December 31, 2013, 2012 and 2011, we made tax deductible discretionary contributions to the pension benefit plans of \$38.6, \$34.5 and \$57.7, respectively. Additionally, during the year ended December 31, 2011, we made tax deductible discretionary contributions to other benefit plans of \$30.0. Employer contributions to other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.

Our estimated future payments for pension benefits and postretirement benefits, which reflect expected future service, as appropriate, are as follows:

	Pension Benefits	Other Benefits
2014	\$ 138.2	\$ 43.4
2015	147.9	43.5
2016	141.0	43.9
2017	145.6	44.7
2018	148.3	45.4
2019 – 2023	656.5	225.8

In addition to the defined benefit plans, we maintain the WellPoint 401(k) Retirement Savings Plan, CareMore 401(k) Pension Plan and the Amerigroup Retirement Savings Plan which are qualified defined contribution plans covering substantially all employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled \$102.5, \$91.0 and \$87.8 during 2013, 2012 and 2011, respectively.

## Property And Equipment (Summary Of Property And Equipment) (Details) (USD \$) In Millions, unless otherwise specified

Dec. 31, 2013 Dec. 31, 2012

specified		
<b>Property, Plant and Equipment [Line Items]</b>		
Property and equipment, gross	\$ 3,485.0	\$ 3,194.8
Accumulated depreciation and amortization	(1,683.5)	(1,477.5)
Property and equipment, net	1,801.5	1,717.3
Land and Improvements [Member]		
<b>Property, Plant and Equipment [Line Items]</b>		
Property and equipment, gross	35.4	45.9
Buildings and Components [Member]		
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	384.0	406.0
Data Processing Equipment, Furniture and Other Equipment [Member	]	
<b>Property, Plant and Equipment [Line Items]</b>		
Property and equipment, gross	861.5	783.3
Computer Software, Purchased and Internally Developed [Member]		
<b>Property, Plant and Equipment [Line Items]</b>		
Property and equipment, gross	1,879.0	1,656.5
Leasehold Improvements [Member]		
<b>Property, Plant and Equipment [Line Items]</b>		
Property and equipment, gross	\$ 325.1	\$ 303.1

## Retirement Benefits (Components Of Net Periodic Benefit Cost (Credit)) (Details) (USD \$)

## 12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

(21.0)

(13.3)

\$ 14.1

14.1

(17.3)

10.2

(12.0)

\$ 18.6

Pension Benefits [Member]

Expected return on assets

Recognized actuarial loss

Amortization of prior service credit

Net periodic benefit cost (credit)

Defined Benefit Plan Disclosure [Line Items	1		
Service cost	\$ 14.2	\$ 16.4	\$ 17.3
<u>Interest cost</u>	67.8	76.4	84.7
Expected return on assets	(133.1)	(134.7)	(128.2)
Recognized actuarial loss	28.3	30.5	26.4
Amortization of prior service credit	(0.8)	(0.8)	(0.8)
Settlement loss	11.0	13.8	21.3
Net periodic benefit cost (credit)	(12.6)	1.6	20.7
Other Benefits [Member]			
<b>Defined Benefit Plan Disclosure [Line Items</b>	1		
Service cost	6.7	6.8	6.3
<u>Interest cost</u>	22.4	27.5	31.4

(22.1)

11.2

(13.3)

\$ 4.9

Consolidated Statements of	12 Months Ended
T (TICE 4)	12 Months Lindea

Consolidated Statements of	1	2 Months En	nded		
Income (USD \$)					
In Millions, except Per Share data, unless otherwise	Dec. 31,	Dec. 31,	Dec. 31,		
specified	2013	2012	2011		
Revenues					
Premiums	\$ 66,119.1	\$ 56,496.7	\$ 55,969.6		
Administrative fees	4,031.9	3,934.1	3,854.6		
Other revenue	40.4	83.2	41.0		
Total operating revenue	70,191.4	60,514.0	59,865.2		
Net investment income	659.1	686.1	703.7		
Net realized gains on investments	271.9	334.9	235.1		
Other than temporary impairment losses on investments:					
Total other-than-temporary impairment losses on investments	(100.6)	(41.2)	(114.7)		
Portion of other-than-temporary impairment losses recognized in other	1.7	3.4	21.4		
comprehensive income					
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)		
Total revenues	71,023.5	61,497.2	60,710.7		
Expenses		10.010.1			
Benefit expense	56,237.1	48,213.6	47,647.5		
Selling, general and administrative expense:					
Selling expense	1,526.9	1,586.9	1,616.8		
General and administrative expense	8,426.0	7,093.6	6,818.8		
Total selling, general and administrative expense	9,952.9	8,680.5	8,435.6		
<u>Interest expense</u>	602.7	511.8	430.3		
Amortization of other intangible assets	245.3	233.0	239.4		
Loss on extinguishment of debt	145.3	0	0		
<u>Total expenses</u>	67,183.3	57,638.9	56,752.8		
Income from continuing operations before income tax expense	3,840.2	3,858.3	3,957.9		
<u>Income tax expense</u>	1,205.9	1,207.3	1,311.2		
Income from continuing operations	2,634.3	2,651.0	2,646.7		
(Loss) income from discontinued operations, net of tax	(144.6)	4.5	0		
Net income	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7		
Basic net income (loss) per share:					
Basic - continuing operations (in dollars per share)	\$ 8.83	\$ 8.25	\$ 7.35		
Basic - discontinued operations (in dollars per share)	\$ (0.49)	\$ 0.01	\$ 0.00		
Basic net income per share	\$ 8.34	\$ 8.26	\$ 7.35		
<b>Diluted net income (loss) per share:</b>					
<u>Diluted - continuing operations (in dollars per share)</u>	\$ 8.67	\$ 8.17	\$ 7.25		
<u>Diluted</u> - <u>discontinued</u> operations (in dollars per share)	\$ (0.47)	\$ 0.01	\$ 0.00		
Diluted net income per share	\$ 8.20	\$ 8.18	\$ 7.25		
<u>Dividends per share</u>	\$ 1.50	\$ 1.15	\$ 1.00		

#### **Investments**

#### **Investments** [Abstract]

**Investments** 

## 12 Months Ended Dec. 31, 2013

#### **Investments**

A summary of current and long-term investments, available-for-sale, at December 31, 2013 and 2012 is as follows:

		Cost or		Gross	_6	tross Unrea	ılized	l Losses		Cor Ot T	on-Credit mponent of her-Than- emporary pairments
	A	mortized Cost	Uı	realized Gains		Less than 12 Months		Months Greater	Estimated air Value		cognized in AOCI
December 31, 2013:											
Fixed maturity securities:											
United States Government securities	\$	300.8	\$	2.5	\$	(3.4)	\$	_	\$ 299.9	\$	_
Government sponsored securities		174.4		0.4		(1.3)		_	173.5		_
States, municipalities and political subdivisions, tax-exempt		5,899.5		202.9		(90.1)		(9.6)	6,002.7		(0.6)
Corporate securities		7,614.1		205.2		(95.2)		(15.5)	7,708.6		(0.1)
Options embedded in convertible securities		89.2		_		_		_	89.2		_
Residential mortgage-backed securities		2,269.4		48.0		(41.4)		(7.1)	2,268.9		_
Commercial mortgage-backed securities		479.0		10.5		(2.6)		(0.3)	486.6		_
Other debt securities		456.2		5.8		(2.5)		(0.8)	 458.7		(0.1)
Total fixed maturity securities		17,282.6		475.3		(236.5)		(33.3)	17,488.1	\$	(0.8)
Equity securities		1,195.9		578.9		(8.0)		_	1,766.8		
Total investments, available-for-sale	\$	18,478.5	\$	1,054.2	\$	(244.5)	\$	(33.3)	\$ 19,254.9		
December 31, 2012											
Fixed maturity securities:											
United States Government securities	\$	330.3	\$	13.1	\$	(0.2)	\$	_	\$ 343.2	\$	_
Government sponsored securities		153.6		2.6		_		_	156.2		_
States, municipalities and political subdivisions, tax-exempt		5,501.3		388.2		(5.7)		(1.6)	5,882.2		_
Corporate securities		7,642.0		387.0		(17.0)		(8.0)	8,004.0		(1.7)
Options embedded in convertible securities		67.2		_		_		_	67.2		_
Residential mortgage-backed securities		2,204.7		103.1		(1.1)		(1.9)	2,304.8		(0.4)
Commercial mortgage-backed securities		323.2		22.5		_		_	345.7		_
Other debt securities		236.8		7.6		(0.2)		(3.1)	241.1		(1.3)
Total fixed maturity securities		16,459.1		924.1		(24.2)		(14.6)	17,344.4	\$	(3.4)
Equity securities		897.0		358.0		(12.5)			1,242.5		
Total investments, available-for-sale	\$	17,356.1	\$	1,282.1	\$	(36.7)	\$	(14.6)	\$ 18,586.9		

At December 31, 2013, we owned \$2,755.5 of mortgage-backed securities and \$423.8 of asset-backed securities out of a total available-for-sale investment portfolio of \$19,254.9. These securities included sub-prime and Alt-A securities with fair values of \$32.2 and \$102.4, respectively. These sub-prime and Alt-A securities had accumulated net unrealized gains of \$1.7 and \$6.4, respectively. The average credit rating of the sub-prime and Alt-A securities was "BB" and "CCC", respectively.

The following tables summarize for fixed maturity securities and equity securities in an unrealized loss position at December 31, 2013 and 2012, the aggregate fair value and gross unrealized loss by length of time those securities have been continuously in an unrealized loss position.

	Le	ss than 12 Moi	nths	12 Months or Greater					
	Number of Securities	Estimated Fair Value	Gross Unrealized Loss	Number of Securities	Estimated Fair Value	Gross Unrealized Loss			
(Securities are whole amounts)									

#### December 31, 2013:

December 31, 2013.						
Fixed maturity securities:						
United States Government securities	27	\$ 179.2	\$ (3.4)	_	\$ _	\$ _
Government sponsored securities	22	73.4	(1.3)	_	_	_
States, municipalities and political subdivisions, tax-exempt	806	2,070.9	(90.1)	42	82.4	(9.6)
Corporate securities	1,448	2,586.6	(95.2)	107	81.3	(15.5)
Residential mortgage-backed securities	605	1,243.0	(41.4)	80	116.2	(7.1)
Commercial mortgage-backed securities	52	177.7	(2.6)	4	5.6	(0.3)
Other debt securities	65	185.3	(2.5)	17	16.2	(0.8)
Total fixed maturity securities	3,025	6,516.1	(236.5)	250	301.7	(33.3)
Equity securities	426	120.8	(8.0)	_	_	_
Total fixed maturity and equity securities	3,451	\$ 6,636.9	\$ (244.5)	250	\$ 301.7	\$ (33.3)
December 31, 2012						
Fixed maturity securities:						
United States Government securities	17	\$ 48.5	\$ (0.2)	_	\$ _	\$ _
States, municipalities and political subdivisions, tax-exempt	184	420.1	(5.7)	1	46.9	(1.6)
Corporate securities	457	1,066.5	(17.0)	74	52.6	(8.0)
Residential mortgage-backed securities	79	211.0	(1.1)	44	25.5	(1.9)
Commercial mortgage-backed securities	4	10.1	_	3	4.1	_
Other debt securities	7	 5.4	 (0.2)	21	28.9	(3.1)
Total fixed maturity securities	748	1,761.6	(24.2)	143	158.0	(14.6)
Equity securities	961	149.6	 (12.5)		 	_
Total fixed maturity and equity securities	1,709	\$ 1,911.2	\$ (36.7)	143	\$ 158.0	\$ (14.6)

The amortized cost and fair value of fixed maturity securities at December 31, 2013, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.

	A:	mortized Cost	 stimated air Value
Due in one year or less	\$	423.9	\$ 426.3
Due after one year through five years		4,580.5	4,712.1
Due after five years through ten years		5,105.4	5,196.6
Due after ten years		4,424.4	4,397.6
Mortgage-backed securities		2,748.4	2,755.5
Total available-for-sale fixed maturity securities	\$	17,282.6	\$ 17,488.1

The major categories of net investment income for the years ended December 31 are as follows:

	2013	2012	2011
Fixed maturity securities	\$ 638.9	\$ 671.2	\$ 692.4
Equity securities	45.9	38.4	34.0
Cash and cash equivalents	1.0	2.5	3.7
Other	19.8	16.2	2.4
Investment income	705.6	728.3	732.5
Investment expense	(46.5)	(42.2)	(28.8)
Net investment income	\$ 659.1	\$ 686.1	\$ 703.7

Net realized investment gains/losses and net change in unrealized appreciation/depreciation in investments for the years ended December 31 are as follows:

	 2013	 2012	 2011
Net realized gains (losses) on investments:			
Fixed maturity securities:			
Gross realized gains from sales	\$ 225.9	\$ 401.0	\$ 289.2
Gross realized losses from sales	 (125.7)	 (54.8)	 (65.1)

Net realized gains from sales of fixed maturity securities	100.2	346.2	224.1
Equity securities:			
Gross realized gains from sales	224.1	82.0	75.4
Gross realized losses from sales	(100.5)	(93.8)	(68.0)
Net realized gains (losses) from sales of equity securities	123.6	(11.8)	7.4
Other realized gains on investments	48.1	0.5	3.6
Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in income:			
Fixed maturity securities	(42.5)	(11.8)	(24.2)
Equity securities	(13.9)	(17.5)	(27.9)
Other invested assets, long-term	(42.5)	(8.5)	(41.2)
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)
Change in net unrealized (losses) gains on investments:			
Fixed maturity securities	(679.8)	199.8	155.9
Equity securities	225.4	94.7	(124.6)
Total change in net unrealized (losses) gains on investments	(454.4)	294.5	31.3
Deferred income tax benefit (expense)	159.7	(104.6)	(10.7)
Net change in net unrealized (losses) gains on investments	(294.7)	189.9	20.6
Net realized gains on investments, other-than-temporary impairment losses recognized in income and net change in net unrealized (losses) gains on investments	\$ (121.7)	\$ 487.0	\$ 162.4
(105505) gains on investments	. (,		<del></del>

A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.

Proceeds from fixed maturity securities, equity securities and other invested assets and the related gross realized gains and gross realized losses for the years ended December 31 are as follows:

	2013	2012	2011
Proceeds	\$ 13,662.8	\$ 15,915.6	\$ 12,654.3
Gross realized gains	498.1	483.5	368.2
Gross realized losses	(226.2)	(148.6)	(133.1)

A significant judgment in the valuation of investments is the determination of when an other-than-temporary decline in value has occurred. We follow a consistent and systematic process for recognizing impairments on securities that sustain other-than-temporary declines in value. We have established a committee responsible for the impairment review process. The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors including, but not limited to: (i) the length of time and the extent to which the fair value has been less than book value, (ii) the financial condition and near term prospects of the issuer, (iii) our intent and ability to retain impaired equity security investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv) our intent to sell or the likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v) whether the debtor is current on interest and principal payments, (vi) the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors) and (vii) general market conditions and industry or sector specific factors. For securities that are deemed to be other-than-temporarily impaired, the security is adjusted to fair value and the resulting losses are recognized in the consolidated statements of income. The new cost basis of the impaired securities is not increased for future recoveries in fair value.

Other-than-temporary impairments recorded in 2013, 2012 and 2011 were primarily the result of the continued credit deterioration on specific issuers in the bond markets and certain equity securities' fair values remaining below cost for an extended period of time. There were no individually significant other-than-temporary impairment losses on investments by issuer during 2013, 2012 or 2011.

Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have an adverse material impact on our results of operations or shareholders' equity.

The changes in the amount of the credit component of other-than-temporary impairment losses on fixed maturity securities recognized in income, for which a portion of the other-than-temporary impairment losses was recognized in other

comprehensive income, was not material for the years ended December 31, 2013, 2012 or 2011.

At December 31, 2013 and 2012, no investments exceeded 10% of shareholders' equity.

As of December 31, 2013 we did not hold any fixed maturity investments that did not produce income during 2013. The carrying value of fixed maturity investments that did not produce income during 2012 was \$1.8 at December 31, 2012.

As of December 31, 2013 we had committed approximately \$341.6 to future capital calls from various third-party investments in exchange for an ownership interest in the related entity.

At December 31, 2013 and 2012, securities with carrying values of approximately \$449.9 and \$431.5, respectively, were deposited by our insurance subsidiaries under requirements of regulatory authorities.

### **Restructuring Activities**

12 Months Ended Dec. 31, 2013

## Restructuring Charges [Abstract]

**Restructuring Activities** 

#### **Restructuring Activities**

As a result of restructuring activities implemented during 2012 and 2011, we recorded liabilities for employee termination costs and lease and other contract exit costs. The restructuring activities are classified as components of general and administrative expenses in the consolidated statements of income for the respective period in which they occurred. There were no restructuring activities implemented during 2013.

The 2012 restructuring activities were initiated primarily as a result of personnel changes, organizational realignment to create efficiencies in our business processes and certain integration activities associated with the Amerigroup acquisition. Activity related to these liabilities for the year ended December 31, 2013 and 2012, by segment, is as follows:

	and	Commercial and Specialty Business		ernment isiness	Other	Total
2012 Restructuring Activities						
Employee termination costs:						
Costs incurred in 2012	\$	70.8	\$	64.5	\$ 3.5	\$138.8
2012 payments		(10.8)		(9.8)	(0.6)	(21.2)
Liabilities for employee termination costs ending balance at December 31, 2012		60.0		54.7	2.9	117.6
2013 payments		(34.6)		(34.6)	(1.7)	(70.9)
Liabilities released in 2013		(12.0)		(15.9)	(0.6)	(28.5)
Liabilities for employee termination costs ending balance at December 31, 2013		13.4		4.2	0.6	18.2
Lease and other contract exit costs:						
Costs incurred in 2012		8.8		3.0	0.1	11.9
2012 payments		(0.1)			_	(0.1)
Liabilities for lease and other contract exit costs ending balance at December 31, 2012		8.7		3.0	0.1	11.8
2013 payments		(5.7)		(2.0)	(0.1)	(7.8)
Liabilities released in 2013		(0.6)		(0.2)	_	(0.8)
Liabilities for lease and other contract exit costs ending balance at December 31, 2013		2.4		0.8		3.2
Total liabilities for 2012 restructuring activities ending balance at December 31, 2013	\$	15.8	\$	5.0	\$ 0.6	\$ 21.4

The 2011 restructuring activities were initiated as a result of a change in strategic focus primarily in response to Health Care Reform. At December 31, 2013, our total liabilities for 2011 restructuring activities were \$17.5, of which \$1.9 related to employee termination costs and \$15.6 related to lease and other contract exit costs. Payments for lease and other contract exit costs will continue to occur over the remaining terms of the related contracts.

## Accumulated Other Comprehensive Income (Loss)

<u>Comprehensive Income (Loss), Net of</u> Tax, Attributable to Parent [Abstract]

<u>Accumulated Other Comprehensive Income</u> (Loss)

#### 12 Months Ended

Dec. 31, 2013

#### **Accumulated Other Comprehensive Income (Loss)**

A reconciliation of the components of accumulated other comprehensive income at December 31 is as follows:

	2013	2012
Investments:		
Gross unrealized gains	\$ 1,054.2	\$ 1,282.1
Gross unrealized losses	(277.8)	(51.3)
Net pretax unrealized gains	776.4	1,230.8
Deferred tax liability	(267.4)	(427.1)
Net unrealized gains on investments	509.0	803.7
Non-credit components of OTTI on investments:		
Unrealized losses	(0.8)	(3.4)
Deferred tax asset	0.3	1.2
Net unrealized non-credit component of OTTI on investments	(0.5)	(2.2)
Cash flow hedges:		
Gross unrealized losses	(49.7)	(54.3)
Deferred tax asset	17.4	19.0
Net unrealized losses on cash flow hedges	(32.3)	(35.3)
Defined benefit pension plans:		
Deferred net actuarial loss	(427.2)	(686.8)
Deferred prior service credits	3.0	3.9
Deferred tax asset	169.9	269.1
Net unrecognized periodic benefit costs for defined benefit	(254.2)	(412.9)
pension plans Postretirement benefit plans:	(254.3)	(413.8)
Deferred net actuarial loss	(160.6)	(101.0)
Deferred prior service credits	(169.6)	(191.0)
Deferred tax asset	27.0	34.6
	27.0	34.0
Net unrecognized periodic benefit costs for postretirement benefit plans	(40.2)	(53.4)
Foreign currency translation adjustments:		
Gross unrealized gains	2.2	0.2
Deferred tax liability	(0.7)	(0.1)
Net unrealized gains on foreign currency translation adjustments	1.5	0.1
Accumulated other comprehensive income	\$ 183.2	\$ 299.1

Other comprehensive income (loss) reclassification adjustments for the years ended December 31 are as follows:

	_	2013	 2012	2011
Investments:				
Net holding loss on investment securities arising during the period, net of tax benefit of \$223.6, \$5.4 and \$38.2, respectively	\$	(407.2)	\$ (3.2)	\$ (71.6)
Reclassification adjustment for net realized gain on investment securities, net of tax expense of (\$60.6),				
(\$104.0) and (\$49.6), respectively		112.5	 193.1	 92.2
Total reclassification adjustment on investments		(294.7)	189.9	20.6

Non-credit component of OTTI on investments, net of tax (expense) benefit of (\$0.9), (\$2.4) and \$0.5,	1.7	4.5	(0
respectively	1.7	4.5	(0)
Cash flow hedges:			
Holding gain (loss), net of tax (expense) benefit of (\$1.6), (\$0.1) and \$5.3, respectively	3.0	0.1	(10
Other:			
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax (expense) benefit of (\$106.8), (\$7.1) and \$81.7, respectively	172.7	(10.9)	(119
Foreign currency translation adjustment, net of tax expense of (\$0.6), (\$0.3) and (\$0.2), respectively	1.4	0.6	0
Net (loss) gain recognized in other comprehensive income, net of tax benefit (expense) of \$53.1, (\$108.5) and \$75.9, respectively	\$ (115.9)	\$ 184.2	\$ (109

### **Medical Claims Payable**

12 Months Ended Dec. 31, 2013

## Medical Claims Payable [Abstract]

Medical Claims Payable

#### **Medical Claims Payable**

A reconciliation of the beginning and ending balances for medical claims payable for the years ended December 31 is as follows:

	Years Ended December 31					31
		2013		2012		2011
Gross medical claims payable, beginning of year	\$	6,174.5	\$	5,489.0	\$	4,852.4
Ceded medical claims payable, beginning of year		(27.2)		(16.4)		(32.9)
Net medical claims payable, beginning of year		6,147.3		5,472.6		4,819.5
Business combinations and purchase adjustments		_		804.4		100.9
Net incurred medical claims:						
Current year		55,894.3		48,080.1		47,281.6
Prior years redundancies		(599.1)		(513.6)		(209.7)
Total net incurred medical claims		55,295.2		47,566.5		47,071.9
Net payments attributable to:	Τ					
Current year medical claims		49,887.2		42,832.4		41,999.0
Prior years medical claims		5,451.5		4,863.8		4,520.7
Total net payments		55,338.7		47,696.2		46,519.7
Net medical claims payable, end of year		6,103.8		6,147.3		5,472.6
Ceded medical claims payable, end of year		23.4		27.2		16.4
Gross medical claims payable, end of year	\$	6,127.2	\$	6,174.5	\$	5,489.0

Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period end are continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the originally established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated. The prior year redundancy of \$599.1 shown above for the year ended December 31, 2013 represents an estimate based on paid claim activity from January 1, 2013 to December 31, 2013. Medical claim liabilities are usually described as having a "short tail," which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the \$599.1 redundancy relates to claims incurred in calendar year 2012.

The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the years ended December 31, 2013, 2012 and 2011, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.

	(Favorable) Unfavorable Developments by Changes in Key Assumptions					
		2013	2012		2011	
Assumed trend factors	\$	(428.4)	\$	(394.4)	\$	(264.8)
Assumed completion factors		(170.7)		(119.2)		55.1
Total	\$	(599.1)	\$	(513.6)	\$	(209.7)

The favorable development recognized in 2013 resulted primarily from trend factors in late 2012 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development. The favorable development recognized in 2012 resulted primarily from trend factors in late 2011 developing more favorably than originally expected as well as a smaller but significant contribution from completion factor development. The favorable development recognized in

2011 was driven by trend factors in late 2010 developing more favorably than originally expected. This impact was partially offset by completion factors developing unfavorably due to slight increases in payment cycle times.

Retirement Benefits	12 Months Ended						
(Narrative) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011				
Defined Benefit Plan Disclosure [Line Items]							
Cash, investment income receivable and amounts due to/from brokers, excluded from fair	\$ 3.9	\$ 3.2					
values of pension benefit assets and other benefit assets	\$ 3.9	\$ 3.2					
Contributions made to 401k retirement benefit plan	102.5	91.0	87.8				
Equity Securities [Member]							
<b>Defined Benefit Plan Disclosure [Line Items]</b>							
Weighted-average target allocation for plan assets	45.00%						
Fixed Maturity Securities [Member]							
Defined Benefit Plan Disclosure [Line Items]							
Weighted-average target allocation for plan assets	46.00%						
All Other Investments [Member]							
Defined Benefit Plan Disclosure [Line Items]							
Weighted-average target allocation for plan assets	9.00%						
Pension Benefits [Member]	,,,,,,						
Defined Benefit Plan Disclosure [Line Items]							
Estimated net actuarial loss that will be amortized from accumulated other comprehensive							
income into net periodic benefit costs over next year	18.8						
Estimated prior service credit that will be amortized from accumulated other comprehensive							
income into net periodic benefit costs over next year	0.8						
Accumulated benefit obligation for the defined benefit pension plans	1,758.2	1,941.8					
Projected benefit obligation	60.7						
Accumulated benefit obligation	60.7						
Fair value of plan assets	0						
Settlement loss	11.0	13.8	21.3				
Tax deductible discretionary contributions	38.6	34.5	57.7				
Other Benefits [Member]							
Defined Benefit Plan Disclosure [Line Items]							
Estimated net actuarial loss that will be amortized from accumulated other comprehensive							
income into net periodic benefit costs over next year	9.4						
Estimated prior service credit that will be amortized from accumulated other comprehensive							
income into net periodic benefit costs over next year	14.5						
Impact on postretirement benefit obligation of one percentage point increase in cost trend	44.2						
Impact on service and interest costs of one percentage point increase in cost trend	1.8						
Impact on postretirement benefit obligation of one percentage point decrease in cost trend	38.1						
Impact on service and interest costs of one percentage point decrease in cost trend	1.5						
Tax deductible discretionary contributions			\$ 30.0				
Other Benefits [Member]   Pre Medicare [Member]			,				
Defined Benefit Plan Disclosure [Line Items]							
Assumed health care cost trend rate to be used for next year to measure expected cost of							
other benefits	8.00%						
Ultimate health care cost trend rate	4.50%						
Year in which ultimate trend rate reached	2025						

Other Benefits [Member] | Post Medicare [Member]

## **Defined Benefit Plan Disclosure [Line Items]**

Assumed health care cost trend rate to be used for next year to measure expected cost of	6.00%
other benefits	0.00%
<u>Ultimate health care cost trend rate</u>	4.50%
Year in which ultimate trend rate reached	2021

#### **Income Taxes**

# 12 Months Ended Dec. 31, 2013

# Income Tax Disclosure [Abstract]

**Income Taxes** 

#### **Income Taxes**

The components of deferred income taxes at December 31 are as follows:

	2013	2012
Deferred tax assets relating to:		
Retirement benefits	\$ 287.8	\$ 405.3
Accrued expenses	342.8	431.2
Insurance reserves	213.1	221.2
Net operating loss carryforwards	17.2	19.2
Bad debt reserves	124.8	108.2
State income tax	32.9	79.3
Deferred compensation	52.0	55.7
Investment basis difference	166.3	138.2
Other	84.0	47.0
Total deferred tax assets	1,320.9	1,505.3
Valuation allowance	(24.1)	(18.1)
Total deferred tax assets, net of valuation allowance	1,296.8	1,487.2
Deferred tax liabilities relating to:		
Unrealized gains on securities	266.5	431.0
Acquisition related:		
Trademarks and other non-amortizable intangible assets	2,200.5	2,200.5
Subscriber base, provider and hospital networks	370.9	447.7
Internally developed software and other amortization differences	703.9	599.3
Retirement benefits	231.5	214.1
Debt discount	186.9	189.7
State deferred tax	55.3	165.9
Depreciation and amortization	33.1	73.9
Other	190.4	151.6
Total deferred tax liabilities	4,239.0	4,473.7
Net deferred tax liability	\$ (2,942.2)	\$ (2,986.5)
Deferred tax asset-current	\$ 383.0	\$ 236.4
Deferred tax liability-noncurrent	(3,325.2)	(3,222.9)
Net deferred tax liability	\$ (2,942.2)	\$ (2,986.5)

Changes in the valuation allowance during 2013 included an increase of \$12.1 impacting tax expense related to additional state operating losses and a reduction of \$6.1 impacting goodwill related to acquisition goodwill adjustments for a net increase of \$6.0.

Changes in the valuation allowance during 2012 included an \$11.0 release related to federal credits and loss carryforwards as tax settlements were completed and establishment of an \$18.1 allowance related to state net operating losses net of the federal benefit.

Significant components of the provision for income taxes for the years ended December 31 consist of the following:

	2013	2012	2011
Current tax expense (benefit):			
Federal	\$1,226.4	\$1,060.2	\$1,150.4
State and local	(42.6)	95.7	21.6
Total current tax expense	1,183.8	1,155.9	1,172.0

Deferred tax expense	22.1	51.4	139.2
Total income tax expense	\$1,205.9	\$1,207.3	\$1,311.2

State and local current tax expense is reported gross of federal benefit, and includes amounts related to true up of prior years' tax, audit settlements, uncertain tax positions and state tax credits. Such items are included in multiple lines in the following rate reconciliation table on a net of federal tax basis.

A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December 31, is as follows:

	2013		2012		2011	
	Amount	Percent	Amount	Percent	Amount	Percent
Amount at statutory rate	\$1,344.1	35.0 %	\$1,350.4	35.0 %	\$1,385.3	35.0 %
State and local income taxes net of federal tax benefit	24.4	0.6	25.5	0.6	42.3	1.1
Tax exempt interest and dividends received deduction	(64.9)	(1.7)	(59.3)	(1.5)	(58.6)	(1.5)
Audit settlements	_	_	(200.5)	(5.2)	(49.7)	(1.3)
Other, net	(97.7)	(2.5)	91.2	2.4	(8.1)	(0.2)
Total income tax expense	\$1,205.9	31.4 %	\$1,207.3	31.3 %	\$1,311.2	33.1 %

During the year ended December 31, 2013 we recognized income tax benefits of \$65.0, or \$0.21 per diluted share, resulting from a favorable tax election made subsequent to the Amerigroup acquisition. This benefit is included in Other, net above.

During the year ended December 31, 2012, we recognized income tax benefits of \$200.5, or \$0.62 per diluted share, for settlement of certain of our open tax issues with the Internal Revenue Service, or IRS, following approval by the Joint Committee on Taxation. This included amounts related to not-for-profit conversion and corporate reorganizations in prior years, as well as amounts associated with issues related to certain of our acquired companies. This income tax benefit includes the release of gross unrecognized tax benefits from uncertain tax positions, discussed below, release of a valuation allowance, discussed above, and recognition of interest income. This income tax benefit, and resulting decrease in the effective tax rate, was partially offset due to the non-tax deductibility of litigation settlement expenses associated with the settlement of a class action lawsuit in June 2012 and an increase in our state deferred tax asset valuation allowance attributable to the uncertainty associated with some of our state net operating loss carryforwards.

During the year ended December 31, 2011, following approval by the Joint Committee on Taxation, we settled the audit of our 2003 and 2004 (short year) federal tax returns, which had been in the appeals process with the IRS. This resulted in a tax benefit of \$39.3. In addition, during the year ended December 31, 2011, we completed a state tax examination, resulting in additional tax benefits for audit settlements of \$10.4.

The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December 31, is as follows:

	 2013		2012	
Balance at January 1	\$ 143.5	\$	229.1	
Additions for tax positions related to:				
Current year	5.0		50.1	
Prior years	_		13.0	
Reductions related to:				
Tax positions of prior years	(45.3)			
Settlements with taxing authorities	 		(148.7)	
Balance at December 31	\$ 103.2	\$	143.5	

The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is included in the amounts described in the following paragraph.

As of December 31, 2013, \$61.7 of unrecognized tax benefits would impact our effective tax rate in future periods, if recognized. Also included in the table above is \$10.9 that would be recognized as an adjustment to additional paid-in capital and \$5.7 that would be recognized as an adjustment to goodwill, neither of which would affect our effective tax rate. The December 31, 2013 balance also includes \$0.8 of tax positions for which ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. Excluding the impact of interest and penalties, the disallowance of the shorter deductibility period would not affect our effective tax rate, but would accelerate the payment of cash to the taxing authority to an earlier period.

For the years ended December 31, 2013, 2012 and 2011, we recognized approximately \$2.6, \$(9.0) and \$(0.1) in interest, respectively. We had accrued approximately \$18.3 and \$15.7 for the payment of interest at December 31, 2013 and 2012, respectively.

As of December 31, 2013, as further described below, certain tax years remain open to examination by the IRS and various state and local authorities. In addition, we continue to discuss certain industry issues with the IRS. As a result of these examinations and discussions, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could change within a range of approximately \$8.3 to \$(84.8).

We are a member of the IRS Compliance Assurance Process, or CAP. The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.

As of December 31, 2013, the examinations of our 2013 through 2010 tax years continue to be in process. The issues in 2010 have been resolved, but still require final approval from the Joint Committee on Taxation before they can be finalized. The 2011 tax year is at IRS Appeals, but at this time no hearing date has been established. The other years are being discussed with the IRS.

In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported with general and administrative expense.

At December 31, 2013, we had unused federal tax net operating loss carryforwards of approximately \$44.8 to offset future taxable income. The loss carryforwards expire in the years 2017 through 2024. During 2013, 2012 and 2011 federal income taxes paid totaled \$1,172.0, \$1,188.2 and \$1,153.9, respectively.

Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities And Equity Securities In An Unrealized Loss Position) (Details) (USD \$)	Dec. 31, 2013 securities	Dec. 31, 2012 securities
In Millions, unless otherwise specified		
Investment [Line Items]		
Number of Securities, 12 Months or Less	3,451	1,709
Estimated Fair Value, 12 Months or Less	\$ 6,636.9	\$ 1,911.2
Gross Unrealized Losses, Less than 12 Months	(244.5)	(36.7)
Number of Securities, 12 Months or Greater	250	143
Estimated Fair Value, 12 Months or Greater	301.7	158.0
Gross Unrealized Losses, 12 Months or Greater	(33.3)	(14.6)
Fixed Maturity Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	3,025	748
Estimated Fair Value, 12 Months or Less	6,516.1	1,761.6
Gross Unrealized Losses, Less than 12 Months	(236.5)	(24.2)
Number of Securities, 12 Months or Greater	250	143
Estimated Fair Value, 12 Months or Greater	301.7	158.0
Gross Unrealized Losses, 12 Months or Greater	(33.3)	(14.6)
Fixed Maturity Securities [Member]   United States Government Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	27	17
Estimated Fair Value, 12 Months or Less	179.2	48.5
Gross Unrealized Losses, Less than 12 Months	(3.4)	(0.2)
Number of Securities, 12 Months or Greater	0	0
Estimated Fair Value, 12 Months or Greater	0	0
Gross Unrealized Losses, 12 Months or Greater	0	0
Fixed Maturity Securities [Member]   Government Sponsored Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	22	
Estimated Fair Value, 12 Months or Less	73.4	
Gross Unrealized Losses, Less than 12 Months	(1.3)	0
Number of Securities, 12 Months or Greater	0	
Estimated Fair Value, 12 Months or Greater	0	
Gross Unrealized Losses, 12 Months or Greater	0	0
Fixed Maturity Securities [Member]   States, Municipalities And Political Subdivisions - Tax-		
Exempt [Member]		
Investment [Line Items]	007	104
Number of Securities, 12 Months or Less	806	184
Estimated Fair Value, 12 Months or Less	2,070.9	420.1
Gross Unrealized Losses, Less than 12 Months	(90.1)	(5.7)

Number of Securities, 12 Months or Greater	42	1
Estimated Fair Value, 12 Months or Greater	82.4	46.9
Gross Unrealized Losses, 12 Months or Greater	(9.6)	(1.6)
Fixed Maturity Securities [Member]   Corporate Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	1,448	457
Estimated Fair Value, 12 Months or Less	2,586.6	1,066.5
Gross Unrealized Losses, Less than 12 Months	(95.2)	(17.0)
Number of Securities, 12 Months or Greater	107	74
Estimated Fair Value, 12 Months or Greater	81.3	52.6
Gross Unrealized Losses, 12 Months or Greater	(15.5)	(8.0)
Fixed Maturity Securities [Member]   Residential Mortgage-Backed Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	605	79
Estimated Fair Value, 12 Months or Less	1,243.0	211.0
Gross Unrealized Losses, Less than 12 Months	(41.4)	(1.1)
Number of Securities, 12 Months or Greater	80	44
Estimated Fair Value, 12 Months or Greater	116.2	25.5
Gross Unrealized Losses, 12 Months or Greater	(7.1)	(1.9)
Fixed Maturity Securities [Member]   Commercial Mortgage-Backed Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	52	4
Estimated Fair Value, 12 Months or Less	177.7	10.1
Gross Unrealized Losses, Less than 12 Months	(2.6)	0
Number of Securities, 12 Months or Greater	4	3
Estimated Fair Value, 12 Months or Greater	5.6	4.1
Gross Unrealized Losses, 12 Months or Greater	(0.3)	0
Fixed Maturity Securities [Member]   Other Debt Securities [Member]		
<u>Investment [Line Items]</u>		
Number of Securities, 12 Months or Less	65	7
Estimated Fair Value, 12 Months or Less	185.3	5.4
Gross Unrealized Losses, Less than 12 Months	(2.5)	(0.2)
Number of Securities, 12 Months or Greater	17	21
Estimated Fair Value, 12 Months or Greater	16.2	28.9
Gross Unrealized Losses, 12 Months or Greater	(0.8)	(3.1)
Equity Securities [Member]		
Investment [Line Items]		
Number of Securities, 12 Months or Less	426	961
Estimated Fair Value, 12 Months or Less	120.8	149.6
Gross Unrealized Losses, Less than 12 Months	(8.0)	(12.5)
Number of Securities, 12 Months or Greater	0	0
Estimated Fair Value, 12 Months or Greater	0	0
Gross Unrealized Losses, 12 Months or Greater	\$ 0	\$ 0

Accumulated Other Comprehensive Income (Loss) (Other Comprehensive	12 Months Ended			
Income (Loss) Reclassification Adjustments) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]				
Net holding loss on investment securities arising during the period, net of tax benefit of \$223.6, \$5.4 and \$38.2, respectively	\$ (407.2)	\$ (3.2)	\$ (71.6)	
Reclassification adjustment for net realized gain on investment securities, net of tax expense of (\$60.6), (\$104.0) and (\$49.6), respectively	112.5	193.1	92.2	
Total reclassification adjustment on investments	(294.7)	189.9	20.6	
Non-credit component of OTTI on investments, net of tax (expense) benefit of (\$0.9), (\$2.4) and \$0.5, respectively	1.7	4.5	(0.7)	
Holding gain (loss), net of tax (expense) benefit of (\$1.6), (\$0.1) and \$5.3, respectively	3.0	0.1	(10.0)	
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax (expense) benefit of (\$106.8), (\$7.1) and \$81.7, respectively	172.7	(10.9)	(119.8)	
Foreign currency translation adjustment, net of tax expense of (\$0.6), (\$0.3) and (\$0.2), respectively	1.4	0.6	0.2	
Net (loss) gain recognized in other comprehensive income, net of tax benefit (expense) of \$53.1, (\$108.5) and \$75.9, respectively	\$ (115.9)	\$ 184.2	\$ (109.7)	

## Derivative Financial Instruments

Derivative Instruments and Hedging Activities Disclosure [Abstract]

**Derivative Financial Instruments** 

12 Months Ended Dec. 31, 2013

### **Derivative Financial Instruments**

A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December 31, 2013 and 2012 is as follows:

	Contractual/ Notional				ated Fair 'alue		
	_	mount	<b>Balance Sheet Location</b>	I	Asset	(L	iability)
December 31, 2013							
<b>Hedging instruments</b>							
Interest rate swaps	\$	1,660.0	Other assets/other liabilities	\$	30.9	\$	(20.7)
Non-hedging instruments							
Derivatives embedded in convertible securities		295.0	Fixed maturity securities		89.2		_
Interest rate swaps		72.6	Equity securities		1.8		(2.5)
Options		7,891.6	Equity securities/other assets		776.5		(787.7)
Futures			Equity securities		3.5		(1.6)
Subtotal non-hedging		8,259.2	Subtotal non-hedging		871.0		(791.8)
Total derivatives	\$	9,919.2	Total derivatives		901.9		(812.5)
	-		Amounts netted	(	(791.8)		791.8
			Net derivatives	\$	110.1	\$	(20.7)
December 31, 2012							
Hedging instruments							
Interest rate swaps	\$	1,650.0	Other assets/other liabilities	\$	58.6	\$	(0.1)
Non-hedging instruments							
Derivatives embedded in convertible securities		278.8	Fixed maturity securities		67.2		_
Credit default and interest rate swaps		95.9	Equity securities				(7.3)
Options		6,271.8	Equity securities		385.6		(411.2)
Futures			Equity securities		2.1		(0.4)
Subtotal non-hedging		6,646.5	Subtotal non-hedging		454.9		(418.9)
Total derivatives	\$	8,296.5	Total derivatives		513.5		(419.0)
			Amounts netted		(418.9)		418.9
			Net derivatives	\$	94.6	\$	(0.1)

#### Fair Value Hedges

We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to LIBOR. A summary of our outstanding fair value hedges at December 31, 2013 and 2012 is as follows:

	Year Entered	Outstanding Notional Amount				Interest Rate	
Type of Fair Value Hedges	Into		2013		2012	Received	<b>Expiration Date</b>
Interest rate swap	2013	\$	10.0	\$	_	4.350 %	August 15, 2020
Interest rate swap	2012		200.0		200.0	4.350	August 15, 2020
Interest rate swap	2012		625.0		625.0	1.875	January 15, 2018

Interest rate swap	2012	200.0	200.0	2.375	2017
Interest rate swap	2011	200.0	200.0	5.250	January 15, 2016
Interest rate swap	2010	25.0	25.0	5.250	January 15, 2016
Interest rate swap	2006	200.0	200.0	5.000	December 15, 2014
Interest rate swap	2005	200.0	200.0	5.000	December 15, 2014
Total notional amount outstanding		\$ 1,660.0	\$ 1,650.0	-	

A summary of the effect of fair value hedges on our income statement for the years ended December 31, 2013, 2012 and 2011 is as follows:

Type of Fair Value Hedges	Income Statement Location of Hedge Gain	Hedge Gain Recognized	Hedged Item	Income Statement Location of Hedged Item Loss	ì	ged Item Loss ognized
Year ended December 31, 2013						
Interest rate swaps	Interest expense	\$ 31.5	Fixed rate debt	Interest expense	\$	(31.5)
Year ended December 31, 2012						
Interest rate swaps	Interest expense	\$ 38.2	Fixed rate debt	Interest expense	\$	(38.2)
Year ended December 31, 2011						
Interest rate swaps	Interest expense	\$ 45.1	Fixed rate debt	Interest expense	\$	(45.1)

## Cash Flow Hedges

We have historically entered into forward starting pay fixed interest rate swaps, with the objective of eliminating the variability of cash flows in the interest payments on various debt issuances. These swaps have all terminated and no amounts were outstanding at December 31, 2013 or 2012. The unrecognized loss for all terminated cash flow hedges included in accumulated other comprehensive income was \$32.3 and \$35.3 at December 31, 2013 and 2012. As of December 31, 2013, the total amount of amortization over the next twelve months for all cash flow hedges will increase interest expense by approximately \$5.0.

A summary of the effect of cash flow hedges on our financial statements for the years ended December 31, 2013, 2012 and 2011 is as follows:

			<b>Effective Portion</b>					
			Income Statement			Ineffectiv	e Por	tion
Type of Cash Flow Hedge	Reco in ( Comp	x Hedge Loss ognized Other rehensive ) Income	Location of Loss Reclassification from Accumulated Other Comprehensive Income	Red Acc	dge Loss classified from cumulated Other prehensive Income	Income Statement Location of Loss Recognized	,	ge Loss ognized
Year ended December 31, 2013								
Forward starting pay fixed swaps	\$		Interest expense	\$	(4.6)	None	\$	_
Year ended December 31, 2012								
Forward starting pay fixed swaps	\$	(4.0)	Interest expense	\$	(4.2)	Interest expense	\$	(0.1)
Year ended December 31, 2011								_
Forward starting								

pay fixed swaps \$ (18.2) Interest expense \$ (1.8) None \$ —

We test for cash flow hedge effectiveness at hedge inception and re-assess at the end of each reporting period. No amounts were excluded from the assessment of hedge effectiveness.

### Non-Hedging Derivatives

A summary of the effect of non-hedging derivatives on our income statement for the years ended December 31, 2013, 2012 and 2011 is as follows:

Type of Non-hedging Derivatives	Income Statement Location of Gain (Loss) Recognized	Ga	erivative in (Loss) cognized
Year ended December 31, 2013			
Derivatives embedded in convertible securities	Net realized gains on investments	\$	31.5
Interest rate swaps	Net realized gains on investments		2.2
Options	Net realized gains on investments		(111.7)
Futures	Net realized gains on investments		22.3
Swaptions	Net realized gains on investments	\$	3.0
Total		\$	(52.7)
Year ended December 31, 2012			
Derivatives embedded in convertible securities	Net realized gains on investments	\$	(2.4)
Credit default and interest rate swaps	Net realized gains on investments		(3.9)
Options	Net realized gains on investments		(66.0)
Futures	Net realized gains on investments		(6.7)
Total		\$	(79.0)
Year ended December 31, 2011			
Derivatives embedded in convertible securities	Net realized gains on investments	\$	(7.6)
Credit default and interest rate swaps	Net realized gains on investments		(53.3)
Options	Net realized gains on investments		9.6
Futures	Net realized gains on investments		(5.9)
Total		\$	(57.2)

#### Fair Value

# 12 Months Ended Dec. 31, 2013

# Fair Value Disclosures [Abstract]

Fair Value

### Fair Value

Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:

Level Input:	Input Definition:
Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II	Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in the consolidated balance sheets:

Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.

Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. United States Government securities represent Level I securities, while Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions and mortgage-backed securities. For securities not actively traded, the third party pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the third party pricing services' qualifications and procedures used to determine fair values. In addition, we periodically review the third party pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

Equity securities, available-for-sale: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security's current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, or EBITDA, and/or revenue multiples that are not observable in the markets.

Other invested assets, current: Other invested assets, current include securities held in rabbi trusts that are classified as trading. Fair values are based on quoted market prices.

Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.

*Derivatives:* Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties

using valuation models that incorporate market observable inputs for similar derivative transactions.

In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan assets not defined above (see Note 11, "Retirement Benefits," for fair values of benefit plan assets):

*Mutual funds*: Fair values are based on quoted market prices, which represent the net asset value, or NAV, of shares held.

Common and collective trusts: Fair values of common/collective trusts that replicate traded money market funds are based on cost, which approximates fair value. Fair values of common/collective trusts that invest in securities are valued at the NAV of the shares held, where the trust applies fair value measurements to the underlying investments to determine the NAV.

*Partnership interests*: Fair values are estimated based on the plan's proportionate share of the undistributed partners' capital as reported in audited financial statements of the partnership.

Contract with insurance company: Fair value of the contract in the insurance company general investment account is determined by the insurance company based on the fair value of the underlying investments of the account.

Investment in DOL 103-12 trust: Fair value is based on the plan's proportionate share of the fair value of investments held by the trust, qualified as a Department of Labor Regulation 2520.103-12 entity, or DOL 103-12 trust, as reported in audited financial statements of the trust, where the trustee applies fair value measurements to the underlying investments of the trust.

Life insurance contracts: Fair value is based on the cash surrender value of the policies as reported by the insurer.

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December 31, 2013 and 2012 is as follows:

	Level I	Level II	Level III	Total
December 31, 2013				
Assets:				
Cash equivalents	\$ 632.3	\$ —	\$ —	\$ 632.3
Investments available-for-sale:				
Fixed maturity securities:				
United States Government securities	299.9		_	299.9
Government sponsored securities	_	173.5	_	173.5
States, municipalities and political subdivisions, tax- exempt	_	6,002.7	_	6,002.7
Corporate securities	_	7,593.4	115.2	7,708.6
Options embedded in convertible securities	_	89.2	_	89.2
Residential mortgage-backed securities	_	2,268.9	_	2,268.9
Commercial mortgage-backed securities	_	480.1	6.5	486.6
Other debt securities	35.6	408.3	14.8	458.7
Total fixed maturity securities	335.5	17,016.1	136.5	17,488.1
Equity securities	1,475.7	249.7	41.4	1,766.8
Other invested assets, current	16.3	_	_	16.3
Securities lending collateral	408.5	561.3	_	969.8
Derivatives excluding embedded options (reported with other assets)	_	58.4	_	58.4
Total assets	\$2,868.3	\$17,885.5	\$ 177.9	\$20,931.7
Liabilities:				
Derivatives excluding embedded options (reported with other liabilities)	\$ —	\$ (20.7)	\$ —	\$ (20.7)
Total liabilities	\$ —	\$ (20.7)	\$ —	\$ (20.7)
December 31, 2012:				
Assets:				
Cash equivalents	\$ 728.3	\$ —	\$ —	\$ 728.3

Fixed maturity securities:				
United States Government securities	343.2	_	_	343.2
Government sponsored securities		156.2		156.2
States, municipalities and political subdivisions, tax- exempt	_	5,882.2	_	5,882.2
Corporate securities	_	7,882.9	121.1	8,004.0
Options embedded in convertible securities	_	67.2	_	67.2
Residential mortgage-backed securities	_	2,300.5	4.3	2,304.8
Commercial mortgage-backed securities	_	345.7	_	345.7
Other debt securities	33.8	203.4	3.9	241.1
Total fixed maturity securities	377.0	16,838.1	129.3	17,344.4
Equity securities	1,103.1	113.2	26.2	1,242.5
Other invested assets, current	14.8	_	_	14.8
Securities lending collateral	231.7	332.9		564.6
Derivatives excluding embedded options (reported with other assets)	_	58.6	_	58.6
Total assets	\$2,454.9	\$17,342.8	\$ 155.5	\$19,953.2
Liabilities:				
Derivatives excluding embedded options (reported with other liabilities)	\$ —	\$ (0.1)	\$ —	\$ (0.1)
Total liabilities	\$	\$ (0.1)	\$ —	\$ (0.1)

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended December 31, 2013, 2012 and 2011 is as follows:

	rporate curities	M	sidential ortgage- backed curities	N	ommercial Aortgage- backed ecurities	Other Debt curities	Equity curities	Total
Year Ended December 31, 2013:								
Beginning balance at January 1, 2013	\$ 121.1	\$	4.3	\$	_	\$ 3.9	\$ 26.2	\$155.5
Total gains (losses):								
Recognized in net income	(30.3)		_		_	(0.1)	(4.8)	(35.2)
Recognized in accumulated other comprehensive income	(3.5)		_		_	0.6	9.5	6.6
Purchases	51.9		_		_	1.6	17.6	71.1
Sales	(4.8)		_		_	_	(7.1)	(11.9)
Settlements	(15.5)		(1.9)		(6.1)	(0.7)	_	(24.2)
Transfers into Level III	3.0		13.1		12.6	9.8	_	38.5
Transfers out of Level III	(6.7)		(15.5)		_	(0.3)	_	(22.5)
Ending balance at December 31, 2013	\$ 115.2	\$	_	\$	6.5	\$ 14.8	\$ 41.4	\$177.9
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2013	\$ (30.8)	\$		\$	_	\$ (0.1)	\$ (6.5)	\$ (37.4)
Year Ended December 31, 2012:								
Beginning balance at January 1, 2012	\$ 195.1	\$	_	\$	6.3	\$ 59.0	\$ 24.4	\$284.8
Total gains (losses):								
Recognized in net income	15.2		_		_	0.1	(0.9)	14.4
Recognized in accumulated other								
comprehensive income	(19.7)		_		0.1	0.7	(14.2)	(33.1)
Purchases	77.8		3.0		3.4	_	4.9	89.1
Business combinations	2.6		_		_	_	_	2.6
Sales	(29.8)		_		_	(16.6)	(0.5)	(46.9)
Settlements	(67.8)		(0.1)		(0.1)	(1.3)	_	(69.3)
Transfers into Level III	2.9		1.4		1.9	12.0	12.5	30.7

Transfers out of Level III		(55.2)			 (11.6)	 (50.0)	 	(116.8)
Ending balance at December 31, 2012	\$	121.1	\$	4.3	\$ 	\$ 3.9	\$ 26.2	\$155.5
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2012	\$	_	\$	_	\$ _	\$ _	\$ (0.7)	\$ (0.7)
			_					
Year Ended December 31, 2011:								
Beginning balance at January 1, 2011	\$	278.4	\$	3.8	\$ 7.8	\$ 81.4	\$ 17.3	\$388.7
Total gains (losses):								
Recognized in net income		5.2		_	_	(1.7)	(7.0)	(3.5)
Recognized in accumulated other comprehensive income		(3.0)		0.1	0.1	_	4.1	1.3
Purchases		31.2		2.8	2.6	12.2	10.2	59.0
Sales		(27.6)		(9.1)	(8.2)	(22.9)	(0.4)	(68.2)
Settlements		(130.5)		(0.8)	(1.4)	(17.7)	_	(150.4)
Transfers into Level III		41.4		9.7	5.4	7.8	0.2	64.5
Transfers out of Level III	_			(6.5)		(0.1)		(6.6)
Ending balance at December 31, 2011	\$	195.1	\$		\$ 6.3	\$ 59.0	\$ 24.4	\$284.8
Change in unrealized losses included in net income related to assets still held for the year ended December 31, 2011	\$	(0.6)	\$		\$ 	\$ (1.2)	\$ (7.0)	\$ (8.8)

Transfers between levels, if any, are recorded as of the beginning of the reporting period. There were no material transfers into or out of Level III during the years ended December 31, 2013 or 2011 and no material transfers into Level III during the year ended December 31, 2012. During the year ended December 31, 2012, the transfers out of Level III of corporate securities were for certain sub-prime securities transferred from Level III to Level II as a result of inputs that were previously unobservable becoming observable due to increased volume and level of trading in active markets. In addition, the transfers out of Level III of other debt securities were for certain inverse floating rate securities transferred from Level III to Level II as a result of those securities' impending maturity and settlement and recent trading activity of similar securities in observable markets.

During the years ended December 31, 2013, 2012 or 2011, there were no material transfers from Level I to Level II or from Level II to Level I.

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, "Business Acquisitions and Divestitures", we completed our acquisition of Amerigroup on December 24, 2012. The values of net assets acquired in our acquisition of Amerigroup and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of Amerigroup's assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Amerigroup were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets can be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Refer to Note 13, "Debt," for additional disclosure regarding the Amerigroup senior unsecured notes recorded at their acquisition date fair value during 2012 (nonrecurring fair value measurement). Other than the assets acquired and liabilities assumed in our acquisition of Amerigroup described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2013 and 2012.

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain only one quoted price for each security from third party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. When broker

quotes are used, we generally obtain only one broker quote per security. As we are responsible for the determination of fair value, we perform monthly analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the third party pricing services engaged and the valuation techniques and inputs used. Our analysis includes a review of month-to-month price fluctuations. If unusual fluctuations are noted in this review, we may obtain additional information from other pricing services to validate the quoted price. There were no adjustments to quoted market prices obtained from third party pricing services during the years ended December 31, 2013, 2012 or 2011.

In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance sheets.

Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.

The carrying amounts reported in the consolidated balance sheets for cash, accrued investment income, premium and self-funded receivables, other receivables, income taxes receivable, unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and certain other current liabilities approximate fair value because of the short term nature of these items. These assets and liabilities are not listed in the table below.

The following methods and assumptions were used to estimate the fair value of each class of financial instrument:

Other invested assets, long-term: Other invested assets, long-term include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities' undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.

Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.

*Long-term debt - commercial paper*: The carrying amount for commercial paper approximates fair value as the underlying instruments have variable interest rates at market value.

Long-term debt - notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.

Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.

A summary of the carrying value and fair value by level of financial instruments not recorded at fair value on our consolidated balance sheets at December 31, 2013 and 2012 are as follows:

		Carrying		Fair Value						
				evel I	Level II	Level III	Total			
De	ecember 31, 2013									
As	ssets:									
	Other invested assets, long-term	\$ 1,542.6	\$	_	\$ —	\$ 1,542.6	\$ 1,542.6			
Li	abilities:									
De	ebt:									
	Short-term borrowings	400.0		_	400.0	_	400.0			
	Commercial paper	379.2		_	379.2	_	379.2			
	Notes	12,746.4		_	13,014.3	_	13,014.3			
	Convertible debentures	966.0		_	2,030.6	_	2,030.6			

Assets:

Other invested assets, long-term	\$ 1,387.7	\$ —	\$ —	\$ 1,387.7	\$ 1,387.7
Liabilities:					
Debt:					
Short-term borrowings	250.0	_	250.0	_	250.0
Commercial paper	570.9	_	570.9	_	570.9
Notes	13,198.9	_	14,407.1	_	14,407.1
Convertible debentures	958.1	_	1,613.4	_	1,613.4

## **Property And Equipment**

## 12 Months Ended Dec. 31, 2013

## **Property, Plant and Equipment** [Abstract]

**Property And Equipment** 

#### **Property and Equipment**

A summary of property and equipment at December 31 is as follows:

	2013	2012
Land and improvements	\$ 35.4	\$ 45.9
Building and components	384.0	406.0
Data processing equipment, furniture and other equipment	861.5	783.3
Computer software, purchased and internally developed	1,879.0	1,656.5
Leasehold improvements	325.1	303.1
Property and equipment, gross	3,485.0	3,194.8
Accumulated depreciation and amortization	(1,683.5)	(1,477.5)
Property and equipment, net	\$1,801.5	\$1,717.3

Depreciation expense for 2013, 2012 and 2011 was \$105.3, \$102.9 and \$95.7, respectively. Amortization expense on computer software and leasehold improvements for 2013, 2012 and 2011 was \$351.8, \$260.6 and \$204.6, respectively, which includes amortization expense on computer software, both purchased and internally developed, for 2013, 2012 and 2011 of \$313.6, \$239.5 and \$183.9, respectively. Capitalized costs related to the internal development of software of \$1,561.0 and \$1,316.8 at December 31, 2013 and 2012, respectively, are reported with computer software.

During the years ended December 31, 2013 and 2012, we recognized \$47.7 and \$66.8, respectively, of impairments related to computer software (primarily internally developed) due to project cancellation or asset replacement, some of which resulted from a change in strategic focus needed to effectively manage business operations in a post-Health Care Reform environment.

**Investments (Proceeds and Realized Gains and Losses** 

12 Months Ended

From Investments) (Details)

(USD \$)

In Millions, unless otherwise Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011 specified

## **Investments [Abstract]**

Proceeds	\$ 13,662.8	\$ 15,915.6	\$ 12,654.3
Gross realized gains	498.1	483.5	368.2
Gross realized losses	\$ (226.2)	\$ (148.6)	\$ (133.1)

## **Segment Information** (Financial Data By Reportable Segment) (Details) (USD \$)

## 12 Months Ended

(Details) (OSD $\psi$ )
In Millions, unless otherwise
specified

In Millions, unless otherwise	Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011
specified	

specified			
<b>Segment Reporting Information [Line Items]</b>			
Operating revenue	\$ 70,191.4	\$ 60,514.0	\$ 59,865.2
Operating gain (loss)	4,001.4	3,619.9	3,782.1
Depreciation and amortization of property and equipment	457.1	363.5	300.3
Commercial and Specialty Business [Member]			
<b>Segment Reporting Information [Line Items]</b>			
Operating revenue	38,790.1	38,852.9	39,961.2
Operating gain (loss)	3,093.3	3,339.7	3,344.5
Depreciation and amortization of property and equipment	<u>t</u> 0	0	0
Government Business [Member]			
<b>Segment Reporting Information [Line Items]</b>			
Operating revenue	31,366.7	21,625.7	19,874.0
Operating gain (loss)	927.1	341.8	461.6
Depreciation and amortization of property and equipment	<u>t</u> 0	0	0
Other [Member]			
<b>Segment Reporting Information [Line Items]</b>			
Operating revenue	34.6	35.4	30.0
Operating gain (loss)	(19.0)	(61.6)	(24.0)
Depreciation and amortization of property and equipment	<u>t</u> \$ 457.1	\$ 363.5	\$ 300.3

## Retirement Benefits (Reconciliation Of The

## 12 Months Ended

Benefit Obligation) (Details)

(USD \$)

In Millions, unless otherwise specified

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

Pension Benefits [Member]

## **Reconciliation of benefit obligation**

Benefit obligation at beginning of year	\$ 1,948.5	\$ 1,851.3					
Service cost	14.2	16.4	17.3				
Interest cost	67.8	76.4	84.7				
Actuarial loss (gain)	(129.9)	129.6					
Benefits paid	(135.9)	(125.2)					
Benefit obligation at end of year	1,764.7	1,948.5	1,851.3				
Other Benefits [Member]							
Reconciliation of benefit obligation	Reconciliation of benefit obligation						
Benefit obligation at beginning of year	623.0	651.3					
Benefit obligation at beginning of year  Service cost	623.0 6.7	651.3 6.8	6.3				
			6.3 31.4				
Service cost	6.7	6.8					
Service cost Interest cost	6.7 22.4	6.8 27.5					

Derivative Financial Instruments (Notional		
Amounts, Balance Sheet		
Location And Estimated Fair	D 21	D 21
Values Of Derivative	Dec. 31, 2013	Dec. 31, 2012
Financial Instruments) (Details) (USD \$)	2013	2012
In Millions, unless otherwise		
specified		
Derivative [Line Items]		
Contractual Notional Amount	\$ 9,919.2	\$ 8,296.5
Total derivative assets	901.9	513.5
Amounts netted	(791.8)	(418.9)
Net derivative assets	110.1	94.6
<u>Total derivative liabilities</u>	(812.5)	(419.0)
Amounts netted	791.8	418.9
Net derivative liabilities	(20.7)	(0.1)
Hedging Instruments [Member]   Other Assets/Other Liabilities   Interest Rate Swaps [Member]		
<b>Derivative [Line Items]</b>		
Contractual Notional Amount	1,660.0	1,650.0
<u>Total derivative assets</u>	30.9	58.6
<u>Total derivative liabilities</u>	(20.7)	(0.1)
Non-Hedging Instruments [Member]		
Derivative [Line Items]		
Contractual Notional Amount	8,259.2	6,646.5
<u>Total derivative assets</u>	871.0	454.9
Total derivative liabilities	(791.8)	(418.9)
Non-Hedging Instruments [Member]   Fixed Maturity Securities [Member]   Derivatives Embedded In Convertible Securities [Member]		
<b>Derivative [Line Items]</b>		
Contractual Notional Amount	295.0	278.8
<u>Total derivative assets</u>	89.2	67.2
<u>Total derivative liabilities</u>	0	0
Non-Hedging Instruments [Member]   Equity Securities [Member]   Interest Rate Swaps [Member]		
Derivative [Line Items]		
Contractual Notional Amount	72.6	
<u>Total derivative assets</u>	1.8	
<u>Total derivative liabilities</u>	(2.5)	
Non-Hedging Instruments [Member]   Equity Securities [Member]   Credit Default And Interest Rate Swaps [Member]		
<b>Derivative [Line Items]</b>		
Contractual Notional Amount		95.9
<u>Total derivative assets</u>		0
Total derivative liabilities		(7.3)
Non-Hedging Instruments [Member]   Equity Securities [Member]   Options [Member]		
Derivative [Line Items]		
Contractual Notional Amount		6,271.8

**Derivative Financial** 

Total derivative assets  Total derivative liabilities  Non-Hedging Instruments [Member]   Equity Securities [Member]   Futures [Member]		385.6 (411.2)
Derivative [Line Items]		
Contractual Notional Amount	0	0
<u>Total derivative assets</u>	3.5	2.1
Total derivative liabilities	(1.6)	(0.4)
Non-Hedging Instruments [Member]   Equity Securities and Other Assets [Member]   Options [Member]		
Derivative [Line Items]		
Contractual Notional Amount	7,891.6	
<u>Total derivative assets</u>	776.5	
Total derivative liabilities	\$ (787.7)	

### 12 Months Ended

Capital Stock (Narrative) (Details) (USD \$)  Oct. Jul. May Feb. Nov. Jul. May Jan. 22, 23, 15, 20, 06, 24, 16, 24, 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 22, 23, 15, 20, 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb. Nov. Jul. May Jan. 2013  Oct. Jul. May Feb	Mar. 04, 2009
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	
Incentive compensation plan, increase in shares available	33,000,000
Number of registered shares for issue under the incentive 60,100,000 compensation plan	
Stock incentive plan vesting period, years	
Stock option term, years         \$         \$           Share-based compensation cost         \$         \$           146,000,000 134,800,000         134,800,000	
Tax benefit from share-based compensation expense         52,600,000         52,000,000         48,600,000	
Intrinsic value of options exercised	
Tax benefit from stock options  exercised	
Cash received from exercise of stock options Fair value of shares vested	
Approximate number of performance restricted stock units granted	
Approximate number of performance restricted stock units earned	
Unrecognized compensation cost related to restricted stock	
Weighted-average remaining requisite service period, months  Common steels available for	
Common stock available for future grants  Maximum amount of stock  24,900,000	
employees are permitted to purchase per calender year	
Payroll deductions, percent of gross compensation, minimum	
Payroll deductions, percent of gross compensation, maximum  Employee steels available as also	
Employee stock purchase plan purchase price per share as a percent of closing price  95.00%	
Common stock purchased under Stock Purchase Plan  0 0 0	
Shares Available For Issuance Under Stock Purchase Plan Cook Dividend par Share S S S S S S S S S S S S S S S S S S S	

Dec. Sep. Jun. Mar. Dec. Sep. Jun. Mar.

Cash dividend record date

Increase in stock repurchase program authorization
Accelerated share repurchase program, amount authorized
Accelerated share repurchase program, shares repurchased

Number of shares subject to purchase call options

Derivative, Cost of Hedge

<u>Derivative, Price Risk Option</u> <u>Strike Price, Per Share</u>

**Derivative Assets** 

3,500,000,000.0

20,700,000 39,700,000

Investments (Net Realized Investment Gains/Losses And Net Change In Unrealized Appreciation/Depreciation In Investments) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	, ,			
Investment [Line Items]					
Gross realized gains from sales	\$ 498.1	\$ 483.5	\$ 368.2		
Gross realized losses from sales	(226.2)	(148.6)	(133.1)		
Other realized gains (losses) on investments	48.1	0.5	3.6		
Net realized gains on investments	271.9	334.9	235.1		
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)		
Total change in net unrealized gains (losses) on investments	(454.4)	294.5	31.3		
<u>Deferred income tax benefit (expense)</u>	159.7	(104.6)	(10.7)		
Net change in net unrealized gains (losses) on investments	(294.7)	189.9	20.6		
Net realized gains (losses) on investments, other-than-temporary impairment losses recognized in income and net change in net unrealized gains (losses) on investments	(121.7)	487.0	162.4		
Fixed Maturity Securities [Member]					
Investment [Line Items]					
Gross realized gains from sales	225.9	401.0	289.2		
Gross realized losses from sales	(125.7)	(54.8)	(65.1)		
Net realized gains (losses) from sales	100.2	346.2	224.1		
Other-than-temporary impairment losses recognized in income	(42.5)	(11.8)	(24.2)		
Total change in net unrealized gains (losses) on investments	(679.8)	199.8	155.9		
Equity Securities [Member]					
<u>Investment [Line Items]</u>					
Gross realized gains from sales	224.1	82.0	75.4		
Gross realized losses from sales	(100.5)	(93.8)	(68.0)		
Net realized gains (losses) from sales	123.6	(11.8)	7.4		

(13.9)

225.4

\$ (42.5)

(17.5)

94.7

\$ (8.5)

(27.9)

(124.6)

\$ (41.2)

Other-than-temporary impairment losses recognized in income

Other-than-temporary impairment losses recognized in income

Total change in net unrealized gains (losses) on investments

Other Long-term Investments [Member]

**Investment** [Line Items]

Retirement Benefits (Fair Values Of Pension Benefit Assets And Other Benefit Assets By Asset Category And Level Inputs) (Details) (USD \$) In Millions, unless otherwise specified Defined Benefit Plan Disclosure [Line Items]	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Total pension benefit assets	\$ 587.7	\$ 583.9	\$ 774.9	\$ 771.7
Pension Benefits [Member]	Ψ 307.7	Ψ 505.7	Ψ / / 1.2	ψ //1./
Defined Benefit Plan Disclosure [Line Items]				
Total pension benefit assets	1,944.0	1,817.9	1,721.8	
Other Benefits [Member]	,	,	,	
Defined Benefit Plan Disclosure [Line Items]				
Total pension benefit assets	349.8	320.3	301.1	
U.S. Securities [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
Total pension benefit assets	0	0	317.6	429.8
Partnership Interests [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
<u>Total pension benefit assets</u>	160.3	177.7	166.1	153.1
Insurance Company Contracts [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
<u>Total pension benefit assets</u>	197.4	202.5	195.5	188.8
Life Insurance Contracts [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
Total pension benefit assets	230.0	203.7	95.7	0
Total   Pension Benefits [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
Total pension benefit assets	1,940.3	1,814.7		
Total   Other Benefits [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
Total pension benefit assets	349.6	320.3		
Total   U.S. Securities [Member]   Pension Benefits [Member]				
<b>Defined Benefit Plan Disclosure [Line Items]</b>				
<u>Total pension benefit assets</u>	613.8	514.3		
Total   U.S. Securities [Member]   Other Benefits [Member]				
Defined Benefit Plan Disclosure [Line Items]				
Total pension benefit assets	39.0	23.2		
Total   Foreign Securities [Member]   Pension Benefits [Member]				
Defined Benefit Plan Disclosure [Line Items]	2010	272.7		
Total pension benefit assets	296.8	272.5		
Total   Foreign Securities [Member]   Other Benefits [Member]				
Defined Benefit Plan Disclosure [Line Items]	10.6	11 6		
<u>Total pension benefit assets</u>	18.6	11.6		

Total   Mutual Funds [Member]   Pension Benefits [Member]  Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	37.4	30.9
Total   Mutual Funds [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	4.7	36.1
Total   Government Securities [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	189.4	210.1
Total   Government Securities [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	14.3	4.3
Total   Corporate Securities [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	272.1	240.5
Total   Corporate Securities [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	14.2	9.2
Total   Asset-Backed Securities [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	127.0	138.7
Total   Asset-Backed Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	11.2	13.8
Total   Common And Collective Trusts [Member]   Pension Benefits		
[Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	46.6	28.9
Total   Common And Collective Trusts [Member]   Other Benefits		
[Member]  Defined Penefit Plan Disalegure II inc Items]		
Defined Benefit Plan Disclosure [Line Items]	2.2	2.1
Total   Partnership Interests [Member]   Parsian Panelits [Member]	2.2	2.1
Total   Partnership Interests [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]  Tetal paraign barrefit assets	150 1	1765
Total pension benefit assets  Total Pension benefit assets  The state of the state	159.1	176.5
Total   Partnership Interests [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]  Tetal paraign barrefit assets	1.2	1.2
Total pension benefit assets  Total Harmonia Communicator (March ed.) Pension Pensita	1.2	1.2
Total   Insurance Company Contracts [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	197.4	202.5
Total   Life Insurance Contracts [Member]   Other Benefits [Member]	177.4	202.3
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	230.0	203.7
<del>-</del>		203.7
Total   Treasury Futures Contracts [Member]   Pension Benefits [Member]	I	

2)
1
09.6
_
2
.3
_
2
2.5
6
9
1
1
2.1
099 2 2 6

<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	4.3	0
Level I [Member]   Asset-Backed Securities [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level I [Member]   Asset-Backed Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level I [Member]   Common And Collective Trusts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level I [Member]   Common And Collective Trusts [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level I [Member]   Partnership Interests [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level I [Member]   Partnership Interests [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level I [Member]   Insurance Company Contracts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level I [Member]   Life Insurance Contracts [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level I [Member]   Treasury Futures Contracts [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0.7	(0.2)
Level I [Member]   Investment In DOL 103-12 Trust [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level II [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]  Total paraign handit assets	457.2	106 1
Total pension benefit assets  Level H [Member]   Other Reportis [Member]	457.2	426.1
Level II [Member]   Other Benefits [Member]  Defined Benefit Plan Disclosure [Line Items]		
Defined Deficite Fair Discussife [Line Itellis]		

Total pension benefit assets	37.5	40.2
Level II [Member]   U.S. Securities [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   U.S. Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Foreign Securities [Member]   Pension Benefits		
[Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level II [Member]   Foreign Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level II [Member]   Mutual Funds [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Mutual Funds [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Government Securities [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	11.5	18.0
Level II [Member]   Government Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Corporate Securities [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	272.1	240.5
Level II [Member]   Corporate Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	9.9	9.2
Level II [Member]   Asset-Backed Securities [Member]   Pension Benefits [Member]	8	
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	127.0	138.7
Level II [Member]   Asset-Backed Securities [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	11.2	13.8

Level II [Member]   Common And Collective Trusts [Member]   Pension		
Benefits [Member]  Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	46.6	28.9
Level II [Member]   Common And Collective Trusts [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	2.2	2.1
Level II [Member]   Partnership Interests [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Partnership Interests [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Insurance Company Contracts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Life Insurance Contracts [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Treasury Futures Contracts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level II [Member]   Investment In DOL 103-12 Trust [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	14.2	15.1
Level III [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	356.5	379.0
Level III [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]  Tetal parsian hanefit assets	221.2	204.0
Total pension benefit assets  Lavel III [Member]   I.S. Segurities [Member]   Pension Pensits	231.2	204.9
Level III [Member]   U.S. Securities [Member]   Pension Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level III [Member]   U.S. Securities [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level III [Member]   Foreign Securities [Member]   Pension Benefits [Member]		

Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level III [Member]   Foreign Securities [Member]   Other Benefits	U	O
[Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level III [Member]   Mutual Funds [Member]   Pension Benefits		
[Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level III [Member]   Mutual Funds [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level III [Member]   Government Securities [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level III [Member]   Government Securities [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level III [Member]   Corporate Securities [Member]   Pension Benefits		
[Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level III [Member]   Corporate Securities [Member]   Other Benefits		
[Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level III [Member]   Asset-Backed Securities [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	0	0
Level III [Member]   Asset-Backed Securities [Member]   Other Benefits		
[Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level III [Member]   Common And Collective Trusts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level III [Member]   Common And Collective Trusts [Member]   Other Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Total pension benefit assets	0	0
Level III [Member]   Partnership Interests [Member]   Pension Benefits		
[Member]		
Defined Benefit Plan Disclosure [Line Items]		

Total pension benefit assets	159.1	176.5
Level III [Member]   Partnership Interests [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	1.2	1.2
Level III [Member]   Insurance Company Contracts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	197.4	202.5
Level III [Member]   Life Insurance Contracts [Member]   Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	230.0	203.7
Level III [Member]   Treasury Futures Contracts [Member]   Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
<u>Total pension benefit assets</u>	0	0
Level III [Member]   Investment In DOL 103-12 Trust [Member]   Other		
Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Items]</b>		
Total pension benefit assets	\$ 0	\$ 0

Schedule II-Condensed Financial Information Of				3 Month	s Ended				12 N	Ionths E	nded
Registrant (Statements Of Income) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013		Mar. 31, 2013		Sep. 30, 2012		Mar. 31, 2012		Dec. 31, 2012	Dec. 31, 2011
Net investment income									\$ 659.1	\$ 686.1	\$ 703.7
Net realized losses on									271.9	334.9	235.1
investments											
Total other-than-temporary impairment losses on investments									(100.6)	(41.2)	(114.7)
Portion of other-than-temporary impairment losses recognized in other comprehensive income									1.7	3.4	21.4
Other-than-temporary impairment losses recognized in income									(98.9)	(37.8)	(93.3)
Other revenue									40.4	83.2	41.0
<u>Total revenues</u>	17,901.7	17,855.5	17,690.3	17,576.0	15,438.3	15,247.4	15,396.3	15,415.2	71,023.5	61,497.2	60,710.7
General and administrative expense									8,426.0	7,093.6	6,818.8
Interest expense									602.7	511.8	430.3
Loss on extinguishment of debt									145.3	0	0
Loss before income tax credits and equity in net income of subsidiaries									3,840.2	3,858.3	3,957.9
Net income	148.2	656.2	800.1	885.2	464.2	691.2	643.6	856.5	2,489.7	2,655.5	2 646 7
Wellpoint Inc [Member]	140.2	030.2	000.1	003.2	707.2	071.2	043.0	050.5	2,407.7	2,033.3	2,040.7
Net investment income									61.2	95.3	116.6
Net realized losses on investments									(83.2)	(28.5)	(17.9)
Total other-than-temporary											
impairment losses on investments									(51.6)	(15.3)	(18.3)
Portion of other-than-temporary impairment losses recognized in other comprehensive income									0.2	1.3	0.3
Other-than-temporary impairment losses recognized in									(51.4)	(14.0)	(18.0)
income											
Other revenue									4.4	3.5	3.1
Total revenues									(69.0)	56.3	83.8
General and administrative									196.6	211.9	53.4
expense Interest expense									598.4	507.0	407.3
Loss on extinguishment of debt									145.3	0	0
Total expenses									940.3	718.9	460.7
Loss before income tax credits									740.5	710.7	400.7
and equity in net income of subsidiaries									(1,009.3)	(662.6)	(376.9)
Income tax credits									(369.7)	(172.1)	(207.0)
Equity in net income of subsidiaries									3,129.3		,
Net income									\$	\$	\$
<u>rectificonic</u>										<sup>9</sup> 2,655.5	

## Restructuring Activities (Tables)

## Restructuring Charges [Abstract]

**Restructuring Activities** 

# 12 Months Ended Dec. 31, 2013

The 2012 restructuring activities were initiated primarily as a result of personnel changes, organizational realignment to create efficiencies in our business processes and certain integration activities associated with the Amerigroup acquisition. Activity related to these liabilities for the year ended December 31, 2013 and 2012, by segment, is as follows:

		Commercial and Specialty Business		Government Business		Total
2012 Restructuring Activities						
Employee termination costs:						
Costs incurred in 2012	\$	70.8	\$	64.5	\$ 3.5	\$138.8
2012 payments		(10.8)		(9.8)	(0.6)	(21.2)
Liabilities for employee termination costs ending balance at December 31, 2012		60.0		54.7	2.9	117.6
2013 payments		(34.6)		(34.6)	(1.7)	(70.9)
Liabilities released in 2013		(12.0)		(15.9)	(0.6)	(28.5)
Liabilities for employee termination costs ending balance at December 31, 2013		13.4		4.2	0.6	18.2
Lease and other contract exit costs:						
Costs incurred in 2012		8.8		3.0	0.1	11.9
2012 payments		(0.1)				(0.1)
Liabilities for lease and other contract exit costs ending balance at December 31, 2012		8.7		3.0	0.1	11.8
2013 payments		(5.7)		(2.0)	(0.1)	(7.8)
Liabilities released in 2013		(0.6)		(0.2)	_	(0.8)
Liabilities for lease and other contract exit costs ending balance at December 31, 2013		2.4		0.8	_	3.2
Total liabilities for 2012 restructuring activities ending balance at December 31, 2013	\$	15.8	\$	5.0	\$ 0.6	\$ 21.4

Organization (Details)	Dec. 31, 2013 county states counties medical_member individuals				
Organization, Consolidation and Presentation of Financial Statements [Abstract]					
Number of medical membership members	35,700,000				
<u>Individuals served</u>	67,800,000				
Number of counties in the Kansas City area not served	30				
Number of counties in the New York City metropolitan area the Company serves as independent licensee	10				
Number of states in which the Company is licensed to conduct insurance operations	50				

## **Commitments And Contingencies**

**Commitments and Contingencies Disclosure** [Abstract]

Commitments And Contingencies Commitments and Contingencies

Litigation

In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.

12 Months Ended

Dec. 31, 2013

In the Los Angeles County Superior Court, we defended a lawsuit filed by the Los Angeles City Attorney alleging the wrongful rescission of individual insurance policies and representations made concerning rescission practices and policies. The suit named WellPoint as well as Blue Cross of California, or BCC, and BC Life & Health Insurance Company, or BCL&H (which name changed to Anthem Blue Cross Life and Health Insurance Company in July 2007), both WellPoint subsidiaries. The lawsuit generally alleged unfair business practices and a purported practice of rescinding new individual members following the submission of large claims. The Los Angeles City Attorney filed an amended complaint in October 2010, adding claims of misrepresentation arising from several public statements made by the Company during 2010. The Los Angeles City Attorney requested two thousand five hundred dollars (\$2,500) per alleged violation of the California Business and Professions Code. The lawsuit was recently settled for \$6.0. The court entered final approval of the settlement and judgment on July 10, 2013.

We are defending a certified class action filed as a result of the 2001 demutualization of Anthem Insurance Companies, Inc., or AICI. The lawsuit names AICI as well as Anthem, Inc., or Anthem, n/k/a WellPoint, Inc., and is captioned Ronald Gold, et al. v. Anthem, Inc. et al. AICI's 2001 Plan of Conversion, or the Plan, provided for the conversion of AICI from a mutual insurance company into a stock insurance company pursuant to Indiana law. Under the Plan, AICI distributed the fair value of the company at the time of conversion to its Eligible Statutory Members, or ESMs, in the form of cash or Anthem common stock in exchange for their membership interests in the mutual company. Plaintiffs in Gold allege that AICI distributed value to the wrong ESMs. Cross motions for summary judgment were granted in part and denied in part on July 26, 2006 with regard to the issue of sovereign immunity asserted by co-defendant, the state of Connecticut, or the State. The court also denied our motion for summary judgment as to plaintiffs' claims on January 10, 2005. The State appealed the denial of its motion to the Connecticut Supreme Court. We filed a cross-appeal on the sovereign immunity issue. On May 11, 2010, the Court reversed the judgment of the trial court denying the State's motion to dismiss the plaintiff's claims under sovereign immunity and dismissed our cross-appeal. The case was remanded to the trial court for further proceedings. Plaintiffs' motion for class certification was granted on December 15, 2011. We and the plaintiffs filed renewed cross-motions for summary judgment on January 24, 2013. Argument on the renewed motions was held on April 19, 2013. On August 19, 2013, the court denied plaintiffs' motion for summary judgment. The court deferred a final ruling on our motion for summary judgment, instead requesting supplemental argument which occurred on November 7, 2013. The matter was taken under advisement. We intend to vigorously defend the Gold lawsuit; however, its ultimate outcome cannot be presently determined.

We are currently a defendant in eleven putative class actions relating to out-of-network, or OON, reimbursement that were consolidated into a single multi-district lawsuit called In re WellPoint, Inc. Out-of-Network "UCR" Rates Litigation that is pending in the United States District Court for the Central District of California. The lawsuits were filed in 2009. The plaintiffs include current and former members on behalf of a putative class of members who received OON services for which the defendants paid less than billed charges, the American Medical Association, four state medical associations, OON physicians, chiropractors, clinical psychologists, podiatrists, psychotherapists, the American Podiatric Association, California Chiropractic Association and the California Psychological Association on behalf of a putative class of all physicians and all non-physician health care providers. The plaintiffs have filed several amended complaints alleging that the defendants violated the Racketeer Influenced and Corrupt Organizations Act, or RICO, the Sherman Antitrust Act, ERISA, federal regulations, and state law by using an OON reimbursement database called Ingenix and in our use of non-Ingenix OON reimbursement

motions to dismiss have been granted in part and denied in part by the Court. The most recent pleading filed by the plaintiffs is a Fourth Amended Complaint to which we filed a motion to dismiss most, but not all, of the claims. In July 2013 the court issued an order granting in part and denying in part our motion. The court held that the state and federal anti-trust claims along with the RICO claims should be dismissed in their entirety with prejudice. The court further found that the ERISA claims, to the extent they involved non-Ingenix methodologies, along with those that involved our alleged non-disclosures should be dismissed with prejudice. The court also dismissed most of the plaintiffs' state law claims with prejudice. The only claims that remain after the court's decision are an ERISA benefits claim relating to claims priced based on Ingenix, a breach of contract claim on behalf of one subscriber plaintiff, a breach of implied covenant claim on behalf of one plaintiff, and one subscriber plaintiff's claim under the California Unfair Competition Law. The plaintiffs filed a motion for reconsideration of the motion to dismiss order, which the court granted in part and denied in part. The court ruled that the plaintiffs adequately allege that one Georgia provider plaintiff is deemed to have exhausted administrative remedies regarding non-Ingenix methodologies based on the facts alleged regarding that plaintiff so those claims are back in the case. Fact discovery is complete. The plaintiffs filed a motion for class certification in November 2013. The plaintiffs seek the following classes: (1) a subscriber ERISA class as to OON claims processed using the Ingenix database as the pricing methodology; (2) a physician provider class as to OON claims processed using Ingenix; (3) a non-physician provider class as to OON claims processed using Ingenix; (3) a provider ERISA class as to OON claims processed using non-Ingenix pricing methodologies; (4) a California subscriber breach of contract/unfair competition class; and (5) a subscriber breach of implied covenant class for all WellPoint states except California. We deposed all of the plaintiffs' class certification experts. Our response to the class certification is due in February 2014. Earlier in the case, in 2009, we filed a motion in the United States District Court for the Southern District of Florida, or the Florida Court, to enjoin the claims brought by the medical doctors and doctors of osteopathy and certain medical associations based on prior litigation releases, which was granted in 2011. The Florida Court ordered the plaintiffs to dismiss their claims that are barred by the release. The plaintiffs then filed a petition for declaratory judgment asking the court to find that these claims are not barred by the releases from the prior litigation. We filed a motion to dismiss the declaratory judgment action, which was granted. The plaintiffs appealed the dismissal of the declaratory judgment to the United States Court of Appeals for the Eleventh Circuit, but the dismissal was upheld. The enjoined physicians have not yet dismissed their claims. The Florida Court found the enjoined physicians in contempt and sanctioned them in July 2012. The barred physicians are paying the sanctions and have appealed the Florida Court's sanctions order to the United States Court of Appeals for the Eleventh Circuit. Oral argument on that appeal occurred in October 2013. We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.

methodologies. We have filed motions to dismiss in response to each of those amended complaints. Our

Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.

With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves, for all of those proceedings is from \$0 to approximately \$250.0 at December 31, 2013. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.

#### Other Contingencies

From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like HMOs and health insurers generally, exclude certain health care and other services from coverage under our HMO, PPO and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one

such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable settlements of coverage claims.

In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.

The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary organization consisting of the state life and health insurance guaranty associations located throughout the U.S. State life and health insurance guaranty associations, working together with NOLHGA, provide a safety net for their state's policyholders, ensuring that they continue to receive coverage even if their insurer is declared insolvent. We are aware that the Pennsylvania Insurance Commissioner, or Insurance Commissioner, has placed Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, or collectively Penn Treaty, in rehabilitation, an intermediate action before insolvency. The state court denied the Insurance Commissioner's petition for the liquidation of Penn Treaty and ordered the Insurance Commissioner to file an updated plan of rehabilitation, which proposed plan was filed on April 30, 2013. The state court has ordered a hearing on the proposed plan for which a date has not yet been set. The Insurance Commissioner has filed a Notice of Appeal asking the Pennsylvania Supreme Court to reverse the order denying the liquidation petition. The Supreme Court has probable jurisdiction over the appeal and issued a schedule for filing briefs. In the event rehabilitation of Penn Treaty is unsuccessful and Penn Treaty is declared insolvent and placed in liquidation, we and other insurers may be required to pay a portion of their policyholder claims through state guaranty association assessments in future periods. Given the uncertainty around whether Penn Treaty will ultimately be declared insolvent and, if so, the amount of the insolvency, the amount and timing of any associated future guaranty fund assessments and the availability and amount of any potential premium tax and other offsets, we currently cannot estimate our net exposure, if any, to this potential insolvency. We will continue to monitor the situation and may record a liability and expense in future reporting periods, which could be material to our cash flows and results of operations.

### **Contractual Obligations and Commitments**

We are a party to an agreement with Express Scripts, Inc., or Express Scripts, to provide pharmacy benefit management, or PBM, services for our plans, excluding Amerigroup and certain self-insured members, which have exclusive agreements with different PBM services providers, provided however that Amerigroup will be transitioning to the Express Scripts agreement during 2014. The initial term of this agreement expires on December 31, 2019. Under this agreement, Express Scripts is the exclusive provider of certain specified PBM services, such as pharmacy network management, home delivery, pharmacy customer service, claims processing, rebate management, drug utilization and specialty pharmaceutical management services. Accordingly, the agreement contains certain financial and operational requirements obligating both Express Scripts and us. Express Scripts' primary obligations relate to the performance of such services and meeting certain pricing guarantees and performance standards. Our primary obligations relate to oversight, provision of data, payment for services and certain minimum volume requirements. The failure by either party to meet the respective requirements could potentially serve as a basis for financial penalties or early termination of the contract. We believe we have appropriately recognized all rights and obligations under this contract at December 31, 2013.

During the first quarter of 2010, we entered into a new agreement with International Business Machines Corporation to provide information technology infrastructure services. This new agreement supersedes certain prior agreements and also includes provisions for additional services. Our remaining commitment under this agreement at December 31, 2013 was \$251.2 through March 31, 2015. We have the ability to terminate this agreement upon the occurrence of certain events, subject to early termination fees.

On March 31, 2009, we entered into an agreement with Affiliated Computer Services, Inc. to provide certain print and mailroom services that were previously performed in-house. Our remaining commitment under this agreement at December 31, 2013 was \$141.4 through March 31, 2016. We have the ability to terminate this agreement upon the occurrence of certain events, subject to early termination fees.

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the geographic regions in which we conduct business. As of December 31, 2013, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.

**Reinsurance (Effect Of** 

**Reinsurance On Certain** 

12 Months Ended

Assets And Liabilities) (Details) (USD \$)

In Millions, unless otherwise Dec. 3 specified

Dec. 31, 2013 Dec. 31, 2012

## **Reinsurance Disclosures [Abstract]**

Policy liabilities, assumed	\$ 55.4	\$ 62.4
Unearned income, assumed	0.4	0.5
Premiums payable, ceded	17.1	18.1
Premiums receivable, assumed	\$ 14.1	\$ 16.6

#### **Earnings Per Share**

# 12 Months Ended Dec. 31, 2013

### **Earnings Per Share [Abstract]**

Earnings Per Share

#### **Earnings per Share**

The denominator for basic and diluted earnings per share at December 31 is as follows:

	2013	2012	2011
Denominator for basic earnings per share—weighted-average shares	298.5	321.5	360.2
Effect of dilutive securities—employee stock options, non-vested restricted stock awards and convertible debentures	5.3	3.3	4.9
Denominator for diluted earnings per share	303.8	324.8	365.1

During the years ended December 31, 2013, 2012 and 2011, weighted-average shares related to certain stock options of 4.2, 12.6 and 10.5, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive.

Medical Claims Payable (Narrative) (Details) (USD \$) In Millions, unless otherwise specified

12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

## **Medical Claims Payable [Abstract]**

Net incurred medical claims in prior years redundancies \$ 599.1 \$ 513.6 \$ 209.7

#### **Segment Information (Tables)**

## 12 Months Ended Dec. 31, 2013

#### **Segment Reporting [Abstract]**

Financial Data By Reportable Segment

Financial data by reportable segment for the years ended December 31 is as follows:

	5	ommercial and Specialty Business	_	overnment Business	Other	Total
Year ended December 31, 2013						
Operating revenue	\$	38,790.1	\$	31,366.7	\$ 34.6	\$70,191.4
Operating gain (loss)		3,093.3		927.1	(19.0)	4,001.4
Depreciation and amortization of property and equipment		_		_	457.1	457.1
Year ended December 31, 2012						
Operating revenue	\$	38,852.9	\$	21,625.7	\$ 35.4	\$60,514.0
Operating gain (loss)		3,339.7		341.8	(61.6)	3,619.9
Depreciation and amortization of property and equipment		_		_	363.5	363.5
Year ended December 31, 2011						
Operating revenue	\$	39,961.2	\$	19,874.0	\$ 30.0	\$59,865.2
Operating gain (loss)		3,344.5		461.6	(24.0)	3,782.1
Depreciation and amortization of property and equipment		_		_	300.3	300.3

<u>Major Product Revenues From External</u> <u>Customers</u> The major product revenues for each of the reportable segments for the years ended December 31, are as follows:

	2013	2012	2011
Commercial and Specialty Business			
Managed care products	\$33,903.6	\$34,091.5	\$35,387.8
Managed care services	3,472.1	3,444.8	3,374.5
Dental/Vision products and services	952.5	903.9	826.8
Other	461.9	412.7	372.1
Total Commercial and Specialty Business	38,790.1	38,852.9	39,961.2
<b>Government Business</b>			
Managed care products	30,959.3	21,244.7	19,533.0
Managed care services	407.4	381.0	341.0
Total Government Business	31,366.7	21,625.7	19,874.0
Other			
Other	34.6	35.4	30.0
Total product revenues	\$70,191.4	\$60,514.0	\$59,865.2

Reconciliation Of Revenue From Reportable
Segments To The Consolidated Statements Of
Income

A reconciliation of reportable segment operating revenues to the amounts of total revenues included in the consolidated statements of income for the years ended December 31 is as follows:

	2013	2012	2011
Reportable segments operating revenues	\$70,191.4	\$60,514.0	\$59,865.2
Net investment income	659.1	686.1	703.7
Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in			
income	(98.9)	(37.8)	(93.3)
Total revenues	\$71,023.5	\$61,497.2	\$60,710.7

A reconciliation of reportable segment operating gain to income from continuing operations before income taxes included in the consolidated statements of income for the

## Consolidated Statements Of Income

years ended December 31 is as follows:

	2013	2012	2011
Reportable segments operating gain	\$4,001.4	\$ 3,619.9	\$3,782.1
Net investment income	659.1	686.1	703.7
Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)
Interest expense	(602.7)	(511.8)	(430.3)
Amortization of other intangible assets	(245.3)	(233.0)	(239.4)
Loss on extinguishment of debt	(145.3)		
Income from continuing operations before income tax expense	\$3,840.2	\$ 3,858.3	\$3,957.9

Capital Stock (Fair Values Of Options Granted During The Period Estimated Using	12 Months Ended				
Weighted-Average Assumptions) (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		
Capital [Abstract]					
Risk-free interest rate	1.25%	1.41%	2.84%		
Volatility factor	35.00%	34.00%	34.00%		
Dividend yield (annual)	2.40%	1.60%	1.50%		

Weighted-average expected life (years) 4 years 0 months 4 years 1 month 4 years 0 months

#### **Retirement Benefits (Tables)**

12 Months Ended Dec. 31, 2013

<u>Defined Benefit Pension Plans and</u> <u>Defined Benefit Postretirement Plans</u> <u>Disclosure [Abstract]</u>

Reconciliation Of The Benefit Obligation

The reconciliation of the benefit obligation is as follows:

	Pension Benefits		Other 1	Benefits
	2013	2012	2013	2012
Benefit obligation at beginning of year	\$1,948.5	\$1,851.3	\$623.0	\$ 651.3
Service cost	14.2	16.4	6.7	6.8
Interest cost	67.8	76.4	22.4	27.5
Actuarial (gain) loss	(129.9)	129.6	4.8	(28.4)
Benefits paid	(135.9)	(125.2)	(49.4)	(34.2)
Benefit obligation at end of year	\$1,764.7	\$1,948.5	\$607.5	\$ 623.0

<u>Changes In The Fair Value Of Plan</u> Assets

The changes in the fair value of plan assets are as follows:

	Pension	Pension Benefits		Benefits	
	2013	2012	2013	2012	
Fair value of plan assets at beginning of year	\$1,817.9	\$1,721.8	\$320.3	\$ 301.1	
Actual return on plan assets	223.4	186.8	37.0	21.9	
Employer contributions	38.6	34.5	31.3	38.4	
Benefits paid	(135.9)	(125.2)	(38.8)	(41.1)	
Fair value of plan assets at end of year	\$1,944.0	\$1,817.9	\$ 349.8	\$ 320.3	

Net Amount Included In Consolidated Balance Sheets

The net amount included in the consolidated balance sheets is as follows:

	rension benefits		Other	benefits
	2013	2012	2013	2012
Noncurrent assets	\$ 240.8	\$ 3.0	\$ —	\$ —
Current liabilities	(3.5)	(11.5)	_	_
Noncurrent liabilities	(58.0)	(122.1)	(257.7)	(302.7)
Net amount at December 31	\$ 179.3	\$(130.6)	\$(257.7)	\$(302.7)

Net Amounts Included In Accumulated
Other Comprehensive Loss (Income)
Not Been Recognized As Components
Of Net Periodic Benefit Costs

The net amounts included in accumulated other comprehensive loss (income) that have not been recognized as components of net periodic benefit costs are as follows:

	Pension	Benefits	Other	Benefits
	2013	2012	2013	2012
Net actuarial loss	\$ 427.2	\$ 686.8	\$ 169.6	\$ 191.0
Prior service credit	(3.0)	(3.9)	(102.4)	(103.0)
Net amount before tax at December 31	\$ 424.2	\$ 682.9	\$ 67.2	\$ 88.0

Schedule Of Assumptions Used In Calculating The Benefit Obligations [Table Text Block]

The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:

	Pension Benefits		Other 1	Benefits
	2013	2012	2013	2012
Discount rate	4.39%	3.60%	4.48%	3.71%
Rate of compensation increase	3.00%	3.50%	3.00%	3.50%
Expected rate of return on plan assets	7.66%	7.66%	7.00%	7.00%

Components Of Net Periodic Benefit

The components of net periodic benefit cost included in the consolidated statements of

		2013		2012		2011
Pension Benefits						
Service cost	\$	14.2	\$	16.4	\$	17.3
Interest cost		67.8		76.4		84.7
Expected return on assets	(	(133.1)	(	(134.7)	(	(128.2)
Recognized actuarial loss		28.3		30.5		26.4
Amortization of prior service credit		(0.8)		(0.8)		(0.8)
Settlement loss		11.0		13.8		21.3
Net periodic benefit cost	\$	(12.6)	\$	1.6	\$	20.7
Other Benefits						
Service cost	\$	6.7	\$	6.8	\$	6.3
Interest cost		22.4		27.5		31.4
Expected return on assets		(22.1)		(21.0)		(17.3)
Recognized actuarial loss		11.2		14.1		10.2
Amortization of prior service credit		(13.3)		(13.3)		(12.0)
Net periodic benefit cost	\$	4.9	\$	14.1	\$	18.6

Weighted-Average Assumptions Used In Calculating The Benefit Obligations For All Plans

The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:

	2013	2012	2011
Pension Benefits			
Discount rate	3.60%	4.29%	5.15%
Rate of compensation increase	3.50%	3.50%	3.75%
Expected rate of return on plan assets	7.91%	8.00%	8.00%
Other Benefits			
Discount rate	3.71%	4.36%	5.24%
Rate of compensation increase	3.50%	3.50%	3.75%
Expected rate of return on plan assets	7.00%	7.00%	6.75%

<u>Fair Values of Pension Benefit Assets</u> <u>and Other Benefit Assets by Asset</u> <u>Category and Level Inputs</u> The fair values of our pension benefit assets and other benefit assets at December 31, 2013, excluding \$3.9 of cash, investment income receivable and amounts due to/from brokers, by asset category and level inputs, as defined by FASB guidance regarding fair value measurements and disclosures (see Note 7, "Fair Value," for additional information regarding the definition of level inputs), are as follows:

	L	Level I		Level II		Level III		Total
December 31, 2013:								
Pension Benefit Assets:								
Equity securities:								
U.S. securities	\$	613.8	\$	_	\$	_	\$	613.8
Foreign securities		296.8		_		_		296.8
Mutual funds		37.4		_		_		37.4
Fixed maturity securities:								
Government securities		177.9		11.5		_		189.4
Corporate securities		_		272.1		_		272.1
Asset-backed securities		_		127.0		_		127.0
Other types of investments:								
Common and collective trusts		_		46.6		_		46.6
Partnership interests		_		_	1	59.1		159.1
Insurance company contracts		_		_	1	97.4		197.4
Treasury futures contracts		0.7				_		0.7

Total pension benefit assets	\$ 1	,126.6	\$ 457.2	\$ 356.5	\$1	,940.3
Other Benefit Assets:						
Equity securities:						
U.S. securities	\$	39.0	\$ _	\$ _	\$	39.0
Foreign securities		18.6	_	_		18.6
Mutual funds		4.7	_	_		4.7
Fixed maturity securities:						
Government securities		14.3	_	_		14.3
Corporate securities		4.3	9.9	_		14.2
Asset-backed securities		_	11.2	_		11.2
Other types of investments:						
Common and collective trusts		_	2.2	_		2.2
Partnership interests		_	_	1.2		1.2
Life insurance contracts		_	_	230.0		230.0
Investment in DOL 103-12 trust			14.2			14.2
Total other benefit assets	\$	80.9	\$ 37.5	\$ 231.2	\$	349.6

The fair values of our pension benefit assets and other benefit assets at December 31, 2012, excluding \$3.2 of cash, investment income receivable and amounts due to/from brokers, by asset category and level inputs, as defined by FASB guidance regarding fair value measurements and disclosures (see Note 7, "Fair Value," for additional information regarding the definition of level inputs) are as follows:

	L	evel I	Lev	vel II	Le	vel III	_1	otal
December 31, 2012:								
Pension Benefit Assets:								
Equity securities:								
U.S. securities	\$	514.3	\$		\$	_	\$	514.3
Foreign securities		272.5				_		272.5
Mutual funds		30.9		_		_		30.9
Fixed maturity securities:								
Government securities		192.1		18.0		_		210.1
Corporate securities		_	2	240.5				240.5
Asset-backed securities		_	1	138.7		_		138.7
Other types of investments:								
Common and collective trusts		_		28.9		_		28.9
Partnership interests		_				176.5		176.5
Insurance company contracts		_				202.5		202.5
Treasury futures contracts		(0.2)						(0.2)
Total pension benefit assets	\$1,	009.6	\$ 4	126.1	\$	379.0	\$1,	814.7
					_		_	
Other Benefit Assets:								
Equity securities:								
U.S. securities	\$	23.2	\$	_	\$	_	\$	23.2
Foreign securities		11.6				_		11.6
Mutual funds		36.1				_		36.1
Fixed maturity securities:								
Government securities		4.3				_		4.3
Corporate securities		_		9.2		_		9.2
Asset-backed securities		_		13.8		_		13.8
Other types of investments:								
Common and collective trusts				2.1				2.1
Partnership interests				_		1.2		1.2
Life insurance contracts						203.7		203.7

Investment in DOL 103-12 trust		15.1		15.1
Total other benefit assets	\$ 75.2	\$ 40.2	\$ 204.9	\$ 320.3

Reconciliation Of The Beginning And Ending Balances Of Plan Assets Measured At Fair Value Using Level III Inputs A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December 31, 2013, 2012 and 2011 is as follows:

	U.S. Equity curities	rtnership nterests	Co	Insurance Company Contracts		y Insurance	
Year Ended December 31, 2013:							
Beginning balance at January 1, 2013	\$ _	\$ 177.7	\$	202.5	\$	203.7	\$583.9
Actual return on plan assets:							
Relating to assets still held at the reporting date	_	2.2		(5.6)		26.3	22.9
Purchases	_	15.6		9.5		_	25.1
Sales	_	(35.2)		(9.0)		_	(44.2)
Ending balance at December 31, 2013	\$	\$ 160.3	\$	197.4	\$	230.0	\$587.7
	 ,						
Year Ended December 31, 2012:							
Beginning balance at January 1, 2012	\$ 317.6	\$ 166.1	\$	195.5	\$	95.7	\$774.9
Actual return on plan assets:							
Relating to assets still held at the reporting date		4.5		5.5		13.2	23.2
Purchases	_	14.1		8.8		94.8	117.7
Sales	(317.6)	(7.0)		(7.3)		_	(331.9)
Ending balance at December 31, 2012	\$ 	\$ 177.7	\$	202.5	\$	203.7	\$583.9
	,						
Year Ended December 31, 2011:							
Beginning balance at January 1, 2011	\$ 429.8	\$ 153.1	\$	188.8	\$	_	\$771.7
Actual return on plan assets:							
Relating to assets still held at the reporting date	4.8	5.8		2.7		1.0	14.3
Purchases	_	7.6		11.6		94.7	113.9
Sales	(117.0)	(0.4)		(7.6)			(125.0)
Ending balance at December 31, 2011	\$ 317.6	\$ 166.1	\$	195.5	\$	95.7	\$774.9

Estimated Future Payments For Pension Benefits And Postretirement Benefits Our estimated future payments for pension benefits and postretirement benefits, which reflect expected future service, as appropriate, are as follows:

	Pension Benefits		ther nefits
2014	\$ 138.2	\$	43.4
2015	147.9		43.5
2016	141.0		43.9
2017	145.6		44.7
2018	148.3		45.4
2019 – 2023	656.5		225.8

Capital Stock (Cash Dividend				0 Montl	ns Ended	ì			12 M	onths E	Ended
Activity) (Details) (USD \$) In Millions, except Per Share data, unless otherwise specified	Oct. 22, 2013	Jul. 23, 2013	May 15, 2013	Feb. 20, 2013	Nov. 06, 2012	Jul. 24, 2012	May 16, 2012	Jan. 24, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
<b>Capital [Abstract]</b>											
<u>Declaration Date</u>	Oct. 22, 2013	Jul. 23, 2013	May 15, 2013	Feb. 20, 2013	Nov. 06, 2012	Jul. 24, 2012	May 16, 2012	Jan. 24, 2012			
Record Date	Dec. 09, 2013	Sep. 10, 2013	Jun. 10, 2013	Mar. 08, 2013	Dec. 07, 2012	Sep. 10, 2012	Jun. 08, 2012	Mar. 09, 2012			
Payment Date	Dec. 23, 2013	Sep. 25, 2013	Jun. 25, 2013	Mar. 25, 2013	Dec. 21, 2012	Sep. 25, 2012	Jun. 25, 2012	Mar. 23, 2012			
Cash Dividend per Share	\$	\$	\$	\$	\$	\$	\$	\$			
	0.3750	0.3750	0.3750	0.3750	0.2875	0.2875	0.2875	0.2875			
<u>Total</u>	\$ 110.5	\$ 111.4	\$ 112.7	\$ 113.4	\$ 87.1	\$ 90.7	\$ 93.5	\$ 95.8	\$ 448.0	\$ 367.1	\$ 357.8

Consolidated Statements of			3	Montl	hs Endo	ed			12 N	Months E	anded
Comprehensive Income (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	30,	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Other Comprehensive Income [Abstract]	2										
Net income	\$ 148.2	\$ 656.2	\$ 800.1	\$ 885.2	\$ 464.2	\$ 691.2	\$ 643.6	\$ 856.5	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7
Other comprehensive (loss) income, net of tax:											
Change in net unrealized gains/losses on investments									(294.7)	189.9	20.6
Change in non-credit component of other-than-temporary impairment losses on investments									1.7	4.5	(0.7)
Change in net unrealized gains/losses on cash flow hedges									3.0	0.1	(10.0)
Change in net periodic pension and postretirement benefits									172.7	(10.9)	(119.8)
Foreign currency translation adjustments									1.4	0.6	0.2
Other comprehensive (loss) income									(115.9)	184.2	(109.7)
<u>Total comprehensive income</u>									\$ 2,373.8	\$ 2,839.7	\$ 2,537.0

Retirement Benefits (Net Amounts Included In Accumulated Other Comprehensive Loss (Income) Not Been

**Recognized As Components** 

Of Net Periodic Benefit

Costs) (Details) (USD \$)

In Millions, unless otherwise

specified

## **Defined Benefit Plan Disclosure [Line Items]**

Net actuarial loss	\$ 427.2	\$ 686.8
Prior service credit	(3.0)	(3.9)
Pension Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Ite</b>	ems]	
Net actuarial loss	427.2	686.8
Prior service credit	(3.0)	(3.9)
Net amount before tax at December 31	424.2	682.9
Other Benefits [Member]		
<b>Defined Benefit Plan Disclosure [Line Ite</b>	ems]	
Net actuarial loss	169.6	191.0
Prior service credit	(102.4)	(103.0)
Net amount before tax at December 31	\$ 67.2	\$ 88.0

Dec. 31, 2013 Dec. 31, 2012

## Business Acquisitions and Divestitures

Business Combinations
[Abstract]

Rusiness Acquisitions And

Business Acquisitions And Divestitures

## 12 Months Ended Dec. 31, 2013

#### **Business Acquisitions and Divestitures**

Amerigroup

In December 2012, we completed our acquisition of Amerigroup, one of the nation's leading managed care companies focused on meeting the health care needs of financially vulnerable Americans. This acquisition furthers our goal of creating better health care quality at more affordable prices for our customers. Amerigroup also advances our capabilities in effectively and efficiently serving the growing Medicaid population, including the expanding dual eligibles, seniors, persons with disabilities and long-term services and support markets.

We paid \$92.00 per share in cash to acquire all of the outstanding shares of Amerigroup for total cash consideration of \$4,755.8. In addition, 0.5 shares of Amerigroup restricted stock converted to 0.7 shares of WellPoint restricted stock, valued at \$17.1, and 0.1 shares underlying Amerigroup stock options converted to 0.2 shares underlying WellPoint stock options, valued at \$2.6. We also incurred \$24.0 of transaction costs, which were recorded to general and administrative expense during the year ended December 31, 2012.

In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the fair value of Amerigroup's assets acquired and liabilities assumed, including identifiable intangible assets. In 2013, we finalized our purchase accounting and made a measurement period adjustment to the fair value of certain assets acquired and liabilities assumed at the date of acquisition. The effect of these adjustments on the preliminary purchase price allocation recorded at December 31, 2012 was an increase to goodwill of \$28.9, an increase in other intangible assets of \$20.0, a decrease in current liabilities of \$1.6, and an increase in noncurrent liabilities of \$50.5. The below table and the accompanying consolidated balance sheets reflect the impact of these adjustments.

The excess of the consideration transferred over the estimated fair value of net assets acquired resulted in non-tax-deductible goodwill of \$3,062.0, all of which was allocated to our Government Business segment. Goodwill recognized from the acquisition of Amerigroup primarily relates to the future economic benefits arising from expected synergies and is consistent with our stated intentions to strengthen our position and expand operations in the government sector to serve Medicaid and Medicare enrollees.

The following table summarizes the estimated fair values of Amerigroup assets acquired and liabilities assumed:

Current assets	\$ 2,716.5
Goodwill	3,062.0
Other intangible assets	975.0
Other noncurrent assets	 406.1
Total assets acquired	7,159.6
Current liabilities	1,416.6
Noncurrent liabilities	967.5
Total liabilities assumed	2,384.1
Net assets acquired	\$ 4,775.5

Of the \$975.0 of total other intangible assets acquired, \$65.0 represents finite-lived customer relationships with an amortization period of three years, \$30.0 represents provider and hospital networks with an amortization period of twenty years and \$880.0 represents indefinite-lived state Medicaid contracts and trade names.

The results of operations of Amerigroup for the period following December 24, 2012 are included in our consolidated financial statements within our Government Business segment and represented \$219.0 of our operating revenue and an offset to net income of \$6.1 for the year ended December 31, 2012. The pro-forma effects of this acquisition for periods prior to acquisition were not considered material to our consolidated results of operations.

#### 1-800 CONTACTS

In December 2013, we entered into a definitive agreement to sell our 1-800 CONTACTS business to the private equity firm Thomas H. Lee Partners, L.P. Additionally, we entered into an asset purchase agreement with Luxottica Group to sell our glasses.com related assets (collectively, 1-800 CONTACTS). The operating results for 1-800 CONTACTS are reported as discontinued operations in the accompanying consolidated statements of income. These results were previously reported in the Commercial and Specialty Business segment. Additionally, the assets and liabilities of 1-800-CONTACTS are reported as held for sale in the accompanying consolidated balance sheets. This divestiture will enable us to focus on our core growth opportunities across both our Commercial and Specialty and Government business segments.

Summarized financial information for the 1-800 CONTACTS discontinued operations for the years ended December 31, 2013 and 2012 is as follows:

Revenues	\$ 434.7	214.5
Income from discontinued operations before tax	17.3	7.2
Income tax (benefit) expense	 (2.6)	2.7
Income from discontinued operations	19.9	4.5
Loss on disposal from discontinued operations, net of tax	 (164.5)	
Discontinued operations, net of tax	\$ (144.6)	4.5

In connection with the sale of 1-800 CONTACTS, we recognized a loss on disposal of \$221.8, net of an income tax benefit of \$57.3 for the year ended December 31, 2013. The loss on disposal was calculated as the difference between the fair value, as determined by the sales agreements less costs to sell, and the carrying value of the held for sale assets at December 31, 2013. The sale was completed on January 31, 2014 and did not result in any material difference to the loss on disposal shown above.

The assets and liabilities of 1-800 CONTACTS are reported as held for sale in the accompanying consolidated balance sheets at December 31, 2013 and 2012 and consist of the following:

	2	2013	2012
Assets			
Cash and cash equivalents	\$	4.8	\$ 9.3
Property and equipment		27.6	21.0
Goodwill		409.9	620.7
Other intangibles		415.4	437.3
Other assets		49.2	9.7
Total assets	\$	906.9	\$ 1,098.0
Liabilities			
Accounts payable and other accrued expenses	\$	34.2	\$ 33.8
Deferred income taxes		142.5	158.1
Other liabilities		4.7	15.2
Total liabilities	\$	181.4	\$ 207.1

### 12 Months Ended

Investments (Narrative) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 Mortgage- Backed Securities [Member]	Dec. 31, 2013 Asset- Backed Securities [Member]	Dec. 31, 2013 Sub-Prime Mortgage- Backed And Asset-Backed Securities [Member]	Dec. 31, 2013 Alt A Mortgage Backed And Asset Backed Securities [Member]
<b>Investment</b> [Line Items]						
Available-for-sale securities			\$ 2,755.5	\$ 423.8	\$ 32.2	\$ 102.4
Available-for-sale Securities, Fair Value Disclosure	19,254.9	18,586.9				
Accumulated net unrealized gains					1.7	6.4
Carrying value of fixed maturity investments that did not produce income		1.8				
Future capital calls from various third-party investments	341.6					
Securities on deposit under regulatory requirements	\$ 449.9	\$ 431.5				

### **Goodwill And Other Intangible Assets (Summary**

Of The Change In The

**Carrying Amount Of Goodwill** 

By Reportable Segment) (Details) (USD \$)

In Millions, unless otherwise specified

#### 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012

Change in the	<u>carrying amount o</u>	<u>f goodwill by r</u>	eportable segment

Change in the carrying amount of goodwin by reportable segment	<u> </u>	
Goodwill, Beginning Balance	\$ 16,889.8	\$ 13,858.7
Goodwill acquired		3,033.1
Measurement period adjustments	27.4	(2.0)
Goodwill, Ending Balance	16,917.2	16,889.8
Accumulated impairment as of December 31, 2013	(41.0)	
Commercial and Specialty Business [Member]		
Change in the carrying amount of goodwill by reportable segment		
Goodwill, Beginning Balance	11,555.3	11,555.6
Goodwill acquired		0
Measurement period adjustments	(1.3)	(0.3)
Goodwill, Ending Balance	11,554.0	11,555.3
Accumulated impairment as of December 31, 2013	(41.0)	
Government Business [Member]		
Change in the carrying amount of goodwill by reportable segment	<u> </u>	
Goodwill, Beginning Balance	5,334.5	2,303.1
Goodwill acquired		3,033.1
Measurement period adjustments	28.7	(1.7)
Goodwill, Ending Balance	5,363.2	5,334.5
Accumulated impairment as of December 31, 2013	0	
Other [Member]		
Change in the carrying amount of goodwill by reportable segment	<u> </u>	
Goodwill, Beginning Balance	0	0
Goodwill acquired		0
Measurement period adjustments	0	0
Goodwill, Ending Balance	0	0
Accumulated impairment as of December 31, 2013	\$0	

Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) (USD \$)

### 12 Months Ended

Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2011

**Capital [Abstract]** 

Options granted during the year	\$ 14.64	\$ 16.50	\$ 17.84
Restricted stock and stock awards granted during to	the year \$ 63.06	\$ 65.91	\$ 66.16

Derivative Financial Instruments (Effect Of Cash Flow Hedges On Financial	12 Months Ended					
Statements) (Details) (Forward Starting Pay Fixed Swaps [Member], Cash Flow Hedge [Member], USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011			
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Ineffective Portion Hedge Gain (Loss) Recognized	\$ 0		\$0			
Interest Expense [Member]						
<b>Derivative Instruments, Gain (Loss) [Line Items]</b>						
Effective Portion Pretax Hedge Gain (Loss) Recognized in Other Comprehensive (Loss) Income	0	(4.0)	(18.2)			
Effective Portion Hedge Gain (Loss) Reclassified from Accumulated Other Comprehensive Income	(4.6)	(4.2)	(1.8)			
Ineffective Portion Hedge Gain (Loss) Recognized		\$ (0.1)				

#### **Segment Information**

## 12 Months Ended Dec. 31, 2013

#### **Segment Reporting [Abstract]**

**Segment Information** 

#### **Segment Information**

On May 20, 2013, we announced certain organizational and executive leadership changes to align with how our new Chief Executive Officer is managing our operations. Beginning with the three months ended June 30, 2013, our organizational structure is comprised of three reportable segments: Commercial and Specialty Business; Government Business; and Other.

Our Commercial and Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the Commercial and Specialty Business segment offer fully-insured products; provide a broad array of managed care services to self-funded customers including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services; and provide an array of specialty and other insurance products and services such as behavioral health benefit services, dental, vision, life and disability insurance benefits, radiology benefit management, analytics-driven personal health care guidance and long-term care insurance.

Our Government Business segment includes Medicare and Medicaid businesses, National Government Services and services provided to the Federal Government in connection with FEP. Our Medicare business includes services such as Medicare Advantage, Medicare Part D, and Medicare Supplement, while our Medicaid business includes our managed care alternatives through publicly funded health care programs, including Medicaid, state Children's Health Insurance Programs and Medicaid expansion programs. National Government Services acts as a Medicare contractor in several regions across the nation.

Our Other segment includes other businesses that do not meet the quantitative thresholds for an operating segment as defined by FASB guidance, as well as corporate expenses not allocated to the other reportable segments.

We define operating revenues to include premium income, administrative fees and other revenues. Operating revenues are derived from premiums and fees received primarily from the sale and administration of health benefit products. Operating gain is calculated as total operating revenue less benefit expense and selling, general and administrative expense.

Through our participation in various federal government programs, we generated approximately 20.3%, 23.7% and 23.5% of our total consolidated revenues from agencies of the U.S. government for the years ended December 31, 2013, 2012, and 2011, respectively. These revenues are contained in the Government Business segment.

The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, "Basis of Presentation and Significant Accounting Policies," except that certain shared administrative expenses for each segment are recognized on a pro rata allocated basis, which in aggregate approximates the consolidated expense. Any difference between the allocated expenses and actual consolidated expense is included in other expenses not allocated to reportable segments. Intersegment sales and expenses are recorded at cost and eliminated in the consolidated financial statements. We evaluate performance of the reportable segments based on operating gain or loss as defined above. We evaluate investment income, net realized gains on investments, other-than-temporary impairment losses recognized in income, interest expense, amortization expense, loss on extinguishment of debt and income taxes, and asset and liability details on a consolidated basis as these items are managed in a corporate shared service environment and are not the responsibility of segment operating management.

Financial data by reportable segment for the years ended December 31 is as follows:

	Commercial and Specialty Business		Government		Other		Total
Year ended December 31, 2013							
Operating revenue	\$	38,790.1	\$	31,366.7	\$	34.6	\$ 70,191.4
Operating gain (loss)		3,093.3		927.1		(19.0)	4,001.4

Depreciation and amortization of property and equipment	_	_	457.1	457.1
Year ended December 31, 2012				
Operating revenue	\$ 38,852.9	\$ 21,625.7	\$ 35.4	\$ 60,514.0
Operating gain (loss)	3,339.7	341.8	(61.6)	3,619.9
Depreciation and amortization of property and equipment	_	_	363.5	363.5
Year ended December 31, 2011				
Operating revenue	\$ 39,961.2	\$ 19,874.0	\$ 30.0	\$ 59,865.2
Operating gain (loss)	3,344.5	461.6	(24.0)	3,782.1
Depreciation and amortization of property and equipment	_	_	300.3	300.3

The major product revenues for each of the reportable segments for the years ended December 31, are as follows:

	2013	2012	2011
Commercial and Specialty Business			
Managed care products	\$ 33,903.6	\$ 34,091.5	\$ 35,387.8
Managed care services	3,472.1	3,444.8	3,374.5
Dental/Vision products and services	952.5	903.9	826.8
Other	461.9	412.7	372.1
Total Commercial and Specialty Business	38,790.1	38,852.9	39,961.2
Government Business			
Managed care products	30,959.3	21,244.7	19,533.0
Managed care services	407.4	381.0	341.0
Total Government Business	31,366.7	21,625.7	19,874.0
Other			
Other	34.6	35.4	30.0
Total product revenues	\$ 70,191.4	\$ 60,514.0	\$ 59,865.2

The classification between managed care products and managed care services in the above table primarily distinguishes between the level of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.

Asset and equity details by reportable segment have not been disclosed, as we do not internally report such information.

A reconciliation of reportable segment operating revenues to the amounts of total revenues included in the consolidated statements of income for the years ended December 31 is as follows:

	2013	2012	2011
Reportable segments operating revenues	\$ 70,191.4	\$ 60,514.0	\$ 59,865.2
Net investment income	659.1	686.1	703.7
Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)
Total revenues	\$ 71,023.5	\$ 61,497.2	\$ 60,710.7

A reconciliation of reportable segment operating gain to income from continuing operations before income taxes included in the consolidated statements of income for the years ended December 31 is as follows:

	2013	2012			2011
Reportable segments operating gain	\$ 4,001.4	\$	3,619.9	\$	3,782.1
Net investment income	659.1		686.1		703.7

Net realized gains on investments	271.9	334.9	235.1
Other-than-temporary impairment losses recognized in income	(98.9)	(37.8)	(93.3)
Interest expense	(602.7)	(511.8)	(430.3)
Amortization of other intangible assets	(245.3)	(233.0)	(239.4)
Loss on extinguishment of debt	(145.3)		
Income from continuing operations before income tax expense	\$ 3,840.2	\$ 3,858.3	\$ 3,957.9

Earnings Per Share		12 Months Ended				
(Narrative) (Details) In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011			
Earnings Per Share [Abstract]						
Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive	4.2	12.6	10.5			

Schedule II-Condensed Financial Information of	3 Months Ended					12 Months Ended					
Registrant (Statement of Comprehensive Income) (Details) (USD \$) In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	31,	Dec. 31, 2012	30,	Jun. 30, 2012	Mar. 31, 2012	31,	Dec. 31, 2012	Dec. 31, 2011
Net income	\$ 148.2	\$ 656.2	\$ 800.1	\$ 885.2	\$ 464.2	\$ 691.2	\$ 643.6	\$ 856.5	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7
Other comprehensive (loss) income, net of tax:											
Change in net unrealized gains/losses on investments									(294.7)	189.9	20.6
Change in non-credit component of other-than-temporary impairment losses on investments									1.7	4.5	(0.7)
Change in net unrealized gains/losses on cash flow hedges									3.0	0.1	(10.0)
Change in net periodic pension and postretirement benefits									172.7	(10.9)	(119.8)
Foreign currency translation adjustments									1.4	0.6	0.2
Other comprehensive (loss) income									(115.9)	184.2	(109.7)
Total comprehensive income									2,373.8	2,839.7	2,537.0
Wellpoint Inc [Member]											
Net income									2,489.7	2,655.5	2,646.7
Other comprehensive (loss) income, net of tax:											
Change in net unrealized gains/losses on investments									(294.7)	189.9	20.6
Change in non-credit component of other-than-temporary impairment losses on investments									1.7	4.5	(0.7)
Change in net unrealized gains/losses on cash flow hedges									3.0	0.1	(10.0)
Change in net periodic pension and postretirement benefits									172.7	(10.9)	(119.8)
Foreign currency translation adjustments									1.4	0.6	0.2
Other comprehensive (loss) income									(115.9)	184.2	(109.7)
Total comprehensive income									\$ 2,373.8	\$ 2,839.7	\$ 2,537.0

Selected Quarterly Financial Data (Details) (USD \$)				3 Month	s Ended				12 N	Months E	nded
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013		Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012		Dec. 31, 2012	Dec. 31, 2011
Selected Quarterly Financial Information [Abstract]											
<u>Total revenues</u>	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
	17,901.7	17,855.5	17,690.3	17,576.0	15,438.3	15,247.4	15,396.3	15,415.2	71,023.5	61,497.2	2 60,710.7
Income (loss) from continuing operations before income taxes	469.9	879.7	1,208.1	1,282.5	480.2	1,019.6	1,048.7	1,309.8	3,840.2	3,858.3	3,957.9
Income from continuing operations	308.9	653.8	799.3	872.3	463.4	687.5	643.6	856.5	2,634.3	2,651.0	2,646.7
Income (loss) from discontinued operations	(160.7)	2.4	0.8	12.9	0.8	3.7	0	0	(144.6)	4.5	0
Net income	\$ 148.2	\$ 656.2	\$ 800.1	\$ 885.2	\$ 464.2	\$ 691.2	\$ 643.6	\$ 856.5	\$ 2,489.7	\$ 2,655.5	\$ 2,646.7
Basic net income per share - continuing operations	\$ 1.05	\$ 2.20	\$ 2.67	\$ 2.88	\$ 1.52	\$ 2.16	\$ 1.96	\$ 2.56	\$ 8.83	\$ 8.25	\$ 7.35
Basic net income (loss) per share discontinued operations	\$ (0.55)	\$ 0.01	\$ 0.00	\$ 0.04	\$ 0.00	\$ 0.01	\$ 0.00	\$ 0.00	\$ (0.49)	\$ 0.01	\$ 0.00
Basic net income per share	\$ 0.50	\$ 2.21	\$ 2.67	\$ 2.92	\$ 1.52	\$ 2.17	\$ 1.96	\$ 2.56	\$ 8.34	\$ 8.26	\$ 7.35
Diluted net income per share - continuing operations	\$ 1.02	\$ 2.15	\$ 2.64	\$ 2.85	\$ 1.51	\$ 2.14	\$ 1.94	\$ 2.53	\$ 8.67	\$ 8.17	\$ 7.25
<u>Diluted net income (loss) per</u> <u>share - discontinued operations</u>	\$ (0.53)	\$ 0.01	\$ 0.00	\$ 0.04	\$ 0.00	\$ 0.01	\$ 0.00	\$ 0.00	\$ (0.47)	\$ 0.01	\$ 0.00

\$ 0.49 \$ 2.16 \$ 2.64

Diluted net income per share

\$ 2.89

\$ 1.51

\$ 2.15

\$ 1.94

\$ 2.53

\$ 8.20 \$ 8.18

\$ 7.25

<b>Income Taxes (Narrative)</b>	12 Months Ended
(Details) (USD \$)	12 Months Ended

(Details) (USD \$)	12 Months Ended					
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011			
Income Tax Contingency [Line Items]						
Valuation Allowance Deferred Tax Asset Release	\$ 6.1	\$ 11.0				
Valuation Allowance Deferred Tax Asset Increase	12.1	18.1				
Valuation Allowance, Deferred Tax Asset, Net Change in Amount	6.0					
Unrecognized tax benefits that would impact effective tax rate	61.7					
Unrecognized tax benefits that would impact additional paid in capital	10.9					
Unrecognized tax benefits that would impact goodwill	5.7					
Tax positions for which ultimate deductibility is highly certain	0.8					
Interest recognized	2.6	(9.0)	(0.1)			
Interest balance accrued	18.3	15.7				
<u>Unrecognized tax benefit change reasonably possible due to tax settlements - lower amount</u>	8.3					
<u>Unrecognized tax benefit change reasonably possible due to tax settlements - upper amount</u>	(84.8)					
Federal tax net operating loss carry forwards	44.8					
Operating loss carryforwards, expiration dates	2017 through 2024					
Income Taxes Paid	1,172.0	1,188.2	1,153.9			
Section 338(g) Election [Member]						
Income Tax Contingency [Line Items]						
Tax benefit resulting from a favorable tax election made subsequent to the Amerigroup acquisition	65.0					
Income tax benefit per diluted share	\$ 0.21					
Internal Revenue Service (IRS) [Member]						
Income Tax Contingency [Line Items]						
Income tax benefit from audit settlement		200.5	39.3			
Income tax benefit per diluted share		\$ 0.62				
State Tax Examination [Member]						
<b>Income Tax Contingency [Line Items]</b>						
Income tax benefit from audit settlement			\$ 10.4			

#### **Income Taxes (Tables)**

## 12 Months Ended Dec. 31, 2013

#### **Income Tax Disclosure [Abstract]**

Components Of Deferred Income Taxes

The components of deferred income taxes at December 31 are as follows:

	2013	2012
Deferred tax assets relating to:		
Retirement benefits	\$ 287.8	\$ 405.3
Accrued expenses	342.8	431.2
Insurance reserves	213.1	221.2
Net operating loss carryforwards	17.2	19.2
Bad debt reserves	124.8	108.2
State income tax	32.9	79.3
Deferred compensation	52.0	55.7
Investment basis difference	166.3	138.2
Other	84.0	47.0
Total deferred tax assets	1,320.9	1,505.3
Valuation allowance	(24.1)	(18.1)
Total deferred tax assets, net of valuation allowance	1,296.8	1,487.2
Deferred tax liabilities relating to:		
Unrealized gains on securities	266.5	431.0
Acquisition related:		
Trademarks and other non-amortizable intangible assets	2,200.5	2,200.5
Subscriber base, provider and hospital networks	370.9	447.7
Internally developed software and other amortization		
differences	703.9	599.3
Retirement benefits	231.5	214.1
Debt discount	186.9	189.7
State deferred tax	55.3	165.9
Depreciation and amortization	33.1	73.9
Other	 190.4	 151.6
Total deferred tax liabilities	 4,239.0	 4,473.7
Net deferred tax liability	\$ (2,942.2)	\$ (2,986.5)
Deferred tax asset-current	\$ 383.0	\$ 236.4
Deferred tax liability-noncurrent	(3,325.2)	(3,222.9)
Net deferred tax liability	\$ (2,942.2)	\$ (2,986.5)
		,

### <u>Components Of Provision For Income</u> Taxes

Significant components of the provision for income taxes for the years ended December 31 consist of the following:

	2013	2012	2011
Current tax expense (benefit):			
Federal	\$1,226.4	\$1,060.2	\$1,150.4
State and local	(42.6)	95.7	21.6
Total current tax expense	1,183.8	1,155.9	1,172.0
Deferred tax expense	22.1	51.4	139.2
Total income tax expense	\$1,205.9	\$1,207.3	\$1,311.2

Reconciliation Of Income Tax Expense
Computed At The Statutory Federal
Income Tax Rate

A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for the years ended December 31, is as follows:

	20	2013		012	2011		
	Amount	Percent	Amount	Percent	Amount	Percent	
Amount at statutory rate	\$1,344.1	35.0 %	\$1,350.4	35.0 %	\$1,385.3	35.0 %	

State and local income taxes net of federal tax benefit	24.4	0.6	25.5	0.6	42.3	1.1
Tax exempt interest and dividends received deduction	(64.9)	(1.7)	(59.3)	(1.5)	(58.6)	(1.5)
Audit settlements	_	_	(200.5)	(5.2)	(49.7)	(1.3)
Other, net	(97.7)	(2.5)	91.2	2.4	(8.1)	(0.2)
Total income tax expense	\$1,205.9	31.4 %	\$1,207.3	31.3 %	\$1,311.2	33.1 %

Change In The Carrying Amount Of Gross
Unrecognized Tax Benefits From
Uncertain Tax Positions

The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December 31, is as follows:

	2013	2012
Balance at January 1	\$ 143.5	\$ 229.1
Additions for tax positions related to:		
Current year	5.0	50.1
Prior years		13.0
Reductions related to:		
Tax positions of prior years	(45.3)	
Settlements with taxing authorities	 	 (148.7)
Balance at December 31	\$ 103.2	\$ 143.5

#### **Debt**

#### **Debt Disclosure [Abstract]**

Debt

Debt

#### Short-term Borrowings

We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal Home Bank of Atlanta, collectively, the FHLBs, and as a member we have the ability to obtain short-term cash advances subject to certain minimum collateral requirements. At December 31, 2013 and 2012, \$400.0 and \$250.0, respectively, were outstanding under our short-term FHLBs borrowings. These outstanding short-term FHLBs borrowings at December 31, 2013 and 2012 had fixed interest rates of 0.170% and 0.206%, respectively.

#### Long-term Debt

The carrying value of long-term debt at December 31 consists of the following:

	2013	2012
Senior unsecured notes:		
6.000%, due 2014	\$ —	\$ 399.8
5.000%, due 2014	518.0	535.9
1.250%, due 2015	624.9	624.8
5.250%, due 2016	1,109.6	1,114.0
2.375%, due 2017	399.6	401.5
5.875%, due 2017	545.1	697.4
1.875%, due 2018	614.5	625.2
2.300%, due 2018	647.5	_
7.500%, due 2019	_	556.9
7.000%, due 2019	452.9	599.3
4.350%, due 2020	688.9	701.0
3.700%, due 2021	699.4	699.3
3.125%, due 2022	846.3	845.9
3.300%, due 2023	996.9	996.7
5.950%, due 2034	447.3	498.8
5.850%, due 2036	775.6	895.7
6.375%, due 2037	651.4	796.7
5.800%, due 2040	216.2	296.8
4.625%, due 2042	893.9	893.7
4.650%, due 2043	994.4	994.2
5.100%, due 2044	599.1	_
Senior convertible debentures:		
2.750%, due 2042	966.0	958.1
Surplus notes:		
9.000%, due 2027	24.9	25.0
Variable rate debt:		
Commercial paper program	379.2	570.9
Capital leases	_	0.3
Total long-term debt	14,091.6	14,727.9
Current portion of long-term debt	(518.0)	(557.1)
Long-term debt, less current portion	\$13,573.6	\$14,170.8

All long-term debt shown above is a direct obligation of WellPoint, Inc., except for the Amerigroup debt described below, the surplus notes and capital leases.

unsecured notes due 2014, plus applicable premium for early redemption and accrued and unpaid interest to the redemption date, for cash totaling \$411.0. We recognized a loss on extinguishment of debt of \$10.0 for the redemption of these notes.

On July 30, 2013, we initiated a cash tender offer and consent solicitation to purchase up to \$300.0 aggregate principal amount of our outstanding 5.875% notes due 2017 and 7.000% notes due 2019 (the "First Tranche Offer") and to purchase up to \$300.0 aggregate principal amount of our outstanding 5.950% notes due 2034, 5.850% notes due 2036, 6.375% notes due 2037 and 5.800% notes due 2040 (the "Second Tranche Offer"), collectively, the "Tender Offers". The Tender Offers were each subject to increase up to an additional \$100.0 at our election. On August 12, 2013, we increased the Second Tranche Offer to \$400.0 and on August 13, 2013 we repurchased \$300.0 of the First Tranche Offer notes and \$400.0 of the Second Tranche Offer notes for cash totaling \$837.7. Holders who tendered their notes prior to the early tender date received the principal amounts, applicable premium for early redemption and accrued and unpaid interest to the early tender offer settlement date. We recognized a loss on extinguishment of debt of \$135.3 for the repurchase of these notes.

On July 30, 2013, we issued \$650.0 of 2.300% notes due 2018 and \$600.0 of 5.100% notes due 2044 under our shelf registration statement. We used the proceeds from this offering in part to fund the purchase price of the 6.000% senior unsecured notes and the Tender Offers, discussed above, and the balance for general corporate purposes. Interest on the notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing on January 15, 2014. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

As a result of our acquisition of Amerigroup on December 24, 2012, the carrying amount of Amerigroup's \$475.0 of 7.500% senior unsecured notes due 2019 were included in our consolidated balance sheet as of December 31, 2012. In accordance with FASB accounting guidance for business combinations, the notes were recorded at their estimated fair value of \$556.9 on the date of acquisition. The fair value of the notes was estimated based on the most recent quoted market price for the notes, which we consider to be a Level II input in accordance with FASB guidance for fair value measurements. On January 25, 2013, we redeemed the outstanding principal balance of these notes, plus applicable premium for early redemption, for cash totaling \$555.6. The weighted-average redemption price of the notes was approximately 117% of the principal amount outstanding.

On September 10, 2012, we issued \$625.0 of 1.250% notes due 2015, \$625.0 of 1.875% notes due 2018, \$1,000.0 of 3.300% notes due 2023 and \$1,000.0 of 4.650% notes due 2043 under our shelf registration statement. We used the net proceeds of this offering to pay a portion of the consideration for our acquisition of Amerigroup and the balance for general corporate purposes. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

At maturity on August 1, 2012, we repaid the \$800.0 outstanding balance of our 6.800% senior unsecured notes.

On May 7, 2012, we issued \$850.0 of 3.125% notes due 2022 and \$900.0 of 4.625% notes due 2042 under our shelf registration statement. We used the proceeds from this offering for working capital and for general corporate purposes, including, but not limited to, repayment of short-term and long-term debt. The notes have a call feature that allows us to repurchase the notes at any time at our option and a put feature that allows a note holder to require us to repurchase the notes upon the occurrence of both a change in control event and a downgrade of the notes below an investment grade rating.

At maturity on January 17, 2012, we repaid the \$350.0 outstanding balance of our 6.375% senior unsecured notes.

Surplus notes are unsecured obligations of Anthem Insurance Companies, Inc., or Anthem Insurance, a wholly owned subsidiary, and are subordinate in right of payment to all of Anthem Insurance's existing and future indebtedness. Any payment of interest or principal on the surplus notes may be made only with the prior approval of the Indiana Department of Insurance, or IDOI, and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana insurance laws.

We have a senior credit facility, or the facility, with certain lenders for general corporate purposes. The facility, as amended, provides credit up to \$2,000.0 and matures on September 29, 2016. The interest rate on the facility is based on either, (i) the LIBOR rate plus a predetermined percentage rate based on our credit

rating at the date of utilization, or (ii) a base rate as defined in the facility agreement plus a predetermined percentage rate based on our credit rating at the date of utilization. Our ability to borrow under the facility is subject to compliance with certain covenants. There were no amounts outstanding under the facility at December 31, 2013 or 2012.

We have an authorized commercial paper program of up to \$2,500.0, the proceeds of which may be used for general corporate purposes. The weighted-average interest rate on commercial paper borrowings at December 31, 2013 and 2012 was 0.420% and 0.396%, respectively. Commercial paper borrowings have been classified as long-term debt as our practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year and we have the ability to redeem our commercial paper with borrowings under the senior credit facility described above.

#### Convertible Debentures

On October 9, 2012, we issued \$1,500.0 of senior convertible debentures, or the Debentures. The Debentures are governed by an indenture, or the Indenture, dated as of October 9, 2012 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures bear interest at a rate of 2.750% per year, payable semi-annually in arrears in cash on April 15 and October 15 of each year, and mature on October 15, 2042, unless earlier redeemed, repurchased or converted into shares of common stock at the applicable conversion rate. The Debentures also have a contingent interest feature that will require us to pay additional interest based on certain thresholds and for certain events, as defined in the Indenture, beginning on October 15, 2022.

Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April 15, 2042, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ended December 31, 2012, if the last reported sale price of our common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2) during the five business day period after any 10 consecutive trading day period, or the measurement period, in which the trading price per \$1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the applicable conversion rate on each such day; (3) if we call any or all of the Debentures for redemption, at any time prior to the close of business on the third scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events, as defined in the Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately preceding the Debentures' maturity date of October 15, 2042, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are redeemable at our option at any time on or after October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.

Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock or a combination of cash and shares of common stock based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures will be 13.2319 shares of our common stock per \$1,000 (whole dollars) of principal amount of Debentures, which represents a 25.0% conversion premium based on the closing price of \$60.46 per share of our common stock on October 2, 2012 (the date the Debentures' terms were finalized) and is equivalent to an initial conversion price of \$75.575 per share of our common stock. As of December 31, 2013, our common stock was last traded at a price of \$92.39 per share. If the Debentures had been converted or matured at December 31, 2013, we would be obligated to pay the principal of the Debentures plus an amount in cash or shares equal to \$342.0. The Debentures and underlying shares of our common stock have not been and will not be registered under the Securities Act of 1933, as amended, or the Securities Act, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act; the restrictions for which expired in October 2013. We used approximately \$371.0 of the net proceeds from the issuance to repurchase shares of our common stock concurrently with the offering of the Debentures, and the remaining balance was used for general corporate purposes, including but not limited to additional purchases of shares of our common stock pursuant to our share repurchase program and the repayment of short-term and/or long-term debt.

We have accounted for the Debentures in accordance with the cash conversion guidance in FASB guidance for debt with conversion and other options. As a result, the value of the embedded conversion option has been bifurcated from its debt host and recorded as a component of "additional paid-in capital" (net of deferred taxes and equity issuance costs) in our consolidated balance sheet.

The following table summarizes at December 31, 2013 the related balances, conversion rate and conversion price of the Debentures:

Outstanding principal amount	\$ 1,500.0
Unamortized debt discount	534.0
Net debt carrying amount	966.0
Equity component carrying amount	543.6
Conversion rate (shares of common stock per \$1,000 of principal amount)	13.2917
Effective conversion price (per \$1,000 of principal amount)	75.2345

The remaining amortization period of the unamortized debt discount as of December 31, 2013 is approximately 29 years. The unamortized discount will be amortized into interest expense using the effective interest method based on an effective interest rate of 5.130%, which represents the market interest rate for a comparable debt instrument that does not have a conversion feature. During the year ended December 31, 2013, we recognized \$49.2 of interest expense related to the Debentures, of which \$41.3 represented interest expense recognized at the stated interest rate of 2.750% and \$7.9 represented interest expense resulting from amortization of the debt discount.

Total interest paid during 2013, 2012 and 2011 was \$597.2, \$479.1, and \$432.9, respectively.

We were in compliance with all applicable covenants under all of our outstanding debt agreements at December 31, 2013.

Future maturities of all long-term debt outstanding at December 31, 2013 are as follows: 2014, \$897.2; 2015, \$624.9; 2016, \$1,109.6; 2017, \$944.7; 2018, \$1,262.0 and thereafter, \$9,253.2.

			12 Months Ended		9 Months Ended	
Commitments And Contingencies (Details) (USD \$)	Dec. 31, 2013 Minimum [Member]		Dec. 31, 2013 Affiliated Computer Services, Inc. [Member]	Dec. 31, 2013 International Business Machines Corporation [Member]	Sep. 30, 2013 Los Angeles City Attorney [Member]	Sep. 30, 2013 Litigation Case Name [Member] class_actions
Commitments And Contingencies	<u> </u>					
[Line Items]						
Punitive charges requested per alleged violation of the California Business and Professional Code					\$ 2,500	
Litigation Settlement					6,000,000	
Number of putative class actions consolidated into a single lawsuit						11
Possible losses, in excess of established reserves, minimum	0					
Possible losses, in excess of established reserves, maximum		250,000,000				
Long-term purchase commitment, amount			\$ 141,400,000	\$ 251,200,000		